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Abstract
Hyponatremia is a potentially dangerous serum electrolyte disorder, and is associated
with increased morbidity and mortality. Older adults are frequently prescribed
psychotropic drugs, and may be at an increased risk of hyponatremia. Currently, there is
limited information about this risk in real-world practice, leading to poor consensus and
inconsistent messaging in pharmaceutical reference manuals and clinical practice
guidelines.
This thesis used linked health administrative records from Ontario, Canada to
examine the association between hospitalization with hyponatremia and psychotropic
drug use within 30 days of drug initiation. Specifically, four population-based,
retrospective cohort studies were conducted with a focus on: i) antidepressants (study 1),
(ii) antipsychotics (study 2), and iii) antiepileptics (studies 3 and 4). In each study, a
group of eligible drug users was propensity score matched to non-users with similar
indicators of baseline health. Hospitalization with hyponatremia was assessed using a
hospital diagnosis code and when possible, laboratory measurements (serum sodium
concentration ≤132 mmol/L). Conditional logistic regression analysis was used to
estimate odds ratios (approximated as relative risks (RR)) and 95% confidence intervals
(CI)).
Second-generation antidepressant use was associated with a higher 30-day risk of
hospitalization with hyponatremia compared to non-use (RR 5.46 [95% CI 4.32 to 6.91]).
This association was consistent in a subpopulation with available laboratory
measurements (RR 4.23 [95% CI 2.50 to 7.19]; absolute risk increase 1.31% [95% CI
0.87% to 1.75%]).
Atypical antipsychotic use was associated with a slightly higher 30-day risk of
hospitalization with hyponatremia compared to non-use (RR 1.62 [95% CI 1.15 to 2.29]).
Antiepileptic use was associated with a higher 30-day risk of hospitalization with
hyponatremia compared to non-use (carbamazepine use, RR 8.20 [95% CI 5.40 to
12.46]); valproic acid (V), phenytoin (P), and topiramate (T) use, RR 2.62 [95% CI 1.57
to 4.36]). The association with carbamazepine use was consistent in a subpopulation with
available laboratory measurements (RR 4.50 [95% CI 1.60 to 12.64]; absolute risk
increase 1.03% [95% CI 0.14% to 1.90%]).
i

Results of this thesis can be used to increase physician awareness and inform safer
prescribing to minimize hyponatremia from psychotropic drugs in a vulnerable segment
of the population.

Keywords: hyponatremia, low serum sodium, psychotropic drugs, antidepressant drugs,
antipsychotic drugs, antiepileptic drugs.
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CHAPTER 1: Introduction
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1.1 Background and Overview
Older adults represent a rapidly growing segment of the population around the world,
including Canada. With an increase in the number of Canadians over the age of 65, the
number of prescription drugs has also risen. Between 1997 and 2006, the Ontario
population over 65 years of age increased by 18% while their prescription drug claims
increased by 214%.1 Psychotropic drugs are a category of medications that are widely
used to manage symptoms of mental and neurological disorders.2 In Canada, more than
7% of the general population is taking a psychotropic drug, with the highest use
occurring among older adults.3 According to the Canadian Community Health Survey:
Mental Health and Well-Being (CCHS 1.2), the prevalence of psychotropic drug use was
11.8% in older adults.3 Some of the most frequently prescribed classes of psychotropic
drugs in the CCHS were antidepressants, antipsychotics, and antiepileptics.
Antidepressant drugs are indicated for the treatment of mood and anxiety disorders,
with over 8% of Canadians over the age of 65 living with such a condition.4 Secondgeneration antidepressant drugs are preferred medications as they have fewer
anticholinergic and cardiovascular side effects than older antidepressant agents, such as
tricyclics.5 Among community-dwelling older adults in Ontario, the prevalence of
antidepressant drug use increased from 5.6% in 1993 to 10.9% in 2002.6 This large spike
seen over the nine-year period was largely attributable to the greater availability of
second-generation antidepressants, particularly selective serotonin reuptake inhibitors
(SSRIs). Some of the most frequently prescribed second-generation antidepressants in
Ontario include: fluoxetine, paroxetine, sertraline, citalopram, escitalopram, fluvoxamine
(SSRIs), venlafaxine, duloxetine (selective norepinephrine reuptake inhibitors; SNRIs),
and mirtazapine (noradrenergic and specific serotonergic antidepressant; NaSSA).6–8
These drugs are indicated for similar uses, of which major depression is the most
common.9 Of these second-generation antidepressants, SSRIs are the oldest and most
commonly used in routine care; however SNRIs and NaSSAs have been growing in
popularity.
Second-generation antipsychotics (more commonly referred to as atypical
antipsychotics) are indicated for use in patients with schizophrenia, bipolar and unipolar
mood disorders.10 Despite being an unapproved indication, most use occurs in patients
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with dementia.11 In 2008, an estimated 400,000 older Canadians were living with
dementia, and this number is projected to double by 2038.12 Atypical antipsychotics have
a similar efficacy profile as typical (first-generation) antipsychotics but are preferred as
they have fewer adverse effects, particularly extra-pyramidal symptoms.13 From 1993 to
2002, the prevalence of antipsychotic drug use among community-dwelling older adults
in Ontario increased from 2.2% to 3.0%, respectively, with a significant shift towards use
of atypical antipsychotic drugs (82.5% of all antipsychotics dispensed).14 In a study of
307 community-dwelling older adults with dementia, olanzapine (7.9%), risperidone
(6.7%), and quetiapine (3.3%) were the most commonly used antipsychotic drugs.15
Similarly, these three atypical antipsychotic drugs are among the most commonly
prescribed antipsychotics in Ontario.
Antiepileptic drugs are mainly used to treat epilepsy, but are also often used to treat
conditions such as pain and psychiatric disorders. The prevalence and incidence of
epilepsy are both increasing in older adults.16 According to the CCHS, over 16,000
(0.4%) older adult Canadians had epilepsy in the year 2010.17 While no studies have been
conducted in Ontario, a Manitoba study noted an increase in the prevalence of
antiepileptic use from 0.08% to 2.3% from 1999 to 2013.18 Carbamazepine, phenytoin,
and valproic acid were amongst the most commonly prescribed drugs for the treatment of
epilepsy, while carbamazepine and valproic acid were also frequently prescribed for nonepileptic conditions.18 These antiepileptics are older drugs that are still widely used in
routine care. As well, several newer antiepileptic drugs became popular over the last 15
years; one such drug is topiramate.18 These four drugs have all been indicated for initial
use as monotherapy, and do not have major differences in their ability to control
seizures.19
Even though these drugs have been deemed safe in clinical trials, adverse drug
events can still occur. An adverse drug event (ADE) is defined as, “an injury resulting
from the use of a drug.”20 Older adults are especially susceptible to ADEs due to agerelated changes in pharmacokinetics (i.e. absorption, distribution, metabolism, and
excretion) and pharmacodynamics (the physiologic effects of the drug).21 Additionally,
older adults tend to have multiple comorbidities, and are usually prescribed a greater
number of drugs, increasing the likelihood of an ADE.5,22–24 A recent report from the
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Canadian Institute for Health Information noted that close to two-thirds of older adults
are prescribed at least five drugs at a time, and more than one-quarter are prescribed 10 or
more drugs.25 Among older adults, ADEs are a common cause of hospital admission, and
a significant cause of morbidity and mortality.24 For example, adults over the age of 70
are 3.5 times more likely to be admitted to hospital due to an ADE associated with
psychotropic drug use compared to younger individuals.26 ADEs also pose a significant
financial burden on the healthcare system, with each hospitalization in Ontario costing an
average of $7,500.27 Yet, approximately 30% of all ADEs in the outpatient setting are
potentially preventable.28
Hyponatremia (a low serum sodium concentration) is a common electrolyte
disturbance encountered within various clinical settings and populations. It is also a type
of ADE that has been observed in patients taking a range of antidepressants,
antipsychotics, and antiepileptics. In general, hyponatremia is present in 1% to 15% of
hospital admissions, and is especially prevalent in older adults.29–33 It is recognized that
patients with hyponatremia may experience dramatic consequences such as confusion,
falls, fractures, seizures, and death.31,34–36 Causes of hyponatremia are multifactorial, with
complex pathophysiologies, but when it occurs with frequently prescribed drugs, their
propensity for causing hospitalization and death is of particular significance. Druginduced hyponatremia is often avoidable yet it still occurs in routine practice. As seen in
small studies and case reports, many psychotropic drugs can induce hyponatremia by
affecting water homeostasis. Currently, the evidence available regarding the risk of
hyponatremia from popular psychotropic drugs in older adults is limited. Existing studies
focus on hospitalized patients (who tend to be very ill) or are lacking in data quality
(limitations summarized in Chapter 2). Furthermore, it is of interest to determine if the
potential risk of hyponatremia is influenced by certain factors, such as chronic kidney
disease, congestive heart failure, and diuretic use as hyponatremia occurs commonly in
these settings.
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1.2 Objectives and Hypotheses
This thesis was undertaken to improve the current knowledge around the risk of
hyponatremia from common psychotropic drugs in non-hospitalized older adults in
routine care. Currently, there are more than 5.5 million Canadians over the age of 65.
With a rapidly aging population and increased use of psychotropic drugs, prevention of
ADEs such as hyponatremia is becoming crucial. Addressing the specific objectives of
this thesis will inform key stakeholders of the potential risk, which will inform strategies
to mitigate hospitalizations with hyponatremia.
The objectives of this thesis were addressed in four population-based, retrospective
cohort studies of older adults in Ontario, Canada with a focus on select i) secondgeneration antidepressant, ii) atypical antipsychotic, and iii) antiepileptic drugs
(collectively referred to as “psychotropic drugs” throughout this thesis). See Table 1-1 for
the specific drugs examined in each study. These drugs were selected based on two main
factors: evidence from pre-existing literature (i.e. case reports and observational studies)
and prevalence of use in an outpatient setting within a Canadian context.

Table 1-1. Psychotropic drugs examined in each study
Study

Psychotropic drug class

Drug names

1

Antidepressant drugs

Paroxetine, Fluoxetine, Citalopram, Escitalopram,
Fluvoxamine, Sertraline, Mirtazapine, Duloxetine, Venlafaxine

2

Antipsychotic drugs

Risperidone, Olanzapine, Quetiapine
Carbamazepine (examined alone)

3
Antiepileptic drugs
4

Valproic Acid, Phenytoin, Topiramate

6

1.2.1

Primary Objective

Within each study:
Objective 1: To estimate the 30-day risk of hospitalization with hyponatremia in new
users of a psychotropic drug compared to non-users. This will be assessed using:
i.

A hospital diagnosis code

ii.

Serum sodium laboratory measurements (only available for a subpopulation)
Hypothesis: There will be a higher 30-day risk of hospitalization with
hyponatremia in new users of a psychotropic drug compared to non-users.

1.2.2

Secondary Objectives

Within each study:
Objective 2: To determine if the association between new use of a psychotropic drug and
hospitalization with hyponatremia is modified by the following factors:
i.

Drug type (within each class)

ii.

Drug dose (higher vs. normal dose)

iii.

Chronic kidney disease (present vs. absent)

iv.

Congestive heart failure (present vs. absent)

v.

Diuretic use (use vs. non-use)
Hypotheses:
i.

The relative association between psychotropic drug use and hospitalization
with hyponatremia will not be modified by psychotropic drug typea (i.e.
the association will not differ across the drugs within the class).
a

With the exception of carbamazepine (antiepileptic drug), which will be

examined separately from the other antiepileptic drugs.
ii.

The relative association between psychotropic drug use and hospitalization
with hyponatremia will be modified by psychotropic drug dose (i.e. the
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association will be greater in patients prescribed a higher dose compared
to those prescribed a normal dose).
iii.

The relative association between psychotropic drug use and hospitalization
with hyponatremia will be modified by chronic kidney disease (i.e. the
association will be greater in patients with chronic kidney disease
compared to those without chronic kidney disease).

iv.

The relative association between psychotropic drug use and hospitalization
with hyponatremia will be modified by congestive heart failure (i.e. the
association will be greater in patients with congestive heart failure
compared to those without congestive heart failure).

v.

The relative association between psychotropic drug use and hospitalization
with hyponatremia will be modified by diuretic use (i.e. the association
will be greater in patients prescribed diuretics compared to those not
prescribed diuretics).

In studies where there are an adequate number of events:
Objective 3: To estimate the 30-day risk of hospitalization with both hyponatremia and
delirium in new users of a psychotropic drug compared to non-users.
Hypothesis: There will be a greater 30-day risk of hospitalization with both
hyponatremia and delirium in new users of a psychotropic drug compared to
non-users.
Within each study:
Objective 4: To determine the risk factors associated with hospitalization with
hyponatremia in psychotropic drug users and in non-users (to provide context).

8

1.3 Thesis Organization
An integrated manuscript style will be used to present the work of this thesis in a series of
three manuscripts. This dissertation is presented in an integrated-article format, organized
into seven chapters. Chapter 2 provides an examination of the current literature on
psychotropic drugs and hyponatremia, and presents the conceptual model. Chapter 3
presents an overview of the methodology used in this thesis. Chapters 4 to 6 contain the
articles that comprise the main results and discussion of the thesis: Chapter 4 has been
accepted for publication at the American Journal of Kidney Diseases; Chapter 5 has been
published at the Canadian Journal of Kidney Health and Disease; and Chapter 6 has been
accepted for publication at Epilepsia. Chapter 7 provides an integrated discussion of
Chapters 4 through 6. Specifically, this chapter summarizes the major findings of this
thesis and links all chapters together. Information on clinical importance, implications for
clinical practice, strengths and limitations, future directions, and conclusions are also
discussed.
Several appendices are included to supplement each of the chapters within this
thesis. Specifically, Appendix A contains supporting information corresponding to
Chapter 2; Appendix B contains supplementary information and results corresponding to
Chapter 4; Appendix C contains supplementary information and results corresponding to
Chapter 5; and Appendix D contains supplementary information and results
corresponding to Chapter 6; Appendix E contains the validation study that was completed
in preparation for this thesis; and Appendix F contains the ethics approval forms for
Chapters 4 to 6.
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2.1 Introduction
This chapter provides an overview of hyponatremia and psychotropic drugs, and
examines the current state of knowledge related to the study objectives for this research.
The following databases were used to locate articles: PubMed, Ovid MEDLINE,
EMBASE, and Google Scholar.

2.2 Hyponatremia
2.2.1 Physiology
The concentration of sodium in the blood is normally maintained within a safe range
between 135 and 145 millimoles per litre (mmol/L).1 The kidneys are responsible for
maintaining serum osmolarity by regulating total body water and sodium content. Fluid
balance is controlled by the hypothalamic production of antidiuretic hormone (ADH),
which promotes thirst and water retention by binding to vasopressin receptors on the
kidneys, aiding in the reabsorption of water and sodium ions in the distal tubule. In the
presence of non-osmotic stimuli, homeostatic conditions may be disrupted, resulting in
hyponatremia.2 Hyponatremia occurs when the sodium concentration drops below 135
mmol/L.3 It denotes an excess of total water relative to sodium content in the body.
Hyponatremia can be broadly classified as dilutional or depletional. The most
common type is dilutional (hypotonic) hyponatremia. Based on a patient’s medical
history, volume status, urine osmolality, and serum sodium concentration, hypotonic
hyponatremia can be classified into one of three categories: i) hypervolemia (increase in
total body sodium with greater increase in total body water), ii) hypovolemia (decrease in
total body water with a greater deficit in sodium), or iii) euvolemia (normal body sodium
with increase in total body water). These hyponatremic states occur in the presence of
certain comorbidities, medications, and lifestyle factors. Euvolemic hyponatremia is the
most common type, and has several etiologies, with the syndrome of inappropriate
antidiuretic hormone (SIADH) accounting for nearly 60%.4 Figure 2-1 describes the
different states of hypotonic hyponatremia and provides an overview of common
causes.4–6 Overall, the causes of hyponatremia are multifactorial, with complex
pathophysiologies.
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Hypotonic Hyponatremia
Serum sodium
≤135 mmol/L

Hypervolemic
hyponatremia
↑↑ total body water
↑ total body sodium

Hypovolemic
hyponatremia
↓ totaly body water
↓↓ total body sodium

Renal
solute loss
-diuretics
-osmotic
diuresis
-aldosterone
deficiency

Renal
failure
-acute
-chronic

Extrarenal
solute loss
-diarrhea
vomitting
-poor solute
intake

Edematous
disorders
-heart failure
-liver
cirrhosis
-nephrotic
syndrome

Euvolemic
hyponatremia
↑ total body water
Normal body sodium

Endocrinopathies
-hypothyroidism
-glucocorticoid
deficiency

SIADH*
-Drugs (psychotropic,
antineoplastic,
antidiabetic, etc)
-CNS disorders
-Psychiatric disorders
-Pulmonary
disorders
-Malignancy

Figure 2-1. Classifications of hyponatremia
Abbreviations: SIADH=syndrome of inappropriate antidiuretic hormone secretion; CNS=central nervous
system; *Only common causes of SIADH are listed

2.2.2 The Clinical Picture
Clinical manifestations of hyponatremia are primarily neurologic and correlate with
severity and rapidity of changes in serum sodium.4,7 Acute onset hyponatremia
(developing within 24 to 48 hours) tends to be more severe (serum sodium concentration
≤125 mmol/L), resulting in more dramatic outcomes compared to chronic hyponatremia.
Typical symptoms of mild acute hyponatremia include nausea, headache, and fatigue. As
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hyponatremia becomes more severe, patients may experience confusion, seizures, coma,
respiratory arrest, permanent brain damage, and even death.6 A summary of the possible
clinical manifestations of varying degrees of hyponatremia can be found in Table 2-1.
The neurologic sequelae seen with severe hyponatremia largely occur as a result of
changes in brain cell volume driven by high intracellular osmolality, which causes
swelling (cerebral edema).8 However, the brain has the unique ability to protect against or
minimize cellular swelling in chronic hyponatremia. Therefore, symptoms of
hyponatremia can vary by patient, and not all patients with low serum sodium present
with clinical symptoms or adverse sequelae. Many patients with chronic hyponatremia
are often able to adapt to changes in sodium, resulting in fewer symptoms.9
Table 2-1. Symptoms associated with varying degrees of hyponatremia4
Classification

Clinical Manifestations

Mild hyponatremia
(≤132 mmol/L)
Moderate hyponatremia
(≤128 mmol/L)
Severe hyponatremia
(≤125 mmol/L)

Headache, nausea, vomiting, fatigue, confusion, anorexia, muscle cramps,
depressed reflexes; may be asymptomatic
Malaise, unsteadiness, headache, nausea, vomiting, fatigue, confusion,
anorexia, muscle cramps, depressed reflexes; may be asymptomatic
Delirium, headache, restlessness, lethargy, seizures, brainstem herniation,
respiratory arrest, coma, death

2.3 Epidemiology of Hyponatremia in Older Adults
Hyponatremia is the most common type of electrolyte disorder encountered in clinical
practice.10 The reported incidence and prevalence of hyponatremia varies depending on
the definition used and the patient population studied. In a study by Hawkins et al., the
prevalence of hyponatremia was assessed in 120,137 patients (of all ages) in Singapore.
Between 4% and 7% of patients living in the community (i.e. those who presented to a
primary care clinic) were noted to have a serum sodium concentration <136 mmol/L.11 In
older adults, this estimate is higher, with nearly 7% to 11% of community-based older
adults and over 18% of long-term care residents with hyponatremia (serum sodium
concentrations <137, <136, <135 mmol/L).10–14 In hospitalized and critically ill patients,
hyponatremia is more prevalent and severe with a wide range of estimates cited.11,15–19
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Hyponatremia occurs more frequently in the elderly population, as they have a
higher number of comorbid conditions and use several medications known to cause
hyponatremia, and also because of age-related physiological changes that may affect
electrolyte balance. This imbalance can occur in a number of ways, including decreases
in total body water, an impaired ability to dilute urine, and diminished renal blood flow
and glomerular filtration.5,20 Older adults can lose up to 25% of their original kidney
mass simply due to the aging process.21 As well, analysis of serum sodium concentrations
in a healthy population has shown an age-related decline of approximately 1 mmol/L per
decade.22 In the study by Hawkins et al., the risk of hyponatremia increased with age
when defined by a serum sodium concentration of <136 mmol/L (age 61 to 70 years: OR
1.06 [95% CI 1.01 to 1.12]; age 71 to 80 years: OR 1.39 [95% CI 1.32 to 1.37]; and age
>81 years: OR 1.89 [95% CI 1.78 to 2.01]).11 Each of these relationships became more
pronounced with lower levels of serum sodium.
Also, it has been suggested that there are differences in sodium metabolism,
transport, and intracellular concentration that make women more susceptible to
hyponatremia.23 In a cohort study of 4123 older patients (mean age, 77 years) by Terzian
et al., women had a greater prevalence of hyponatremia than men (4.6% vs. 2.6%).24 In
addition, Movig et al. found that female sex was a significant risk factor for
hyponatremia (serum sodium concentration, ≤125 mmol/L) (OR 1.19 [95% CI 1.09 to
1.30]).25
Both symptomatic and asymptomatic hyponatremia are associated with poor patient
outcomes. Some of the most commonly cited reasons for hospital admission among older
adults with symptomatic hyponatremia include nausea/vomiting, tiredness/weakness, and
encephalopathy.26 Acute hyponatremic encephalopathy is a serious medical emergency
with a morbidity and mortality rate of 42%.3 Traditionally, mild hyponatremia was
considered asymptomatic. However, recent evidence has demonstrated that even mild
chronic hyponatremia is associated with adverse events in older adults, such as impaired
gait, attention deficits, bone loss, falls, and fractures (serum sodium concentration, <135
mmol/L).27–32 For example, a case-control study by Renneboog et al. examined the
frequency of falls in patients (mean age, 72 years) with chronic hyponatremia admitted to
an emergency department. Among these patients with hyponatremia, 21% were admitted
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with a fall compared with 5% of matched controls (adjusted odds ratio (OR) 67 [95%
confidence interval (CI) 7.5 to 607]; p <0.001).31 The authors also showed that
‘asymptomatic’ hyponatremia (mean serum sodium concentration, 128 mmol/L) was
associated with gait disturbances and attention deficits. In another case-control study by
Gankem Kenge et al., 513 older adults with bone fractures after a fall were age- and sexmatched to 513 older adults with no history of bone fractures.27 A serum sodium
concentration <135 mmol/L was present in 13% of cases vs. 4% of controls, and was
associated with a greater risk of bone fracture in cases compared to controls (adjusted OR
4.2 [95% CI 5.54 to 12.86]). Hyponatremia is also associated with significant
mortality.1,15,33,24,34–38 For example, Terzian et al. found that hyponatremia (serum sodium
concentration, <130 mmol/L) at hospital admission was a significant predictor of
mortality.24 They reported that in-hospital mortality was 16.0% among patients admitted
with hyponatremia vs. 8.0% among those admitted without this condition. In a study by
Tierney et al., patients (mean age, 61 years) with hyponatremia (serum sodium
concentration, <130 mmol/L) at hospital admission were seven times as likely to die in
hospital and twice as likely to die post-discharge compared to patients with normal serum
sodium levels.33 In a large population-based study by Chawla et al., mild hyponatremia
(serum sodium concentration, <135 mmol/L) was associated with significant mortality
compared to those with normal serum sodium levels (6.1% vs. 2.3%). A meta-analysis by
Corona et al. examined data from 81 studies and found an increased risk of overall
mortality (relative risk (RR) 2.60 [95% CI 2.31 to 2.93]) among patients with
hyponatremia.38 In many of these studies, hyponatremia was independently associated
with mortality; however an increased death rate is not always attributed to hyponatremia
itself and often occurs due to the presence of other underlying factors (discussed below).
Besides contributing to poor patient outcomes, hyponatremia also poses a
significant burden on the healthcare system. In the United States, hyponatremia is
recorded as a principal or secondary discharge diagnosis in approximately 1 million
hospitalizations every year. In addition, an estimated 105,000 to 120,000 emergency
room visits and 1.4 to 3.4 million outpatient visits for hyponatremia occur each year.39
Hyponatremia has been linked to longer lengths of hospital stay, a greater need for
hospital resources, and increased costs.34–36,39–41 For example, Wald et al. found that
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hyponatremia at hospital admission was associated with a 14% longer length of stay
compared to those without hyponatremia;36 Zilberberg et al. found that a greater number
of patients with hyponatremia were admitted to the intensive care unit compared to those
without hyponatremia (17.3% vs. 10.9%, p <0.001);35 and Boscoe et al. determined that
the annual cost of hyponatremia ranged from $1.6 billion to $3.6 billion.39 Cost estimates
were derived under a variety of scenarios (e.g. treatment setting, low vs. high prevalence,
symptomatic vs. asymptomatic hyponatremia, etc.). In a study of older adults admitted to
the emergency department, Turgutalp et al. found that morbidity, mortality, and hospital
costs increased in parallel to decreasing serum sodium levels and increasing age.26

2.3.1 Hyponatremia with Specific Conditions, Drugs, and Settings
Hyponatremia can occur in a number of different situations. As seen in Figure 2-1, there
are number of ways hyponatremia can occur. Congestive heart failure, chronic kidney
disease, and diuretic use are of particular interest to this thesis, as they are clinically
important causes of hyponatremia, and affect a large proportion of the population. Other
common factors related to hyponatremia are also discussed.
Congestive Heart Failure: Hyponatremia is a very common finding in patients with
congestive heart failure (CHF). CHF affects nearly 600,000 Canadians, with the highest
prevalence in older adults.42,43 It occurs as a result of low cardiac output and/or
pulmonary or systemic congestion.44 The low cardiac output triggers a compensatory
response by the body that activates neurohumoral systems, and particularly ADH release.
ADH increases free-water reabsorption in the renal collecting ducts, increasing blood
volume and diluting plasma sodium concentrations.45 Hyponatremia is strongly correlated
with poor patient outcomes in both inpatients and outpatients with CHF.46 In a large
study of over 47,000 patients, nearly 20% admitted to hospital with CHF were reported to
have a serum sodium concentration <135 mmol/L and was associated with a 75%
increase in 60- to 90-day mortality compared to patients with normal serum sodium
levels.47 A number of other studies noted similar estimates in patients with varying
degrees of CHF.48–50
Chronic kidney disease: Approximately 35% of older adult Canadians are living with
chronic kidney disease (CKD).51 CKD is a condition characterized by a gradual loss of
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kidney function or presence of kidney damage, and can be categorized into six stages
(stages 1, 2, 3a, 3b, 4, and 5; from least to most severe).52 As mentioned previously,
kidney function can decline substantially in older adults simply due to the aging process.
As kidney function declines, patients have a greater tendency to develop hyponatremia
due to a diminished ability to regulate water homeostasis.53 In a study examining 655,493
US veterans with non-dialysis-dependent CKD, the prevalence of hyponatremia (serum
sodium concentration, ≤135 mmol/L) was 13.5%, with nearly 26% of all patients
developing hyponatremia during the mean follow-up of 5 years.54 Patients with CKD
may also develop nephrotic syndrome (kidney disease with proteinuria,
hypoalbuminemia, and edema) which is a very rare cause of hyponatremia.4
Diuretics: Diuretics are among the most commonly prescribed medications and are used
as first-line antihypertensive treatment in the elderly.55 Hyponatremia is a well-known
complication of diuretic use, including community-acquired hyponatremia.56 All diuretics
can cause hyponatremia to some extent, however thiazide diuretics are most frequently
implicated.7 These diuretics inhibit sodium chloride reabsorption in the distal convoluted
tubule of the kidney, which leads to direct inhibition of urinary diluting capacity.57 In a
study of 2613 adult outpatients newly treated for hypertension, thiazide diuretic use was
associated with a higher risk of hyponatremia compared to use of other antihypertensive
medications (incidence rate ratio, 1.61 [95% CI, 1.15 to 2.25]).58 In the study by Liamis
et al., both thiazide diuretics and potassium-sparing diuretics were significant risk factors
for community-acquired hyponatremia (OR 1.66 [95% CI 1.18 to 2.33] and OR 3.64
[95% CI 1.94 to 6.82], respectively).10
Cirrhosis: Cirrhosis is characterized by heavy scarring of the liver, reduced blood flow
through the liver, and a reduced ability to regenerate.59 The prevalence of cirrhosis in
Canada is less than 1% but is increasing in older adults.60 Cirrhosis results in increased
primary systemic arterial vasodilation, which subsequently triggers the neurohumoral
systems and leads to hyponatremia as seen in CHF. Hyponatremia in cirrhotic patients is
also a strong predictor of poor outcomes.61,62 In a study of approximately 1000 inpatients
and outpatients with cirrhosis and ascites, the prevalence of hyponatremia was 57% and
40%, respectively (serum sodium concentration, ≤135 mmol/L).63
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Diabetes Mellitus: Nearly 50% of individuals with type II diabetes mellitus (DM) are
over the age of 65.64 DM occurs as a result of defects in insulin secretion and/or action,
and is characterized by the chronic elevation of blood glucose levels.65 A number of
pathophysiological mechanisms may lead to hyponatremia in diabetic patients. Mainly,
elevated blood glucose concentrations (hyperglycemia) can induce the movement of
water from intracellular to extracellular space, resulting in extracellular dilution of
sodium.66 Hyponatremia can also occur due to increased thirst and water intake and
increased ADH release in DM.66 In a study by Liamis et al., DM was a significant
predictor of hyponatremia (serum sodium concentration, ≤135 mmol/L) in 5179
community-based adults over the age of 55 (OR 1.98 [95% CI 1.47-2.68]).10
Cancer: Thousands of older adults are diagnosed with various types of cancer each
year.67 Hyponatremia has been observed with various malignancies, but occurs most
frequently in small-cell lung cancer.20 Hyponatremia usually occurs through SIADH,
specifically from ectopic production of ADH by the tumor tissue.68 In a prospective study
of 106 patients admitted to a cancer hospital with various types of cancer, the incidence
of hyponatremia was nearly 4% (serum sodium concentration, ≤130 mmol/L).69 Other
factors may also lead to hyponatremia, such as diarrhea and vomiting caused by cancer
therapy.
Hypothyroidism: Hypothyroidism is one of the most prevalent endocrine disorders. It is a
condition in which the thyroid gland produces insufficient thyroid hormone.70 The
proposed mechanisms by which hyponatremia occurs include alterations in renal
perfusion and a reduced glomerular filtration rate (GFR) from thyroid hormone
deficiency.71,72 Compared to other conditions, hyponatremia is less commonly found in
patients with hypothyroidism and is mostly seen in older patients when the disorder is
severe.73 As such, estimates of hyponatremia are not well-established.74 In a small study
(188 patients) by Baajafer et al., the prevalence of hyponatremia (serum sodium
concentration, <135 mmol/L) among patients diagnosed with hypothyroidism was 4%.75
Pneumonia: Pneumonia is a very common infection, with an estimated 5.6 million cases
occurring each year.76 The mechanism of hyponatremia in pneumonia is unclear, but
increased ADH secretion and resetting of the osmostat for ADH secretion have both been
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implicated. In a retrospective study of 340 patients hospitalized with community-acquired
pneumonia (mean age, 74 years), hyponatremia (serum sodium concentration, ≤135
mmol/L) was present in 28% of patients with pneumonia at hospital admission, and was
influenced by severity of pneumonia. In another large retrospective cohort study using
health administrative databases (7965 patients), hyponatremia (serum sodium
concentration, <135 mmol/L on at least 2 measurements within 24 hours of admission)
was present in 8% of patients hospitalized with pneumonia.77
Central nervous system disorders: Hyponatremia is known to occur in patients with
various CNS disorders, such as vascular injury, head trauma, lesions, infection, and
psychosis.78 CNS disorders can cause dysfunction of the hypothalamic system involved
in the normal regulation of ADH secretion, resulting in increased ADH levels.79 In the
study by Miller et al., hyponatremia occurred in 54% of nursing home patients with a
CNS disorder.14 Sherlock et al. conducted a retrospective cohort study of 1698
neurosurgical patients and found that hyponatremia (serum sodium concentration, <130
mmol/L) developed in 11% of patients, and was present in 6.3% of patients with pituitary
disorders, 20% with subarachnoid hemorrhage, and 9.6% with brain trauma.80
Antineoplastic drugs: Various anticancer drugs have been linked to the development of
hyponatremia through SIADH.7,81 Some of the common types of medications include
vinca alkaloids, platinum compounds, and alkylating agents.82–89 In a retrospective study
of adverse event reports, hyponatremia or SIADH was reported in 1.3/100,000 patients
treated with vincristine (a vinca alkaloid).90 Patients on cyclophosphamide therapy may
also develop hyponatremia due increased ingestion of fluids for the prevention of
chemical cystitis.7
Antidiabetic drugs: Antidiabetic drugs are frequently used to achieve normoglycemia
and relieve symptoms of diabetes. Medications such as chlorpropamide, tolbutamide, and
insulin have all been associated with hyponatremia.91 These drugs can cause
hyponatremia through various mechanisms, but usually it occurs through potentiation of
ADH effect on the kidneys. In a study of 176 chlorpropamide-treated patients, 11 (6.3%)
exhibited hyponatremia (serum sodium concentration, <130 mmol/L) during a mean
follow-up period of 7.4 years.92
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Pre-existing hyponatremia/low baseline sodium: Patients who have had lower serum
sodium levels (either symptomatic or asymptomatic hyponatremia) tend to be at a greater
risk of future or worsening hyponatremia. In a study by Bissram et al., pre-existing
hyponatremia upon hospital admission (mean serum sodium concentration, <134
mmol/L) was significantly associated with a subsequent hospitalization with
hyponatremia (p < 0.05).93 Of these patients, 66% had altered mental status, which
improved after treatment of the hyponatremia.
Residential Status: Compared to community-based older adults, residents of long-term
care facilities or nursing homes are more susceptible to hyponatremia.13,14 This may be
attributed to increased administration of hypotonic fluids, lower sodium diets, and tube
feeding in this patient population.14,18 Additionally, patients living in long-term care
facilities tend to have a larger number of and more severe comorbidities and take more
medications, which may predispose them to hyponatremia.
Psychotropic drugs: Several psychotropic drugs have been implicated in the
development of hyponatremia and will be described further in the following section.

2.4 Hyponatremia from Psychotropic Drugs
Medications are one of the most frequent causes of hyponatremia. Certain
antidepressants, antipsychotics, and antiepileptics (psychotropic drugs), are important
causes of hyponatremia. As with most drugs, psychotropic drug-induced hyponatremia
most commonly occurs through SIADH. Although the exact mechanism by which these
drugs can induce SIADH is not clear, it is speculated that they interfere with the normal
secretion of ADH by stimulating its release from the hypothalamus, by potentiating its
effect (or acting directly) in the distal convoluted tubules of the kidneys, or by resetting
the osmostat (threshold for ADH secretion is reset downward).94 The mechanisms of
hyponatremia for the psychotropic drugs of interest are summarized in Table 2-2.
Hyponatremia risk from these drugs is poorly characterized. This can be owing to
the fact that hyponatremia is a very complex condition to understand, particularly in
patients with mental health disorders. In these patients, hyponatremia is frequently underdiagnosed as its symptoms can often be mistaken for symptoms associated with the
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underlying illness or for common side effects of the psychotropic drugs, such as
confusion.95 Additionally, patients with psychiatric disorders can also experience
psychogenic polydipsia, a condition characterized by excessive fluid consumption.96 It is
estimated that nearly 20% of inpatients with chronic psychiatric disorders experience
polydipsia.97 Although rare, hyponatremia may result if the kidneys are unable to excrete
the excess fluid. The mechanism of hyponatremia in these patients likely occurs from a
defect in thirst regulation or from increased secretion or renal action of ADH.98 These
factors make the timely diagnosis and treatment of hyponatremia very challenging.

Table 2-2. Mechanisms of psychotropic drug-induced hyponatremia
Syndrome of Inappropriate Antidiuretic Hormone
Increased hypothalamic production
of ADH
Second-generation antidepressants
Atypical antipsychotics
Carbamazepine, Valproic acid

2.4.1

Potentiation of ADH effect

Reset Osmostat

Carbamazepine

Venlafaxine
Carbamazepine

Data from Epidemiological Studies

A review of the scientific literature for evidence of hyponatremia from select secondgeneration antidepressant, atypical antipsychotic, and antiepileptic drugs was performed.
Relevant case reports, case series, systematic reviews of case reports, cohort and casecontrol studies were included in this review. To inform the primary objective of this
thesis, methodological quality was assessed for those studies examining the risk of
hyponatremia using a modified version of the Downs and Black checklist for
nonrandomized studies, which assesses the completeness and clarity of reporting, bias,
and external validity (Appendix A Table A-1).99
2.4.1.1 Antidepressant Drugs and Hyponatremia
Two years after the introduction of the first SSRI, hyponatremia was initially reported
following fluoxetine use in 1989.100 Since then, a number of case reports and descriptive
studies have surfaced, describing the relationship between second-generation
antidepressants and hyponatremia (case reports summarized in Appendix A Table A-2).
Twelve descriptive/clinical studies of hyponatremia from second-generation
antidepressants were identified. The results of these studies and their limitations are
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summarized in Table 2-3. None of these studies included a control group, most were
based on case notes or chart reviews, and reported only crude estimates of incidence. The
incidence of hyponatremia from SSRIs was variable, ranging from less than 1% to 40%,
with most events occurring in older adults.101–113 Estimates of incidence from SNRIs
were even wider, ranging from less than 1% to 71%.107,108,111,114,115 The incidence with
mirtazapine (NaSSA) is not as well-established with an estimate of less than 0.01%.108,115
The population-based study (surveillance program of over 260,000 psychiatric inpatients)
by Letmaier et al. resulted in more modest incidence estimates (less than 1% for all drugs
considered).108 The large variability in incidence reflects the heterogeneity of the
populations studied (inpatients, outpatients, specific psychiatric populations), and the
definitions used (serum sodium <135 or <130 mmol/L). Seven of these studies were
based on inpatients,102,104,106,108,112,116,117 while three looked at a combination of in and
outpatients.103,109,114 None of these studies focused on community-based older adults.
About half of these studies defined hyponatremia using a serum sodium threshold of
<135 mmol/L,101,102,104,106,116,117 while three of the studies used a threshold of <130
mmol/L.108,114,117 Hyponatremia tended to occur within the first four weeks following
initiation of an antidepressant drug.108–110,112 In the study by Liu et al. of 736 spontaneous
reports of patients who developed hyponatremia while taking an SSRI, fluoxetine was
implicated in 75% of the cases, paroxetine in 12%, sertraline in 12% and fluvoxamine in
1%, with a majority of the cases (83%) occurring in the elderly. While this study
certainly generates potential hypotheses, it was based on voluntary reports of spontaneous
adverse events, which is subject to reporting bias (typically under-reporting).110
Five observational studies reported effect measures for the association between
hyponatremia and the second-generation antidepressants of interest. The results of these
studies, their limitations and data quality scores are summarized in Table 2-4. These
studies had variable methodological quality, with study methods’ quality scores ranging
from 12 to 17 (with higher quality studies receiving a higher score, range 0 to 21). The
mean age of patients included in these studies were all greater than 60 years of age. This
is consistent with literature in that hyponatremia commonly affects older adults. All these
studies found a significant risk of hyponatremia following use of a second-generation
antidepressant. However, the majority of these risk estimates were based on small sample
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sizes of psychiatric inpatients with the exception of the population-based study conducted
by Coupland et al., which reported the lowest risk of hyponatremia. In this populationbased retrospective cohort study of over 60,000 community-based older adults, a
significant risk of hyponatremia was observed with several SSRIs, but not with
mirtazapine or venlafaxine (grouped together) (hazard ratio (HR) 1.52 [95% CI 1.33 to
1.75]).107 Given the size of the study, differences between the individual SSRIs was
possible to elucidate. The authors found that fluoxetine, citalopram, and escitalopram
were associated with significantly higher risks of hyponatremia but interestingly,
paroxetine and sertraline were not. A possible explanation for the null findings with these
specific drugs is that patients were followed-up for an average of 5 years (SD 3.3 years),
during a time at which a risk of hyponatremia might not be present. As hyponatremia
occurs within the first few weeks of initiating a second-generation antidepressant, it is
possible that a null association with paroxetine, sertraline, and mirtazapine/venlafaxine
was observed due to the longer follow-up period. The largest risk of hyponatremia was
reported in a small case-control study (64 cases, 192 controls) by Siegler et al., who
found that fluoxetine use was associated with a 21-fold increased risk of hyponatremia in
psychiatric inpatients (95% CI 5.3 to 86.9).118 In one case-control study by Movig et al., a
risk of hyponatremia was highest in older patients (OR 6.3 [95% CI 1.0 to 41.0]) in
subgroup analysis (29 cases, 78 controls).119 However, in both of these studies, the
confidence intervals were very wide, indicating that there is a large potential for random
error. As well, the Seigler study was based only on a single center and a single SSRI; the
Movig study combined inpatients and outpatients who tend to be different from each
other. Four of these five studies did not consider other commonly used second-generation
antidepressants including duloxetine, citalopram, escitalopram, and mirtazapine, which
makes it challenging to generalize the results across other commonly used secondgeneration antidepressants.111,118–120 The large disparities observed across these measures
of effect can be attributed to the differences in the populations studied, the types of study
designs, the definitions of hyponatremia, and sample sizes.
There is inconclusive evidence regarding potential differences between individual
second-generation antidepressants in their propensity for causing hyponatremia, and for
the relationship between second-generation antidepressant dose and hyponatremia. This
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is owing to the small sample sizes in most of these studies, which precludes meaningful
stratified analysis. The drug-specific findings in the study by Coupland et al. are novel,
and need to be replicated in other settings to confirm the findings. One small study of 14
inpatients with dementia found that citalopram dose was significantly correlated with
lower serum sodium levels.121 However, in the review of spontaneously reported cases of
SSRI-induced hyponatremia by Liu et al., no dose-response relationship was apparent.110
Concomitant diuretic use is a well-established risk factor for hyponatremia in patients
taking second-generation antidepressants. Using data from a multidrug surveillance
program, Letmaier et al. found that hyponatremia occurred more frequently when an
SSRI was used in combination with a diuretic compared to when the SSRI was used
alone (0.14% vs. 0.02%, p <0.001); a similar result was observed with venlafaxine (0%
vs. 0.51%, p <0.001).108 Kirby et al. investigated concomitant diuretic use as an effect
measure modifier in their assessment of SSRI and venlafaxine use and hyponatremia in
psychiatric inpatients. The association was significantly modified by concomitant
thiazide diuretic use (diuretic use: OR 11.2 [95% CI 2.2 to 58.1] vs. diuretic non-use: OR
2.5 [95% CI 1.1 to 5.4]).111 A similar finding was observed in the study of psychiatric
patients by Movig et al. (concomitant diuretic use: OR 13.5 [95% CI 1.8 to 101]).119
Studies to date have not investigated whether antidepressant drug-induced hyponatremia
is influenced by the presence of kidney disease and heart failure, which are two clinically
important groups of patients.
In these studies, several important risk factors for hyponatremia among older adults
taking second-generation antidepressants were identified. In the prospective study of
older psychiatric inpatients taking SSRIs and venlafaxine, Kirby et al., found that renal
disease, cancer, a group of ‘other’ comorbidities which included diabetes,
hypoaldosteronism, and hypothyroidism, and severity of medical illness were all
significantly associated with hyponatremia.111 Siegler et al. found the following risk
factors to be significantly associated with hyponatremia: female sex, systolic blood
pressure, elevated serum creatinine levels, abnormal serum potassium levels, diabetes
mellitus, hypertension, chronic obstructive pulmonary disease, diuretics, tricyclic
antidepressants, and calcium channel blockers.118 Movig et al. found that loop diuretics,
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thiazide diuretics, peptic ulcer drugs, proton pump inhibitors, heart failure, and
hypothyroidism were significant risk factors for hospitalization for hyponatremia.120
In summary, most of the observed associations were based on case reports and
descriptive studies that lack control groups, providing only a crude estimate of incidence
of hyponatremia. The risk of hyponatremia from second-generation antidepressant drug
use was quite variable (HR of 1.52; ORs of 3.5 to 21.4). Only the study by Coupland et
al. was of good quality,107 while the remaining studies were of moderate quality.113,118–120
Most of these estimates were based on inpatients or combined in- and outpatients in their
analyses. Inpatients are fundamentally different from the outpatient population, as they
tend to be older and sicker, which means the results are not necessarily generalizable to
populations living the community or long-term care facilities. Due to the small sample
sizes in four of these studies, adequate control for confounding was not possible. There
are a number of demographic factors, concomitant drugs, comorbidities, and healthcare
system use factors that were not or could not be accounted for. In many of these studies,
follow-up time was variable or not indicated, and often included periods where the risk of
hyponatremia was negligible. Lastly, all the studies were conducted outside of Canada,
where prescribing practices differ from other parts of the world. Given the limitations of
the current literature, there is a need to conduct further studies that address the limitations
of previous research.

28

Table 2-3. Descriptive and clinical studies of hyponatremia from second-generation antidepressant drugs
Study/
Country
Letmaier et
al.
(2012)108

Study
Type

Outcome
definition

Retrospective

Serum
sodium
<130
mmol/L

Prospective

Serum
sodium
<130
mmol/L

Prospective
(longitudinal study)

Serum
sodium
<135
mmol/L

Sample Size/
Population
Studied
263 864
psychiatric
inpatients

Germany,
Austria,
Switzerland
Roxanas et
al.
(2007)114

58 outpatients
and inpatients
>65 years of
age

Relevant drugs
studied

Time to
Hyponatremia

Citalopram
Escitalopram
Paroxetine
Sertraline
Duloxetine
Venlafaxine
Mirtazapine

-Not reported

Venlafaxine

-Median time
to onset: 4
days (range 3
to 5 days)

Paroxetine

-Mean time to
onset: 9.3
days

Results

Significant
Risk Factors

Limitations

-Incidences:
0.078% Citalopram
0.085%
Escitalopram
0.033% Paroxetine
0.053% Sertraline
0.106% Duloxetine
0.077% Venlafaxine
0.004% Mirtazapine
-10 pts developed
HN (17.2%) within 3
to 5 days

-Not assessed

-Reporting bias
(Under-reporting
likely)
-No control group

-Not assessed

-No control group
-Small N

-9/75 pts developed
HN (12%)

-Low BMI OR
0.74 (95% CI
0.56 to 0.99), p
<0.04

-No control
-Small N

Australia
Fabian et
al.
(2004)101
United
States of
America

Mean age: 76 y
75 outpatients
(63-90 years
old) diagnosed
with major
depressive
episode
Mean age: 75 y

Wee and
Lim
(2004)106

Retrospective
(chart
view)

Serum
sodium
<135
mmol/L

116 inpatients

Prospective
(pilot
study)

Serum
Sodium
<135
mmol/L

15 inpatients
who were
diagnosed with
major

Mean age: 79 y

SSRIs (did not
specify
individual drugs)

-Not reported

Paroxetine

-HN developed
after 2 weeks
of treatment

Australia

Fabian et
al.
(2003)116

-7/40 pts who
started on an SSRI
developed HN
(17.5%)
-16/63 pts who are
already on an SSRI
developed HN
(25.4%)
-6/15 pts developed
HN (40%)

-Low baseline
sodium OR 0.40
(95% CI 0.22 to
0.73), p <0.003
-Diuretic use
p<0.025

-Not assessed

-No control group
-Small N
-Single center

-No control group
-Very small N
(pilot)
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United
States of
America
Jung et al.
(2011)115

depression

Retrospective

Korea

Wilkinson
et al.
(1999)109

United
States of
America
Critchlow
(1998)117
Ireland

Strachan
and
Shephard
(1998)112
Australia

Mean age: 76 y
249 inpatients
with depression
Mean age: 51 y

‘Definite’ or
‘probable’
hyponatre
mia using
likelihood
criteria

845 inpatient
and outpatient
elderly pts >65
years old

Retrospective
(chart
review)

Serum
sodium
<135
mmol/L

32 psychiatric
inpatients

Retrospective
(chart
review)

Serum
sodium
<135
mmol/L
and <130
mmol/L

1010 psychiatric
inpatients >65
years old on
various
medications

Retrospective

New
Zealand

Bouman et
al.
(1998)102

Serum
sodium
<135
mmol/L

Retrospective
(chart
review)

Serum
Sodium
<134
mmol/L

Paroxetine
Sertraline
Escitalopram
Fluoxetine
Venlafaxine
Mirtazapine

-Not reported

Paroxetine
Fluoxetine

-Median time
to onset: 13
days (range 3
to 120 days)

SSRI

-Not reported

Not specified

Paroxetine
Fluoxetine

-11/240 pts
developed HN

-Not assessed

-No control group
-Small N

-14 HN cases
-Matched with 56
controls (no HN)
-All taking
paroxetine or
fluoxetine
-Incidence: 0.47%
people treated/year
-8/32 patients (25%)
developed HN

-Low body
weight OR 0.92
(95% CI 0.86 to
0.99), p<0.04

-No control group
-Single center

-Not assessed

-No control group
-Small N

-Not reported

-11/51 (22%)
developed HN while
taking SSRIs

-Not assessed

-All psychiatric
inpatients
-No control group
-Pts on several
medications which
may also cause
HN

-Not reported

-13 pts developed
HN (24.5%)

-Not assessed

-Incomplete data
-Small N
-No control group
-Single center

SSRIs: 8/93 (8.6%)
Venlafaxine: 3/71
(4.2%)
Mirtazapine: 0

Mean age: not
specified

Mean age: 79 y

Mean age: not
specified
53 inpatients
Mean age: 74 y
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Liu et al
(1996)110
Unspecified
location

Pillans et
al.
(1994)103
New
Zealand

Retrospective
(case
review)

Retrospective
(case
review)

Terms
"waterelectrolyte
imbalance"
, "HN", and
"inappropriate ADH
syndrome"

A review of 736
reports of HN

Not
specified

376 in and
outpatients >65
years old

Mean age: not
specified

Fluoxetine
Paroxetine
Sertraline
Fluvoxamine

-Median time
to onset: 13
days (range 3
to 120 days)

Of 736 cases,

Fluoxetine

-Not reported

-7 women
developed HN
-Incidence rate of
fluoxetineassociated reports
of HN was 5.4 for
1000 patients
(0.54%)

-Not assessed

-All case reports
of SSRIs
-No control group
-Reporting bias
(voluntary
reporting, true
incidence
underestimated)
-Quality of reports
can vary greatly
-Incidence cannot
be determined

-Not assessed

-No control group
-Reporting bias
(voluntary
reporting, true
incidence
underestimated)
-All documented
cases were
female

75.3% Fluoxetine
12.4% paroxetine
11.7% sertraline
1.5% fluvoxamine

-Most (83%) of
the published
cases involved
pts 65 years of
age or more

Mean age: not
specified (>65 y)

Abbreviations: y=year; SIADH=syndrome of inappropriate antidiuretic hormone secretion; OR=odds ratio; CI=confidence interval; BMI=body mass index;
SSRI=selective serotonin reuptake inhibitor; pt=patient; HN=hyponatremia
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Table 2-4. Studies reporting a measure of association for the risk of hyponatremia from second-generation antidepressant drugs
Study/
Country
Coupland
et al.
(2011)107
United
Kingdom

Kirby et al.
(2002)111

Design
Retrospective
Cohort
(population
-based)

Retrospective
Cohort

Australia

Outcome
definition
Read
Codes
(diagnoses
made in
primary
and
secondary
care)

Serum
sodium
<135
mmol/L

Sample Size/
Population
Studied
60 746
outpatients (≥65
y) diagnosed as
having a new
episode of
depression

Relevant
drugs
studied
Citalopram
Escitalopram
Fluoxetine
Paroxetine
Sertraline
Mirtazapine
Venlafaxine

Follow-up
window
-Not predefined
-Mean
follow up of
5 years

Incidence:

-Not
reported

-29/74 exposed
pts developed
HN (39%)
-13/125
unexposed pts
developed HN
(10%)

Mean age: 75 y

199 psychiatric
inpatients
Mean age: 74 y

Fluoxetine
Sertraline
Paroxetine
Fluvoxamine
Venlafaxine

Results

Significant Risk
Factors

Quality
Score

-Not assessed

-Residual
confounding
-Confounding by
indication
-Average 5-year
follow-up
-Read codes
used
(performance
characteristics
unknown)

17

-Renal diease
p=0.005
-Cancer p=0.01
-Other (diabetes,
hypoaldosteronism, hypothyroidism, and
severity of
medical illness)
p=0.02

-Small sample
size
-All psychiatric
inpatients
-Single center

13

-Abnormal
potassium level
(>5.0 mmol/l) OR

-Small sample
size
-Did not

16

-SSRIs:
Adjusted HR
1.52
(95% CI 1.31.75)
-SNRI/NaSSA:
Adjusted HR
1.28 (0.98-1.67)

Fluoxetine: 3/5
(60%)
Sertraline: 8/28
(29%)
Fluvoxamine: 0
Venlafaxine:
10/14 pts (71%)

Limitations

-Adjusted OR
3.5
(95% CI 1.4-8.9)

Movig et
al.
(2002)119

Matched
Casecontrol

Serum
sodium
≤130

107 psychiatric
in- and outpatients

SSRIs
(did not
specify

-Not
reported

-General
population:
Adjusted OR 3.9
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mmol/L
The
Netherlands

(29 cases,
hyponatremia;
78 controls, no
hyponatremia)
(all ages)

individual
drugs)

(95% CI 1.213.1)
-Over 65 y:
Adjusted OR 6.3
(95% CI 1.041.0)

24 (95% CI 2.0283)
-Older age (>65
years) OR 6.3
(95% CI 1.0-41)

Mean age: 68 y

Movig et
al.
(2002)120

Matched
Casecontrol

The
Netherlands

Siegler et
al.
(1995)118
USA

Casecontrol

Primary or
secondary
diagnosis
of hyponatremia
(ICD-10
code
276.1) or
SIADH
(ICD-10
code
253.6)

811 outpatients
(203 cases,
hyponatremia;
608 controls, no
hyponatremia)
(all ages)

Serum
sodium
≤130
mmol/L

256 psychiatric
inpatients (64
cases,
hyponatremia;
192 controls, no
hyponatremia)

Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Venlafaxine

-Median
time to
onset: 10
days
(range 1 to
108 days)

-Adjusted OR
3.96
(95% CI 1.3311.83)

-Thiazide diuretics
use OR 3.21 (95%
CI 1.68-6.15)
-Heart failure OR
3.28 (95% CI
1.68-6.41)
-Hypo-thyroidism
OR 18.29 (95% CI
1.96-171)

Fluoxetine

-Not
reported

-Adjusted OR
21.4 (95% CI
5.3-86.9)

-Female sex OR
4.0 (95% CI 1.213.3)
-Systolic blood
pressure OR 1.02
(95% CI 1.0-1.04)
-Elevated serum
creatinine levels
OR 2.1 (95% CI
1.3-3.6)

Mean age: 71 y

Mean age: 62 y

consider milder
levels of
hyponatremia
-In-patients may
differ from
outpatients
-Two centers
-Not exclusively
elderly
population (19
cases, 30
controls ≥65
years); very
wide CI in age
≥65
-Could not
determine
incidence
-Small sample
size
-Diagnostic
codes used
(limited
sensitivity)
-Unknown risk in
elderly
population
-Could not
determine
incidence
-Small sample
size
-Single center
-All psychiatric
inpatients
-Single drug
studied

15

12
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-Abnormal serum
potassium levels
OR 19.1 (95% CI
4.2-87.7)
-Diabetes mellitus
OR 4.4 (95% CI
1.1-18.4)
-Hyper-tension
OR 5.7 (95% CI
2.1-15.2)
-Chronic
obstructive
pulmonary
disease OR 90.6
(95% CI 5.6-1453)
-Diuretics OR 8.2
(95% CI 2.2-30.8)
-Tricyclic antidepressants OR
4.9 (95% CI 1.615.2)
-Calcium channel
blockers OR 4.0
(95% CI 1.1-14.2)

Abbreviations: y=year; ICD-10=International Classification of Diseases, 10th revision; SIADH=syndrome of inappropriate antidiuretic hormone secretion;
OR=odds ratio; HR=hazard ratio; CI=confidence interval; SSRI=selective serotonin reuptake inhibitor; SNRI=selective norepinephrine reuptake inhibitor;
pt=patient; HN=hyponatremia
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2.4.1.2 Antipsychotic Drugs and Hyponatremia
Hyponatremia from atypical antipsychotic drugs is far less understood compared to
antidepressant drugs. Hyponatremia occurs in about 4% of patients with schizophrenia
and to a lesser extent with other conditions.95 Older antipsychotic agents such as
haloperidol and phenothiazines have been implicated in the development of
hyponatremia, but similar information for atypical antipsychotics is lacking.122,123 Most
observations of hyponatremia from atypical antipsychotic drugs are limited to case
reports (summarized in Appendix A Table A-1).
The incidence of hyponatremia from atypical antipsychotics is not well-established,
with only the one drug surveillance study by Letmaier et al. reporting an incidence of less
than 0.01% for risperidone.108 A systematic review conducted by Meulendijks et al.
identified 120 cases of hyponatremia from 1978 to 2008 from any type of antipsychotic
drugs.95 The authors reported that hyponatremia developed at a median of 19 days after
commencing treatment. Even though this number is based on combined information from
both typical and atypical antipsychotics, a risk window of three to four weeks for atypical
antipsychotics is biologically plausible. The results and limitations of these two studies
are summarized in Table 2-5.
To date, only one case-control study has evaluated the association between atypical
antipsychotic use and hyponatremia, which was of moderate quality (quality score of 14).
The results and limitations of this study are summarized in Table 2-6. The reporting of
hyponatremia was significantly associated with the use of atypical antipsychotics
compared to use of other drugs (adjusted reporting odds ratio (ROR) 1.58 [95% CI 1.46
to 1.70]).124 In subgroup analysis, risperidone and olanzapine were both significantly
associated with hyponatremia, but quetiapine was not. This study was based on
spontaneous reports available from a World Health Organization (WHO) database of
adverse drug reactions, which is subject to under-reporting and misclassification, leading
to biased estimates of association.125 In this study, estimates were adjusted only for age,
sex, and concomitant medication use, which means residual confounding may be present.
As well, there is potential for confounding by indication, as hyponatremia may have
occurred due to the psychogenic polydipsia. In addition, follow-up time for the
development of hyponatremia was not clear. Nonetheless, these findings do highlight a
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potential signal of hyponatremia following atypical antipsychotic drug treatment, which
needs to be replicated in additional studies.
The systematic review by Meulendijks et al. was also based on spontaneous
reports, and only examined the effect of dose on the development of hyponatremia. A
non-significant negative correlation between the defined daily dose and serum sodium
levels was observed for atypical antipsychotics (r = -0.16).95 However, the authors
concluded that further investigations are warranted to confirm this finding. Whether the
risk of hyponatremia is higher in patients with kidney disease, heart failure or in those
taking diuretics is currently unknown, but is worth investigating from a clinical
standpoint. As well, there are no studies that have looked at the risk factors of
hyponatremia among patients taking atypical antipsychotics.
In summary, there is insufficient evidence in the literature demonstrating a risk of
hyponatremia from atypical antipsychotic use. The majority of the evidence comes from
single case reports or case series. The studies that do exist also stem from case reports,
which are severely impacted by reporting bias and potential misclassification. In addition,
the individuals that these studies are based on may not necessarily be representative of
individuals in non-hospitalized settings. Only one study of spontaneous case reports has
been conducted to date, and highlights a potential signal. This warrants further
exploration through carefully designed epidemiological studies, better control for
confounding, with a pre-defined follow-up window.
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Table 2-5. Descriptive and clinical studies of hyponatremia from atypical antipsychotic drugs
Study /
Country
Letmaier et
al. (2012)108
Germany,
Austria,
Switzerland
Meulendijks
et al.
(2010)95
English,
Dutch,
German,
French and
Spanish
articles

Design
Retrospective

Outcome
definition
Serum sodium
<130 mmol/L

Sample Size/
Population
Studied
263 864
psychiatric
inpatients

Relevant
drugs studied

Time to
Hyponatremia

Risperidone

-Not reported

-Incidence:
0.004%

-Not assessed

-Reporting bias
(under-reporting
likely)
-No control
group

Antipsychotics
(typical and
atypical)

-Median time
to onset: 19
days

-23/123 – probable
-99/123 – possible
-1/123 – unlikely
-atypical
antipsychotics:
48/123 reports

-Not assessed

-Based primarily
on case reports
-Could not
estimate risks
-Reporting bias
-Publication
bias

Results

Significant Risk
Factors

Mean age: 49 y
Retrospective
(Systematic
Review)

‘hyponatremia’,
‘inappropriate
ADH
syndrome’,
‘sodium blood
level’, ‘sodium
deficiency’,
‘sodium
depletion’,
‘waterelectrolyte
balance’, and
‘polydipsia’

123 reports of
hyponatremia
Mean age: 46 y

Abbreviations: y=year; ADH=antidiuretic hormone

Limitations
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Table 2-6. Studies reporting a measure of association for the risk of hyponatremia from atypical antipsychotic drugs
Study /
Country

Design

Mannesse
et al.
(2010)124

Matched
Casecontrol

90
countries
(WHO
Vigibase
database
of adverse
drug
reactions)

Outcome
definition
WHO
preferred term
Hyponatremia
/ SIADH (as
documented in
case reports)

Sample Size/
Population
Studied
145 253 case
reports (15 728
cases,
hyponatremia;
129 252
controls, other
adverse events)
Mean age: 59 y
(cases 67 y;
controls 52 y)

Relevant
drugs
studied
Risperidone
Olanzapine
(other
atypical and
typical antipsychotics)

Follow-up
window
-Not
reported

Results
-ROR 1.58
(95% CI 1.461.70)
-Risperidone:
ROR 1.52 (95%
CI 1.3-1.77)
-Olanzapine: ROR
1.45 (95% CI
1.23-1.71)
-Quetiapine: ROR
1.34
(95% CI 0.941.91)

Significant
Risk Factors
-Not assessed

Limitations

Quality
Score

-Reporting bias
(spontaneous
reports)
-Selection bias

Abbreviations: y=year; WHO=World Health Organization; SIADH=syndrome of inappropriate antidiuretic hormone secretion; ROR=reporting odds ratio;
CI=confidence interval
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2.4.1.3 Antiepileptic Drugs and Hyponatremia
The literature describing hyponatremia from antiepileptics varies by drug.
Carbamazepine was the first antiepileptic drug to be implicated in the development
hyponatremia in 1966.126 Since then, a number of cases reports describing hyponatremia
with carbamazepine have been conducted (summarized in Appendix A Table A-1).
Fourteen descriptive/clinical studies and one randomized controlled trial describing
the relationship between carbamazepine and hyponatremia were identified. The results of
these studies and their limitations are summarized in Table 2-7. Hyponatremia was
observed in patients of all ages (mean ages ranging from 30 to 72 years of age). Eight of
these studies did not use a control group in their assessments.108,127–133 In three controlled
studies, patients exposed to carbamazepine had a significantly greater frequency of
hyponatremia than those who were no exposed.134–136 The incidence of carbamazepineinduced hyponatremia ranged widely from less than 1% to 42%.128–130,132–135,137–139
Similar to antidepressants, the broad range of incidences observed reflect the patient
populations studied and the range of definitions used for hyponatremia. Eleven of these
studies defined hyponatremia using a serum sodium threshold of <135 mmol/L127–
129,131,133,134,136–140

while the remaining studies used stricter definitions of hyponatremia

(<132 mmol/L and <130 mmol/L)108,132,135 or did not specify a definition.130 Most of
these estimates were based on small studies of unique populations, primarily inpatients
with intellectual disabilities or affective disorders making them underpowered to detect
significant changes in serum sodium. Except for the surveillance program study by
Letmaier et al., all sample sizes were small (<700 patients). In one of the larger studies,
Kalff et al. studied 674 in- and outpatients with epilepsy and found that hyponatremia
developed in 1.8% of patients taking carbamazepine alone and in 5.7% of patients taking
carbamazepine with other antiepileptics (mostly valproic acid and barbiturates).140 No
hyponatremia developed in those who were taking antiepileptics other than
carbamazepine (control group). However, no statistical tests were used in this study to
compare the three groups. Both acute and chronic hyponatremia have been associated
with carbamazepine use, and occurred up to three months following treatment.131,140,141
Despite being a well-understood problem, no studies characterized the risk of
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hyponatremia from carbamazepine. It would be of clinical significance to quantify this
risk for neurologists and other physicians.
In a cross-sectional study by Dong et al., 451 patients taking carbamazepine were
evaluated, and age and dose were significant risk factors for the development of
hyponatremia, but not sex.127 In the study by O’Hare et al., age was also significantly
associated with development of hyponatremia (p = 0.01). In a self-controlled study by
Udhe et al., hyponatremia correlated with a high daily dose of carbamazepine (r = 0.62, p
<0.05).138 Some additional studies support this dose correlation,133,134,137 while others do
not.132,139 Additionally, Udhe et al. found that patients with lower baseline serum sodium
levels had the greatest decrements in serum sodium following carbamazepine use (r =
0.69, p <0.02).138 Hyponatremic effects are greater in patients who simultaneously use
diuretics and other drugs known to cause hyponatremia.142,143 It is not clear from the
literature if patients taking carbamazepine who have kidney disease or congestive heart
failure are at greater risk of developing hyponatremia than those without such conditions.
There is less information in the literature about hyponatremia associated with
valproic acid (case reports summarized in Appendix A Table A-1). Only one case-control
study examining the association between valproic acid and hyponatremia was found,
which was of moderate quality (quality score of 15). Results and limitations of this study
are summarized in Table 2-8. In this study, spontaneous reports of all types of adverse
drug reactions made to the WHO were evaluated (22 606 reports in total). Of these, four
females (>57 years of age) developed hyponatremia following the initiation of valproic.
A modest increased risk of hyponatremia from valproic acid was found (adjusted ROR
1.83 [95% CI 1.61 to 2.08]).144 The cases used in this assessment were considered
‘strongly’ suggestive of a causal relationship with hyponatremia. The time to develop
hyponatremia from valproic acid remains unclear due the limited available evidence. It is
possible that a dose effect exists, although this needs to be confirmed in other studies.144–
146

The relationship between hyponatremia and topiramate or phenytoin is not clear. In
the product information sheet for topiramate, hyponatremia is described as a rare adverse
event.147 However, topiramate is a newer antiepileptic, and limited experience with this
drug may explain why no case reports or studies were found in the literature. As for
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phenytoin, there is conflicting information about its effect on hyponatremia. Some studies
demonstrated a reversal of hyponatremia by phenytoin. In a few cases, phenytoin was
successfully used in patients taking carbamazepine or with SIADH to reverse antidiuretic
effects.148–150 However, this finding was not consistent in a prospective study that
examined the role of phenytoin in patients with SIADH.151 This may be because the
“reversal” of hyponatremia by phenytoin was actually caused by a reduction in serum
carbamazepine levels during combined therapy.152
In summary, the majority of the evidence describing hyponatremia from
carbamazepine is based on small clinical studies in select groups of patients of a variety
of ages, with only one study focusing on patients over the age of 65. It is apparent from
these studies that carbamazepine leads to a decrease in serum sodium levels. However, it
is not clear whether these results are generalizable non-hospitalized older adults, who are
healthier than the unique populations examined in these studies. Only one study reported
the time to onset of hyponatremia of one to three months, which makes it challenging to
understand the risk window associated with this drug. Furthermore, the risk of
hyponatremia following carbamazepine in non-hospitalized older adults has yet to be
quantified. Evidence for valproic acid and hyponatremia is based mostly on case reports.
One study characterized a reporting odds ratio of hyponatremia from valproic acid, but
this was based on spontaneous cases, which is hampered by limitations such as reporting
bias. Furthermore, adequate control for confounding was not possible. The available
evidence regarding potential association with hyponatremia and phenytoin and
topiramate is limited and conflicting. Population-based epidemiological studies with a
well-defined control group, adequate control for confounding, and pre-defined follow-up
are needed to better understand the potential risk of hyponatremia with these drugs in a
Canadian context.
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Table 2-7. Descriptive and clinical studies of hyponatremia from carbamazepine (antiepileptic drug)
Study /
Country
Letmaier et
al. (2012)108

Design
Retrospective

Germany,
Austria,
Switzerland

Rowan et al.
(2005)135
United
States of
America

Dong et al.
(2005)127

Ireland

Serum
sodium
<130
mmol/L

Sample Size /
Population
Studied
263 864
psychiatric
inpatients

Relevant drugs
studied

Time to
Hyponatremia

Results

Significant
Risk Factors

Carbamazepine

-Not reported

-Incidence: 0.103%

-Not assessed

Carbamazepine

-Not reported

-19/171 pts
(remaining in study)
developed HN
(11.1%)

-Not assessed

Carbamazepine

-Not reported

-Prevalence of HN
was 13.5%

-Advanced
age p<0.0001
-Dose
P<0.0001

-Small N
-No control group
(no measure of
association)
-Patients of all ages
-Exposure time
unknown
-Could not estimate
incidence

Carbamazepine

-Not reported

-Exposed: 22/53
(41.5%) developed
HN
-Control: 6/64
(9.4%) developed

-Not assessed

-Small N
-All patients with
intellectual disability

Mean age: 49 y

Randomized,
Doubleblind,
Double
Dummy,
Parallel
Study
(efficacy
study)

Serum
sodium
<130
mmol/L

Crosssectional
Study

Serum
sodium
<135
mmol/L

Retrospective
(chart
review)

Serum
sodium
<135
mmol/L

United
States of
America

Kelly and
Hillery
(2001)134

Outcome
definition

-18 Veterans
Affairs Medical
Centers
-593 elderly pts
with newly
diagnosed
seizures
-197 pts on
carbamazepine
-395 pts on other
AEDs
Mean age: 72 y
-Patients were
≥15 years old
from MINCEP
Epilepsy Care
patient database
-451
carbamazepine
treated pts
Mean age: 38 y
-117 individuals
from a
residential center
with an
intellectual

Limitations
-Reporting bias
(Under-reporting
likely)
-No control group
(no measure of
association)
-No adjustment for
confounders
-Study population
was predominantly
men
-Efficacy study (did
not examine risk of
hyponatremia)
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disability

Critchlow
(1998)117
Ireland

Retrospective
(chart
review)

Serum
sodium
<135
mmol/L

Mean age: 42 y
1010 psychiatric
inpatients >65
years old on
various
medications

HN

Carbamazepine

-Not reported

-1/51 (2%)
developed HN while
taking
carbamazepine

-Not assessed

-All psychiatric
inpatients
-No control group
(no measure of
association)
-Patients on several
medications which
may also cause HN

Carbamazepine

-Not reported

-Prevalence 32/60
(48%)

-Not assessed

-Small N
-No control group
(no measure of
association)

Carbamazepine

-Not reported

-4/33 developed HN
(12%)

-Not assessed

-Small N
-No control group
(no measure of
association)
-Study of overdose

Carbamazepine

-Not reported

-2/40 developed HN
(5%)
-Statistical, but not
clinically significant
decrease in sodium
levels

-Not assessed

-All mentally
retarded patients
-Small N

Mean age: not
specified
AbdulHussain and
White
(1996)129

Retrospective
(chart
review)

Serum
sodium
<135
mmol/L

United
Kingdom

Seymour
(1993)130

Retrospective

Not
specified

Prospective

Serum
sodium
<135
mmol/L

Australia

Kastner et
al. (1992)136
Unspecified
location

-67 pts from
learning
disability
hospitals; 146
serum assays
examined
(uncontrolled)
Mean age: not
specified
-Retrospective
review of
pharmacology
records at 2
teaching
hospitals where
33 cases of
carbamazepine
overdose (≥100
umol/L) were
identified
Mean age: 30 y
- Mentally
retarded pts
-Exposed: 40 pts
on
carbamazepine
-Control: 40 age,
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sex-matched pts,
other AEDs

Yassa et al.
(1988)131

Prospective

Serum
sodium
<135
mmol/L

Prospective

Serum
sodium
<135
mmol/L

Canada

Lahr
(1985)139
United
States of
America

Kalff et al.
(1984)140
Netherlands

Retrospective

Serum
sodium
<135
mmol/L

Mean age: not
specified
-20 pts with
bipolar and
unipolar
disorders
following
carbamazepine
treatment
Mean age: 61 y
-Mentally
retarded pts
-Group 1: 60 pts
on
carbamazepine
-Group 2: agematched
controls, 31 pts
on other AEDs
-Group 3: agematched controls
with no history of
epilepsy
Mean age: not
specified
-674 in and outpatient epileptics
-Group 1: 113 on
carbamazepine
monotherapy
-Group 2: 460 on
carbamazepine
and other AEDs
-Group 3:
Control, on other
AEDs (no

Carbamazepine

-Within 1 to 3
months

-5/20 developed HN
(25%) within 1-3
months

-Not assessed

-Small N
-No control group
(no measure of
association)

Carbamazepine

-Not reported

-13/60 pts
developed HN
(21.7%)

-Increased age
p = 0.005
-CBZ level
>6 ug/ml,
p<0.001

-Small N
-Single center

Carbamazepine

-Not reported

-Group 1: 2/113
developed HN
(1.8%)
-Group 2: 26/460
developed HN
(5.7%)
-Group 3: 0
developed HN

-Not assessed

-Two centers only
-No characterization
of significance
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carbamazepine)

Uhde and
Post
(1983)138

Prospective

Serum
sodium
<135
mmol/L

United
States of
America

O’Hare et al.
(1980)132

Prospective

Serum
sodium
<132
mmol/L

Prospective

Serum
sodium
<135
mmol/L

Ireland

Perucca
(1978)137
United
Kingdom

Henry et al.
(1977)133
United

Prospective

Serum
sodium
<135
mmol/L

Mean age: not
specified
-Mentally ill pts
on placebo first,
followed by
carbamazepine
for bipolar,
schizoaffective,
unipolar
disorders
-ages: 22 to 66
Mean age: not
specified
-55 pts on
carbamazepine
for epilepsy (52)
and trigeminal
neuralgia (2)
(uncontrolled)
Mean age: 28 y
-Epileptic pts
-Exposed: 80 pts
on
carbamazepine
or
carbamazepine
combination
-Control: 50
patients on other
AEDs
Mean age: 33
yrs
-16 pts on
carbamazepine
for epilepsy (14)
and trigeminal

Carbamazepine

-Not reported

-4/12 pts developed
HN (33.3%) with
carbamazepine use
-No pts developed
HN when on
placebo
-Low baseline levels
resulted in greater
sodium decrements
(r = 0.69, p < 0.02)

-Not assessed

-Small N
-Single center

Carbamazepine

-Not reported

-7/55 developed HN
(12.7%)
-range 117-132
mmol/L

-Age (p=0.01)

-Small N
-No control group

Carbamazepine
or
carbamazepine
combination

-Not reported

-5/80 developed HN
(6.3%)

-Not assessed

-Small N

Carbamazepine

-Not reported

-5/16 developed HN
(31.3%)

-Not assessed

-Small N
-No control group
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Kingdom

neuralgia (2)
Mean age: 37 y

Abbreviations: y=year; CI=confidence interval; pt=patient; HN=hyponatremia; AED=antiepileptic drug

Table 2-8. Studies reporting a measure of association for the risk of hyponatremia from valproic acid (antiepileptic drug)
Study /
Country
Beers et al.
(2010)144
The
Netherlands

Design
Casecontrol
Study

Outcome
definition
Not
specified

Sample Size /
Population
Studied
-Study of reports
submitted to the
Netherlands
Pharmacovigilance Centre
-22 606 reports of
ADRs with
valproic acid
-Cases: reports of
HN in valproic
acid users
-Controls: all other
reports

Relevant
drugs studied
Valproic acid

Follow-up
window
-Not
reported

Results
-HN suspected
in 238/22 606
reports (1.05%)
-Adjusted ROR
1.83 (95% CI
1.61, 2.08)

Significant
Risk Factors
-Not assessed

Mean age: not
specified

Abbreviations: ROR=reporting odds ratio; CI=confidence interval; pt=patient; HN=hyponatremia; ADR=adverse drug reaction

Limitations
-Spontaneous
reporting
system
-Possibility of
duplicate
reports
-Selection bias

Quality
Score
15
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2.5 Factors Affecting Psychotropic Drug Use
There are a number of factors related to psychotropic drug use, and are further
described below.
Age: Several studies have shown that older adults are more likely to use
psychotropic drugs compared to younger age groups.153–157 Older adults tend to
have more mental health and neurological problems which can explain the higher
prevalence of psychotropic drug use among this age group.158 In a populationbased study by Alonso et al., adults over the age of 65 were three times more
likely to use a psychotropic drug compared to adults 18 to 24 years of age (OR
3.1 [95% CI 2.4 to 4.0]).156 Mamdani et al., studied patients over the age of 65,
and found that antidepressant use increased linearly with age until about 85 to 89
years (p <0.001).159
Sex: In a review examining psychotropic drug use by gender, 28 studies from
various countries consistently showed that women used more psychotropic drugs
then men.160 According to the CCHS, the prevalence of psychotropic drug use
was 9.5% in women and 5.0% in men.161 Several reasons have been postulated for
this finding. This could be because women are more likely to perceive illness,
visit their physicians, share their problems with their physician, be more open
about the use of psychotropic drugs, or directly request a prescription.162,163
Another suggestion is a longer life expectancy among women can result in more
effects of aging, losses and health problems, which increases their likelihood of
using a psychotropic drug.162
Residential Status: A number of studies have reported increased psychotropic
drug use among older adults residing in long-term care facilities in Canada and
around the world.164–170 In a study conducted in Ontario, up to 55% of older adults
residing in a long-term care facility were prescribed at least one psychotropic
drug.170 In a study of older Swedish adults, those living in a long-term care
facility were more likely to use antidepressant and antipsychotic drugs than those
not living in such facilities (antidepressant drugs, OR 3.82 [95% CI 1.60 to 9.10];
antipsychotic drugs, OR 2.72 [95% CI 1.29 to 5.74]).171 In another large Swedish
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study, antiepileptic drugs were more commonly used among institutionalized
residents compared to community-dwelling older adults (OR 3.98 [95% CI 3.86
to 4.10]).172 This is attributed to the increased prevalence of dementia, depression,
anxiety, epilepsy, and other psychiatric disorders observed in these types of
facilities.
Physician visits: The number of annual visits to a physician increases the
likelihood that an older adult will be prescribed a psychotropic drug.162,173,174 This
relationship is quite apparent, as a visit to a physician is required in order to
obtain a prescription. Nearly 75% of visits to a physician result in at least one
prescription of any kind.175 In a study by Gustafsson et al., community-dwelling
older adults who had visited a physician within the previous three months were
more likely to use a psychotropic drug then those who had not visited a physician
(52% versus 22%, p < 0.001).
Mental health and neurological disorders: Psychotropic drugs such as
antidepressants, antipsychotics, and antiepileptics are frequently used in the
treatment of mental health and neurological disorders. Naturally, presence of
these disorders is correlated with use of specific types of psychotropic drugs. For
example, in a study examining psychotropic drug use among nursing home
residents, depression was a significant predictor of psychotropic drug use (OR
3.5, p < 0.01).176 In another study of older adults, compared to non-users,
psychotropic drug users had higher mean (standard deviation [SD]) scores for
anxiety (1.4 (0.5) vs. 1.7 (0.6), p < 0.001) and depression (13.1 (9.1) vs. 18.9
(11.3), p < 0.001).177 Paterniti et al. found that psychotropic drug users were four
times more likely to report symptoms of anxiety and depression than non-users
(OR 4.0 [95% CI 2.5 to 6.5]).178 In a study by Kamble et al., long-term care
residents with schizophrenia or bipolar disorder were more likely to use
antipsychotic drugs compared to residents without these conditions (OR 11.15
[95% CI 7.84 to 15.87]; p < 0.05 and OR 3.97 [95% CI 2.52 to 6.24]; p < 0.05,
respectively).179
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Other Comorbidities: The presence of comorbidities (related or unrelated to
hyponatremia), have been associated with psychotropic drug use.162 Since older
adults suffer from more diseases than younger individuals, they tend to use more
psychotropic and non-psychotropic drugs. A possible reason for this is that the
presence of multiple comorbidities can worsen an individual’s mental health
status, which may result in the need for a psychotropic drug.180 It is also possible
that adults with other comorbidities are more conscious of their health, making
them more likely to visit their physician and receive medications to treat their
medical problems.

2.6 Conceptual Model
Based on the review of the literature, a conceptual model was developed to depict
the hypothesized relationship between psychotropic drug use and hyponatremia
(Figure 2-2).
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Demographic
Characteristics
Age
Sex
Residential Status

Exposure
Psychotropic Drugs

Mental Health and
Neurological Disorders
Mood Disorders
Anxiety Disorders
Bipolar/Unipolar Disorders
Dementia
Schizophrenia
Epilepsy
Pain Disorders
Delirium

ANTIDEPRESSANTS
ANTIPSYCHOTICS
ANTIEPILEPTICS

Other Characteristics
Low Baseline Sodium Levels
History of Hyponatremia

Concomitant Drugs
Diuretics
Antineoplastics
Antidiabetics
NSAIDs
Antibiotics
Antihypertensive Agents

Outcome
Hospitalization with
HYPONATREMIA

Comorbidities
Heart Failure
Kidney Diseases
Liver Diseases
Malignancies
Pulmonary
Disorders
Endocrine Disorders
CNS Disorders
Pneumonia

Healthcare System
Usage
Physician Visits
Procedures/Tests
Prescription Drug Use

Figure 2-2. Conceptual model of the hypothesized relationship between psychotropic drug use and hyponatremia
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2.7 The Need for Research
2.7.1 Summary of Limitations of the Current Literature
A thorough review of the literature has identified several gaps and limitations with
existing research: i) most observed associations were based on case reports and
descriptive studies that lack control groups, providing only a crude estimate of prevalence
or incidence of hyponatremia; ii) studies assessing the risk of hyponatremia from one of
the three psychotropic drug classes of interest were generally of moderate methodological
quality, iii) many of the studies were older, based on small sample sizes, were conducted
in a single center, and studied highly specific patient populations, making it challenging
to generalize results to the contemporary outpatient/community setting; iv) follow-up
time was variable, and often included periods where the risk of hyponatremia was
negligible; v) all studies were conducted outside of Canada where the healthcare system,
prescription drug coverage, and prescribing practices may differ; and vi) many studies
did not or could not (due to limited power) consider several potentially confounding
variables. Additionally, it is unclear whether the risk of hyponatremia from psychotropic
drugs is higher in certain high-risk groups such as those with heart failure and kidney
disease, or in those simultaneously taking diuretics. As well, there is limited information
regarding the existence of a dose-dependent risk of hyponatremia among psychotropic
drug users.

2.7.2 Gaps in Prescribing Reference Manuals
The weak evidence available regarding these risks has led to poor consensus and
inconsistent messaging in pharmaceutical reference manuals, online sources and clinical
practice guidelines (current warnings and recommendations are summarized in Appendix
A Table A-2). For example, the Compendium of Pharmaceuticals and Specialties (CPS)
and UptoDate® are pharmaceutical references frequently used by physicians and nurse
practitioners.181,182 In both of these references, hyponatremia is listed as an adverse event
for all of the study antidepressants, risperidone, and carbamazepine, while for olanzapine
and quetiapine similar information is only available in UptoDate®. Recommendations for
the management of low serum sodium levels in these patients are unclear. Carbamazepine
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is the only drug for which both the CPS and UptoDate® suggest to monitor serum
sodium, but the strategies differ. For antidepressants and antipsychotics, UptoDate®
suggests monitoring serum sodium concentration closely when initiating or adjusting the
dose in older adults, but no such suggestions are made in the CPS.

2.8 Conclusion
Hyponatremia is a clinically important adverse drug event that is a significant cause of
morbidity and mortality, even when mild. As the number of adults over the age of 65
continues to grow, the economic burden that drug-induced adverse events place on the
healthcare system will increase. The available evidence surrounding psychotropic druginduced hyponatremia is limited, with many questions remaining unanswered. This
research has the potential to overcome the limitations of prior research, and can provide a
better understanding of the risk of hyponatremia with psychotropic drugs commonly used
in routine care, and will contribute to emerging knowledge regarding the safety of their
use in older adults. Associations between the psychotropic drugs of interest and
hyponatremia can be better understood at the population-level by taking advantage of
Canada’s universal health care system and large healthcare databases in Ontario.
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3.1 Introduction
Pharmacoepidemiology is an evolving discipline that studies, “the frequency and
distribution of health and disease in populations, as a result of the use and effects
(beneficial or adverse) of drugs.”1 Although randomized controlled trials are considered
the “gold standard” study design, they have an inability to examine rare events and
usually do not represent the entire clinical picture. Observational pharmacoepidemiologic
studies are ideal for investigating drug-outcome relationships in real world practice as
they typically use large comprehensive datasets, such as health administrative data.
However, as with any observational study, pharmacoepidemiologic studies are subject to
biases and confounding. In order to minimize these effects, special consideration must be
given to the methodology. The purpose of this chapter is to provide an overview of the
data sources and the data analytic methods used in this thesis.

3.2 Health Administrative Data Sources
The Institute for Clinical Evaluative Sciences houses a number of linked health
administrative databases, nine of which were used in this thesis. Using a unique
identifier, the ICES Key Number (IKN), is common to all datasets and is used to link
them. A description of each of the datasets is provided below.
Registered Persons Database: The Ontario Registered Persons Database (RPDB) is a
population-based registry that contains demographic information on all individuals who
have been issued an Ontario health card number. Information on date of birth, date of
death, gender, income (categorized into quintiles of average neighbourhood income), and
location of residence (rural or urban) was obtained from the RPDB.
Ontario Drug Benefits: The Ontario Drug Benefit (ODB) is a province-wide program
that provides coverage for more than 4,400 drug products to adults over the age of 65 and
other special populations.2 This database contains information from 1997 onward on
prescription drug claims for outpatients and long-term care residents. For this thesis, the
ODB was used to identify exposure to psychotropic drugs, as well as other important
concomitant medications. Prescription claims are accurately recorded in the database
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with an error rate of 0.7% (95% CI 0.5% to 0.9%).3 This database was also used to
determine residential status (community-dwelling or long-term care).
Canadian Institutes for Health Information Discharge Abstract Database: The
Canadian Institutes for Health Information Discharge Abstract Database (CIHI-DAD)
contains patient-level data for acute, chronic, rehab, and day surgery institutions in
Ontario. Inpatient information is available from 1988 onward. This database was used to
ascertain baseline comorbidities and outcome information, including the primary
outcome of hospitalization with hyponatremia. After a patient is discharged from
hospital, a medical records coder draws up an abstract from the chart, compiling
administrative and clinical data on that particular stay.4 CIHI-DAD provides the ability to
record up to 25 diagnoses, each with a corresponding diagnosis type. Since 2002,
diagnoses have been coded with International Classification of Diseases, 10th revision
(ICD-10) codes. Prior to this, ICD-9 codes were used. Similarly, procedures were coded
using the Canadian Classification of Procedures (CCP) until 2002 after which the
Canadian Classification of Interventions (CCI) system was adopted.
Canadian Institutes for Health Information National Ambulatory Care Reporting
System: The Canadian Institutes for Health Information National Ambulatory Care
Reporting System (CIHI-NACRS) includes information on patient visits to hospital and
community-based ambulatory care facilities. Specifically, information on day surgery,
outpatient clinic visits, renal dialysis visits, and emergency department visits are
captured. In NACRS, up to 10 diagnoses can be recorded, each with a corresponding
diagnosis type. Information is abstracted and coded in the same way as in the DAD. In
this thesis, information from emergency department visits was used for baseline
assessments of comorbidities and as a measure of health care utilization.
Ontario Mental Health Reporting System (OMHRS): OMHRS collects data on adult
patients who are admitted to an inpatient mental health bed. This includes beds in
general, provincial psychiatric, and specialty psychiatric facilities. Collection of data in
OMHRS began in October 2005. Prior to this, information was captured in the CIHI
DAD. Therefore, in this thesis both datasets were used to identify patients with a mental

69

health disorder. In the CIHI-DAD, specific diagnoses were identified using ICD-10
codes, while OMHRS contains Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV) codes. Appropriate codes were compiled based on expert opinion.
Ontario Health Insurance Plan: The Ontario Health Insurance Plan (OHIP) database
includes claims made by physicians and other health care providers for insured services
provided to all residents of Ontario. Most Ontario physicians are paid on a fee-for-service
basis and submit claims to OHIP for reimbursement. Records contain several important
pieces of information such as the type of service provided, service provider, diagnostic
information, the date that it occurred, and the associated fee code. The OHIP database
was used to obtain baseline information on important baseline comorbidities and
measures of health care usage.
ICES Physician database: The ICES Physician database contains information related to
practicing physicians in Ontario, such as age, gender, specialty, and year of graduation.
This database was used to abstract the specialty of the prescriber physician for the
exposure of interest.
Cerner: Cerner is an electronic medical record system used by 12 hospitals in
southwestern Ontario. This system stores laboratory information for inpatients,
outpatients, and emergency room visits in one repository and is available since June
2003. For this thesis, the Cerner data holdings were linked to the other ICES healthcare
databases. Data were available for a subpopulation residing in or near the hospital
catchment area.5 Among this subpopulation, serum sodium laboratory data were used to
define outcomes and to ascertain baseline serum sodium levels.
Gamma-Dynacare: Gamma-Dynacare is a medical laboratory provider that contains
outpatient laboratory data for the province since 2002. For this thesis, serum sodium data
were used define outcomes and to ascertain baseline serum sodium levels.
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3.3 Data Analytic Techniques
3.3.1

Overview

In pharmacoepidemiologic studies, exposure to a specific treatment is influenced by a
number of patient, physician, and health care system factors.6 Consequently, the baseline
characteristics between exposed and unexposed patients may differ systematically, and
may ultimately influence the estimated treatment effect. Propensity score methods are
often used to reduce the impact of this treatment selection bias. Propensity score methods
mimic aspects of a randomized study by “balancing” observed baseline characteristics or
covariates between exposed and unexposed subjects.7 The propensity score is the
predicted probability of exposure to treatment conditional on observed covariates. This
means that among subjects with the same propensity score, the distribution of baseline
covariates are similar between exposed and unexposed groups.8 Four types of propensity
score methods exist: matching on the propensity score, stratification on the propensity
score, inverse probability of treatment weighting using the propensity score, or covariate
adjustment using the propensity score.7

3.3.2

Estimating the Propensity Score Model

In each study comprising this thesis, the method of propensity score matching was
selected. Given that a much larger number of unexposed subjects (compared to exposed
subjects) were available for matching, this method was deemed suitable for each of the
studies. Specifically, greedy nearest neighbor matching without replacement using a
caliper width of ±0.2 of the standard deviation of the logit of the propensity score was
selected as the matching technique. In this method, a randomly selected exposed subject
is matched to an unexposed subject that has the closest propensity score within the
specified caliper width (i.e. the difference in propensity scores between matched subjects
differs by a maximum of ±0.2 of the standard deviation of the logit of the propensity
score). The matching process is repeated until exposed subjects have been matched to
eligible unexposed subjects. If an eligible match cannot be found, the exposed subject is
excluded from the matching process.
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The propensity score was derived for psychotropic drug treatment using a logistic
regression model. This model included psychotropic drug exposure (dependent variable)
and an extensive list of covariates (independent variables) related to either the treatment
and/or outcome (potential confounders), as well as other covariates to ensure that both
exposed and unexposed groups were as similar as possible on a wide range of baseline
characteristics.7 Factors that were considered potential confounders for the relationship
between psychotropic drug use and hyponatremia are broadly outlined in the Literature
Review (section 2.5). Exposed and unexposed patients were then matched (using the
desired matching ratio) on the logit of the propensity score within a caliper of ±0.2
standard deviations. As well, other relevant factors that were considered important
confounders or were of interest for subgroup analyses were directly matched on.
3.3.2.1 Matching Factors
In each of the studies comprising this thesis, exposed and unexposed subjects were
matched on age, sex, residential status, index date, chronic kidney disease, congestive
heart failure, diuretic use, or constituency in the catchment area with linked lab data.
Within each study, the major labeled indications for which the drugs were likely
prescribed for were also directly matched on (second-generation antidepressants study:
mood and/or anxiety disorder; atypical antipsychotics study: dementia, schizophrenia,
bipolar disorder, unipolar depression/anxiety, and/or Parkinson’s disease; antiepileptics
study: epilepsy/seizure)
Age, sex, and residential status are important confounders for the relationship
between psychotropic drug use and hyponatremia. It is well-documented that older
adults, women, and long-term care residents tend to experience hyponatremia and be
prescribed more psychotropic drugs, compared to younger individuals, women, and
patients living in the community.9–22 Since hyponatremia is known to occur in the
presence of chronic kidney disease, congestive heart failure, and diuretic use, and since
they all affect a large proportion of the population, they were of interest to subgroup
analyses. As such, these factors were directly matched on to retain matched pairs.
Similarly, analyses by sodium lab data was of interest but was only available for a
subpopulation so an indicator variable for the constituency in the catchment area with
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linked lab data was directly matched on to retain matched pairs for analysis of lab values.
Lastly, the indications for which the drugs are typically prescribed were also matched on
directly to remove the effects of confounding by indication.
3.3.2.2 Strengths of Propensity Score Matching
For each of the studies contained within this thesis, propensity score matching using a
caliper width of ±0.2 standard deviations was the ideal method for several reasons. In
empirical and simulation studies, propensity score matching was found to remove a
greater degree of the systematic differences in observed covariates between exposed and
unexposed groups.30 Since exposed and unexposed patients are, by definition, inherently
different from each other, there is greater potential for treatment selection bias to
influence the results. In addition, a sample that is matched on the propensity score is
similar on all the covariates that are included in the propensity score.31 Thus, for each
study, a large number of covariates (>100) were included in the propensity score models
(see Appendix B, C, and D for the list of variables included in each study). This
technique allowed for balance on a wide range of prognostically important variables. As
well, a caliper width of ±0.2 standard deviations has been shown to eliminate nearly 98%
to 99% of the bias due to observed covariates in many studies.32
3.3.2.3 Limitations of Propensity Score Matching
A key limitation of the propensity score matching approach is that a large number of
exposed and unexposed patients are lost due to incomplete matching, resulting in reduced
generalizability of the results to these subjects. However, upon examination, these
patients tended to be sicker and older, which puts them at a greater risk of the outcome.

3.3.3

Assessing Balance in Measured Covariates

In order to ensure similarity between exposed and unexposed groups, baseline
characteristics were examined before and after matching. Standardized differences were
used to compare the two groups. Unlike t-tests or Wilcoxon rank-sum tests, standardized
differences are independent of sample size, and their use is recommended in propensityscore matched studies.33 This metric describes differences between group means relative
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to the pooled standard deviation. The standardized differences for continuous and
categorical baseline variables are calculated as follows:
(1) Continuous baseline variable
d=

(𝑥
̅̅̅1 − 𝑥
̅̅̅)
2
2
2
√𝑠1 + 𝑠2
2

Where:
𝑥1 and ̅̅̅
̅̅̅
𝑥2 denote the sample mean in exposed and unexposed groups, respectively;
𝑠12 and 𝑠22 denote the sample variance in exposed and unexposed groups, respectively.

(2) Categorical baseline variable
d=

(𝑝
̂1 − 𝑝
̂)
2
̂(1
−𝑝
̂)
̂(1
−𝑝
̂)]
1
1 +𝑝
2
2
√[𝑝
2

Where:
𝑝
̂1 and 𝑝
̂2 denote the proportion in exposed and unexposed groups, respectively

A standard difference that is less than 10% has been widely accepted as indicative of
negligible imbalance in a baseline covariate between treatment groups.34

3.3.4 Outcomes
To answer the primary objective of this thesis, hyponatremia was assessed using an ICD10 code and using serum sodium laboratory values. When a patient presents to hospital
with hyponatremia, they may be confused or delirious, which is indicative of the severity
of hyponatremia. Generally, the lower serum sodium levels are, the more severe the
symptoms of hyponatremia will be (as described in the literature review, section 2.2.2).
Therefore, to understand if the observed hyponatremia was symptomatic, a combined
outcome of hyponatremia and delirium was assessed in a secondary objective. Often,
patients with mild hyponatremia do not display overt signs or symptoms, which may not
be of clinical significance to health care professionals. As the sensitivity of this combined
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outcome was very low, it was only feasible to evaluate this if there were an adequate
number of events (i.e. >5 events).

3.3.5

Analysis

For all binary outcomes, conditional logistic regression was used to estimate odds ratios,
and the Wald method to estimate 95% confidence intervals. This method was selected to
account for the correlation within matched sets. This was done using the SAS procedure
PROC LOGISTIC with a STRATA statement, which specifies the stratification
variable(s) and requests the appropriate conditional logistic model.35 To calculate 95%
confidence intervals for risk differences, a repeated measures model with PROC
GENMOD was used.36 This method adjusts for the correlation within matched sets.
Multivariable logistic regression models were used to determine the risk factors
associated with the primary outcome in psychotropic drug users and non-users. This was
adjusted for known risk factors of the outcome.
3.3.5.1 Effect measure modification
Separate interaction terms for potential effect measure modifiers (pre-specified) were
included in the primary outcome main effects model to assess effect measure
modification. Interaction p-values based on the Wald test for homogeneity were used to
determine if the primary association differed significantly by levels of a third variable.
3.3.5.2 Sensitivity Analyses
Despite the measures taken to control for confounding through the design and analysis of
these studies, residual confounding or other sources of error could have potentially
influenced the results. As such, a number of sensitivity analyses were conducted (when
possible) to ensure that confounding did not influence the primary results.
In each study, a separate analysis was conducted using a negative control or tracer
outcome. This is an outcome that is not expected to be associated with the exposure, and
a null association with this outcome reassures us that the primary result is not a spurious
finding.37 More specifically, if an association between two variables A-B is considered
implausible and is used as a negative control for an association X-Y, then presence of an
association between A and B will suggest bias in the association X-Y.37
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In two of the studies, the primary outcome was re-assessed using a new time zero in
retained matched pairs. The presence of a null association at that time would enhance
causal inference in the primary analysis. Specifically, a new cohort entry date occurring
in the 90 days prior to the original cohort entry date was selected - a time when both
groups were not exposed to any study psychotropic drugs. Exclusion criteria were reapplied to both groups at this new time zero.
In study 1, as the magnitude of the effect was quite large, a quantitative bias
analysis was conducted to ensure hidden bias wasn’t meaningfully influencing the results.
Although conditioning on the propensity score allows for an unbiased estimation of the
treatment effect, this is under the assumption that all variables affecting treatment
assigned were measured.35 This means that two subjects with the same observed
covariates may nonetheless differ in terms of unobserved covariates (i.e. unmeasured
confounders). Hidden bias exists when these unobserved covariates cannot be accounted
for in the anlaysis.38,39 This analysis helped to determine the potential impact that
unmeasured confounding had on the findings. Specifically, it quantified the magnitude of
bias that would need to be present to alter the conclusions of the study.39

3.3.6 Missing Values
The datasets were mostly complete for all variables included in the studies. There were
three variables for which information was missing. These included location of residence,
income quintile, and prescriber information. Only location of residence and income
quintile were included in the propensity score models. Prescriber information was
examined only out of interest. Location of residence was missing in less than 1% of each
cohort. These patients were included in the urban category. Similarly, income
information was missing in less than 0.1% of each cohort. These patients were included
in the third income quintile (average income category). Prescriber information was
missing in less than 15% of each cohort.
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4.1 Introduction
Mood and anxiety disorders are common and affect approximately 1 in 8 older adults.1–3
Second-generation antidepressants are frequently recommended in the treatment of these
disorders, with over 180 million prescriptions dispensed in the United States in 2013.4–7
While generally well tolerated, a potentially dangerous side effect of these medications is
hyponatremia. Hyponatremia can lead to adverse sequelae such as confusion, seizures,
and even death.8 The accepted mechanism of hyponatremia with antidepressants occurs
through the syndrome of inappropriate antidiuretic hormone.9,10
Most prior studies of antidepressant-induced hyponatremia are descriptive with
variable definitions of hyponatremia and lengths of follow-up. Reported estimates of
incidence range widely from less than 1% to 40% for selective serotonin reuptake
inhibitors (SSRIs) and up to 70% for venlafaxine, with most events observed in older
adults within four weeks of antidepressant initiation.11–18 In three small retrospective
studies of risk (maximum sample size 812 patients), older antidepressant users were up to
six times more likely to develop hyponatremia compared to non-users.19–21
Whether the results of prior studies generalize to the contemporary North American
non-hospitalized setting remains uncertain since most studies consisted of small samples
of patients, did not investigate newer second-generation antidepressants used in practice
today, and were limited to patients admitted to psychiatric hospitals or long-term care
facilities where patient health and monitoring differs from the community. Thus, using a
population-based cohort, we aimed to investigate the 30-day risk of hospitalization with
hyponatremia in older adults who were newly dispensed a second-generation
antidepressant in the non-hospitalized setting.

4.2 Methods
4.2.1

Study Design and Setting

We conducted a retrospective, population-based, cohort study of older adults from 1 June
2003 through 1 March 2012 using linked health care databases in Ontario, Canada.
Ontario has approximately 2.2 million residents over the age of 65 who are eligible to
receive universal access to hospital care, physician services and prescription drug

81

coverage.22 These datasets were linked using unique encoded identifiers and were
analyzed at the Institute for Clinical Evaluative Sciences (ICES). We conducted this
study according to a pre-specified protocol that was approved by the institutional review
board at Sunnybrook Health Sciences Centre, Toronto, Canada. Participant informed
consent was not required for this study. We followed the Strengthening the Reporting of
Observational Studies in Epidemiology guidelines for the reporting of our study
(Appendix B Table B-1).23

4.2.2

Data Sources

We used records from nine linked databases to identify patient characteristics, drug use,
covariate information, and outcome data. We used the Ontario Registered Persons
Database to obtain vital statistics. This database contains demographic information on all
residents who have been issued a provincial health card. We identified drug information
using the Ontario Drug Benefit program database. This database documents all outpatient
prescriptions dispensed to patients aged 65 and older, with an error rate less than one
percent (1%).24 We used the Canadian Institute for Health Information (CIHI) Discharge
Abstract Database to obtain diagnostic and procedural information on all hospital
admissions. Similarly, we used the CIHI National Ambulatory Care Reporting System
database to identify information relating to emergency department visits. We also used
the Ontario Mental Health Reporting System database to identify diagnostic information
on admissions to mental health facilities. We obtained covariate information from the
Ontario Health Insurance Plan database, which includes health claims for inpatient and
outpatient physicians’ services. We also used the ICES Physician Database to ascertain
study antidepressant prescriber information. We obtained hospital-based serum sodium
measurements from Cerner (a medical laboratory service provider) for a subpopulation in
southwestern Ontario, residing in the catchment area of 12 hospitals where linked
laboratory data were available (this catchment area has been previously defined).25 We
also identified outpatient serum sodium measurements using Gamma-Dynacare Medical
Laboratories (an outpatient laboratory service provider in Ontario). We have previously
used these databases to research adverse drug events and health outcomes in several
studies (including outcomes of hyponatremia and health services).26–30
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We used International Classification of Diseases, 9th revision (ICD-9; pre-2002)
and 10th revision (ICD-10; post-2002) codes to assess baseline comorbidities in the 5
years prior to cohort entry. Only ICD-10 codes were used to identify outcomes as these
events were ascertained following the implementation of this coding system. Codes used
to ascertain baseline comorbidities and outcomes are detailed in Appendix B Table B-2.
The databases were complete for all variables used in this study, with the exception of
income quintile, rural residence, and prescriber information, which were missing in less
than 0.5%, 0.1%, and 12% of older adults, respectively.

4.2.3

Patients

We established a cohort of older adults who had evidence of a hospital diagnosis or
physician claim for a mood or anxiety disorder in the five years prior to a new
prescription for one of nine second-generation study antidepressants: citalopram,
escitalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, mirtazapine
or sertraline (referred to as the ‘users’ group). We defined new use as no prescriptions for
any type of antidepressant drug in the prior six months. The date of the eligible
prescription served as the index date (cohort entry date) for users. We restricted the
cohort to those who had a prescription for only one type of study second-generation
antidepressant on their index date in order to compare mutually exclusive groups in
subgroup analyses. We also established a control group from the Ontario population who
were not prescribed any antidepressants (referred to as the ‘non-users’ group), and
randomly assigned them an index date based on the distribution of index dates among
users.28,31
We excluded the following patients from both groups: (1) those who were
discharged from a hospital in the two days prior to their index date to ensure (in the case
of the users) that the drug was not initiated in a hospital setting (as patients continuing
antidepressant drug treatment would have their oral outpatient prescription dispensed the
day of or the day after hospital discharge) and (2) those with evidence of end-stage renal
disease prior to their index date since in these patients sodium blood levels are regulated
through dialysis. Among non-users, we excluded those who did not have at least one
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outpatient medication dispensed in the 90 days prior to their index date to ensure active
usage of the Ontario Drug Benefits program.
A propensity score for the predicted probability of receiving a new secondgeneration antidepressant drug was derived from a logistic regression model in which
treatment status was regressed on over 100 variables that were potentially associated with
the exposure or outcome (Appendix B Table B-3).32 We used greedy matching to match
each user to a non-user (1:1) based on the following characteristics: the logit of the
propensity score (within a caliper of ±0.2 standard deviations); age (within two years);
sex; index date (within one year); residential status (community-dwelling or long-term
care); evidence of a mood or anxiety disorder, chronic kidney disease, congestive heart
failure; diuretic use; and constituency in the catchment area where linked laboratory data
were available. We matched on these characteristics to ensure good balance of
prognostically important characteristics and to facilitate subgroup analyses (to keep
matched pairs intact).32 We applied matching without replacement where users and nonusers could only be selected once for inclusion in the study. Greedy matching without
replacement within specified caliper widths has been shown to produce less biased
estimates compared to other matching algorithms.33

4.2.4

Outcomes

We assessed outcomes within 30 days of the second-generation antidepressant
prescription as most cases of hyponatremia have the greatest potential to occur during
this period.13,34 As well, we expected fewer crossovers between the two groups during the
first 30 days.
4.2.4.1 Primary Outcome
We defined the primary outcome of hospitalization with hyponatremia as any hospital
admission with evidence of ICD-10 code E87.1 (hypo-osmolality or hyponatremia) in
any of the 25 diagnostic fields in the CIHI Discharge Abstract Database. Based on an
Ontario validation study assessing hospital admission with hyponatremia, the presence of
code E87.1 identifies older patients with a median serum sodium value of 125 mmol/L
(interquartile range [IQR] 120 to 130 mmol/L), whereas its absence identifies a median
value of 137 mmol/L (IQR 135 to 139 mmol/L).35 Although the specificity of the hospital
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diagnosis code is greater than 99%, the sensitivity is limited particularly for milder forms
of hyponatremia (sensitivity of 11% for serum sodium ≤132 mmol/L). As such, we
examined a subpopulation with linked hospital laboratory values. The full study is
included in Appendix E.
4.2.4.2 Secondary Outcome
We assessed a secondary outcome of hospitalization with both hyponatremia and
delirium using diagnostic codes. We expected the specificity of this combination of
diagnosis codes to be high, but the sensitivity to be low, with an underestimation of the
true incidence of the event.

4.2.5

Statistical Analyses

We compared baseline characteristics between second-generation antidepressant users
and non-users using standardized differences. This metric describes differences between
group means relative to the pooled standard deviation, and a difference is considered
meaningful if greater than 10%.36 We expressed risk in both relative and absolute terms.
To account for correlation within pairs, we used conditional logistic regression to
estimate odds ratios and associated 95% confidence intervals (CIs) and a generalized
linear model to estimate absolute risk differences and associated 95% CIs. Using
statistical tests for interactions, we analyzed the primary outcome in five pre-specified
subgroups: 1) second-generation antidepressant type, 2) second-generation antidepressant
dose (higher dose vs. normal dose; higher dose defined by a higher than median starting
daily dose for the study cohort), 3) evidence of chronic kidney disease, 4) evidence of
congestive heart failure, and 5) baseline use of a diuretic. Chronic kidney disease and
congestive heart failure were identified using separate algorithms of hospital diagnosis
codes validated for adults in our study region.37,38 Matched pairs were retained in all
subgroups. We conducted several additional analyses to support our primary findings.
All odds ratios were approximated as relative risks (appropriate given the
incidences observed). We performed all analyses using SAS version 9.4 (SAS Institute,
Cary, North Carolina). Detailed methods are provided in Chapter 3.
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4.2.5.1 Additional Analyses
First, given the limited sensitivity of the hospital diagnosis code for hyponatremia, we
examined the association between second-generation antidepressant use and
hospitalization with a serum sodium concentration ≤132 mmol/L among the
subpopulation with linked laboratory data.
Second, we examined the association between second-generation antidepressant use
and an outpatient serum sodium concentration ≤132 mmol/L among a subgroup for which
information on outpatient serum sodium levels was available.
Third, to test the specificity of our findings, we examined whether the 30-day risk
of hospitalization with bowel obstruction differed in second-generation antidepressant
users vs. non-users. Since there is no plausible reason why second-generation
antidepressant use would increase the risk of bowel obstruction, we reasoned that a null
association with this outcome would enhance causal inference in our hyponatremia
analyses.39
Fourth, to assess the temporality of our findings, we re-examined the primary
outcome in our cohort at a date that preceded the index date by 90 days (i.e. 90 days prior
to the original index date), and followed retained matched pairs to assess the 30-day risk
of hospitalization with hyponatremia (exclusion criteria were re-applied at the new index
date). We reasoned that a null association in this analysis would provide reassurance that
the two groups were similar in their baseline risk for hospitalization with hyponatremia in
the absence of second-generation antidepressant use.
Fifth, to assess whether hidden bias could meaningfully influence the results, we
conducted a sensitivity analysis to determine the magnitude of bias that would need to be
present from unmeasured confounder(s) to alter the conclusions of the study.40,41 In this
analysis, we examined the association between second-generation antidepressant use and
hyponatremia under different scenarios by varying the strength of association between
antidepressant use and the unmeasured confounder(s) as well as hyponatremia and the
unmeasured confounder(s).
Finally, we investigated the characteristics associated with hospitalization with
hyponatremia separately in users and non-users. These characteristics included age (per
year); sex; evidence of chronic kidney disease, congestive heart failure, diabetes, liver
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disease, cancer, hypothyroidism, previous hyponatremia; and receipt of a diuretic,
antiepileptic, antipsychotic, or antineoplastic medication.

4.3 Results
4.3.1

Baseline Characteristics

Cohort selection is presented in Figure 4-1. We identified 172 552 second-generation
antidepressant users and 297 501 non-users who were eligible for our study.
Antidepressant users were more likely to be women (68% vs. 59%), and were more likely
to reside in a long-term care facility (9% vs. 4%), have higher comorbidity scores, be
prescribed a greater number of medications, and had more baseline health care service
use than non-users. After matching, 138 246 patients remained in each group. Matched
second-generation antidepressant users and non-users were nearly identical on all
measured characteristics (standardized differences <10%) (Table 4-1; full table presented
in Appendix B Table B-4). The mean age was 76 years and 68% were women. Among
users, the most frequently prescribed second-generation antidepressant was citalopram
(46%) and family physicians were the most frequent prescribers (78%). Amongst those
with baseline values, the mean (standard deviation) serum sodium concentration was no
different in second-generation antidepressant users (140.4 (3.3)) and non-users (140.5
(3.2)).
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289 274 Ontario residents >65 years of age
who were dispensed a new oral outpatient
prescription for one of the following secondgeneration antidepressant drugs prior to the
index date: citalopram, escitalopram,
paroxetine, fluoxetine, fluvoxamine, venlafaxine,
duloxetine, mirtazapine or sertraline (from June
2003 to March 2012).

19 832 Discharged from a hospital or
emergency room in the two days prior
to the index date
2 331 Evidence of end-stage renal
disease prior to the index date

1 474 915 Ontario residents >65 years of age
who were not dispensed an oral outpatient
prescription for any antidepressant drug in the
six months prior to the randomly assigned index
date (from June 2003 to March 2012).

464 384 Without at least one
outpatient medication dispensed in
the 90 days prior to the index date
Excluded

4 859 Evidence of end-stage renal
disease prior to the index date

94 559 No evidence of a mood or
anxiety disorder in the five years prior
to the index date

697 592 No evidence of a mood or
anxiety disorder in the five years prior
to the index date

172 552

Remaining

138 246 antidepressant
users

Matched
(1:1)

Figure 4-1. Cohort selection

10 579 Discharged from a hospital or
emergency room in the two days prior
to the index date

297 501

138 246 antidepressant
non-users
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Table 4-1. Baseline characteristics of second-generation antidepressant users and non-users*
Characteristic
Antidepressant
users
(n=172 552)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residence
Long-term care
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Mood disorder
Anxiety disorderd
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancere
Diabetes mellitus
Pneumonia
Coronary artery diseasef
Angina
Previous hyponatremia
Lung disease
Epilepsy/seizure
Acute kidney injury
Delirium
Peripheral vascular disease

Unmatched
Antidepressant
non-users
(n=297 501)

Standardized
Differencea

Antidepressant
users
(n=138 246)

Matched
Antidepressant
non-users
(n=138 246)

Standardized
Differencea

76 (7.5)
116 830 (67.7%)

75 (7.2)
177 662 (59.2%)

5.9%
16.7%

76 (7.3)
93 303 (67.5%)

76 (7.2)
93 303 (67.5%)

0.3%
0

35 747 (20.7%)
35 935 (20.8%)
33 863 (19.6%)
33 049 (19.2%)
33 958 (19.7%)
21 796 (12.6%)
14 989 (8.7%)

59 184 (19.9%)
61 849 (20.8%)
58 284 (19.6%)
58 377 (19.6%)
59 807 (20.1%)
34 381 (11.6%)
10 812 (3.6%)

2.0%
0.1%
0.1%
1.2%
1.1%
3.3%
21.1%

28 057 (20.3%)
28 853 (20.9%)
27 166 (19.7%)
26 684 (19.3%)
27 486 (19.9%)
17 660 (12.8%)
6859 (5.0%)

28 574 (20.7%)
28 954 (20.9%)
27 279 (19.7%)
26 504 (19.2%)
26 935 (19.5%)
17 015 (12.3%)
6859 (5.0%)

0.9%
0.2%
0.2%
0.3%
1.0%
1.4%
0

0.8 (1.5)
13.5 (3.8)

0.6 (1.3)
12.5 (3.7)

14.0%
25.0%

0.6 (1.3)
13.0 (3.8)

0.6 (1.4)
13.1 (3.7)

3.0%
0.8%

44 363 (25.7%)
159 901 (92.7%)
25 766 (14.9%)
10 798 (6.3%)
129 149 (74.8%)
6608 (3.8%)
20 098 (11.7%)
26 002 (15.1%)
14 371 (8.3%)
9350 (5.4%)
54 319 (31.5%)
40 486 (23.5%)
3889 (2.3%)
53 458 (31.0%)
1763 (1.0%)
3745 (2.2%)
4015 (2.3%)
2974 (1.7%)

34 484 (11.6%)
282 632 (95.0%)
35 778 (12.0%)
17 931 (6.0%)
226 854 (76.3%)
10 759 (3.6%)
32 199 (10.8%)
43 459 (14.6%)
26 405 (8.9%)
10 796 (3.6%)
89 377 (30.0%)
62 974 (21.2%)
3941 (1.3%)
78 087 (26.3%)
2056 (0.7%)
4689 (1.6%)
3640 (1.2%)
3973 (1.3%)

0.4%
10.0%
8.5%
1.0%
3.3%
1.1%
2.6%
1.3%
2.0%
8.6%
3.1%
5.5%
7.0%
10.5%
3.6%
4.4%
8.4%
3.2%

24 207 (17.5%)
129 861 (93.9%)
16 735 (12.1%)
6094 (4.4%)
102 983 (74.5%)
5152 (3.7%)
15 723 (11.4%)
19 741 (14.3%)
11 298 (8.2%)
5681 (4.1%)
40 738 (29.5%)
30 250 (21.9%)
2353 (1.7%)
40 129 (29.0%)
1053 (0.8%)
1964 (1.4%)
2104 (1.5%)
1923 (1.4%)

24 207 (17.5%)
129 861 (93.9%)
16 735 (12.1%)
6094 (4.4%)
101 948 (73.7%)
4966 (3.6%)
15 472 (11.2%)
20 943 (15.1%)
11 234 (8.1%)
5775 (4.2%)
41 051 (29.7%)
30 287 (21.9%)
2257 (1.6%)
40 321 (29.2%)
1092 (0.8%)
2009 (1.5%)
2103 (1.5%)
1999 (1.4%)

0
0
0
0
1.7%
0.7%
0.6%
2.5%
0.2%
0.3%
0.5%
0.1%
0.5%
0.3%
0.3%
0.3%
0
0.5%
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Concurrent medication useg
Number of unique drug products, mean
(SD)
Antiepileptics
Antipsychotics
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Healthcare contacts, mean (SD)h
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Healthcare usei
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Colorectal cancer screening
Cervical cancer screening
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Computed tomography of the head
Chest x-ray
Pulmonary function test
Laboratory measurementsj
Evidence of baseline serum sodium
measurement, N (%)

11.47 (7.4)

9.42 (6.1)

31.0%

10.47 (6.6)

10.41 (6.5)

0.9%

16 212 (9.4%)
13 052 (7.6%)
27 160 (15.7%)
6848 (4.0%)
29 654 (17.2%)
6498 (3.8%)
51 687 (30.0%)
79 341 (46.0%)
34 309 (19.9%)
44 345 (25.7%)
48 093 (27.9%)
64 831 (37.6%)
67 701 (39.2%)

15 602 (5.2%)
11 759 (4.0%)
50 240 (16.9%)
11 287 (3.8%)
48 974 (16.5%)
10 213 (3.4%)
86 612 (29.1%)
149 937 (50.4%)
53 241 (17.9%)
80 594 (27.1%)
88 616 (29.8%)
128 405 (43.2%)
61 887 (20.8%)

16.0%
15.5%
3.1%
0.9%
1.9%
1.8%
1.8%
8.9%
5.1%
3.2%
4.2%
11.4%
41.1%

10 901 (7.9%)
7609 (5.5%)
20 847 (15.1%)
5199 (3.8%)
23 403 (16.9%)
4827 (3.5%)
38 879 (28.1%)
63 863 (46.2%)
26 986 (19.5%)
35 214 (25.5%)
37 652 (27.2%)
53 052 (38.4%)
48 049 (34.8%)

10 499 (7.6%)
7659 (5.5%)
21 461 (15.5%)
5636 (4.1%)
23 457 (17.0%)
5020 (3.6%)
38 550 (27.9%)
63 390 (45.9%)
27 803 (20.1%)
35 342 (25.6%)
37 995 (27.5%)
52 777 (38.2%)
46 320 (33.5%)

1.1%
0.2%
1.2%
2.0%
0.1%
0.8%
0.5%
0.7%
1.5%
0.2%
0.6%
0.4%
2.6%

0.4 (0.8)
1.0 (1.8)
19.3 (19.9)
0.4 (2.9)
0.6 (3.9)

0.2 (0.5)
0.6 (1.3)
14.8 (14.0)
0.2 (1.5)
0.2 (2.0)

25.4%
27.1%
26.8%
13.3%
13.4%

0.3 (0.6)
0.8 (1.5)
16.9 (16.4)
0.2 (1.6)
0.3 (2.3)

0.3 (0.7)
0.8 (1.5)
16.5 (15.3)
0.2 (1.6)
0.2 (2.3)

1.7%
3.4%
2.1%
3.2%
4.0%

108 033 (62.6%)
10 937 (6.3%)
3293 (1.9%)
31 184 (18.1%)
13 196 (7.6%)
35 246 (20.4%)
12 870 (7.5%)
103 460 (60.0%)
23 220 (13.5%)
10 395 (6.0%)
28 544 (16.5%)
74 792 (43.3%)
17 023 (9.9%)

172 302 (57.9%)
14 166 (4.8%)
4401 (1.5%)
47 863 (16.1%)
18 248 (6.1%)
63 516 (21.3%)
22 600 (7.6%)
162 166 (54.5%)
40 668 (13.7%)
15 668 (5.3%)
22 761 (7.7%)
97 878 (32.9%)
25 317 (8.5%)

9.6%
6.9%
3.3%
5.3%
6.0%
2.3%
0.5%
11.0%
0.6%
3.3%
27.5%
21.6%
4.7%

83 879 (60.7%)
7816 (5.7%)
2327 (1.7%)
23 425 (16.9%)
9913 (7.2%)
28 856 (20.9%)
11 054 (8.0%)
81 060 (58.6%)
19 452 (14.1%)
8086 (5.8%)
17 175 (12.4%)
54 158 (39.2%)
12 975 (9.4%)

80 886 (58.5%)
7996 (5.8%)
2311 (1.7%)
23 657 (17.1%)
9844 (7.1%)
27 638 (20.0%)
11 111 (8.0%)
80 776 (58.4%)
19 433 (14.1%)
7967 (5.8%)
16 389 (11.9%)
54 782 (39.6%)
13 134 (9.5%)

4.4%
0.6%
0.1%
0.4%
0.2%
2.2%
0.2%
0.4%
0
0.4%
1.7%
0.9%
0.4%

31 228 (18.1%)

51 076 (17.2%)

2.4%

22 280 (16.1%)

22 280 (16.1%)

0
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Most recent serum sodium, mean (SD)

140.2 (3.4)

140.6 (3.1)

12.3%

140.4 (3.3)

140.5 (3.2)

3.1%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive depression” was included into the anxiety disorder category
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
g Concurrent medication use in the six months preceding the index date were considered.
h Healthcare contacts in the year preceding the index date were considered.
i Healthcare use in the year preceding the index date was considered.
j Serum sodium measurements were obtained at a mean (SD) of 140 (102) days in users and 149 (101) days in non-users (matched groups), prior to the index
date
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4.3.2

Primary Outcome

Results using the hospital diagnosis code to define hyponatremia are presented in Table
4-2. Second-generation antidepressant use vs. non-use was associated with a higher 30day risk of hospitalization with hyponatremia (450/138 246 [0.33%] vs. 84/138 246
[0.06%]; relative risk 5.46 [95% CI 4.32 to 6.91]).
Results from subgroup analyses are presented in Figure 4-2. The relative
association between second-generation antidepressant use and hospitalization with
hyponatremia was consistent in all five subgroup analyses (all p-values for interaction >
0.05). The absolute increase in the incidence of hyponatremia associated with secondgeneration antidepressant use vs. non-use was greater in patients with congestive heart
failure than in those without heart failure (absolute risk increase 0.55% [95% CI 0.42% to
0.68%] vs. 0.22% [95% CI 0.19% to 0.26%]) and in those using a diuretic vs. those not
using a diuretic (absolute risk increase 0.48% [95% CI 0.40% to 0.56%] vs. 0.18% [95%
CI 0.14% to 0.21%]).

4.3.3

Secondary Outcome

Results for the outcome of hospitalization with hyponatremia and delirium are also
presented in Table 4-2. Second-generation antidepressant use vs. non-use was associated
with a higher 30-day risk of hospitalization with concomittant hyponatremia and delirium
(relative risk 4.00 [95% CI 1.74 to 9.16]).

Table 4-2. 30-day outcomes (defined by hospital diagnosis codes) in second-generation
antidepressant users and non-users
Events, No. (%)a
Antidepressant Antidepressant
users
non-usersd
(n=138 246)
(n=138 246)
Primary Outcome
Hospitalization with
hyponatremiab
Secondary Outcome
Hospitalization with
hyponatremia and
deliriumc

Relative Risk
(95% CI)

Absolute Risk
Increase (95% CI), %

450 (0.33)

84 (0.06)

5.46 (4.32 to 6.91)

0.27 (0.23 to 0.30)

28 (0.02)

7 (0.005)

4.00 (1.74 to 9.16)

0.02 (0.01 to 0.02)

CI=confidence interval
a The event rates and absolute risk differences are underestimated as the hospital-based diagnosis codes
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used to define the outcomes have high speciﬁcity but low sensitivity.
b The sensitivity and specificity of the code for hyponatremia is 11% and 99%, respectively.34
c We expected the specificity of this combination of diagnosis codes to be high, but the sensitivity to be
low, with an underestimation of the true incidence of the event.
d An antidepressant non-user group was the referent.
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Events/At Risk, n/N (%)a
Antidepressant
Antidepressant
user
non-user
(n=138 246)
(n=138 246)
Antidepressant Drug Typeb
Citalopram
Escitalopram
Mirtazapine
Paroxetine
Sertraline

Relative Risk
(95% CI)

P-value for
Interaction

231/63 352 (0.36)
62/15 584 (0.40)
19/11 748 (0.16)
57/20 886 (0.28)
51/15 013 (0.34)

41/63 352 (0.06)
13/15 584 (0.08)
6/11 748 (0.05)
8/20 866 (0.04)
7/15 013 (0.05)

5.75 (4.11 to 8.04)
4.77 (2.62 to 8.67)
3.17 (1.27 to 7.93)
8.00 (3.65 to 17.55)
7.29 (3.31 to 16.05)

0.08

Antidepressant Drug Dosec
Higher Dose
29/14 763 (0.20)
Normal Dose 411/118 892 (0.35)

8/14 763 (0.05)
74/118 892 (0.06)

3.63 (1.66 to 7.93)
5.68 (4.42 to 7.30)

0.28

Chronic Kidney Diseased
Yes
No

16/6094 (0.26)
434/132 152 (0.33)

6/6094 (0.10)
78/132 152 (0.06)

2.67 (1.04 to 6.82)
5.68 (4.45 to 7.25)

0.13

Congestive Heart Failuree
Yes
No

105/16 735 (0.63)
345/121 511 (0.28)

14/16 735 (0.08)
70/121 511 (0.06)

7.50 (4.30 to 13.10)
5.04 (3.89 to 6.54)

0.22

Diuretic Usef
Yes
No

237/40 413 (0.59)
213/97 833 (0.22)

43/40 413 (0.11)
41/97 833 (0.04)

5.62 (4.05 to 7.80)
5.30 (3.78 to 7.43)

0.81
.

Risk higher
with medication use

Figure 4-2. The association between second-generation antidepressant use and hospitalization with hyponatremia assessed in five
subgroups*
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CI=confidence interval.
* Antidepressant medication type, antidepressant medication dose, chronic kidney disease, congestive heart failure and use of a diuretic. Sets of medication users
and non-users were matched on presence of chronic kidney disease, congestive heart failure, and baseline diuretic use. For antidepressant medication type and
dose, matched sets were categorized according to this characteristic in medication users. Data marker size is proportional to the inverse of the source variance.
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is
underestimated for some outcomes because the code for hyponatremia has high speciﬁcity but low sensitivity.
b Fluoxetine, fluvoxamine, duloxetine, and venlafaxine were included in the tests for interactions but were removed from presentation as there were too few
events for meaningful analysis. This was also done to comply with privacy regulations, to prevent the risk of re-identification when the size of the numerator is
small (less than or equal to 5).
c Higher dose was defined as a higher than median daily dose. See Appendix B Table B-2 for definitions. Fluoxetine was not considered in the assessment of
higher vs. normal dose as a higher than median daily dose could not be accurately defined.
d Chronic kidney disease was identiﬁed by using an algorithm of hospital diagnosis codes validated for older adults in the study region.37 The algorithm
identiﬁed patients with a median estimated glomerular ﬁltration rate of 38 mL/min/1.73m2 (interquartile range, 27–52 mL/min/1.73m2), whereas its absence
identiﬁed patients with a median estimated glomerular ﬁltration rate of 69 mL/min/1.73m2 (interquartile range, 56–82 mL/min/1.73m2).
e Congestive heart failure has a sensitivity, specificity and positive predictive value of 84.3, 85.4, and 35.8%, respectively. 38
f Diuretic use includes potassium sparing and non-potassium sparing medications.
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4.3.4

Additional Analyses

Among the subpopulation with linked laboratory data, baseline characteristics were
similar between second-generation antidepressant users and non-users (Appendix B
Table B-5, 4186 matched pairs of users and non-users). Amongst those with baseline
values, the mean (standard deviation) serum sodium concentration was no different in
users (139.3 (3.6)) and non-users (139.6 (3.5)). Second-generation antidepressant use vs.
non-use was associated with a higher 30-day risk of hospitalization with hyponatremia
(73/4186 [1.74%] vs. 18/4186 [0.43%]; relative risk 4.23 [95% CI 2.50 to 7.19]; absolute
risk increase 1.31% [95% CI 0.87% to 1.75%]).
In patients who had serum sodium measurements available from an outpatient
laboratory, second-generation antidepressant use remained associated with an increased
30-day risk of hyponatremia compared to non-use (170/22 280 [0.76%] vs. 68/22 280
[0.31%]; relative risk 2.50 [95% CI 1.89 to 3.31]; absolute risk increase 0.45% [95% CI
0.32% to 0.60%]).
In our test of specificity, we did not observe an association between secondgeneration antidepressant use vs. non-use in the 30-day risk of hospitalization with bowel
obstruction (94/138 246 [0.07%] vs. 94/138 246 [0.07%]; relative risk 1.00 [95% CI 0.75
to 1.33]).
When we re-examined the primary outcome in the 90 days prior to the original
index date, baseline characteristics were similar between the two groups (Appendix B
Table B-6; 90 195 matched pairs of drug users and non-users). We did not observe any
significant differences between second-generation antidepressant use and non-use in the
baseline 30-day risk of hospitalization with hyponatremia (relative risk 1.29 [95% CI
0.86 to 1.92]).
In our sensitivity analysis of hidden bias, we demonstrated that it would be very
unlikely that unmeasured confounding was influencing the results (Appendix B Figure B1). To make the observed association non-significant, the unmeasured confounder(s)
would need to produce an eight-fold increase in the odds of second-generation
antidepressant use and a ten-fold increase in the odds of hyponatremia.
When we looked at the characteristics that predict hospitalization with
hyponatremia in second-generation antidepressant users, older age, female sex, liver
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disease, previous hyponatremia, and diuretic use were associated with a higher 30-day
risk of hospitalization with hyponatremia (Table 4-3).

Table 4-3. Risk factors for hyponatremia in second-generation antidepressant users and
non-users*
Hospitalization with hyponatremia
Older age (per year)
Women (vs. men)
Chronic kidney disease (yes vs. no)
Congestive heart failure (yes vs. no)
Diabetes (yes vs. no)
Liver disease (yes vs. no)
Cancer (yes vs. no)
Hypothyroidism (yes vs. no)
Previous hyponatremia (yes vs. no)
Diuretic use (yes vs. no)
Antiepileptic use (yes vs. no)
Antipsychotic use (yes vs. no)
Antineoplastic use (yes vs. no)

Antidepressant users
(n=138 246)
Relative risk (95% CI)
1.08 (1.07 to 1.10)
1.50 (1.19 to 1.90)
0.49 (0.29 to 0.81)
1.05 (0.83 to 1.34)
0.74 (0.50 to 1.10)
1.84 (1.23 to 2.73)
1.08 (0.82 to 1.43)
0.97 (0.73 to 1.27)
8.44 (6.53 to 10.90)
2.03 (1.67 to 2.48)
0.95 (0.67 to 1.35)
0.60 (0.90 to 0.93)
0.87 (0.52 to 1.47)

Antidepressant non-users
(n=138 246)
Relative risk (95% CI)
1.05 (1.02 to 1.08)
1.43 (0.85 to 2.39)
1.14 (0.49 to 2.67)
0.69 (0.37 to 1.28)
1.48 (0.76 to 2.87)
1.50 (0.60 to 3.75)
1.90 (1.12 to 3.21)
1.05 (0.55 to 1.98)
7.92 (4.27 to 14.68)
2.14 (1.36 to 3.37)
1.37 (0.68 to 2.75)
1.14 (0.52 to 2.50)
1.03 (0.40 to 2.65)

CI=confidence interval
* Separate multivariable logistic regression models created for antidepressant drug users and non-users

4.4 Discussion
In this large population-based cohort study consisting of older adults prescribed common
second-generation antidepressant drugs in a non-hospitalized setting, we found a robust
association between second-generation antidepressant use and hospitalization with
hyponatremia. However, the absolute 30-day risk remained low (below 2%). It also
appeared that some of the hyponatremia was symptomatic as evidenced by hospital
admission with hyponatremia and delirium.
Certain groups of patients, such as those with chronic kidney disease, congestive
heart failure, and those receiving diuretics, are usually at a higher risk for
hyponatremia.18,42,43 However, when examined in subgroup analyses, none of these
characteristics modified the relative association between second-generation
antidepressant use and hyponatremia. The absolute risk increases were greatest in patients
with congestive heart failure and in those using diuretics. In second-generation
antidepressant users, characteristics that associated with a higher risk of hospitalization
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with hyponatremia included older age, female sex, liver disease, a history of
hyponatremia, and diuretic use.
We observed a similar strength of association between second-generation
antidepressant use and hospitalization with hyponatremia across each of the drug types
including mirtazapine (a noradrenergic and specific serotonergic antidepressant). In a
population-based cohort study by Coupland et al. (published after the initiation of our
study), there was an increased risk of hyponatremia following use of a selective serotonin
reuptake inhibitor (SSRI) (hazards ratio 1.52 [95% CI 1.33 to 1.75]), but not with use of
mirtazapine/venlafaxine (non-SSRIs) when compared to non-use.44 This combined
estimate was based on a mean follow-up time of 5 years after antidepressant initiation. In
another study by Jung et al., no patients developed hyponatremia while taking
mirtazapine (76 patients), whereas 8% of those taking SSRIs developed the condition.45
Mirtazapine is chemically different from SSRIs and may confer a lower risk of
hyponatremia compared to them. Given the findings of the past and present studies,
future studies should focus on better understanding the risk of mirtazapine-induced
hyponatremia.
The results of this population-based study raise awareness about hyponatremia
from second-generation antidepressants. Although we are reporting observational data,
our findings should be considered when defining practice standards for the prescription of
second-generation antidepressants. Our primary results proved robust in a number of
additional analyses. Overall, our findings are consistent with four other retrospective
studies19–21,44 and are biologically plausible given the current understanding of how this
class of medications induces hyponatremia.9,10 Although an absolute risk increase of
1.3% for hospitalization with hyponatremia may appear small, in the context of the
prevalence of antidepressant use it translates into thousands of events each year.
Therefore, we suggest that guidance be developed on the utility of baseline or postadministration monitoring of serum sodium concentrations in new users of all secondgeneration antidepressant medications. Currently, in the Compendium of Pharmaceuticals
and Specialties, which is the standard for drug monographs, there are no such guidelines
for measurement of serum sodium in this setting (additional details are provided in
Appendix A Table A-2).
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Our study has several strengths. It was a population-based cohort study that allowed
us to estimate an uncommon but important adverse drug event with good precision in a
large sample of older adults who were initiated on a second-generation antidepressant in
routine care. This information is complementary to the data provided in smaller,
regulated randomized trials with eligibility criteria that preclude many older individuals
from being studied.46–48 In this study, the association between second-generation
antidepressant use and hyponatremia proved robust in multiple additional analyses.
Our study does have limitations. First, as with all observational studies, we may
have failed to account for important unmeasured confounding variables. However, we
used a propensity-matched design, which has been widely used in observational studies
of drug safety to minimize sources of confounding.32,49 We also matched on factors that
are known risk factors for hyponatremia, and baseline indicators of health in our secondgeneration antidepressant user and non-user groups were almost identical after the
matching technique was applied. Furthermore, our quantitative bias analysis suggests the
observed association is unlikely to be altered by unmeasured confounding variables.
Second, to minimize effects of confounding and to ensure the comparability of our
matched second-generation antidepressant user and non-user groups, we studied patients
with prior evidence of a mood or anxiety disorder. However, we would expect the risk to
be similar in all patients taking these drugs. Third, the code used to assess hospitalization
with hyponatremia had limited sensitivity and can underestimate the true incidence of
hyponatremia by eight-fold. For this reason, we supplemented our primary outcome
findings by observing a subpopulation with serum sodium values and showed a similar
relative risk of hyponatremia with second-generation antidepressant use. In this
subpopulation we could also more accurately estimate the true 30-day incidence of
hospitalization with hyponatremia after starting a second-generation antidepressant in our
region. Fourth, we could not investigate the long-term risk of hyponatremia, as the
median duration of follow-up for second-generation antidepressant use was only 82 (IQR
30 to 286) days. Several factors might have influenced the short duration observed in our
study, such as a switch to an alternate antidepressant or lack of adherence.50 Fifth, we did
not include the second-generation antidepressant bupropion or older classes of
antidepressants such as tricyclic antidepressants or monoamine oxidase inhibitors in our
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assessment of hyponatremia. In our region, bupropion is prescribed primarily for
smoking cessation purposes so we excluded this drug from consideration. In prior
publications, bupropion was less commonly implicated in the development of
hyponatremia;51 future investigations could consider a comparative effectiveness design
to compare the risk of hyponatremia between bupropion and other second-generation
antidepressants. Although older antidepressant drugs are still used in routine care, their
use has been declining, as second-generation antidepressants are generally safer. Sixth,
with our data sources we could not tell how symptomatic patients were from their
hyponatremia. Rather, all we could determine was that second-generation antidepressant
use compared to non-use was associated with a higher risk of a combined outcome of
hospitalization with hyponatremia and delirium (where delirium was assessed with
database codes that lack sensitivity and with a limited number of events). Finally, given
our data sources we could only study older adults. Younger patients are often healthier
and may not be as susceptible to hyponatremia from second-generation antidepressants.

4.5 Conclusion
In conclusion, initiation of a second-generation antidepressant in routine care in the nonhospitalized setting is associated with an approximate five-fold relative increase in the
30-day risk of hospitalization with hyponatremia. However, the absolute increase in the
30-day incidence is low.
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CHAPTER 5: Atypical Antipsychotic Drugs and
Hyponatremia in Older Adults: A Population-based Cohort
Study*

*A version of this chapter has been published elsewhere as: Gandhi S, McArthur E, Reiss
JP, Mamdani MM, Hackam DG, Weir MA, Garg AX. Atypical antipsychotic medications
and hyponatremia in older adults: A population-based cohort study. Can J Kidney Health
Dis. 2016; 3:21.
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5.1 Introduction
Hyponatremia is one of the most frequently encountered electrolyte disorders in clinical
practice, and occurs in about 7% to 11% of community dwelling older adults.1 Older
adults are particularly susceptible to developing hyponatremia with age-related changes
in homeostatic mechanisms, and an increased number of comorbidities and concomitant
medications known to cause hyponatremia.2 As the sodium concentration falls below 135
mmol/L, there is a greater potential for clinical consequences such as confusion, seizures,
respiratory arrest, fractures, or even death.3–6
Atypical antipsychotic drugs are routinely prescribed for the treatment of
psychiatric disorders such as schizophrenia as well as behavioral and psychological
symptoms of dementia. The use of atypical antipsychotics has been rising, with nearly 15
million prescriptions dispensed in Canada in 2012.7,8 Frequently prescribed atypical
antipsychotics include risperidone, olanzapine, and quetiapine. A number of case reports
have suggested a possible association between atypical antipsychotics and
hyponatremia.9–14 Hyponatremia from older typical antipsychotics has also been
observed, but their use has been declining in routine care, primarily due to their adverse
side effect profile.7,15,16 Like other psychotropic drugs, it is suspected that atypical
antipsychotics can induce hyponatremia by either stimulating antidiuretic hormone
release from the brain or enhancing antidiuretic hormone activity in the kidneys.13
Currently, there are no reliable estimates of incidence or risk of hyponatremia from
atypical antipsychotic drugs in older adults. To date, only one case-control study has
examined the association between atypical antipsychotic drug use and hyponatremia.17
This study looked at a series of voluntary reports of adverse drug reactions made to the
World Health Organization, and found that use of olanzapine and risperidone (as well as
other atypical antipsychotics) was associated with more reporting of hyponatremia
compared to other adverse drug reactions. However, data from spontaneous reporting
systems is subject to biases.18 This may be one reason why the risk of hyponatremia from
atypical antipsychotics is reported inconsistently across popular drug prescribing
references, such as UpToDate® and the Canadian Compendium of Pharmaceuticals and
Specialties.
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We conducted this population-based cohort study in older adults to understand the
association between new use of atypical antipsychotics and the 30-day risk of
hospitalization with hyponatremia relative to non-users of atypical antipsychotics.

5.2 Methods
5.2.1

Study Design and Setting

We used multiple linked health administrative databases to conduct a retrospective,
population-based, cohort study of older adults from 1 June 2003 through 1 March 2012 in
Ontario, Canada. There are over two million residents 65 years and older in Ontario who
have universal access to hospital care, physician services, and prescription drug
coverage.19 These datasets were linked using unique encoded identifiers and were
analyzed at the Institute for Clinical Evaluative Sciences (ICES). We conducted this
study according to a pre-specified protocol that was approved by the institutional review
board at Sunnybrook Health Sciences Centre, Toronto, Canada. The reporting of this
study followed the Strengthening the Reporting of Observational Studies in
Epidemiology guidelines (Appendix C Table C-1).20

5.2.2

Data Sources

We identified information related to patients, drugs, covariates, and outcomes from nine
linked databases. For all residents with a valid provincial health card, we obtained
demographic information and vital statistics using the Ontario Registered Persons
Database. We used the Ontario Drug Benefits program database to identify exposure to
atypical antipsychotics and other medications. This database accurately records
prescription claims for outpatients over the age of 65 (error rate of 0.7%).21 We defined
covariates using the Ontario Health Insurance Plan database, which contains information
on health claims for inpatient and outpatient physicians’ services. We identified
diagnostic and procedural information on all hospitalizations and emergency department
visits using the Canadian Institute for Health Information’s Discharge Abstract Database
and National Ambulatory Care Reporting System database, respectively. Similarly, we
used the Ontario Mental Health Reporting System database to obtain mental health
information. We obtained atypical antipsychotic prescriber information from the ICES
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Physician Database. We identified serum sodium measurements using datasets from
Gamma-Dynacare Medical Laboratories (a laboratory service provider in Ontario) and
Cerner (an electronic medical record system that is used by 12 hospitals in southwestern
Ontario). We have used these databases to research adverse drug events and health
outcomes in several other studies (including outcomes of hyponatremia and health
services).22–26
The databases were complete for almost all variables considered in this study, with
the exception of income quintile, rural residence, and prescriber information (missing in
less than 0.5%, 0.1%, and 11% of older adults, respectively). We used codes from the
International Classification of Diseases, 9th revision (ICD-9) and 10th revision (ICD-10)
to ascertain baseline comorbidities in the five years prior to cohort entry. Outcomes were
identified using only ICD-10 codes as these events would have occurred following
implementation of this coding system in 2002. The diagnostic codes used in our study are
detailed in Appendix C Table C-2.

5.2.3

Cohort

For our exposed group, we considered all older adults in Ontario who had evidence of a
hospital diagnosis or physician claim for a psychiatric condition (dementia,
schizophrenia, bipolar disorder, unipolar depression/anxiety, or Parkinson’s disease)
within the previous five years and who commenced treatment with risperidone,
olanzapine or quetiapine (users). These are the atypical antipsychotics used most
frequently in our region. We defined new use as no prescriptions for any type of
antipsychotic drug in the prior six months. Patients could only be prescribed one atypical
antipsychotic so that we could compare mutually exclusive groups in subgroup analyses.
The date of the prescription served as the index date (cohort entry date). We then
identified a referent group of older adults from the Ontario population who were not
prescribed any kind of antipsychotic drug (non-users). We randomly assigned an index
date to non-users based on the distribution of index dates for the users.
We excluded the following individuals from analyses: (1) patients discharged from
hospital in the two days prior to their index date to ensure new outpatient antipsychotic
use (in the case of the users; or the possibility of a new outpatient atypical antipsychotic
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prescription in the case of non-users), and (2) patients with end-stage renal disease prior
to their index date since serum sodium levels are controlled through dialysis. We
excluded all patients with no outpatient medications of any kind dispensed in the 90 days
prior to their index date to ensure all were active users of the Ontario Drug Benefits
program.
Using a logistic regression model, we derived a propensity score for the predicted
probability of commencing treatment with an atypical antipsychotic drug. The propensity
score included 104 variables that were potentially associated with atypical antipsychotic
drug use and/or hospitalization with hyponatremia (Appendix C Table C-3).27 Then using
greedy matching, we matched 1:1 each atypical antipsychotic drug user to a non-user
based on the following characteristics: age (within two years); sex; index date (within 1
year); residential status (community-dwelling or long-term care); dementia,
schizophrenia, bipolar disorder, unipolar depression/anxiety, Parkinson’s disease, chronic
kidney disease, and congestive heart failure; diuretic use; constituency in the catchment
area where linked serum sodium data were available; and the logit of the propensity score
(within a caliper of ±0.2 standard deviations). A patient could only enter the study once.

5.2.4

Outcomes

We evaluated all outcomes within 30 days of the antipsychotic prescription as we
expected fewer crossovers to occur between the user and non-user groups.
5.2.4.1 Primary Outcome
We evaluated the 30-day risk of hospitalization with hyponatremia by including
hospitalization records with evidence of ICD-10 code E87.1 (hypo-osmolality or
hyponatremia) in any one of 25 diagnostic fields in the CIHI Discharge Abstract
Database. Based on a validation study conducted in our region, the presence of code
E87.1 in a given hospitalization identifies older patients with a median serum sodium
value of 125 mmol/L at hospital admission (interquartile range [IQR] 120 to 130
mmol/L), whereas its absence identifies a median value of 137 mmol/L (IQR 135 to 139
mmol/L). The specificity of the code is over 99%, while sensitivity is 11% for
hyponatremia defined as a serum sodium concentration ≤132 mmol/L. The sensitivity of
the code increases when hyponatremia is defined by lower serum sodium
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concentrations.28 The full study is included in Appendix E.

5.2.5

Statistical Analyses

We used standardized differences to compare baseline characteristics between user and
non-user groups. This metric describes differences between the group means relative to
the pooled standard deviation with a value less than 10% indicating adequate balance.29
We used conditional logistic regression to estimate odds ratios and 95% confidence
intervals (CIs). We evaluated the association between atypical antipsychotic drug use and
a hospitalization with hyponatremia in the following pre-specified subgroups: 1) atypical
antipsychotic type (risperidone, quetiapine, or olanzapine), 2) atypical antipsychotic dose
(higher dose vs. normal dose; higher dose defined by a higher than median starting daily
dose for the study cohort) (precise definitions in Appendix C Table C-2), 3) chronic
kidney disease, 4) congestive heart failure, and 5) diuretic use. We identified chronic
kidney disease and congestive heart failure using separate validated algorithms of
hospital diagnostic codes.30,31 In the case of antipsychotic drug type and dose, we defined
the subgroup by the characteristic in users with non-users following their matched user.
We determined subgroup p-values using interaction terms in the logistic regression
models.
All odds ratios were approximated as relative risks (appropriate given the
incidences observed). We expressed risk in both relative and absolute terms. We
performed all analyses using SAS version 9.4 (SAS Institute, Cary, North Carolina). Any
results where the number of events were less than six were not allowed to be reported in
order to minimize any risk of patient re-identification in our data sources (which we
described as too few events). Detailed methods are provided in Chapter 3.
5.2.5.1 Additional Analyses
We tested the specificity of our findings by evaluating the 30-day risk of hospitalization
with bowel obstruction in the two groups. We expected antipsychotic use would not alter
the risk of bowel obstruction, and reasoned that a null association with this outcome
would enhance causal inference in our hyponatremia analyses.
We re-evaluated the outcome of hospitalization with hyponatremia in our existing
cohort at a time that preceded the index date by 90 days (a time when no patient would
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have been prescribed an atypical antipsychotic drug). After re-applying exclusion criteria
at this time, we followed retained matched pairs to re-assess the 30-day risk. In this
analysis, a null association would enhance the assertion that the two groups were similar
in their baseline risk for hyponatremia in the absence of atypical antipsychotic drug use.
We also examined the risk factors associated with hospitalization with
hyponatremia separately in users and non-users using multiple logistic regression. The
risk factors that we considered were age (per year); sex; chronic kidney disease,
congestive heart failure, diabetes, liver disease, cancer, hypothyroidism, previous
hyponatremia; and receipt of a diuretic, antiepileptic, antidepressant, and antineoplastic
drugs.

5.3 Results
5.3.1

Baseline Characteristics

Prior to matching, we identified 92 090 antipsychotic users and 175 836 non-users who
were eligible for our study. Cohort selection and baseline characteristics are presented in
Figure 5-1 and Table 5-1, respectively. In the unmatched cohort antipsychotic users
compared to non-users were more likely to be older and reside in a long-term care
facility, and prior to cohort entry were more likely to receive a greater number of
medications and health care services compared to non-users. We successfully matched 58
008 users to 58 008 non-users, and baseline characteristics were well balanced between
the two groups (104 characteristics measured; full baseline table presented in Appendix C
Table C-4). The mean age was 81 years and 67% were women. Nearly 48% of the users
were prescribed risperidone and family physicians wrote 70% of the prescriptions.
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119 790 Ontario residents >65 years of age with
evidence of a baseline psychiatric disorder who
were dispensed a new oral outpatient
prescription for one of the following atypical
antipsychotic drugs prior to the index date:
quetiapine, olanzapine or risperidone (from
June 2003 to March 2012).

26 619 Discharged from a hospital
or emergency room in the two days
prior to the index date

608 147 Ontario residents >65 years of age with
evidence of a baseline psychiatric disorder who
were not dispensed an oral outpatient
prescription for any antipsychotic drug in the six
months prior to the randomly assigned index
date (from June 2003 to March 2012).

409 945 Without at least one
outpatient medication dispensed in
the 90 days prior to the index date
Excluded

1081 Evidence of end-stage renal
disease prior to the index date

16 325 Discharged from a hospital or
emergency room in the two days prior
to the index date
6041 Evidence of end-stage renal
disease prior to the index date

92 090

58 008 antipsychotic
users

Figure 5-1. Cohort selection

Remaining

Matched
(1:1)

175 836

58 008 antipsychotic
non-users
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Table 5-1. Baseline characteristics of atypical antipsychotic users and non-users*
Characteristic
Antipsychotic
users
(n=92 090)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residence
Long-term care
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Dementia
Schizophrenia
Bipolar disorder
Unipolar depression/anxiety
Parkinson’s disease
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancerd
Diabetes mellitus
Pneumonia
Coronary artery diseasee
Angina
Previous hyponatremia
Lung disease

Unmatched
Antipsychotic
non-users
(n=175 836)

Standardized
Differencea

Antipsychotic
users
(n=58 008)

Matched
Antipsychotic
non-users
(n=58 008)

Standardized
Differencea

81 (7.8)
58 647 (63.7%)

79 (7.9)
111 968 (63.7%)

29.2%
0

81 (7.7)
38 736 (66.8%)

81 (7.7)
38 736 (66.8%)

0.3%
0

20 160 (21.9%)
18 854 (20.5%)
17 999 (19.6%)
17 607 (19.1%)
17 058 (18.5%)
11 759 (12.8%)
32 644 (35.5%)

37 436 (21.3%)
36 395 (20.7%)
33 861 (19.3%)
33 206 (18.9%)
34 373 (19.6%)
23 484 (13.4%)
26 705 (15.2%)

1.5%
0.6%
0.7%
0.6%
2.6%
1.7%
47.9%

12 331 (21.3%)
11 888 (20.5%)
11 630 (20.1%)
11 213 (19.3%)
10 946 (18.9%)
7671 (13.2%)
16 409 (28.3%)

13 081 (22.6%)
12 057 (20.8%)
11 408 (19.7%)
10 847 (18.7%)
10 615 (18.3%)
7557 (13.0%)
16 409 (28.3%)

3.1%
0.7%
1.0%
1.6%
1.5%
0.6%
0

1.68 (1.8)
13.90 (4.2)

1.56 (1.8)
13.69 (4.0)

6.7%
5.2%

0.87 (1.5)
13.37 (4.2)

0.94 (1.5)
13.69 (4.1)

4.7%
7.8%

71 933 (78.1%)
14 838 (16.1%)
10 174 (11.1%)
28 419 (30.9%)
8652 (9.4%)
19 029 (20.7%)
8127 (8.8%)
65 205 (70.8%)
2980 (3.2%)
10 213 (11.1%)
12 145 (13.2%)
14 245 (15.5%)
8006 (8.7%)
31 417 (34.1%)
20 496 (22.3%)
3403 (3.7%)
26 237 (28.5%)

92 049 (52.4%)
14 072 (8.0%)
11 377 (6.5%)
74 574 (42.4%)
19 015 (10.8%)
33 627 (19.1%)
15 323 (8.7%)
131 562 (74.8%)
6388 (3.6%)
20 354 (11.6%)
25 758 (14.7%)
30 491 (17.3%)
12 843 (7.3%)
61 334 (34.9%)
42 264 (24.0%)
5416 (3.1%)
53 842 (30.6%)

56.2%
25.1%
16.3%
24.2%
4.7%
3.9%
0.4%
9.0%
2.2%
1.5%
4.2%
5.1%
5.1%
1.6%
4.2%
3.4%
4.7%

44 715 (77.1%)
4756 (8.2%)
3295 (5.7%)
15 038 (25.9%)
3780 (6.5%)
10 038 (17.3%)
3140 (5.4%)
40 929 (70.6%)
1664 (2.9%)
6222 (10.7%)
7321 (12.6%)
17 590 (30.3%)
4237 (7.3%)
18 641 (32.1%)
12 166 (21.0%)
1766 (3.0%)
15 489 (26.7%)

44 715 (77.1%)
4756 (8.2%)
3295 (5.7%)
15 038 (25.9%)
3780 (6.5%)
10 038 (17.3%)
3140 (5.4%)
40 419 (69.7%)
1807 (3.1%)
6198 (10.7%)
7864 (13.6%)
18 457 (31.8%)
4755 (8.2%)
19 184 (33.1%)
12 462 (21.5%)
2111 (3.6%)
16 891 (29.1%)

0
0
0
0
0
0
0
1.9%
1.5%
0.1%
2.8%
3.2%
3.3%
2.0%
1.3%
3.3%
5.4%
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Seizure
Acute kidney injury
Acute urinary retention
Delirium
Peripheral vascular disease
Concurrent medication usef
Number of unique drug products, mean
(SD)
Antiepileptics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Healthcare contacts, mean (SD)g
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Healthcare useh
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Colorectal cancer screening
Cervical cancer screening
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Computed tomography of the head

1782 (1.9%)
3453 (3.8%)
3337 (3.6%)
7112 (7.7%)
1939 (2.1%)

2780 (1.6%)
5616 (3.2%)
5179 (3.0%)
6013 (3.4%)
4061 (2.3%)

2.7%
3.0%
3.8%
18.8%
1.4%

879 (1.5%)
1482 (2.6%)
1650 (2.8%)
3424 (5.9%)
1043 (1.8%)

1087 (1.9%)
1501 (2.6%)
1774 (3.1%)
2546 (4.4%)
1238 (2.1%)

2.8%
0.2%
1.3%
6.9%
2.4%

9.71 (6.4)

8.94 (5.5)

13.0%

8.91 (5.9)

9.41 (5.6)

8.7%

10 970 (11.9%)
46 600 (50.6%)
14 245 (15.5%)
3240 (3.5%)
16 580 (18.0%)
5390 (5.9%)
31 051 (33.7%)
39 596 (43.0%)
13 638 (14.8%)
22 902 (24.9%)
26 099 (28.3%)
29 558 (32.1%)
33 031 (35.9%)

16 409 (9.3%)
65 227 (37.1%)
21 969 (12.5%)
6 863 (3.9%)
33 499 (19.1%)
11 025 (6.3%)
61 131 (34.8%)
88 563 (50.4%)
30 146 (17.1%)
49 786 (28.3%)
55 259 (31.4%)
72 878 (41.5%)
45 988 (26.2%)

8.4%
27.5%
8.6%
2.0%
2.7%
1.8%
2.2%
14.8%
6.4%
7.8%
6.7%
19.5%
21.1%

5552 (9.6%)
25 197 (43.4%)
8526 (14.7%)
1958 (3.4%)
10 406 (17.9%)
3267 (5.6%)
18 611 (32.1%)
24 853 (42.8%)
8667 (14.9%)
14 642 (25.2%)
16 169 (27.9%)
19 171 (33.1%)
17 616 (30.4%)

6688 (11.5%)
26 871 (46.3%)
9307 (16.0%)
2151 (3.7%)
10 846 (18.7%)
3236 (5.6%)
18 665 (32.2%)
25 660 (44.2%)
9047 (15.6%)
15 011 (25.9%)
16 254 (28.0%)
19 514 (33.6%)
18 692 (32.2%)

6.4%
5.8%
3.7%
1.8%
2.0%
0.2%
0.2%
2.8%
1.8%
1.5%
0.3%
1.3%
4.0%

0.51 (0.9)
1.29 (2.1)
18.57 (18.0)
0.82 (3.6)
1.69 (7.5)

0.32 (0.8)
0.84 (1.6)
13.61 (13.1)
0.34 (2.1)
0.36 (2.5)

22.6%
24.7%
31.9%
16.9%
26.6%

0.40 (0.8)
1.04 (1.6)
15.84 (15.5)
0.58 (2.5)
0.64 (2.4)

0.39 (0.8)
1.00 (1.7)
16.30 (15.3)
0.49 (2.4)
0.40 (2.2)

1.3%
2.5%
3.0%
3.7%
10.0%

63 335 (68.8%)
4568 (5.0%)
742 (0.8%)
12 411 (13.5%)
4818 (5.2%)
10 653 (11.6%)
2047 (2.2%)
57 414 (62.4%)
5792 (6.3%)
3705 (4.0%)
26 927 (29.2%)

79 930 (45.5%)
9137 (5.2%)
2334 (1.3%)
27 264 (15.5%)
10 904 (6.2%)
29 013 (16.5%)
8290 (4.7%)
100 900 (57.4%)
18 558 (10.6%)
9327 (5.3%)
25 724 (14.6%)

48.5%
1.1%
5.1%
5.8%
4.2%
14.2%
13.7%
10.1%
15.4%
6.1%
35.9%

38 190 (64.8%)
2721 (4.7%)
414 (0.7%)
7247 (12.5%)
2962 (5.1%)
6767 (11.7%)
1447 (2.5%)
34 911 (60.2%)
4040 (7.0%)
2375 (4.1%)
13 261 (22.9%)

38 145 (65.8%)
2883 (5.0%)
477 (0.8%)
7355 (12.7%)
3032 (5.2%)
6823 (11.8%)
1427 (2.5%)
34 766 (59.9%)
4110 (7.1%)
2537 (4.4%)
12 896 (22.2%)

0.2%
1.3%
1.2%
0.6%
0.6%
0.3%
0.2%
0.5%
0.5%
1.4%
1.5%
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Chest x-ray
Pulmonary function test
Laboratory measurementsi
Evidence of baseline serum sodium
measurement, N (%)
Most recent serum sodium, mean (SD)

43 501 (47.2%)
4882 (5.3%)

69 077 (39.3%)
13 764 (7.8%)

16.1%
10.2%

24 600 (42.4%)
2901 (5.0%)

25 086 (43.3%)
3404 (5.9%)

1.7%
3.8%

14 346 (15.6%)

21 948 (23.8%)

20.9%

7242 (12.5%)

7242 (12.5%)

0

140.3 (3.5)

140.4 (3.2)

2.7%

140.4 (3.4)

140.3 (3.4)

4.4%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal
e Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
f Concurrent medication use in the six months preceding the index date were considered.
g Healthcare contacts in the year preceding the index date were considered.
h Healthcare use in the year preceding the index date was considered.
i Serum sodium measurements were obtained at a mean (SD) of 139 (101) days in users and 142 (100) days in non-users, prior to the index date.
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5.3.2

Primary Outcome

Results for the primary outcome are presented in Table 5-2. Atypical antipsychotic use
was associated with a greater 30-day risk of hospitalization with hyponatremia compared
to non-use (86/58 008 [0.15%] vs. 53/58 008 [0.09%]; relative risk 1.62 [95% CI 1.15 to
2.29]).
Results from subgroup analyses are presented in Figure 5-2. The relative
association between atypical antipsychotic drug use and hospitalization with
hyponatremia was not influenced by atypical antipsychotic type, atypical antipsychotic
dose, chronic kidney disease, congestive heart failure or diuretic use (all p-values for
interaction >0.05). Subgroup results for chronic kidney disease could not be presented as
there were too few events.

Table 5-2. 30-day risk of hospitalization with hyponatremia (defined by a hospital
diagnosis code) in atypical antipsychotic drug users and non-users
Events, No. (%)a
Antipsychotic Antipsychotic
users
non-usersc
(n=58 008)
(n=58 008)
Hospitalization with
hyponatremiab

86 (0.15)

53 (0.09)

Relative Risk
(95% CI)

Absolute Risk
Increase (95% CI), %

1.62 (1.15 to 2.29)

0.06 (0.02 to 0.10)

CI=confidence interval
a The event rates and absolute risk differences are underestimated as the hospital-based diagnosis codes
used to define the outcomes have high speciﬁcity but low sensitivity.
b The sensitivity and specificity of the code for hyponatremia is 11% and 99%, respectively30
c An antipsychotic non-user group was the referent.
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Events/At Risk, n/N (%)a
Antipsychotic user
Antipsychotic
(n=58 008)
non-user
(n=58 008)

Relative Risk
(95% CI)

P-value for
Interaction

Antipsychotic Drug Type
Risperidone
Olanzapine
Quetiapine

42/27 581 (0.15)
13/10 150 (0.13)
31/20 277 (0.15)

23/27 581 (0.08)
12/10 150 (0.12)
18/20 277 (0.09)

1.83 (1.10 to 3.04)
1.08 (0.49 to 2.37)
1.72 (0.96 to 3.08)

0.53

Antipsychotic Drug Doseb
Higher Dose
Normal Dose

27/19 791 (0.14)
59/38 217 (0.15)

17/19 791 (0.09)
36/38 217 (0.09)

1.64 (1.08 to 2.48)
1.59 (0.87 to 2.91)

0.93

Congestive Heart Failurec
Yes
No

27/10 038 (0.27)
59/47 970 (0.12)

15/10 038 (0.15)
38/47 970 (0.08)

1.80 (0.96 to 3.38)
1.55 (1.03 to 2.33)

0.70

Diuretic Used
Yes
No

45/19 618 (0.23)
41/38 390 (0.11)

29/19 618 (0.15)
24/38 390 (0.06)

1.55 (0.97 to 2.48)
1.71 (1.03 to 2.83)

0.78

Risk higher
with medication
use

Figure 5-2. The association between antipsychotic use and hospitalization with hyponatremia assessed in four subgroups*
CI=confidence interval.
*Antipsychotic type, Antipsychotic dose, chronic kidney disease, congestive heart failure and use of a diuretic. Sets of drug users and non-users were matched on
presence of chronic kidney disease, congestive heart failure, and baseline diuretic use. For antipsychotic type and dose, matched sets were categorized according
to this characteristic in users. Data marker size is proportional to the inverse of the source variance.
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is
underestimated for some outcomes because the code for hyponatremia has high speciﬁcity but low sensitivity.
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b Higher dose was defined as a higher than median daily dose. See Appendix C Table C-2 for definitions.
c Congestive heart failure has a sensitivity, specificity and positive predictive value of 84.3, 85.4, and 35.8%, respectively. 31
d Diuretic use includes potassium sparing and non-potassium sparing medications.
Chronic kidney disease was included in the test for interactions but was removed from presentation as there were too few events for meaningful analysis. This
was also done to comply with privacy regulations, to prevent the risk of re-identification when the size of the numerator is small (less than or equal to 5). Chronic
kidney disease was identiﬁed by using an algorithm of hospital diagnosis codes validated for older adults in the study region. The algorithm identiﬁed patients
with a median estimated glomerular ﬁltration rate of 38 mL/min/1.73m 2 (interquartile range, 27–52 mL/min/1.73m2), whereas its absence identiﬁed patients with
a median estimated glomerular ﬁltration rate of 69 mL/min/1.73m2 (interquartile range, 56–82 mL/min/1.73m2).30
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5.3.3

Additional Analyses

The risk of hospitalization with bowel obstruction was not significantly different between
atypical antipsychotic users and non-users (55/58 008 [0.09%] vs. 44/58 008 [0.08%];
relative risk 1.25 [95% CI 0.84 to 1.86]; absolute risk increase 0.02% [95% CI -0.01% to
0.05%]).
Baseline characteristics were very similar in the cohort that was assessed in the 90
days prior to the index date (Appendix C Table C-5; 42 698 retained matched pairs of
users and non-users). When we re-examined the 30-day risk of hospitalization with
hyponatremia at that time, we did not observe a significant difference between users and
non-users (relative risk 1.19 [95% CI 0.74 to 1.92]).
In our cohort, older age, cancer, and prior hyponatremia were significant risk
factors for future hyponatremia in atypical antipsychotic users (Table 5-3).
Table 5-3. Risk factors for hospitalization with hyponatremia in antipsychotic medication
users and non-users when each group was analyzed separately*

Hospitalization with hyponatremia
Older age (per year)
Women (vs. men)
Chronic kidney disease (yes vs. no)
Congestive heart failure (yes vs. no)
Diabetes (yes vs. no)
Liver disease (yes vs. no)
Cancer (yes vs. no)
Hypothyroidism (yes vs. no)
Previous hyponatremia (yes vs. no)
Diuretic use (yes vs. no)
Antiepileptic use (yes vs. no)
Antidepressant use (yes vs. no)
Antineoplastic use (yes vs. no)

Antipsychotic users
(n=58 008)

Antipsychotic non-users
(n=58 008)

Relative risk (95% CI)
1.04 (1.01 to 1.07)
1.36 (0.80 to 2.79)
1.44 (0.70 to 2.96)
1.22 (0.73 to 2.04)
0.74 (0.45 to 1.21)
1.51 (0.54 to 4.20)
1.84 (1.05 to 3.23)
1.19 (0.65 to 2.16)
8.21 (4.93 to 13.66)
1.56 (0.98 to 2.50)
1.25 (0.64 to 2.46)
1.24 (0.81 to 1.91)
0.78 (0.24 to 2.58)

Relative risk (95% CI)
1.02 (0.98 to 1.06)
2.36 (1.09 to 5.12)
1.04 (0.37 to 2.97)
1.13 (0.58 to 2.18)
1.09 (0.61 to 1.94)
1.18 (0.28 to 4.92)
0.78 (0.32 to 1.94)
0.71 (0.28 to 1.78)
7.99 (4.26 to14.95)
1.85 (1.03 to 3.32)
1.17 (0.52 to 2.63)
0.97 (0.56 to 1.68)
1.83 (0.53 to 6.28)

CI=confidence interval
* Separate multivariable logistic regression models created for atypical antipsychotic users and non-users.
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5.4 Discussion
Among older adults newly prescribed an atypical antipsychotic drug, we observed a
modest increase in the relative and absolute risks of hospitalization with hyponatremia in
users compared to non-users.
The results of this population-based study inform us about the nature of the
association between atypical antipsychotic drugs and hyponatremia. Our estimate is
similar to that obtained in a previous case-control study that used individual case safety
reports of hyponatremia to estimate a “reporting odds ratio” of 1.55 (95% CI 1.41 to
1.69).17 This is a measure of disproportionality that estimates the extent to which
hyponatremia is reported in association with an atypical antipsychotic drug relative to
reports of hyponatremia with other drugs. The low absolute risk observed in our study is
likely influenced by the low sensitivity of the hospital diagnosis code for hyponatremia
(~11%), which underestimates the true incidence by up to eight-fold.28 Currently,
UpToDate® a popular reference widely used by physicians, warns of the possibility of
hyponatremia and recommends monitoring the concentration of serum sodium in older
adults upon initiation of an atypical antipsychotic drug.32–34 Another important physician
reference in our region, the Canadian Compendium of Pharmaceuticals and Specialties,
does not provide information or recommendations related to hyponatremia with atypical
antipsychotic medications.35–37 Updates to these product monographs are warranted to
make physicians aware of this risk.
Unlike with other psychotropic medications, such as selective serotonin or
norepinephrine reuptake inhibitors (second-generation antidepressants), there is only a
modest risk of hospitalization with hyponatremia from atypical antipsychotic drugs. In
the current study, we could not corroborate our primary findings using laboratory data as
there were too few events in this subpopulation. Additionally, we could not confirm if
patients who did not present to hospital also had hyponatremia, as again there were a
limited number of events to evaluate the outcome of outpatient hyponatremia (using data
from outpatient laboratories). It also would have been useful to know if the hyponatremia
observed in our study was symptomatic (i.e. if patients presented to hospital with both
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hyponatremia and delirium). However, this too was not possible given the limited number
of events. The risk factors for hospitalization with hyponatremia among atypical
antipsychotic drug users were older age, cancer, and a history of hyponatremia.
There are important strengths of our study. The use of Ontario’s healthcare
databases including data on universal prescription drug coverage allowed us to estimate a
rare adverse event with good precision in a large representative sample size. We used a
propensity score-matched design to reduce confounding that is often found in
observational studies. In addition, the results of our two additional analyses support our
primary study finding. The null association seen with atypical antipsychotic drug use and
bowel obstruction provides some reassurance that residual confounding is unlikely to
have influenced the primary results.
There are some limitations of our study. First, as the sensitivity of the hospital
diagnosis code for hyponatremia was low, we would have preferred to supplement our
primary findings using serum sodium laboratory values. With codes however, we were
able to capture those patients whose hyponatremia would be considered clinically
significant (median serum sodium level of 125 mmol/L [IQR 120-130 mmol/l] as found
in our validation study).28 Second, although our user and non-user groups were wellbalanced after matching, unmeasured confounding variables may have influenced our
estimates of risk. For example, it is possible that the patients who used atypical
antipsychotics in our study were more likely than non-users to experience psychogenic
polydipsia, a condition characterized by excessive fluid consumption.38 Third, we could
not be confident of the indication for which the atypical antipsychotic drug was
prescribed. Both users and non-users had evidence of a psychiatric condition in the
previous five years. This restriction was applied to ensure that we had a large
representative sample of similar types of patients in our study. Fourth, we were unable to
look at the long-term risk of hyponatremia, because the median length of time in followup for antipsychotic use was only 57 days. When an antipsychotic is prescribed, only
short duration use is encouraged, particularly in those with dementia (6-12 weeks), which
is an unapproved indication.39,40 Alternatively, poor adherence to the medication could
also explain the short duration observed.41,42 Finally, we could only study older adults
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within our data sources. Younger patients are often healthier and may be less susceptible
to drug-induced hyponatremia.
To our knowledge, this is the first population-based study to examine the
association between atypical antipsychotic drug use and hyponatremia among older
adults. We recommend that additional studies be conducted in this area. Future studies
should consider using serum sodium laboratory values to better estimate the risk of
hyponatremia from atypical antipsychotics. In patients who are chronic users of
antipsychotics, future studies could examine whether there is a long-term risk of
hyponatremia from these drugs. Even mild, chronic forms of hyponatremia can have
important consequences, negatively impacting quality of life.43 Better knowledge of these
risks can help to guide drug prescribing, monitoring and interventions to prevent or
mitigate adverse drug events. For now, we recommend judicious prescribing of atypical
antipsychotic drugs to minimize adverse events. When a patient presents with severe
hyponatremia, atypical antipsychotic drugs can be considered as a potential reason for the
finding.

5.5 Conclusion
We found a modest increase in the 30-day risk of hospitalization with hyponatremia
among older adults prescribed an atypical antipsychotic drug compared to those who
were not. The association was less pronounced than seen with other psychotropic drugs.
Additional studies, preferably using laboratory data, are needed to ensure reproducibility
of the findings.
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CHAPTER 6: Antiepileptic Drugs and Hyponatremia in Older
Adults: Two Population-based Cohort Studies*

*A version of this chapter has been accepted for publication as: Gandhi S, McArthur E,
Mamdani MM, Hackam DG, McLachlan RS, Weir MA, Burneo JG, Garg AX.
Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort
studies. Epilepsia. 2016.
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6.1 Introduction
The incidence of epilepsy is highest in old age, with an estimated 60 to 135 new cases per
100,000 older adults each year.1,2 Carbamazepine, valproic acid, phenytoin and
topiramate are commonly used antiepileptic drugs for the control of focal and generalized
seizures, and can be initiated as monotherapy.3–6 These drugs are also often used in
treatment of non-epileptic conditions such as pain and psychiatric disorders.
Hyponatremia is an adverse effect of several psychotropic drugs, including
carbamazepine and valproic acid, which is suspected to occur mainly through the
syndrome of inappropriate antidiuretic hormone secretion.7 A decrease in the serum
sodium concentration can sometimes result in symptomatic hyponatremia, leading to
hospitalization or death.8,9 These risks are of particular concern in older adults who often
have altered physiology, have multiple comorbidities, and use multiple drugs.
The reported incidence of carbamazepine-induced hyponatremia ranges widely
from less than 1% to 40%.10 Several small clinical studies have noted decreases in the
concentration of serum sodium following carbamazepine use, but most were uncontrolled
and none quantified the magnitude of risk.11–18 Hyponatremia with valproic acid was
identified in a single case-control study but it is not known if phenytoin or topiramate
associate with hyponatremia.19 Based on a few small studies, phenytoin was found to
reverse hyponatremia by inhibiting antidiuretic hormone release, but results were
inconsistent.20,21 A product monograph for topiramate lists hyponatremia as a rare
adverse event when used with other antiepileptic drugs, although no studies have
evaluated this association.22
We examined the 30-day risk of hospitalization with hyponatremia associated with
initiating carbamazepine, valproic acid, phenytoin or topiramate in the non-hospitalized
setting relative to no antiepileptic use.
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6.2 Methods
6.2.1

Study Design and Setting

We conducted two population-based, retrospective cohort studies in Ontario, Canada,
among adults over 65 years between 1 June 2003 and 1 March 2015. Over two million
older adults in Ontario have universal access to hospital care, physician services, and
prescription drug coverage.23 These datasets were linked using unique encoded identifiers
and analyzed at the Institute for Clinical Evaluative Sciences (ICES). The reporting of
this study followed the Strengthening the Reporting of Observational Studies in
Epidemiology guidelines (Appendix D Table D-1).24 This study was approved by the
institutional review board at Sunnybrook Health Sciences Centre, Toronto, Canada.

6.2.2

Data Sources

We used nine linked databases to identify patient information, medication use, outcomes
and other important variables. We identified demographic information and vital statistics
using the Ontario Registered Persons Database. We used the Ontario Drug Benefits
program database to identify prescriptions for antiepileptic drugs and other medications.
For outpatients over the age of 65, this database records prescription claims with an error
rate of 0.7%.25 We defined several variables using the Ontario Health Insurance Plan
database, which contains information on health claims for inpatient and outpatient
physicians’ services. We obtained diagnostic and procedural information on all
hospitalizations and emergency department visits using the Canadian Institute for Health
Information’s Discharge Abstract Database and National Ambulatory Care Reporting
System database, respectively. We used the Ontario Mental Health Reporting System
database to obtain information on mental health admissions. We used the ICES Physician
Database to ascertain study antiepileptic drug prescriber information. In a subpopulation,
we obtained serum sodium laboratory measurements using datasets from GammaDynacare Medical Laboratories (an outpatient laboratory service provider in Ontario) and
Cerner (an electronic medical record system used by 12 hospitals in southwestern Ontario
available from June 2003 to March 2012). We have used these databases to research
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adverse drug events and health outcomes in other studies (including outcomes of
hyponatremia and health services).26–28
We used the International Classification of Diseases, 9th revision (ICD-9) and 10th
revision (ICD-10) to ascertain baseline comorbidities, and only ICD-10 to identify
outcomes as these events occurred after the implementation of this coding system in 2002
(codes detailed in Appendix D Table D-2). The databases were complete for all variables
considered in this study, except for prescriber information, income quintile, and
rural/urban residence, which were missing in less than 12%, 0.5%, and 0.05%,
respectively.

6.2.3

Cohorts

Users: We established two cohorts of older adults who were newly dispensed an
outpatient antiepileptic drug of interest. The first cohort consisted of those dispensed
carbamazepine (referred to as carbamazepine users), an antiepileptic drug where a risk of
hyponatremia is well appreciated. The second cohort consisted of those dispensed any
one of valproic acid, phenytoin, or topiramate (referred to as V-P-T users), three
antiepileptic drugs where the potential risk of hyponatremia is less understood. We
considered any one of V-P-T as a single group of users in our primary analysis to
maximize the sample size and statistical power. We defined the index date (cohort entry
date) as the date of the prescription for the antiepileptic drug. We considered only new
users of these drugs by excluding patients who received a prescription for any type of
antiepileptic drug in the six months preceding the index date. Patients could only be
dispensed one of the four aforementioned antiepileptic drugs so that in additional
analyses we could compare mutually exclusive groups. Each patient could enter either of
the two cohorts only once.
Non-users: For each cohort study, we identified a group of older adults from the Ontario
population who did not have a prescription for any type of antiepileptic drug in the six
months prior to a randomly assigned index date that was assigned based on the
distribution of index dates of the antiepileptic drug users. A non-user was eligible to be a
match in both cohorts.
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From both the user and non-user groups, we excluded the following patients: i)
those with no outpatient medications of any kind dispensed in the 90 days prior to their
index date to ensure active use of the provincial universal drug benefit program, ii) those
discharged from a hospital or emergency department in the two days prior to their index
date to ensure these were new outpatient antiepileptic prescriptions (in the case of users;
or the possibility of a new outpatient antiepileptic prescription for non-users), and iii)
those with end-stage renal disease prior to their index date since serum sodium
concentrations are controlled through dialysis.
Using a logistic regression model, we derived propensity scores for the predicted
probability of receiving antiepileptic treatment given a set of characteristics that were
potentially related to antiepileptic treatment and/or hospitalization with hyponatremia
(Appendix D Table D-3).29 Using greedy matching, we matched each carbamazepine user
1:3 to non-users and each V-P-T user 1:2 to non-users, based on the following
characteristics: age (within two years); sex; index date (within 1 year); residential status
(community-dwelling or long-term care); evidence of epilepsy/seizure, chronic kidney
disease, congestive heart failure, and diuretic use; constituency in the catchment area
where linked serum sodium data were available; and the logit of the propensity score
(within a caliper of ±0.2 standard deviations).
Given that treatment allocation was decided based on routine care, propensity score
matching was used to ensure user and non-user groups were balanced on a wide range of
characteristics. The matching ratios were selected in order to maximize precision while
minimizing the loss of antiepileptic drug users in the respective cohorts.

6.2.4

Outcomes

We evaluated all outcomes within 30 days of the index date. This timeframe was selected
to avoid crossover in drug therapy that could occur with longer periods of follow up.
6.2.4.1 Primary Outcome
The primary outcome was hospitalization with hyponatremia in the 30 days following the
index date, defined by evidence of ICD-10 code E87.1 (hypo-osmolality or
hyponatremia) in any one of 25 diagnostic fields during a given hospitalization. In our
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previous validation study, we found that the code had a sensitivity, specificity, and
positive predictive value of 11%, 99% and 82%, respectively. The presence of the code
for hyponatremia identified older patients with a median serum sodium value of 125
mmol/L at hospital admission (interquartile range [IQR] 120 to 130 mmol/L); when the
code was absent, the median value was 137 (IQR 135 to 139) mmol/L.30 The full study is
included in Appendix E.

6.2.5

Statistical Analyses

We used standardized differences to compare baseline characteristics between each user
and non-user group (a more appropriate method for the size of the studies). This metric
describes differences between the group means relative to the pooled standard deviation
with a value greater than 10% indicating imbalance.31 We used conditional logistic
regression to estimate odds ratios and 95% confidence intervals (CIs) for both cohorts.
All odds ratios were approximated as relative risks (appropriate given the incidences
observed). We expressed risk in both relative and absolute terms. We compared the two
estimates obtained from each cohort by calculating the relative risk ratio (assuming
independent samples).32
We also conducted five pre-specified subgroup analyses. We evaluated the 30-day
risk of hospitalization with hyponatremia for V-P-T use vs. non-use by antiepileptic drug
type (valproic acid, phenytoin, topiramate). In both carbamazepine and V-P-T cohorts,
we evaluated the association in the following subgroups: i) antiepileptic dose (high vs.
normal), ii) chronic kidney disease, iii) congestive heart failure, and iv) diuretic use. We
identified chronic kidney disease and congestive heart failure using validated algorithms
of hospital diagnosis codes from our region.33,34 In the case of antiepileptic type and dose,
we defined the subgroup by the characteristic in users, with non-users following their
matched user. We determined subgroup p-values using interaction terms in the
conditional logistic regression models.
We performed all analyses using SAS version 9.4 (SAS Institute, Cary, North
Carolina). Any results where the number of events were less than six were not allowed to
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be reported in order to minimize any risk of patient re-identification in our data sources
(which we described as too few events). Detailed methods are provided in Chapter 3.
6.2.5.1 Additional Analyses
First, among a subpopulation residing in a catchment area where linked laboratory data
were available, we evaluated the association between antiepileptic use and hospitalization
with hyponatremia within 30 days using serum sodium values (defined by a concentration
≤132 mmol/L) (when possible).35
Second, in another subpopulation for which information on outpatient laboratory
data were available, we examined the association between antiepileptic use and outpatient
hyponatremia within 30 days using serum sodium values (defined by a concentration
≤132 mmol/L).
Third, we evaluated the association between antiepileptic use and hospitalization
with bowel obstruction within 30 days. Since bowel obstruction was not expected to be
influenced by antiepileptic use, we reasoned that a null association with this outcome
would enhance causal inference in our hyponatremia analyses.36
Fourth, we explored which characteristics were associated with hospitalization with
hyponatremia both in carbamazepine and V-P-T users. The characteristics evaluated
included age (per year); sex; evidence of chronic kidney disease, congestive heart failure,
diabetes, liver disease, cancer, hypothyroidism, previous hyponatremia; and receipt of
diuretic, antidepressant, antipsychotic, and antineoplastic drugs.

6.3 Results
6.3.1

Baseline Characteristics

Prior to matching, we identified 24 905 carbamazepine users, 26 365 V-P-T users, and 1
289 530 non-users (cohort selection presented in Figure 6-1). In the unmatched cohorts,
compared to non-users, both carbamazepine and V-P-T users had higher comorbidity
scores, were dispensed a greater number of medications, were more likely to have a
recorded diagnosis of epilepsy/seizure, migraines, mood and anxiety disorders, and were
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more likely to have underwent magnetic resonance imaging and/or computed tomography
of the head. Carbamazepine users were more likely to be diagnosed with trigeminal
neuralgia and neuropathic pain, while V-P-T users were more likely to be diagnosed with
bipolar disorder. 21 191 carbamazepine users were matched 1:3 to 63 573 non-users and
20 155 V-P-T users were matched 1:2 to 40 310 non-users. Less than 5% of non-users
were the same adults in both cohorts. In both matched cohorts, the standardized
difference was at most 10% across the 120 characteristics measured (Tables 6-1 and 6-2;
full tables presented in Appendix D Tables D-4 and D-5). Among carbamazepine users
and non-users, the mean age was 76 years, 63% were women, and 5% resided in a longterm care facility. Among V-P-T users and non-users, the mean age was 76 years, 58%
were women, and 22% resided in a long-term care facility. In both cohorts, family
physicians were the most frequent antiepileptic prescribers (carbamazepine, 72%; V-P-T,
64%), and the mean (standard deviation) baseline sodium value in both users and nonusers when available in our data sources was 140 (3) mmol/L.
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69 449 Ontario residents >65 years of age who
were dispensed a new oral outpatient
prescription for one of the following antiepileptic
drugs prior to the index date: carbamazepine,
valproic acid, phenytoin or topiramate (from
June 2003 to March 2015).

17 640 Discharged from a hospital
or emergency department in the two
days prior to the index date

1 744 884 Ontario residents >65 years of age
who were not dispensed an oral outpatient
prescription for any antiepileptic drug in the six
months prior to the randomly assigned index
date (from June 2003 to March 2015).

431 518 Without at least one
outpatient medication dispensed in
the 90 days prior to the index date
Excluded

539 Evidence of end-stage renal
disease prior to the index date

51 270

17 524 Discharged from a hospital in
the two days prior to the index date
6312 Evidence of end-stage renal
disease prior to the index date

Remaining

1 289 530

21 191
carbamazepine users

Matched
(1:3)

63 573
carbamazepine users

20 155
V-P-T users

Matched
(1:2)

40 310
V-P-T users

Figure 6-1. Cohort selection

136

Table 6-1. Baseline characteristics of carbamazepine users and non-users (1:3 matching ratio)*
Characteristic
Carbamazepine
users
(n= 24 905)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residencec
Long-term care
Comorbid conditionsd
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Epilepsy/seizuree
Migraine
Trigeminal neuralgia
Neuropathic pain
Bipolar disorder
Mood disorder
Anxiety disorder
Benign brain tumour
Brain cancer
Brain injury
Parkinson’s disease
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancerf

Unmatched
Antiepileptic
non-users
(n= 1 289 530)

Standardized
Differencea

Carbamazepine
users
(n=21 191)

Matched
Antiepileptic
non-users
(n=63 573)

Standardized
Differencea

76 (7.1)
15 436 (62.0%)

76 (7.2)
742 126 (57.6%)

0.8%
9.0%

76 (6.9)
13 284 (62.7%)

76 (6.8)
39 852 (62.7%)

0.3%
0

5388 (21.6%)
5171 (20.8%)
4960 (19.9%)
4798 (19.3%)
4495 (18.1%)
4108 (16.5%)
1691 (6.8%)

251 859 (19.5%)
269 597 (20.9%)
252 663 (19.6%)
253 301 (19.6%)
258 046 (20.0%)
182 927 (14.2%)
57 445 (4.5%)

5.2%
0.4%
0.8%
1.0%
5.0%
6.4%
10.2%

4508 (21.3%)
4415 (20.8%)
4314 (20.3%)
4099 (19.3%)
3855 (18.2%)
3461 (16.3%)
984 (4.6%)

13 924 (21.9%)
13 123 (20.6%)
12 960 (20.4%)
12 261 (19.3%)
11 305 (17.8%)
10 623 (16.7%)
2 952 (4.6%)

1.5%
0.5%
0.1%
0.1%
1.1%
1.0%
0

0.8 (1.5)
13.2 (4.3)

0.6 (1.3)
11.5 (4.2)

15.9%
41.0%

0.7 (1.4)
12.9 (4.2)

0.7 (1.4)
13.0 (4.1)

0
2.2%

12 046 (48.4%)
1780 (7.2%)
3235 (13.0%)
734 (3.0%)
143 (0.6%)
683 (2.7%)
11 293 (45.3%)
446 (1.8%)
234 (0.9%)
127 (0.5%)
671 (2.7%)
3516 (14.1%)
1640 (6.6%)
18 180 (73.0%)
842 (3.4%)
2571 (10.3%)
3553 (14.3%)

396 047 (30.7%)
39 661 (3.1%)
11 567 (0.9%)
18 587 (1.4%)
2154 (0.2%)
15 713 (1.2%)
463 445 (35.9%)
7600 (0.6%)
3001 (0.2%)
3896 (0.3%)
24 413 (1.9%)
144 842 (11.2%)
77 172 (6.0%)
953 061 (73.9%)
39 103 (3.0%)
121 865 (9.5%)
168 419 (13.1%)

36.7%
18.6%
49.0%
10.3%
6.7%
11.0%
19.2%
11.1%
9.3%
3.3%
5.4%
8.7%
2.5%
2.1%
2.0%
2.9%
3.5%

9802 (46.3%)
1358 (6.4%)
1377 (6.5%)
535 (2.5%)
561 (2.7%)
2442 (11.5%)
9335 (44.1%)
312 (1.5%
141 (0.7%)
97 (0.5%)
508 (2.4%)
2417 (11.4%)
920 (4.3%)
15 300 (72.2%)
686 (3.2%)
2186 (10.3%)
2969 (14.0%)

29 406 (46.3%)
4095 (6.4%)
3817 (6.0%)
1530 (2.4%)
1667 (2.6%)
7286 (11.5%)
28 233 (44.4%)
952 (1.5%)
437 (0.7%)
266 (0.4%)
1537 (2.4%)
7251 (11.4%)
2760 (4.3%)
45 888 (72.2%)
2026 (3.2%)
6474 (10.2%)
8803 (13.9%)

0
0.1%
2.0%
0.8%
0.2%
0.2%
0.7%
0.2%
0.3%
0.6%
0.1%
0
0
0
0.3%
0.4%
0.5%
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Diabetes mellitus
Diabetic neuropathy
Diabetic retinopathy
Pneumonia
Coronary artery diseaseg
Angina
Previous hyponatremia
Previous delirium
Peripheral vascular disease
Lung disease
Concurrent medication useh
Number of unique drug products, mean
(SD)
Antipsychotics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic antagonists
Statins
Benzodiazepines
Antibiotics
Healthcare contacts, mean (SD)i
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Healthcare usej
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography

7116 (28.6%)
172 (0.7%)
155 (0.6%)
1187 (4.8%)
7785 (31.3%)
5885 (23.6%)
536 (2.2%)
444 (1.8%)
585 (2.4%)
7392 (29.7%)

358 136 (27.8%)
3216 (0.3%)
5031 (0.4%)
43 322 (3.4%)
356 915 (27.7%)
245 038 (19.0%)
16 299 (1.3%)
14 306 (1.1%)
18 175 (1.4%)
310 878 (24.1%)

1.8%
6.5%
3.3%
7.1%
7.9%
11.3%
6.9%
5.6%
6.9%
12.6%

5943 (28.0%)
112 (0.5%)
109 (0.5%)
868 (4.1%)
6276 (29.6%)
4763 (22.5%)
378 (1.8%)
276 (1.3%)
417 (2.0%)
6067 (28.6%)

17 346 (27.3%)
275 (0.4%)
334 (0.5%)
2442 (3.8%)
18 916 (29.8%)
14 575 (22.9%)
1158 (1.8%)
919 (1.5%)
1290 (2.0%)
18 487 (29.1%)

1.7%
1.4%
0.2%
1.3%
0.3%
1.1%
0.3%
1.2%
0.4%
1.0%

8.9 (6.0)

7.1 (4.7)

33.5%

8.4 (5.6)

8.4 (5.4)

0.2%

1473 (5.9%)
7781 (31.2%)
4496 (18.1%)
960 (3.9%)
4136 (16.6%)
1578 (6.3%)
7563 (30.4%)
11 605 (46.6%)
6267 (25.2%)
6940 (27.9%)
7165 (28.8%)
9439 (37.9%)
6597 (26.5%)
9553 (38.4%)

48 323 (3.7%)
215 229 (16.7%)
225 528 (17.5%)
44 902 (3.5%)
204 370 (15.8%)
69 702 (5.4%)
383 139 (29.7%)
627 455 (48.7%)
224 624 (17.4%)
361 121 (28.0%)
385 357 (29.9%)
542 836 (42.1%)
216 925 (16.8%)
388 511 (30.1%)

10.1%
34.6%
1.5%
2.0%
2.1%
4.0%
1.4%
4.1%
19.0%
0.3%
2.4%
8.6%
23.6%
17.4%

1070 (5.1%)
6056 (28.6%)
3766 (17.8%)
799 (3.8%)
3513 (16.6%)
1278 (6.0%)
6053 (28.6%)
9815 (46.3%)
5286 (24.9%)
5789 (27.3%)
6011 (28.4%)
8082 (38.1%)
5289 (25.0%)
7870 (37.1%)

3276 (5.2%)
18 644 (29.3%)
10 934 (17.2%)
2416 (3.8%)
10 393 (16.4%)
3600 (5.7%)
18 324 (28.8%)
29 171 (45.9%)
16 556 (26.0%)
17 310 (27.2%)
17 643 (27.8%)
23 835 (37.5%)
16 528 (26.0%)
23 707 (37.3%)

0.5%
1.7%
1.5%
0.2%
0.6%
1.6%
0.6%
0.9%
2.5%
0.2%
1.4%
1.3%
2.4%
0.3%

0.6 (1.1)
1.0 (1.8)
12.8 (13.0)
0.2 (1.9)
0.4 (3.7)
0.4 (2.0)

0.4 (0.9)
0.5 (1.2)
9.0 (9.2)
0.1 (1.1)
0.1 (1.8)
0.1 (0.7)

19.4%
29.5%
34.4%
6.7%
9.1%
23.9%

0.6 (1.1)
0.8 (1.6)
11.5 (10.9)
0.1 (1.5)
0.3 (3.2)
0.31 (1.0)

0.6 (1.1)
0.8 (1.7)
11.5 (11.2)
0.1 (1.3)
0.3 (3.2)
0.2 (1.1)

0.9%
1.3%
0.4%
0
0.3%
6.6%

14 835 (59.6%)
1750 (7.0%)
380 (1.5%)
4106 (16.5%)

745 101 (57.8%)
53 990 (4.2%)
18 080 (1.4%)
190 435 (14.8%)

3.6%
12.4%
1.0%
4.7%

12 217 (57.7%)
1382 (6.5%)
2572 (12.1%)
1308 (6.2%)

36 567 (57.5%)
4024 (6.3%)
7795 (12.3%)
3971 (6.3%)

0.3%
0.8%
0.4%
0.3%
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Holter monitoring
Thyroid stimulating hormone
Magnetic resonance imaging of the head
Computed tomography of the head
Chest x-ray
Pulmonary function test
Electroencephalography
Laboratory measurementsk
Most recent serum sodium, N (%)
Most recent serum sodium, mean (SD)

1761 (7.1%)
13 181 (52.9%)
1581 (6.3%)
4443 (17.8%)
9594 (38.5%)
2127 (8.5%)
860 (3.5%)

70 045 (5.4%)
665 897 (51.6%)
20 572 (1.6%)
90 235 (7.0%)
388 460 (30.1%)
95 359 (7.4%)
4318 (0.3%)

6.8%
2.6%
24.5%
33.3%
17.8%
4.2%
23.0%

315 (1.5%)
11 073 (52.3%)
997 (4.7%)
3130 (14.8%)
7697 (36.3%)
1766 (8.3%)
454 (2.1%)

890 (1.4%)
32 855 (51.7%)
2942 (4.6%)
9373 (14.7%)
23 389 (36.8%)
5248 (8.3%)
1125 (1.8%)

0.7%
1.2%
0.4%
0.1%
1.0%
0.3%
2.7%

3631 (14.6%)
140.3 (3.4)

183 468 (14.2%)
140.6 (3.0)

1.0%
9.8%

2592 (12.2%)
140.4 (3.3)

7776 (12.2%)
140.5 (3.0)

0
4.1%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.32% missing values in matched users and non-users.
These patients were included in income quintile 3 (“average” income).
c There were less than 0.04% missing values in both matched users and non-users. These patients were included in the urban category.
d Comorbid conditions in the five years preceding the index date were considered.
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the
condition.
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
h Concurrent medication use in the six months preceding the index date were considered.
i Healthcare contacts in the year preceding the index date were considered.
j Healthcare use in the year preceding the index date was considered.
k Serum sodium measurements were obtained at a median (IQR) of 132 (58 to 229) days prior to the index date in users, and 134 (64 to 230) days in non-users.
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Table 6-2. Baseline characteristics of valproic acid (V), phenytoin (P), and topiramate (T) users and non-users (1:2 matching ratio)*
Characteristic

Demographic
Age, years, mean (SD)
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residencec
Long-term care
Comorbid conditionsd
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Epilepsy/seizuree
Migraine
Trigeminal neuralgia
Neuropathic pain
Bipolar disorder
Mood disorder
Anxiety disorder
Benign brain tumour
Brain cancer
Brain injury
Parkinson’s disease
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancerf
Diabetes mellitus

V-P-T
users
(n= 26 365)

Unmatched
Antiepileptic
non-users
(n= 1 289 530)

76 (7.7)
14 780 (56.1%)

76 (7.2)
742 126 (57.6%)

5.6%
3.0%

76 (7.7)
11 708 (58.1%)

76 (7.6)
23 416 (58.1%)

0%
0%

5693 (21.6%)
5424 (20.6%)
5020 (19.0%)
5078 (19.3%)
5044 (19.1%)
3601 (13.7%)
7071 (26.8%)

251 859 (19.5%)
269 597 (20.9%)
252 663 (19.6%)
253 301 (19.6%)
258 046 (20.0%)
182 927 (14.2%)
57 445 (4.5%)

5.1%
0.8%
1.4%
1.0%
2.2%
1.5%
64.7%

4321 (21.4%)
4182 (20.8%)
3897 (19.3%)
3908 (19.4%)
3847 (19.1%)
2835 (14.1%)
4482 (22.2%)

8818 (21.9%)
8280 (20.5%)
7799 (19.4%)
7687 (19.1%)
7726 (19.2%)
5887 (14.6%)
8964 (22.2%)

1.1%
0.5%
0%
0.8%
0.2%
1.5%
0%

1.2 (1.7)
13.5 (4.5)

0.6 (1.3)
11.5 (4.2)

37.5%
45.4%

0.9 (1.5)
13.0 (4.5)

0.9 (1.6)
13.0 (4.3)

0.7%
1.4%

16 029 (60.8%)
2461 (9.3%)
470 (1.8%)
476 (1.8%)
1176 (4.5%)
2461 (9.3%)
15 118 (57.3%)
898 (3.4%)
864 (3.3%)
716 (2.7%)
1522 (5.8%)
3933 (14.9%)
1990 (7.5%)
17 695 (67.1%)
978 (3.7%)
2733 (10.4%)
3910 (14.8%)
7416 (28.1%)

396 047 (30.7%)
39 661 (3.1%)
11 567 (0.9%)
18 587 (1.4%
2154 (0.2%)
15 713 (1.2%)
463 445 (35.9%)
7600 (0.6%)
3001 (0.2%)
3896 (0.3%)
24 413 (1.9%)
144 842 (11.2%)
77 172 (6.0%)
953 061 (73.9%)
39 103 (3.0%)
121 865 (9.5%)
168 419 (13.1%)
358 136 (27.8%)

63.3%
26.2%
7.7%
2.9%
28.9%
36.9%
43.9%
20.2%
23.3%
19.9%
20.3%
10.9%
6.2%
14.9%
3.8%
3.1%
5.1%
0.8%

11 602 (57.6%)
1831 (9.1%)
364 (1.8%)
350 (1.7%)
1962 (9.7%)
4556 (22.6%)
10 918 (54.2%)
466 (2.3%)
353 (1.8%)
360 (1.8%)
1024 (5.1%)
2294 (11.4%)
787 (3.9%)
13 253 (65.8%)
697 (3.5%)
2014 (10.0%)
2856 (14.2%)
5337 (26.5%)

23 204 (57.6%)
3878 (9.6%)
784 (1.9%)
730 (1.8%)
3773 (9.4%)
9210 (22.8%)
22 697 (56.3%)
928 (2.3%)
702 (1.7%)
595 (1.5%)
2001 (5.0%)
4588 (11.4%)
1574 (3.9%)
25 604 (63.5%)
1390 (3.4%)
3924 (9.7%)
5929 (14.7%)
9930 (24.6%)

0.0%
1.8%
1.0%
0.6%
1.3%
0.6%
4.3%
0.1%
0.1%
2.4%
0.5%
0.0%
0.0%
4.7%
0.1%
0.9%
1.5%
4.2%

Standardized
Differencea

V-P-T
users
(n= 20 155)

Matched
Antiepileptic
non-users
(n= 40 310)

Standardized
Differencea
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Diabetic neuropathy
Diabetic retinopathy
Pneumonia
Coronary artery diseaseg
Angina
Previous hyponatremia
Previous delirium
Peripheral vascular disease
Lung disease
Concurrent medication useh
Number of unique drug products, mean
(SD)
Antipsychotics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Antibiotics
Healthcare contacts, mean (SD)i
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Healthcare usej
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring

147 (0.6%)
128 (0.5%)
1910 (7.2%)
7848 (29.8%)
5275 (20.0%)
874 (3.3%)
1454 (5.5%)
573 (2.2%)
7547 (28.6%)

3216 (0.2%)
5031 (0.4%)
43 322 (3.4%)
356 915 (27.7%)
245 038 (19.0%)
16 299 (1.3%)
14 306 (1.1%)
18 175 (1.4%)
310 878 (24.1%)

4.9%
1.4%
17.4%
4.6%
2.5%
13.7%
24.8%
5.8%
10.3%

87 (0.4%)
65 (0.3%)
1174 (5.8%)
5593 (27.7%)
3802 (18.9%)
529 (2.6%)
766 (3.8%)
397 (2.0%)
5515 (27.4%)

159 (0.4%)
144 (0.4%)
2281 (5.7%)
11 096 (27.5%)
7598 (18.8%)
1037 (2.6%)
1436 (3.6%)
795 (2.0%)
11 110 (27.6%)

0.6%
0.6%
0.7%
0.5%
0.0%
0.3%
1.3%
0.0%
0.4%

9.1 (6.7)

7.1 (4.7)

35.3%

8.5 (6.3)

8.4 (5.6)

1.9%

6978 (26.5%)
10 751 (40.8%)
4096 (15.5%)
919 (3.5%)
4417 (16.8%)
1193 (4.5%)
6980 (26.5%)
10 045 (38.1%)
4027 (15.3%)
5673 (21.5%)
6746 (25.6%)
8540 (32.4%)
7956 (30.2%)
9449 (35.8%)

48 323 (3.7%)
215 229 (16.7%)
225 528 (17.5%)
44 902 (3.5%)
204 370 (15.8%)
69 702 (5.4%)
383 139 (29.7%)
627 455 (48.7%)
224 624 (17.4%)
361 121 (28.0%)
385 357 (29.9%)
542 836 (42.1%)
216 925 (16.8%)
388 511 (30.1%)

66.9%
55.2%
5.3%
0%
2.4%
4.1%
7.2%
21.4%
5.8%
15.1%
9.6%
20.2%
31.9%
12.2%

4369 (21.7%)
7617 (37.8%)
2991 (14.8%)
671 (3.3%)
3321 (16.5%)
863 (4.3%)
4951 (24.6%)
7706 (38.2%)
3266 (16.2%)
4343 (21.5%)
5085 (25.2%)
6516 (32.3%)
5633 (27.9%)
7114 (35.3%)

8520 (21.1%)
15 852 (39.3%)
5735 (14.2%)
1394 (3.5%)
6754 (16.8%)
1701 (4.2%)
9791 (24.3%)
14 777 (36.7%)
6583 (16.3%)
8205 (20.4%)
9607 (23.8%)
12 125 (30.1%)
11 896 (29.5%)
14 184 (35.2%)

1.3%
3.2%
1.7%
0.7%
0.7%
0.3%
0.6%
3.3%
0.3%
2.9%
3.2%
4.9%
3.5%
0.2%

0.8 (1.3)
1.3 (1.9)
17.2 (19.1)
0.6 (3.6)
2.7 (11.5)
0.8 (2.9)

0.4 (0.9)
0.5 (1.2)
9.0 (9.2)
0.1 (1.1)
0.1 (1.8)
0.1 (0.7)

33.0%
46.3%
58.4%
19.7%
38.2%
39.5%

0.7 (1.2)
1.0 (1.6)
14.5 (15.5)
0.4 (2.5)
1.2 (4.8)
0.5 (1.6)

0.6 (1.1)
1.0 (1.8)
14.2 (14.7)
0.3 (2.1)
0.8 (4.1)
0.4 (1.5)

3.5%
2.9%
2.1%
3.1%
10.1%
8.5%

17 093 (64.8%)
2639 (10.0%)
389 (1.5%)
4921 (18.7%)
2397 (9.1%)

745 101 (57.8%)
53 990 (4.2%)
18 080 (1.4%)
190 435 (14.8%)
70 045 (5.4%)

14.5%
22.8%
0.6%
10.5%
14.1%

12 566 (62.3%)
1554 (7.7%)
257 (1.3%)
3187 (15.8%)
1528 (7.6%)

24 958 (61.9%)
3378 (8.4%)
555 (1.4%)
6374 (15.8%)
3023 (7.5%)

0.9%
2.5%
0.9%
0.0%
0.3%
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Thyroid stimulating hormone
Magnetic resonance imaging of the head
Computed tomography of the head
Chest x-ray
Pulmonary function test
Electroencephalography
Laboratory measurementsk
Most recent serum sodium, N (%)
Most recent serum sodium, mean (SD)

15 359 (58.3%)
3094 (11.7%)
9758 (37.0%)
12 588 (47.7%)
1996 (7.6%)
2672 (10.1%)

665 897 (51.6%)
20 572 (1.6%)
90 235 (7.0%)
388 460 (30.1%)
95 359 (7.4%)
4318 (0.3%)

13.3%
41.5%
77.7%
36.7%
0.7%
45.1%

11 412 (56.6%)
1492 (7.4%)
5500 (27.3%)
8411 (41.7%)
1497 (7.4%)
826 (4.1%)

22 543 (55.9%)
2982 (7.4%)
11 201 (27.8%)
17 024 (42.2%)
3066 (7.6%)
1240 (3.1%)

1.4%
0.0%
1.1%
1.0%
0.7%
5.5%

3681 (14.0%)
140.3 (3.4)

183 468 (14.2%)
140.6 (3.0)

0.8%
7.9%

2253 (11.2%)
140.4 (3.3)

4506 (11.2%)
140.5 (3.1)

0%
3.1%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.35% and 0.32% missing values in matched users and nonusers, respectively. These patients were included in income quintile 3 (“average” income).
c There were less than 0.07% missing values in matched users and non-users. These patients were included in the urban category.
d Comorbid conditions in the five years preceding the index date were considered.
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the
condition.
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
h Concurrent medication use in the six months preceding the index date were considered.
i Healthcare contacts in the year preceding the index date were considered.
j Healthcare use in the year preceding the index date was considered.
k Serum sodium measurements were obtained at a median (IQR) of 128 (56 to 234) days prior to the index date in users, and 139 (63 to 237) days in non-users.
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6.3.2

Primary Outcome

Carbamazepine use was associated with a higher 30-day risk of hospitalization with
hyponatremia vs. non-use (relative risk 8.20 [95% CI 5.40 to 12.46]) (Table 6-3). The
relative association between carbamazepine use and hospitalization with hyponatremia
was modified by concomitant use of a diuretic (diuretic use: relative risk 14.00 [95% CI
6.82 to 28.76] vs. diuretic non-use: relative risk 5.71 [95% CI 3.37 to 9.69]; interaction pvalue = 0.049). The association was not modified by carbamazepine dose, congestive
heart failure, or chronic kidney disease (p-values for interaction > 0.05) (Figure 6-2).
Subgroup results for chronic kidney disease could not be presented (too few events).
V-P-T use was also associated with a higher 30-day risk of hospitalization with
hyponatremia vs. non-use (relative risk 2.62 [95% CI 1.57 to 4.36]) (Table 6-3). The
association between V-P-T use and hospitalization with hyponatremia was not modified
by drug type, dose, congestive heart failure, chronic kidney disease, or concomitant use
of diuretics (p-values for interaction > 0.05) (Figure 6-3). Subgroup results for drug type,
congestive heart failure and chronic kidney disease could not be presented (too few
events).
The relative risk of hospitalization with hyponatremia observed with
carbamazepine use compared to non-use was 3.13 fold higher (95% CI 1.62 to 6.10) than
the relative risk observed with V-P-T use compared to non-use.
Table 6-3. 30-day risk of hospitalization with hyponatremia (hospital diagnosis code) in
antiepileptic users and non-users
Antiepileptic Drug Typea

Events, No. (%)b

Relative Risk
(95% CI)

Antiepileptic non-usersc
Carbamazepine users

30 / 63 573 (0.05)
82 / 21 191 (0.39)

1.00 (reference)
8.20 (5.40 to 12.46)

Antiepileptic non-usersc
V-P-T users

26 / 40 310 (0.06)
34 / 20 155 (0.17)

1.00 (reference)
2.62 (1.57 to 4.36)

V-P-T=valproic acid, phenytoin, topiramate, CI=confidence interval
a An antiepileptic non-user group was selected as the referent.
b The event rates and absolute risk differences are underestimated by eight-fold, as the hospital-based
diagnosis codes used to define hyponatremia in our region have high speciﬁcity (99%) but low sensitivity
(11%).30
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Events/At Risk, n/N (%)a
Carbamazepine
Carbamazepine
user (n=20 600)
non-user (n=61 800)

Relative Risk
(95% CI)

P-value for
Interaction

Congestive Heart Failureb
Yes
No

16 / 2547 (0.63)
61 / 18 053 (0.34)

8 / 7641 (0.10)
17 / 54 159 (0.03)

6.00 (2.57 to 14.02)
11.32 (6.53 to 19.64)

0.22

Diuretic Usec
Yes
No

46 / 6759 (0.68)
31 / 13 841 (0.22)

15 / 20 277 (0.07)
10 / 41 523 (0.02)

9.73 (5.35 to 17.70)
9.30 (4.56 to 18.97)

0.92

Carbamazepine Dosed
Higher Dose
Normal Dose

41 / 10 260 (0.40)
36 / 10 340 (0.35)

11 / 30 780 (0.04)
14 / 31 020 (0.05)

7.71 (4.16 to 14.30)
12.12 (6.07 to 24.20)

0.34

Risk higher
with carbamazepine use

Figure 6-2. The association between carbamazepine use and hospitalization with hyponatremia assessed in three subgroups*
CI=confidence interval.
*Congestive heart failure, baseline use of a diuretic, and carbamazepine dose. Sets of medication users and non-users were matched on presence of congestive
heart failure and baseline diuretic use. For carbamazepine dose, matched sets were categorized according to this characteristic in users. Data marker size is
proportional to the inverse of the source variance.
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is
underestimated by eight-fold because the code for hyponatremia has high speciﬁcity but low sensitivity. 30
b Congestive heart failure has a sensitivity, specificity and positive predictive value of 84.3, 85.4, and 35.8%, respectively. 34
c Diuretic use includes potassium sparing and non-potassium sparing medications.
d Higher dose was defined as a higher than median daily dose. See Appendix D Table D-2 for definitions.
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Events/At Risk, n/N (%)a
V-P-T
Antiepileptic
user (n=20 155)
non-user (n=40 310)

Relative Risk
(95% CI)

P-value for
Interaction

Diuretic Useb
Yes
No

9 / 5244 (0.17)
25 / 14 911 (0.17)

10 / 10 488 (0.10)
16 / 29 822 (0.05)

1.80 (0.73 to 4.43)
3.13 (1.67 to 5.85)

0.32

V-P-T Dosec
Higher Dose
Normal Dose

13 / 6789 (0.19)
21 / 13 366 (0.16)

10 / 13 578 (0.07)
16 / 26 732 (0.06)

2.60 (1.14 to 5.93)
2.63 (1.37 to 5.03)

0.99

Risk higher
with V-P-T use

Figure 6-3. The association between valproic acid (V), phenytoin (P), topiramate (T) use and hospitalization with hyponatremia
assessed in two subgroups*
CI=confidence interval.
*Baseline use of a diuretic and V-P-T dose. Sets of medication users and non-users were matched on presence of congestive heart failure and baseline diuretic
use. For V-P-T dose, matched sets were categorized according to this characteristic in users. Data marker size is proportional to the inverse of the source variance
a Hyponatremia (and the proportion of patients who had an event) was assessed by using a hospital diagnosis code. The true event rate of hyponatremia is
underestimated by eight-fold because the code for hyponatremia has high speciﬁcity but low sensitivity. 30
b Diuretic use includes potassium sparing and non-potassium sparing medications.
c Higher dose was defined as a higher than median daily dose. See Appendix D Table D-2 for definitions.
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6.3.3

Additional Analyses

Among the subpopulation for which linked laboratory data were available, baseline
characteristics were very similar in carbamazepine users and non-users (Appendix D
Table D-6, 678 carbamazepine users matched to 2034 non-users). Carbamazepine use vs.
non-use was associated with a higher 30-day risk of hospitalization with hyponatremia
(9/678 [1.33%] vs. 6/2034 [0.29%]; relative risk 4.50 [95% CI 1.60 to 12.64]; absolute
risk increase 1.04% [95% CI 0.14% to 1.90%]). There were too few events to report
similar results with V-P-T use.
Carbamazepine use vs. non-use was associated with a higher 30-day risk of
hyponatremia in an outpatient laboratory (26/2592 [1.00%] versus 14/7776 [0.18%],
relative risk 5.57 [95% CI 2.91 to 10.67], absolute risk increase 0.82% [95% CI 0.43% to
1.22%]), as was V-P-T use vs. non-use (19/2253 [0.84%] vs. 17/4506 [0.38%], relative
risk 2.24 [95% CI 1.16 to 4.30], absolute risk increase 0.47% [95% CI 0.05% to 0.88%]).
There was no association between antiepileptic use vs. non-use and the risk of
hospitalization with bowel obstruction in either cohort (carbamazepine, 15/21 191
[0.07%] vs. 33/63 573 [0.05%], relative risk 1.37 [95% CI 0.74 to 2.54]); V-P-T, 13/20
155 [0.06%] vs. 19/40 310 [0.05%], relative risk 1.37 [95% CI 0.68 to 2.77]).
In carbamazepine users, older age, cancer, diuretic use, and a history of
hyponatremia were significant risk factors for hyponatremia; while in V-P-T users,
cancer, hypothyroidism, and a history of hyponatremia were significant risk factors
(Table 6-4).
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Table 6-4. Risk factors for hospitalization with hyponatremia in carbamazepine users and
valproic acid (V), phenytoin (P), and topiramate (T) users*

Hospitalization with hyponatremia
Older age (per year)
Women (vs. men)
Chronic kidney disease (yes vs. no)
Congestive heart failure (yes vs. no)
Diabetes (yes vs. no)
Liver disease (yes vs. no)
Cancer (yes vs. no)
Hypothyroidism (yes vs. no)
Previous hyponatremia (yes vs. no)
Diuretic use (yes vs. no)
Antipsychotic use (yes vs. no)
Antidepressant use (yes vs. no)
Antineoplastic use (yes vs. no)

Carbamazepine users
(n=21 191)

V-P-T users
(n=20 155)

Relative risk (95% CI)
1.07 (1.03 to 1.10)
1.43 (0.86 to 2.36)
1.57 (0.73 to 3.38)
0.87 (0.47 to 1.59)
1.55 (0.93 to 2.61)
0.98 (0.30 to 3.16)
2.02 (1.16 to 3.50)
1.20 (0.63 to 2.30)
6.67 (3.43 to 12.99)
1.73 (1.09 to 2.76)
0.88 (0.35 to 2.23)
1.02 (0.63 to 1.65)
1.24 (0.50 to 3.05)

Relative risk (95% CI)
1.01 (0.96 to 1.06)
1.23 (0.59 to 2.59)
1.19 (0.27 to 5.23)
0.65 (0.21 to 2.04)
2.10 (0.93 to 4.78)
2.91 (0.99 to 8.56)
2.83 (1.32 to 6.04)
5.32 (2.59 to 10.94)
7.64 (3.21 to 18.18)
0.87 (0.38 to 1.97)
0.89 (0.35 to 2.28)
0.64 (0.30 to 1.40)
1.54 (0.43 to 5.48)

CI=confidence interval
* Separate multivariable logistic regression models created for carbamazepine users and V-P-T non-users

6.4 Discussion
We observed that carbamazepine use compared to no antiepileptic use was associated
with an approximate 8.2-fold higher relative risk of hospitalization with hyponatremia
within 30 days of drug initiation. The association between carbamazepine use and
hospitalization with hyponatremia was evident across multiple types of older patients
including those who took normal or higher doses of carbamazepine, those with and
without congestive heart failure, and those with or without concurrent diuretic use.
However, the risk appeared higher in the setting of concurrent diuretic use. Although
subgroup analyses should be interpreted cautiously, a synergistic effect between
carbamazepine and diuretics in the development of hyponatremia is biologically
plausible. Interactions between carbamazepine and diuretics have also been observed in
other reports.37,38
The risk of hyponatremia with three other antiepileptic drugs, valproic acid,
phenytoin and topiramate, is less well understood. Use of any of these three drugs
compared to no antiepileptic use was associated with a 2.6-fold higher relative risk of
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hospitalization with hyponatremia within 30 days of drug initiation. Although this risk
between antiepileptic drug use and hospitalization with hyponatremia was no different
across each antiepileptic drug type, phenytoin use compared to no antiepileptic use was
associated with an approximate four-fold higher relative risk of hospitalization with
hyponatremia (not presented to prevent risk of re-identification). Compared to those who
initiated valproic acid, phenytoin use was associated with an approximate 2.6-fold higher
adjusted relative risk in 30-day hospitalization with hyponatremia. These findings run
contrary to prior studies, which suggest phenytoin rather than predisposing to
hyponatremia minimizes it, through the inhibition of antidiuretic hormone release.20,21
The likelihood a patient will experience an outcome, referred to as the absolute risk
or absolute risk increase, is more useful for patient care than a relative association.
Several results in our study used a diagnosis code to assess the presence of hyponatremia,
which can underestimate the true incidence of hyponatremia by up to a factor of eight.
When we defined the outcome using a sodium value ≤132 mmol/L, carbamazepine use
compared to non-use was associated with a one percent increase in the 30-day absolute
risk of hospitalization with hyponatremia. Despite the small increase in absolute risk,
carbamazepine-induced hyponatremia may account for hundreds of potentially
preventable hospitalizations each year. Mild (chronic) hyponatremia can result in
impaired gait, attention deficits, and falls, while severe hyponatremia can cause
confusion, seizures, coma, or even death.39,40
In the Compendium for Pharmaceuticals and Specialties (CPS; the Canadian
standard for product monographs) and in UpToDate® (a point-of-care medical resource),
hyponatremia is listed as an adverse event of carbamazepine and valproic acid, but not
phenytoin.41,42 If other studies corroborate our findings, changes to these prescribing
references should be considered to include a description of hyponatremia with phenytoin.
If a patient presents to hospital with symptomatic hyponatremia, phenytoin can be
considered as one potential reversible cause. The CPS and UpToDate® recommend
monitoring of serum sodium in older adults upon initiation of carbamazepine. No
recommendations are provided for valproic acid in either reference. The utility and
intensity of monitoring sodium levels before and after antiepileptic drug initiation in
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older adults could be a subject of future investigation, and a strategy of monitoring could
prove prudent particularly in the case of carbamazepine and phenytoin.
Our study has many strengths. We used Ontario’s healthcare databases that
included data on universal prescription drug coverage in older adults. This provided us
with a large representative sample of patients who received the study antiepileptic drugs
in routine care, enabling us to study a rare but important adverse drug event. We also
took a number of approaches to minimize the effects of confounding and bias that are
inherent to observational studies. First, we used a propensity score-matched design to
make our user and non-user groups as comparable as possible on a large set of baseline
indicators of health. We also considered a negative control outcome of bowel obstruction
and observed no association, which provides some reassurance that the primary findings
were less likely to be influenced by residual confounding. Second, to overcome the
limitations of the code, we corroborated our primary results with sodium laboratory
measurements (when possible). Finally, we conducted several additional analyses to
confirm the association was robust.
Our study also has some limitations. First, despite our efforts to eliminate sources
of confounding, we may have failed to account for important unmeasured confounders.
For example, some lesions in the brain are associated both with seizures and
hyponatremia through a syndrome of inappropriate antidiuretic hormone. Nevertheless,
the statistical technique we used resulted in comparison groups that were similar on
multiple indicators of baseline health. Second, the code for hyponatremia had limited
sensitivity, indicating that several patients included in our study could have had
hyponatremia but did not get diagnosed as such. Also, we could have missed those
patients with hyponatremia that did not present to hospital. We would have preferred to
use sodium measurements in the V-P-T cohort, but this was not feasible due to the
limited availability of lab data. Third, there were an inadequate number of patients
prescribed topiramate, precluding us from drawing meaningful conclusions for this drug.
Fourth, we did not know the degree to which the hyponatremia was symptomatic, but we
do know that the code for hyponatremia detects a median sodium value of 125 mmol/L at
hospital admission indicating that the hyponatremia was likely clinically important.30
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Fifth, we could not be confident of the medical indication for the antiepileptic drug use,
nor could we be sure the patient adhered to their prescribed drug regimen, as this
information was not provided in our data sources. Those patients who were prescribed an
antiepileptic drug to treat a psychiatric disorder could have been predisposed to
hyponatremia from primary polydipsia, a condition characterized by compulsive fluid
intake.43 However, we did not expect this to represent a large percent of our population.
Sixth, since the relationship between carbamazepine use and hyponatremia is wellknown, it is possible that a physician was more likely to order a blood test to check the
sodium level in patients taking carbamazepine. Finally, we could only study older adults
within our data sources. Younger patients are often healthier and may be less susceptible
to drug-induced hyponatremia.

6.5 Conclusion
In summary, among older adults prescribed an antiepileptic drug in routine care, we
found a higher risk of hospitalization with hyponatremia with carbamazepine and V-P-T.
The results of our study inform physicians and pharmacists about this potential risk, and
may guide future investigations in developing strategies to monitor sodium levels before
and after initiation of an antiepileptic drug.
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CHAPTER 7: Discussion
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7.1 Introduction
The main objective of this thesis was to better understand the risk of hyponatremia
among older adults taking psychotropic drugs. Specifically, there was an interest to study
select second-generation antidepressants, atypical antipsychotics, and antiepileptic drugs,
all of which are commonly used by this segment of the population. Additionally, this
thesis explored whether the observed risks were modified by the following factors: i)
congestive heart failure, ii) chronic kidney disease, iii) concomitant diuretic use, iv)
psychotropic drug dose, and v) psychotropic drug type. In the second-generation
antidepressants study, a concomitant outcome of hyponatremia and delirium was
evaluated to determine whether the observed hyponatremia was symptomatic. As well,
the risk factors for hyponatremia in patients taking these drugs were examined in each
study. The data sources used in this thesis allowed for a comprehensive examination of
the research questions in a Canadian setting, addressing many limitations of previous
research.

7.2 Integrated Discussion
7.2.1

Summary of Findings

Overall, hyponatremia was significantly associated with three major groups of
psychotropic drugs used in routine care. Although there was a risk of hyponatremia from
atypical antipsychotic drugs (OR=1.62), it was small and may not be as concerning as the
risks of hyponatremia from second-generation antidepressants (OR=5.5), and
antiepileptic drugs (carbamazepine, OR=8.2; valproic acid [V]-phenytoin [P]-topiramate
[T], OR=2.6). Several sensitivity and additional analyses confirmed the robustness of the
results, which provides reassurance that the associations observed are true. As well, the
risk estimates were consistent with those of Movig et al., Kirby et al., (antidepressants)
Mannesse et al., (antipsychotics) and Beers et al. (valproic acid) but extends the
observations made to older adults in non-hospitalized settings in Ontario, with better
precision and control for confounders.1–5 The current studies also extend the results to
other drugs that have not been extensively examined (i.e. mirtazapine, duloxetine,
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escitalopram [second-generation antidepressants], risperidone, olanzapine, quetiapine
[atypical antipsychotics], valproic acid, phenytoin, topiramate [antiepileptics]). However,
the risk of hyponatremia with V-P-T is novel and needs to be confirmed in additional
studies. In addition, even though the absolute risk increases were small, in the context of
a rapidly aging population and increasing use of these drugs, this translates into
thousands of hospitalizations each year.
Symptomatic hyponatremia is often associated with mental status changes, and can
have important medical implications for a patient.6–8 For example, altered mental status
further increases the risk for falls and aspiration pneumonia.8 In the second-generation
antidepressants study, there was some indication of symptomatic hyponatremia, which
emphasizes the severity of this condition. There were too few events in the other studies
to accurately assess this outcome.
A borderline interaction was identified only with carbamazepine and diuretic use.
This observed quantitative interaction is biologically plausible and is clinically relevant,
indicating that the risk of hyponatremia is greater when carbamazepine and diuretics are
taken simultaneously. For each study, the risk of hyponatremia did not vary by drug type,
dose, the presence of chronic kidney disease, and the presence of congestive heart failure.
The failure to detect interactions with other subgroups could truly be indicative of no
difference in risk across the groups or could be due to study related factors (discussed
further in the limitations section).
In second-generation antidepressant users, older age, female sex, liver disease,
previous hyponatremia, and concomitant diuretic use were associated with hospitalization
with hyponatremia. This is consistent with findings from previous studies, and are widely
accepted causes of hyponatremia.1,2,9,10 In atypical antipsychotic users, older age, cancer,
and previous hyponatremia were associated with hospitalization with hyponatremia. This
is the first study to examine the risk factors for this relationship. In carbamazepine users,
older age, cancer, diuretic use, and a history of hyponatremia were significant risk factors
and in V-P-T users, cancer, hypothyroidism, and a history of hyponatremia were
significant risk factors. These were the first studies to examine the potential associations
between these risk factors with carbamazepine/V-P-T use and hyponatremia.
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7.2.2

Clinical Importance and Implications

The findings from this thesis are of clinical value as they add to the evidence-base related
to psychotropic drug-induced hyponatremia. These results should be used to increase
awareness among physicians, nurse practitioners, and pharmacists of the risks of
hyponatremia associated with certain second-generation antidepressants, atypical
antipsychotics, and antiepileptic drugs. In these studies, patients were hospitalized with
hyponatremia, which is a clinically meaningful event. As found in the validation study,
those patients who had a code for hyponatremia present on their record had a median
serum sodium value of 125 mmol/L (IQR 120 to 130 mmol/L) while those patients with
no such code had a median serum sodium value of 137 mmol/L (IQR of 135 to 139
mmol/L).11 A median value of 125 mmol/L indicates that more severe forms of
hyponatremia tend to be recorded as a diagnosis in a patients chart at hospital admission.
Although we cannot be certain if hyponatremia was the responsible cause of the
hospitalization, it certainly may have contributed to it. As well, the symptomatic
hyponatremia observed in the antidepressants study highlights that some of the
hyponatremia was clinically important. Also, the results of this thesis did not show a
difference in the risk across the various second-generation antidepressants, atypical
antipsychotics, and V-P-T. If an elderly patient presents to hospital with symptomatic
hyponatremia, the specific drugs that were studied should all be considered as culprits.
Particular attention should be given to older adults taking carbamazepine and diuretics
simultaneously, as they have a higher risk of developing hyponatremia.
The results of this thesis also have the potential to influence clinical prescribing
practices, particularly in older adults. But first, benefit-risk should be assessed for a
patient when considering prescribing one of these psychotropic drugs. Indeed, the
absolute increases in the risks of hospitalization with hyponatremia were small, so the
amount of benefit from these drugs likely outweighs the amount of risk. Clinicians should
continue to prescribe these drugs as required but should be mindful of the potential risk
of hyponatremia. Careful consideration should be given to those groups who have an
increased likelihood of developing hyponatremia. For example, in this thesis older adults
who had a prior episode of hyponatremia were at particular risk of developing
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hyponatremia after starting a second-generation antidepressant, atypical antipsychotic or
carbamazepine. Serum sodium levels should be assessed in patients prior to starting a
particular drug regimen, to ensure that they are not initially hyponatremic. Development
of a clinical prediction rule in predicting the probability of hyponatremia from any of
these psychotropic drugs can also be considered to inform prescribing.12 Physicians and
nurse practitioners would also benefit from updated prescribing guidelines in the
Compendium of Pharmaceuticals and Specialties (CPS) and UptoDate® for some of the
drug classes.
7.2.2.1 Current Warnings and Recommendations in Prescribing

Guidelines
For second-generation antidepressants, both the CPS and UptoDate® warn of the potential
for hyponatremia with these drugs. However, the CPS provides no recommendations to
monitor serum sodium, and for some drugs, suggests drug discontinuation in the presence
of symptomatic hyponatremia.13–21 UptoDate® suggests monitoring serum sodium levels
in older adults when initiating or adjusting doses.22–30 Updates to the guidelines
concerning groups that are at particular risk for hyponatremia should be provided.
For atypical antipsychotics, hyponatremia is not even listed as an adverse event of
olanzapine and quetiapine in the CPS but for all three drugs, UptoDate® suggests
monitoring serum sodium levels in older adults when initiating or adjusting doses.31–36
Given the findings from the atypical antipsychotics study, the CPS should consider
should warn of the potential risk of hyponatremia with olanzapine and quetiapine. As
well, the risk factors for hyponatremia in these patients should be outlines.
For carbamazepine, the CPS and UptoDate® both list hyponatremia as an adverse
event. The CPS indicates monitoring of serum sodium levels only in patients with renal
disorders or in those taking diuretics.37 On the other hand, UptoDate® suggests
monitoring serum sodium levels in older adults when initiating or adjusting doses.38 For
valproic acid, phenytoin, and topiramate, a risk of hyponatremia is not listed in either
prescribing reference.39–44 The findings with these drugs are novel, which explains the
lack of information provided in these sources. More studies are needed to confirm the
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study findings but clinicians should be cognizant of the potential risk and exercise
caution when prescribing these drugs.
7.2.2.2 Strategies for the Prevention of Drug-Induced

Hyponatremia
Strategies to mitigate hyponatremia need to be explored. The inconsistent messages
across the two prescribing references warrant additional studies to determine the optimal
strategy of managing hyponatremia when using certain second-generation
antidepressants, atypical antipsychotics, or antiepileptic drugs. In many cases, the
guidelines suggest to monitor serum sodium at specific points around the time of
antidepressant/antipsychotic/carbamazepine prescription, or in particular groups of
patients. Based on studies conducted in the area of antidepressants, a few authors have
suggested that a routine serum sodium work-up be conducted within the first 2 weeks of
initiating treatment, particularly in patients with additional risk factors for
hyponatremia.1,45–47 Other strategies are also possible. For example, fluid restriction (less
than 1 to 1.5 L per day) may be a viable option when initiating the drug in a person at
higher risk for hyponatremia.48 If low serum sodium levels persist, physicians may
choose to discontinue the drug or prescribe an alternate drug in patients when feasible.
Alternatively, concomitant use of a “vaptan” (antidiuretic hormone receptor blocker) may
be a possibility.49,50 However, vaptans are new drugs that are very costly so may not be a
desired method of treatment.49 Overall, a cost-benefit analysis should be conducted to
evaluate any one of these strategies.

7.3 Strengths and Limitations
7.3.1

Strengths

Strengths of this thesis have been highlighted in the discussion sections of each chapter;
however, several key strengths deserve mention.
First, use of Ontario’s large healthcare administrative databases provided a
comprehensive examination of psychotropic drug-induced hyponatremia. This thesis used
multiple linked databases from Ontario, which offered a number of advantages (datasets
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summarized in Chapter 3). Ontario is Canada’s most populous province with over two
million older adults enrolled in the provincial health insurance plan. These databases
have been extensively studied in several settings, and have proven validity.51–57 The
Ontario Drug Benefits database was comprehensive (over 4,400 drug products available)
and extremely reliable, with an error rate of only 0.7% (95% CI 0.5% to 0.9%).58,59 The
Canadian Institute of Health Information database included information on all
hospitalizations made in Ontario, allowing for ascertainment of the outcome for all
patients across a broad region. These large databases provided population-based data,
which allowed for a large representative sample, and adequate statistical power to enable
the study of a rare adverse drug event. Rare adverse events are usually not detected in
randomized controlled trials owing to their small sample sizes.60 In addition, answering
the primary question of these studies with a randomized controlled trial would be very
expensive, may not be ethical, and would not reflect real-world practice. A trial would
entail frequent sodium testing, which would introduce “artificial” surveillance, whereas
the cohort study captured the surveillance, as it would occur in routine care. Furthermore,
older individuals and those with significant comorbidities are often excluded from these
studies, which impairs their generalizability.61,62
Second, robust methodology was used in this thesis to minimize the effects of bias
and confounding. In pharmacoepidemiologic studies, exposure to a specific treatment is
influenced by a number of patient, physician, and health care system factors.63
Consequently, the baseline characteristics between exposed and unexposed patients may
differ systematically, and may ultimately influence the estimated treatment effect. In this
thesis, propensity score methods were used to reduce the impact of this treatment
selection bias. A number of variables were included in the propensity score model to
ensure both exposed and unexposed groups were similar on a large range of
characteristics. In addition, a number of sensitivity analyses were conducted to ensure the
role of bias and confounding were minimal. Indeed, the results of these analyses
confirmed that the influence of bias and confounding was negligible. As well, a new-user
design was used to ensure that the observed hyponatremia was attributed to the
psychotropic drug and not due to another reason. The outcome was assessed using a 30-
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day risk window to minimize cross-over between drug therapies, and because
hyponatremia was often identified during this time-frame in prior studies.
Third, the set of studies comprising this thesis are the first to be conducted in a
Canadian setting. To date, prior research on this topic was conducted in other regions of
the world. It was important to conduct Canadian studies as differences in healthcare
systems across countries may result in differential estimates of hyponatremia. Unlike
many other countries, prescription drug use and healthcare coverage is universal for older
adults in Canada. In addition, this thesis overcame several limitations of prior research.
For example, the focus was on outpatients who are usually healthier than inpatients and
are also more representative of the general older adult population.

7.3.2

Limitations

Limitations of this thesis are recognized and described in the discussion section of each
chapter. Overall, this research had some limitations.
In each of these studies, the primary outcome of hyponatremia was assessed using a
hospital diagnosis code, which is known to underestimate the true event rate. In the
validation study by Gandhi et al., while the specificity of the hospital diagnosis code
(ICD-10 code) for hyponatremia was greater than 99%, sensitivity was only 11% when
defined using a serum sodium threshold of ≤132 mmol/L (see appendix E for article).11
As hyponatremia often occurs in the presence of other diseases, it tends to be an underdiagnosed condition. As well, symptoms of hyponatremia resemble common side effects
of medications or symptoms of other underlying conditions, which may complicate the
differential diagnosis. Furthermore, trained coders are not permitted to interpret
laboratory values but can record a diagnosis for a laboratory-based condition if the
diagnosis was explicitly indicated in the patient’s chart. This means that even if the
patient had a low sodium level documented in their chart, it would not get coded as
hyponatremia unless the physician specifically noted the diagnosis. Combined, these
factors contribute to the low sensitivity of the code. For this reason, use of laboratory data
to assess the outcome of hyponatremia was of particular value. However, these data were
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only available for a subpopulation (<5% of the population of Ontario), which resulted in
smaller sample sizes and lower event rates.
It is possible that study related factors contributed to the lack of interactions
identified. There is a possibility that some of the subgroup definitions were imprecise.
For example, the sensitivity and positive predictive value of the codes to define chronic
kidney disease were moderate (38% and 59%, respectively).64 As such, the codes may
have failed to capture the whole spectrum of chronic kidney disease, precluding
identification of a potential interaction. Another likely explanation is that the subgroups
were too underpowered to detect potential interactions.
Despite these studies being population-based with thousands of patients, some
models could not be fit or some analyses were not meaningful due to too few events in
the strata. This was a problem in some subgroup analyses (particularly with chronic
kidney disease), and in the assessment of symptomatic hyponatremia. The association
with hyponatremia and delirium could only be estimated in the antidepressant study, as
this outcome is highly insensitive (but very specific). As previously discussed,
hyponatremia is often asymptomatic and may not require clinical attention. Thus,
presence of symptomatic hyponatremia in the antipsychotics and antiepileptics studies
would have been more informative for clinicians, as this would indicate a certain degree
of severity.
Within the datasets used, only drug dispensing information was available. Just
because a patient filled a prescription does not indicate that they adhered to the
prescribing regimen. However, the median duration of prescription drug use in these
studies was between 50 and 90 days depending on the drug class. Therefore, this is less of
a concern for this study where the outcomes were ascertained with a short follow-up
time.
Many patients take psychotropic drugs for off-label conditions. To avoid selection
bias, in the antidepressants and antipsychotics studies, only patients with a diagnosed
medical condition for a labeled indication of the drug were included. Therefore, the
results may not be generalizable to the segment of the population who take these
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medications for other reasons. Nonetheless, the mechanism of hyponatremia would be the
same in these patients, so similar results would be expected.

7.4 Future Direction
This thesis addressed numerous limitations of previous studies done in the field;
however, there are still many unanswered questions regarding hyponatremia.
First, future population-based research should use laboratory data to evaluate the
risk of hyponatremia, ideally collected within a defined follow-up schedule, particularly
for antipsychotic and antiepileptic drugs (besides carbamazepine). Serum sodium data are
the gold standard for determining the presence of hyponatremia. This is especially useful
for detecting milder forms of hyponatremia. This would provide a more accurate
incidence of the disorder and would allow for a better assessment of severity.
Second, this thesis focused on short-term outcomes but it would be worthwhile for
other studies to determine the long-term impact of hyponatremia in patients taking
psychotropic drugs. As mild chronic hyponatremia is receiving increasing attention as a
potential concern, clinicians may benefit from this knowledge to guide on-going care in
older adults taking these drugs.
Third, drug-induced hyponatremia is a potentially preventable problem if
appropriate management strategies are put into place. Large-scale prospective studies
should be conducted to determine an optimal strategy for the prevention and early
monitoring of hyponatremia in the outpatient setting (described above). This strategy
should especially be considered in older adults who are already at risk for developing
hyponatremia. If these studies find that a particular management strategy results in fewer
hyponatremia events, this would have a significant impact on the healthcare system.

7.5 Conclusion
With a rapidly growing population in Canada and around the world, the use of
psychotropic drugs is becoming more prevalent. Awareness of adverse drug events is an
important part of safe prescribing practices. The knowledge gained from this thesis can
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inform patient care, improve prescribing guidelines, mitigate poor outcomes including
hospitalizations, and guide future studies. Prompt recognition of both symptomatic and
asymptomatic hyponatremia is important for preventing hyponatremia-related
consequences.
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Appendix A
Table A-1. Modified Downs and Black checklist for non-randomized studies1
(Prospective and Retrospective Studies)
Item

Criteria

Reporting
Is the hypothesis/aim/objective of the study clearly described?
1

Possible
Answers
Yes = 1
No = 0
Yes = 1
No = 0

2

Are the main outcomes to be measured clearly described in the Introduction or
Methods section? If the main outcomes are first mentioned in the Results
section, the question should be answered no.

3

Are the characteristics of the patients included in the study clearly described?
In cohort studies and trials, inclusion and/or exclusion criteria should be given.
In case-control studies, a case-definition and the source for controls should be
given.

Yes = 1
No = 0

4

Are the distributions of principal confounders in each group of subjects to be
compared clearly described? A list of principal confounders is provided.

5

Are the main findings of the study clearly described? Simple outcome data
(including denominators and numerators) should be reported for all major
findings so that the reader can check the major analyses and conclusions.
(This question does not cover statistical tests which are considered below).

Yes = 2
Partially = 1
No = 0
Yes = 1
No = 0

6

Does the study provide estimates of the random variability in the data for the
main outcomes? In non-normally distributed data the interquartile range of
results should be reported. In normally distributed data the standard error,
standard deviation or confidence intervals should be reported. If the distribution
of the data is not described, it must be assumed that the estimates used were
appropriate and the question should be answered yes.

Yes = 1
No = 0

7

Have the characteristics of patients lost to follow-up been described? This
should be answered yes where there were no losses to follow-up or where
losses to follow-up were so small that findings would be unaffected by their
inclusion. This should be answered no where a study does not report the
number of patients lost to follow-up.

Yes = 1
No = 0

8

Have actual probability values been reported (e.g. 0.035 rather than <0.05) for
the main outcomes except where the probability value is less than 0.001?

Yes = 1
No = 0

External validity
Were the subjects asked to participate in the study representative of the entire
9
population from which they were recruited? The study must identify the source
population for patients and describe how the patients were selected. Patients
would be representative if they comprised the entire source population, an
unselected sample of consecutive patients, or a random sample. Random
sampling is only feasible where a list of all members of the relevant population
exists. Where a study does not report the proportion of the source population
from which the patients are derived, the question should be answered as
unable to determine.
10

Were those subjects who were prepared to participate representative of the
entire population from which they were recruited? The proportion of those
asked who agreed should be stated. Validation that the sample was
representative would include demonstrating that the distribution of the main

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0
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confounding factors was the same in the study sample and the source
population.
11

Were the staff, places, and facilities where the patients were treated,
representative of the treatment the majority of patients receive? For the
question to be answered yes the study should demonstrate that the
intervention was representative of that in use in the source population. The
question should be answered no if, for example, the intervention was
undertaken in a specialist centre unrepresentative of the hospitals most of the
source population would attend.

Internal validity – bias
If any of the results of the study were based on “data dredging”, was this made
12
clear? Any analyses that had not been planned at the outset of the study
should be clearly indicated. If no retrospective unplanned subgroup analyses
were reported, then answer yes.

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0

13

In trials and cohort studies, do the analyses adjust for different lengths of
follow-up of patients, or in case-control studies, is the time period between the
intervention and outcome the same for cases and controls? Where follow-up
was the same for all study patients the answer should be yes. If different
lengths of follow-up were adjusted for by, for example, survival analysis the
answer should be yes. Studies where differences in follow-up are ignored
should be answered no.

Yes = 1
No = 0
Unable to
determine = 0

14

Were the statistical tests used to assess the main outcomes appropriate? The
statistical techniques used must be appropriate to the data. For example
nonparametric methods should be used for small sample sizes. Where little
statistical analysis has been undertaken but where there is no evidence of bias,
the question should be answered yes. If the distribution of the data (normal or
not) is not described it must be assumed that the estimates used were
appropriate and the question should be answered yes.

Yes = 1
No = 0
Unable to
determine = 0

15

Was compliance with the intervention/s reliable? Where there was
noncompliance with the allocated treatment or where there was contamination
of one group, the question should be answered no. For studies where the effect
of any misclassification was likely to bias any association to the null, the
question should be answered yes.

Yes = 1
No = 0
Unable to
determine = 0

16

Were the main outcome measures used accurate (valid and reliable)? For
studies where the outcome measures are clearly described, the question
should be answered yes. For studies which refer to other work or that
demonstrates the outcome measures are accurate, the question should be
answered as yes.

Yes = 1
No = 0
Unable to
determine = 0

Internal validity – confounding (selection bias)
Were the patients in different intervention groups (trials and cohort studies) or
17
were the cases and controls (case-control studies) recruited from the same
population? For example, patients for all comparison groups should be selected
from the same hospital. The question should be answered unable to determine
for cohort and case-control studies where there is no information concerning
the source of patients included in the study.
Were study subjects in different intervention groups (trials and cohort studies)
18
or were the cases and controls (case-control studies) recruited over the same
period of time? For a study which does not specify the time period over which
patients were recruited, the question should be answered as unable to
determine.
19

Was there adequate adjustment for confounding in the analyses from which the

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
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main findings were drawn? This question should be answered no for trials if:
the main conclusions of the study were based on analyses of treatment rather
than intention to treat; the distribution of known confounders in the different
treatment groups was not described; or the distribution of known confounders
differed between the treatment groups but was not taken into account in the
analyses. In non-randomized studies if the effect of the main confounders was
not investigated or confounding was demonstrated but no adjustment was
made in the final analyses the question should be answered as no.

No = 0
Unable to
determine = 0

Were losses of patients to follow-up taken into account? If the numbers of
patients lost to follow-up are not reported, the question should be answered as
unable to determine. If the proportion lost to follow-up was too small to affect
the main findings, the question should be answered yes.

Yes = 1
No = 0
Unable to
determine = 0

Power
Did the study have sufficient power to detect a clinically important effect where
21*
the probability value for a difference being due to chance is less than 5%?
Sample sizes have been calculated to detect a difference of x% and y%.

Yes = 1
No = 0
Unable to
determine = 0
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Table A-2. Case reports describing hyponatremia from psychotropic drugs
Study/
Country

Case details

Second-generation Antidepressant Drugs
Patil et al. (2014)2
84-year old female
recently diagnosed with
United Kingdom
depression and admitted
with confusion, gait
disturbance, vomiting and
lethargy
Shubrata et al.
64-year old male admitted
(2012)3
with memory deficits,
apathy, and impairment in
India
daily activities. He was
diagnosed with
depressive pseudo
dementia
Cerimele and
87-year old female with
Robinson (2011)4
dementia and major
depressive disorder was
United States of
admitted with aggression,
America
depressed mood, anxiety,
insomnia, and suicidal
ideation
Famularo et al.
76-year old female with
(2009)5
depression was admitted
with lethargy and
Italy
confusion

Gabriel et al.
(2009)6

Relevant
drugs
studied

Outcomes and notes

Citalopram

-1 week after starting citalopram, pt
was hospitalized with a serum sodium
of 110 mmol/L
-After withdrawal of treatment for 6
days, serum sodium rose to 131
mmol/L
-Baseline serum sodium was 138
mmol/L
-Seizure occurred after 4 days of
starting treatment
-Serum sodium dropped to 115 mmol/L
-Sertaline was withdrawn and serum
sodium rose to 134 mmol/L in 4 days
-Baseline serum sodium at admission
was 140 mmol/L
-After 4 days of starting sertraline,
serum sodium dropped to 126 mmol/L
-Treatment was withdrawn and serum
sodium rose to 135 mmol/L in 6 days

Sertraline

Sertraline

Mirtazapine

49-year old male admitted
with severely depressed
mood

Fluvoxamine

85-year old female with
major depression was
hospitalized with unstable
gait and a decrease in
vigilance
76-year old male with
depression and agitation
was admitted after
placement of a partial hip
prosthesis following
fracture

Duloxetine

Canada

Mussig et al.
(2009)7
Germany
Atalay et al. (2007)8
Turkey

Escitalopram
(antidepressant)
and
Quetiapine
(antipsychotic)

-Long term therapy with
hydrochlorothiazide (diuretic)
-After 2 months of starting mirtazapine
therapy, serum sodium dropped to 114
mmol/L
-2 days of mirtazapine and
hydrochlorothiazide withdrawal, serum
sodium returned to 146 mmol/L
-Diuretic drug use is also known to
cause HN
-Started fluvoxamine treatment at
admission
-After 10 days, pt developed
headaches, a grand mal seizure, and
became lethargic
-Serum sodium was 114 mmol/L
-Serum sodium returned to 139-141
mmol/L after 4 days of fluvoxamine
withdrawal
-After 6 days use, serum sodium
was107 mmol/l
-Duloxetine discontinued and serum
sodium normalized within 10 days
-Admission baseline serum sodium
level was 134 mmol/
-After 3 days of dual drugs treatment,
serum sodium was 124-128 mmol/L
-Escitalopram discontinued and serum
sodium rose to 130 mmol/L
-Quetiapine therapy was maintained
for a few days but serum sodium was
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Covyeou and
Jackson (2007)9

75-year old female with
depression was admitted
with confusion

Escitalopram

All pts had recurrent
major depressive
episodes and were in
treatment of a severe
acute episode:

Duloxetine

United States of
America

Kruger (2007)10
Germany

Bavbek et al.
(2006)11
Turkey

Cury et al. (2006)12
Brazil

i) 35-year old female,
baseline serum sodium of
146 mmol/L
ii) 70-year old female,
baseline serum sodium of
140 mmol/L
iii) 45-year old female,
baseline serum sodium of
150 mmol/L
iv) 67-year old male,
baseline serum sodium of
148 mmol/L
v) 56-year old male,
baseline serum sodium of
142 mmol/L
67-year old female with
depression was admitted
with abdominal pain,
nausea, vomiting,
decreased food intake,
and agitation

77-year old male with
depression was admitted
to hospital with lack of
appetite, somnolence and
fever

still below normal values
-Quetiapine discontinued, serum
sodium normalized to 138 mmol/L
-Quetiapine can also cause HN
-Long term therapy with amlodipine,
hydro-chlorothiazide, alprazolam and
esomeprazole
-After 5 days of starting escitalopram
treatment, serum sodium fell from 136
mmol/L to 116 mmol/L
-Escitalopram was discontinued and
serum sodium rose to 139 mmol/L in 5
days
-Pt received medications known to
cause HN
-After 4-6 weeks of initiating
duloxetine, pts complained of physical
symptoms, including fatigue, lethargy,
and headache
-Serum sodium at admission:
i) 122 mmol/L
ii) 120 mmol/L
iii) 118 mmol/L
iv) 121 mmol/L
v) 118mmol/L
-All symptoms of HN and abnormal
serum sodium resolved within 2 weeks
of duloxetine withdrawal

Citalopram
Mirtazapine

Sertraline

-Pt started citalopram treatment 2
months prior admission
-Serum sodium was 110 mmol/L at
admission
-Citalopram was stopped and HN
resolved
-Pt then started mirtazapine therapy
and was discharged
-Serum sodium was normal after 3
weeks of new treatment
-Pt was admitted again after 5 months
with nausea and vomiting
-Serum sodium was 115 mmol/L
-Mirtazapine was withdrawn and HN
resolved
Serum sodium normalized at 2 and 4
weeks after discharge
-Sertraline therapy was started 6
months before
-Baseline serum sodium at admission
was 146 mmol/L
-20 days after increased sertraline
dosage, serum sodium dropped to 125
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Wakita et al.
(2005)13

79-year old female with
depression was admitted
with confusion and fatigue

Paroxetine

61-year old male with
malaise, confusion and
seizure

Citalopram

62-year old female with
major depressive
episodes was admitted
after a syncope and fall
with minor head injury
86-year old female with
depression had a
previous episode of HN
while taking venlafaxine

Escitalopram

78-year old female with
depression was admitted
due to a collapse from
severe aortic stenosis,
complicated by a head
injury
97-year old male with
depression was admitted
with a 5-day history of
progressive weakness,
confusion, lethargy, and
stupor
74-year old male with
recurrent major
depression was admitted
with social withdrawal,
amotivation, anhedonia,
depressed mood,
neglected self-care and
suicidal ideation
83-year old female with
major depression was
admitted with a history of
recurrent depression

Paroxetine

Japan

Flores et al.
(2004)14
Mexico
Nahshoni et al.
(2004)15
Israel
Roxanas (2003)16
Australia

Schouten and
Sepers (2001)17
The Netherlands
Odeh et al. (1999)18
Israel

Burke and Fanker
(1996)19
Australia

Druckenbrod and
Mulsant (1994)20
United States of
America

Mirtazapine

Paroxetine

Fluoxetine

Fluoxetine

mmol/L
-After 21 days of sertraline withdrawal,
serum sodium normalized to 138
mmol/L
-Long-term use of paroxetine
-Stopped for 3 months
-Resumed paroxetine again 3 days
prior to admission
-Serum sodium at admission was 112
mmol/L
-Serum sodium normalized after 5
days of paroxetine withdrawal
-Admitted with serum sodium of 124
mmol/L after 2 weeks of starting
citalopram
-5 days after citalopram withdrawal,
serum sodium rose to 134 mmol/L
-3 weeks prior admission, pt started
escitalopram therapy
-Serum sodium was 110 mmol/L
-After 1 week of withdrawal, serum
sodium normalized to 135 mmol/L
-Baseline serum sodium was 135
mmol/L
-After 4 days of staring mirtazapine,
serum sodium dropped to 130 mmol/L
-After 10 days of mirtazapine
withdrawal, serum sodium rose to 134
mmol/L
-Previous history of HN while taking
another anti-depressant
-Pt was taking hydrochlorothiazide
(diuretic) as well, which could have
contributed to HN
-Baseline serum sodium at admission
was 134 mmol/L
-18 days after paroxetine initiation,
serum sodium dropped to 109 mmol/L
-Serum sodium normalized after 12
days of paroxetine withdrawal
-4 days prior to symptoms, pt started
paroxetine
-At admission, serum sodium was 104
mmol/L
-Serum sodium normalized after 5
days of paroxetine withdrawal
-Fluoxetine was started at admission
(normal serum sodium)
-21 days later, pt fell with minor head
injury
-Serum sodium was 126 mmol/L
-20 days of fluoxetine withdrawal,
serum sodium rose to 138 mmol/L
-Long term use of fluoxetine (on/off)
-1 month of increased dose of
fluoxetine prior to admission
-Serum sodium was 109 mmol/L at
admission
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Blacksten and Birt
(1993)21

92-year old female with
depression was admitted
with weakness

United States of
America
Atypical Antipsychotic Drugs
Koufakis (2016)22
65-year old female with
schizophrenia was
Greece
admitted with seizure

Trevizol et al.
(2016)23
Brazil

Bakhla et al.
(2014)24
India

Ranga et al.
(2014)25

Fluoxetine

Quetiapine

20-year old male with
polydipsia and
schizophrenia was
admitted with nausea,
vomiting, confusion and
disorientation

Quetiapine

63-year old male
diagnosed with recurrent
depressive disorder and
current episode of severe
depression with psychotic
symptoms

Olanzapine

22-year female with
paranoid schizophrenia
was admitted with seizure

Risperidone

48-year old female with
mixed bipolar affective
disorder, schizoid
personality disorder, and
hypocholesterolemia was
admitted in a postictal
confusional state
following a seizure
34-year old male
diagnosed of chronic
schizophrenia
was admitted with
confusion and agitation

Olanzapine

56-year old male with
mood disorder and
delirium was hospitalized
with a hip fracture

Risperidone

India

Dudeja et. al
(2010)26
United Kingdom

Chogtu et al.
(2009)27
India

Kahn et al. (2009)28
United States of
America

Risperidone

-Serum sodium normalized 5 weeks
after fluoxetine withdrawal
-13 days after starting fluoxetine, pt
developed HN
-8 days after discontinuing fluoxetine,
HN resolved

-Pt started quetiapine 3 months prior to
admission
-Admitted with serum sodium of 108
mmol/L
-After 6 days of quetiapine withdrawal,
serum sodium normalized to 135
mmol/L
-Pt started 1 week treatment of
quetiapine
-Hospitalized with serum sodium of
105 mmol/L
-Normalization of serum sodium after 3
days of quetiapine withdrawal
-Polydipsia can also cause HN
-Long term use of escitalopram
(antidepressant) which can also cause
HN
-Pt started olanzapine treatment 1
month prior to admission
-Hospitalized with disorientation and
serum sodium of 118 mmol/L
-After 2 days of olanzapine withdrawal,
serum sodium rose to 138 mmol/L
-After 5 days of starting risperidone
therapy, pt was admitted to hospital
with serum sodium of 118 mmol/L
-Treatment was discontinued at
admission and 3 days later, serum
sodium rose to 134 mmol/L
-Olanzapine therapy for the past 2
years
-Admitted to hospital with serum
sodium of 114 mmol/L
-Discontinuation of olanzapine
normalized serum sodium

-Long term therapy of chlorpromazine
(antipsychotic)
-After 10 days of starting risperidone,
pt had a seizure and a serum sodium
of 111 mmol/L
-Discontinuation of risperidone for 3
days and serum sodium returned to
135 mmol/L
-Pt started chemotherapy with
cyclophosphamide, which can cause
HN
-After 6 days, pt was diagnosed with
acute post-renal failure
-Serum sodium dropped to 129 mmol/L
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Patel et al. (2009)29
United States of
America

Atalay et al. (2007)8
Turkey

Vucicevic et al.
(2007)30
Croatia

Collins and
Anderson (2000)31
United Kingdom

Antiepileptic Drugs
Gupta et al.
(2015)32
United States of
America

64-year old female was
discharged 3 days prior to
re-admission after
suffering from a fall with a
facial bone fracture and
scalp hematoma. She
was re-admitted with
seizure followed by
altered mental status

Quetiapine

76-year old male with
depression and agitation
was admitted after
placement of a partial hip
prosthesis following
fracture

Quetiapine
(antipsychotic)
and
Escitalopram
(antidepressant)

44-year old male on
several psychotropic
drugs was admitted
unconscious

Olanzapine

76-year old female who
had been untreated for
schizophrenia for 23
years was admitted after
head injury (occipital
fracture)

Risperidone

54-year old female with
bipolar disorder had
intentionally overdosed
on valproic acid and
presented to hospital with
drowsiness, disorientation
and nausea

Valproic acid

-Medications were tapered off and
risperidone therapy began
-Baseline serum sodium was 135
mmol/L
-After 2 days of risperidone therapy,
serum sodium dropped to 128 mmol/L
-Discontinued risperidone, serum
sodium normalized after several days
-History of paroxetine and clonazepam
use, which was discontinued when pt
was initially discharged (serum sodium
at 135 mmol/L)
-At discharge, quetiapine was
prescribed
-After single dose of quetiapine, pt was
hospitalized with a serum sodium of
112 mmol/L
-Withdrawal of quetiapine for 2 days,
serum sodium rose to 131 mmol/L
-Previous antidepressant and
antiepileptic drug use could also cause
HN
-Admission baseline serum sodium
level was 134 mmol/
-After 3 days of treatment, serum
sodium was 124-128 mmol/L
-Escitalopram discontinued and serum
sodium rose to 130 mmol/L
-Quetiapine therapy was maintained
for a few days but serum sodium was
still below normal values
-Quetiapine discontinued, serum
sodium normalized to 138 mmol/L
-Escitalopram can also cause HN
-Long term therapy of paroxetine,
fluphenazine, haloperidol and
olanzapine
-Presented to hospital with serum
sodium of 104 mmol/L
-2 hours post admission, pt expired
from cerebral edema
-Long term use of several drugs known
to cause HN
-Baseline serum sodium of 134 mmol/L
at admission
-After 2 weeks of starting risperidone
thepary, serum sodium dropped to 116
mmol/L
-Serum sodium returned back to
baseline after 21 days of risperidone
withdrawal
-Serum sodium was 99 mmol/L at
admission
-Long term therapy of paroxetine,
clonazepam and valproic acid
-After 6 days of valproic acid
withdrawal, serum sodium rose to 135
mmol/L

180

Patel et al. (2010)33

54-year old male with
schizophrenia was
admitted for agitation,
threatening behavior, and
medication refusal

Valproic acid

Carbamazepine

Poland

53-year old female with
trigeminal neuralgia was
referred to clinic due to
recurrent nausea and low
serum sodium values
59-year old male with
hypertension was
admitted with cerebral
edema and seizures

Salawu and
Danburam36 (2007)

29-year old female
presented with seizures

Carbamazepine

44-year old female with
bipolar disorder, posttraumatic stress disorder
and schizo- affective
disorder was admitted
after experiencing 2 new
seizures

Carbamazepine

67-year old male with
trigeminal neuralgia was
admitted electively for

Carbamazepine

United States of
America

Van der Lubbe et
al. (2009)34
The Netherlands
Krysiak and
Okopien35 (2007)

Carbamazepine

Nigeria
Kuz and
Manssourrian
(2005)37
United States of
America

Velissaris et al.
(2003)38

- Long term use of drugs known to
cause HN
-At admission, baseline serum sodium
was 139 mmol/L and pt started
risperidone therapy
-During the course of treatment,
valproic acid was introduced at high
dose for 2 weeks
-Serum sodium dropped to 126 mmol/L
-After 7 days later of tapering dose of
valproic acid, serum sodium rose to
132 mmol/L
-After a few weeks of stopping valproic
acid, serum sodium normalized to 137
mmol/L
-Risperidone is known to cause HN as
well, but its dose was not changed
throughout hospitalization
-Pt had another incident shortly after
where valproic acid was taken and
serum sodium dropped to 127 mmol
-Upon stopping valproic acid, serum
sodium returned to 140 mmol
-Long term carbamazepine use
-Serum sodium range 124-135 mmol/L
-Hospitalized with nausea and serum
sodium of 128 mmol/L
-After 6 days from initiating
hydrochlorotiazide (diuretic)and
carbamazepine therapy, pt
experienced weakness, mild anorexia
and vomiting
-Serum sodium was 126 mmol/L
-Hydrochlorotiazide was discontinued,
but carbamazepine therapy continued
for a few days
-Serum sodium fell to 112 mmol/L
-Serum sodium normalized after
withdrawal of carbamazepine
-Diuretic use could have contributed to
HN
-Baseline serum sodium at 135 mmol/L
-After starting carbamazepine for 7
days, serum sodium fell to 121 mmol/L
-Serum sodium normalized after 2
weeks of carbamazepine withdrawal
-Long term use of carbamazepine,
paroxetine, risperidone and buspirone
-Pt overdosed on carbamazepine and
was admitted with a serum sodium of
122 mmol/L
-Carbamazepine was withdrawn and
serum sodium rose to 136 mmol/L
-Long term use of drugs known to
cause HN
-Long-term carbamazepine use
-Mild HN at admission, serum sodium
at 132 mmol/L
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United Kingdom

coronary artery bypass
grafting

Matsumura et al.
(2001)39

40-year old male with
cerebral palsy, mental
retardation and absence
epilepsy was admitted
with grand mal seizures

Carbamazepine

62-year old male with
epilepsy was admitted
with amnesia and
disorientation after
seizure

Valproic acid

Japan

Miyaoka et al.
(2001)40
Japan

-2 days after cardio-pulmonary bypass,
serum sodium was 128 mmol/L
-Diuretics were discontinued, but
carbamazepine therapy continued
-6 days post-surgery, serum sodium
fell to drop to 125 mmol/L
-Carbamazepine was gradually
decreased and stopped, serum sodium
returned to 132 mmol/L
-Previous HN and use of diuretics
could have contributed to HN
-Pt was treated with carbamazepine,
haloperidol, biperiden, phenytoin,
clonazepam and levome-promazine
-Prior to admission, pt drank excessive
water
-Presented with serum sodium of 98
mmol/L
-2 months earlier, serum sodium was
135 mmol/L
-Use of several drugs known to cause
HN
-Previous HN and excessive water
intake could also have contributed to
HN
-Long-term valproic acid use
-History of previous HN and seizures
(serum sodium range 117-120 mmol/L)
-Serum sodium at 127 mmol/L upon
hospital admission
-Valproic acid was replaced with
another anti-epileptic, zonisamide, and
HN was resolved
-Previous HN could have contributed to
HN

Abbreviations: ADH=antidiuretic hormone; SIADH=syndrome of inappropriate antidiuretic hormone
secretion; pts=patients; HN=hyponatremia
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Table A-3. Hyponatremia warnings and recommendations from drug prescribing
references
Drug

Compendium of Pharmaceuticals and
Specialties®

Second-generation Antidepressant Drugs
Citalopram
Hyponatremia and SIADH have been
reported as a rare adverse event with use
of citalopram. The majority of these
occurrences have been in elderly
individuals, some in patients taking
diuretics or who were otherwise volumedepleted. Elderly female patients in
particular seem to be a group at risk.
Geriatrics (≥65 years of age) - A longer
half-life and decreased clearance have
been demonstrated in the elderly,
therefore lower doses and a lower
maximum dose should be considered. As
with other SSRIs, caution should be
exercised in treating elderly female
patients who may be more susceptible to
adverse events such as hyponatremia and
SIADH.

Escitalopram

Paroxetine

As with other antidepressants, cases of
hyponatremia and SIADH have been
reported with escitalopram as a rare
adverse event. The majority of these
occurrences have been in elderly
individuals, some in patients taking
diuretics or who were otherwise volumedepleted. Elderly female patients in
particular seem to be a group at risk.
Caution should be exercised in patients at
risk, such as the elderly, or patients with
cirrhosis, or if used in combination with
other medications which may cause
hyponatremia.
Metabolism and Nutrition Disorder - Rare:
hyponatremia.
Several cases of hyponatremia have been
reported. The hyponatremia appeared to
be reversible when paroxetine was
discontinued. The majority of these
occurrences have been in elderly
individuals, some in patients taking
diuretics or who were otherwise volume

UptoDate®

Geriatric Patients: High-Risk Medication SSRIs are identified in the Beers Criteria
as potentially inappropriate medications
to be used with caution in patients 65
years and older because of the potential
to cause or exacerbate SIADH or
hyponatremia; monitor sodium
concentration closely when initiating or
adjusting the dose in older adults (Beers
Criteria).
Adverse Reaction Significant: <1%
(Limited to important or life threatening) –
Hyponatremia
Concerns relating to adverse reactions SIADH and hyponatremia: SSRIs and
SNRIs have been associated with the
development of SIADH; hyponatremia
has been reported rarely (including
severe cases with serum sodium <110
mmol/L), predominately in the elderly;
reversible with discontinuation of
treatment. Volume depletion and/or
concurrent use of diuretics likely
increases risk.
Elderly: Use caution in elderly patients;
may be potentially inappropriate in
patients with a history of falls or fractures,
and may cause or exacerbate SIADH or
hyponatremia; monitor sodium closely
with initiation or dosage adjustments in
older adults (Beers Criteria).
Bioavailability and half-life are increased
by 50% in the elderly.

Adverse Reaction Significant: <1%
(Limited to important or life threatening) –
Hyponatremia
Precautions - Elderly: Use caution in
elderly patients; may be potentially
inappropriate in patients with a history of
falls or fractures, and may cause or
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depleted.
Metabolic and Nutritional Disorder Infrequent: hyponatremia (predominantly in
the elderly), which is sometimes due to
SIADH.

Fluoxetine

Several cases of hyponatremia (some with
serum sodium lower than 110 mmol/L)
have been reported. The hyponatremia
appeared to be reversible when fluoxetine
was discontinued. Although these cases
were complex with varying possible
etiologies, some were possibly due to the
SIADH. The majority of these occurrences
have been in older patients and in patients
taking diuretics or who were otherwise
volume depleted.
In two 6-week controlled studies, inpatients ≥60 years of age, 10 of 323
fluoxetine patients and 6 of 327 placebo
recipients had a lowering of serum sodium
below the reference range; this difference
was not statistically significant. The lowest
observed concentration of sodium in a
fluoxetine treated patient was 129 mmol/L.
The observed decreases were not
clinically significant.

Fluvoxamine

As with other SSRIs, hyponatremia has
been rarely reported and appeared to be
reversible when fluvoxamine was
discontinued. Some cases were possibly
due to the SIADH. The majority of reports
were associated with older patients.
Elderly patients, patient taking diuretics,
and patients who are otherwise volume
depleted may be at greater risk for this
event. Discontinuation of fluvoxamine
should be considered in patients with
symptomatic hyponatremia and
appropriate medical intervention should be
instituted. Symptoms may include

exacerbate SIADH or hyponatremia;
monitor sodium closely with initiation or
dosage adjustments in older adults.
Medication associated with potent
anticholinergic properties which may be
inappropriate in older adults depending
on comorbidities (e.g., dementia, delirium)
(Beers Criteria).
Concerns relating to adverse reactions SIADH and hyponatremia: SSRIs and
SNRIs have been associated with the
development of SIADH; hyponatremia
has been reported rarely (including
severe cases with serum sodium <110
mmol/L), predominately in the elderly.
Volume depletion and/or concurrent use
of diuretics likely increases risk.
Adverse Reaction Significant: <1%
(Limited to important or life threatening) –
Hyponatremia
Precautions - Elderly: Use caution in
elderly patients; may be potentially
inappropriate in patients with a history of
falls or fractures, and may cause or
exacerbate syndrome of inappropriate
antidiuretic hormone secretion or
hyponatremia (SIADH); monitor sodium
closely with initiation or dosage
adjustments in older adults (Beers
Criteria).
Concerns relating to adverse reactions SIADH and hyponatremia: SSRIs and
SNRIs have been associated with the
development of SIADH; hyponatremia
has been reported rarely (including
severe cases with serum sodium <110
mmol/L), predominately in the elderly.
Volume depletion and/or concurrent use
of diuretics likely increases risk. Consider
discontinuation if symptomatic
hyponatremia occurs.
Adverse Reaction Significant: <1%
(Limited to important or life threatening) –
Hyponatremia
Precautions - Elderly: Use caution in
elderly patients; may be potentially
inappropriate in patients with a history of
falls or fractures, and may cause or
exacerbate SIADH or hyponatremia;
monitor sodium closely with initiation or
dosage adjustments in older adults
(Beers Criteria). Bioavailability and halflife are increased by 50% in the elderly.
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headache, difficulty concentrating, memory
impairment, confusion, weakness, and
unsteadiness, which may lead to falls.
Post-Market Adverse Drug Reactions Rarely, hyponatremia and SIADH have
been reported

Duloxetine

Sertraline

Hyponatremia may occur as a result of
treatment with SSRIs and SNRIs, including
duloxetine. In many cases, this
hyponatremia appears to be the result of
the SIADH. Cases with serum sodium
lower than 110 mmol/L have been reported
and appeared to be reversible when
duloxetine was discontinued. Elderly
patients may be at greater risk of
developing hyponatremia with SSRIs and
SNRIs. Also, patients taking diuretics or
who are otherwise volume depleted may
be at greater risk. Discontinuation of
duloxetine should be considered in
patients with symptomatic hyponatremia
and appropriate medical intervention
should be instituted. Signs and symptoms
of hyponatremia include headache,
difficulty concentrating, memory
impairment, confusion, weakness, and
unsteadiness, which may lead to falls.
More severe and/or acute cases have
been associated with hallucination,
syncope, seizure, coma, respiratory arrest,
and death.
Hyponatremia may occur as a result of
treatment with SSRIs or SNRIs including
sertraline. In many cases, hyponatremia
appears to be the result of a SIADH.
Cases of serum sodium levels lower than
110 mmol/L have been reported. Elderly
patients may be at greater risk of
developing hyponatremia with SSRIs and
SNRIs. Also patients taking diuretics or
who are otherwise volume-depleted may
be at greater risk. Several cases of
hyponatremia have been reported and
appeared to be reversible when sertraline
was discontinued. Discontinuation of
sertraline should be considered in patients
with symptomatic hyponatremia and
appropriate medical intervention should be
instituted.
Signs and symptoms of hyponatremia
include headache, difficulty concentrating,
memory impairment, confusion, weakness
and unsteadiness which may lead to falls.

Concerns relating to adverse reactions SIADH and hyponatremia: SSRIs and
SNRIs have been associated with the
development of SIADH; hyponatremia
has been reported rarely (including
severe cases with serum sodium <110
mmol/L), predominately in the elderly.
Hyponatremia is reversible with
discontinuation of treatment. Volume
depletion and/or concurrent use of
diuretics likely increases risk.
Geriatric Patients: High-Risk Medication SNRIs are identified in the Beers Criteria
as potentially inappropriate medications
to be used with caution in patients 65
years and older due to its potential to
cause or exacerbate SIADH or
hyponatremia; monitor sodium
concentration closely when initiating or
adjusting the dose in older adults (Beers
Criteria).
Concerns relating to adverse reactions SIADH and hyponatremia: SSRIs and
SNRIs have been associated with the
development of SIADH; hyponatremia
has been reported rarely (including
severe cases with serum sodium <110
mmol/L), predominately in the elderly.
Volume depletion and/or concurrent use
of diuretics likely increases risk.

Adverse Reaction Significant: <1%
(Limited to important or life threatening) –
Hyponatremia
Precautions - Elderly: Use caution in
elderly patients; may be potentially
inappropriate in patients with a history of
falls or fractures, and may cause or
exacerbate syndrome of inappropriate
antidiuretic hormone secretion or
hyponatremia; monitor sodium closely
with initiation or dosage adjustments in
older adults (Beers Criteria).
Concerns relating to adverse reactions SIADH and hyponatremia: SSRIs and
SNRIs have been associated with the
development of SIADH; hyponatremia
has been reported rarely (including
severe cases with serum sodium <110
mmol/L), predominately in the elderly.
Volume depletion and/or concurrent use
of diuretics likely increases risk.
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Venlafaxine

Signs and symptoms associated with more
severe and/or acute cases have included
hallucination, syncope, seizure, coma,
respiratory arrest, and death.
Cases of hyponatremia may occur with
venlafaxine, usually in volume-depleted or
dehydrated patients. Elderly patients,
patients taking diuretics, and patients who
are otherwise volume depleted, may be at
greater risk for this event.
The hyponatremia appeared to be
reversible when venlafaxine was
discontinued.
Metabolic and Nutritional Disorder Infrequent: hyponatremia.

Mirtazapine

Hyponatremia has been reported very
rarely with the use of mirtazapine. Caution
should be exercised in patients at risk,
such as elderly patients or patients
concomitantly treated with medications
known to cause hyponatremia.
Metabolism and Nutrition Disorders hyponatremia.

Atypical Antipsychotic Drugs
Risperidone
Hyponatremia is a less common clinical
trial adverse drug reaction (≤1%) and is
considered an infrequent metabolic and
nutritional disorder with risperidone use. In
cases of overdose, hyponatremia was
reported.

Olanzapine

Not listed

Adverse Reaction Significant: <1%
(Limited to important or life threatening) –
Hyponatremia
Precautions - Elderly: Use caution in
elderly patients; may cause or exacerbate
SIADH or hyponatremia; monitor sodium
closely with initiation or dosage
adjustments in older adults (Beers
Criteria).
Concerns relating to adverse reactions SIADH and hyponatremia: SSRIs and
SNRIs have been associated with the
development of SIADH; hyponatremia
has been reported rarely (including
severe cases with serum sodium <110
mmol/L). Age (the elderly), volume
depletion, and/or concurrent use of
diuretics likely increases risk. Discontinue
treatment in patients with symptomatic
hyponatremia.
Monitoring Parameters: Blood pressure
should be regularly monitored, especially
in patients with a high baseline blood
pressure; may cause mean increase in
hyponatremia.
Precautions - Elderly: Use caution in
elderly patients; may cause or exacerbate
SIADH; monitor sodium closely with
initiation or dosage adjustments in older
adults (Beers Criteria).
Concerns relating to adverse reactions May cause hyponatremia. Use caution in
patients at risk, such as elderly or patients
concomitantly treated with medications
known to cause hyponatremia.
<1% (Limited to important or lifethreatening): Hyponatremia.
Elderly: use may cause or exacerbate
SIADH secretion or hyponatremia;
monitor sodium closely with initiation or
dosage adjustments in older adults
(Beers Criteria).
Elderly: use may cause or exacerbate
SIADH secretion or hyponatremia;
monitor sodium closely with initiation or
dosage adjustments in older adults. May
also be inappropriate in older adults
depending on comorbidities (e.g.,
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dementia, delirium) due to its potent
anticholinergic effects (Beers Criteria).
Quetiapine

Not listed

Antiepileptic Drugs
In patients with pre-existing renal
Carbamazepine
conditions associated with low sodium or
in patients treated concomitantly with
sodium-lowering medicinal products (e.g.
diuretics, medicinal products associated
with inappropriate ADH secretion), serum
sodium levels should be measured prior to
initiating carbamazepine therapy.
Thereafter, serum sodium levels should be
measured after approximately two weeks
and then at monthly intervals for the first
three months during therapy, or according
to clinical need. These risk factors may
apply especially to the elderly and renallycompromised patients
Valproic Acid
Not listed
Phenytoin
Not listed
Topiramate
Not listed

Elderly: use may cause or exacerbate
SIADH secretion or hyponatremia;
monitor sodium closely with initiation or
dosage adjustments in older adults
(Beers Criteria). Dose escalation should
be performed with caution in elderly
patients; consider slower rates of dose
titration and lower target doses.
Carbamazepine is identified as a
potentially inappropriate medication to be
used with caution in patients 65 years and
older due to the potential to cause or
exacerbate SIADH secretion or
hyponatremia; monitor sodium
concentration closely when initiating or
adjusting the dose in older adults (Beers
Criteria).

Not listed
Not listed
Not listed

Abbreviations: SIADH=syndrome of inappropriate antidiuretic hormone secretion; SSRI=Selective
Serotonin Reuptake Inhibitor; SNRI=Serotonin–norepinephrine reuptake inhibitors
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Appendix B
Table B-1. STROBE Checklist

Title and abstract

Introduction
Background/rationale

Item
No
1

2

Objectives

3

Methods
Study design

4

Setting

5

Participants

6

Variables

7

Data sources/measurement

8

Bias

9

Study size

10

Quantitative variables

11

Statistical methods

12

Recommendation

Reported

(a) Indicate the study’s design with a
commonly used term in the title or the
abstract
(b) Provide in the abstract an informative and
balanced summary of what was done and
what was found

Title, Abstract

Explain the scientific background and
rationale for the investigation being reported
State specific objectives, including any prespecified hypotheses

Introduction

Present key elements of study design early in
the paper
Describe the setting, locations, and relevant
dates, including periods of recruitment,
exposure, follow-up, and data collection
(a) Give the eligibility criteria, and the sources
and methods of selection of participants.
Describe methods of follow-up
(b) For matched studies, give matching
criteria and number of exposed and
unexposed

Methods

Clearly define all outcomes, exposures,
predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if
applicable
For each variable of interest, give sources of
data and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than
one group
Describe any efforts to address potential
sources of bias
Explain how the study size was arrived at

Explain how quantitative variables were
handled in the analyses. If applicable,
describe which groupings were chosen and
why
(a) Describe all statistical methods, including
those used to control for confounding
(b) Describe any methods used to examine
subgroups and interactions
(c) Explain how missing data were addressed
(d) If applicable, explain how loss to follow-up
was addressed
(e) Describe any sensitivity analyses

Abstract

Introduction

Methods

Methods,
Appendix
Figure 1
Methods,
Table 1,
Appendix
Table 3
Methods,
Appendix
Table 2
Methods,
Appendix
Tables 2

Discussion
Methods;
based on
availability of
the data
Methods

Methods
Methods
Methods
Not
applicable
Methods
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Results
Participants

13

(a) Report numbers of individuals at each
stage of study—e.g. numbers potentially
eligible, examined for eligibility, confirmed
eligible, included in the study, completing
follow-up, and analyzed
(b) Give reasons for non-participation at each
stage
(c) Consider use of a flow diagram

Descriptive data

14

Outcome data

15

Main results

16

Other analyses

17

Discussion
Key results

18

Limitations

19

Interpretation

20

Generalizability

21

Other information
Funding

22

(a) Give characteristics of study participants
(e.g. demographic, clinical, social) and
information on exposures and potential
confounders
(b) Indicate number of participants with
missing data for each variable of interest
(c) Summarize follow-up time (e.g. average
and total amount)
Report numbers of outcome events or
summary measures over time
(a) Give unadjusted estimates and, if
applicable, confounder-adjusted estimates
and their precision (e.g. 95% confidence
interval). Make clear which confounders were
adjusted for and why they were included
(b) Report category boundaries when
continuous variables were categorized
(c) If relevant, consider translating estimates
of relative risk into absolute risk for a
meaningful time period
Report other analyses done—e.g. analyses of
subgroups and interactions, and sensitivity
analyses

Methods,
Results,
Appendix
Figure 1
Methods,
Appendix
Figure 1
Appendix
Figure 1
Table 1,
Appendix
Tables 4, 5,
6,
Methods
Results,
Table 2, 3
Results,
Table 2, 3,
Figure 1
Results,
Table 2, 3
Figure 1

Methods
Results,
Table 2, 3
Results,
Figure 1,
Appendix
Figure 2,
Appendix
Tables 7, 8

Summarize key results with reference to
study objectives
Discuss limitations of the study, taking into
account sources of potential bias or
imprecision. Discuss both direction and
magnitude of any potential bias
Give a cautious overall interpretation of
results considering objectives, limitations,
multiplicity of analyses, results from similar
studies, and other relevant evidence
Discuss the generalizability (external validity)
of the study results

Discussion

Give the source of funding and the role of the
funders for the present study and, if
applicable, for the original study on which the
present article is based

Acknowledgements

Discussion

Discussion

Discussion
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Table B-2. Coding definitions for exposure, outcomes, and comorbid conditions
Variable
Comorbidities
Mood Disorders

Database

Code/Definition

CIHI-DAD

ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968, 3004, 311,
2962, 2963, 2969
ICD-10 F30, F31, F340, F32, F33, F341, F381, F348, F349,
F380, F388, F39
DSM-IV 29600, 29601, 29602, 29603, 29604, 29605, 29606,
29640, 29641, 29642, 29643, 29644, 29645, 29646, 29650,
29651, 29652, 29653, 29654, 29655, 29656, 29660, 29661,
29662, 29663, 29664, 29665, 29666, 29670, 29680, 29689,
30113, 29383, 29690, 29620, 29621, 29622, 29623, 29624,
29625, 29626, 29630, 29631, 29632, 29633, 29634, 29635,
29636, 30040, 31100
296, 311, Q020
ICD-9 3000, 3002, 3003, 3098, 3083
ICD-10 F40, F41, F42, F430, F431, F438, F439
DSM-IV 30001, 30021, 30022, 30029, 30023, 30030, 30981,
30830, 30002, 29384, 30000
300
ICD-9 425, 5184, 514, 428
ICD-10 I500, I501, I509, I255, J81
CCP 4961, 4962, 4963, 4964
CCI 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 1HZ53SYFR
428, R701, R702, Z429
ICD-9 4030, 4031, 4039, 4040, 4041, 4049, 582, 583, 580,
581, 584, 585, 586, 587, 5880, 5888, 5889, 5937
ICD-10 E102, E112, E132, E142, I12, I13, N08, N18, N19
403, 585
ICD-9 401, 402, 403, 404, 405
ICD10 I10, I11, I12, I13, I15
401, 402, 403,
ICD-9 4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 7824,
V026, 2750, 2751, 7891, 7895, 571
ICD-10 B16, B17, B18, B19, I85, R17, R18, R160, R162,
B942, Z225, E831, E830, K70, K713, K714, K715, K717,
K721, K729, K73, K74, K753, K754, K758, K759, K76, K77
571, 573, 070, Z551, Z554
ICD-9 243, 2440, 2441, 2442, 2443, 2448, 2449
ICD-10 E030, E031, E032, E033, E034, E035, E038, E039,
E890
243, 244
ICD-9 150, 154, 155, 157, 162, 174, 175, 185, 203, 204, 205,
206, 207, 208
ICD-10 971, 980, 982, 984, 985, 986, 987, 988, 989, 990,
991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56,
C61, C82, C83, C85, C91, C92, C93, C94, C95, C00, D05
203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 174,
175, 183, 185
ICD-9 250
ICD-10 E10, E11, E13, E14
250, K029, K030, Q040
ICD-9 480, 481, 482, 483, 484, 485, 486, 7700
ICD-10 J12, J13, J14, J15, J16, J17, J18, P23
ICD-9 410 412, 414, 4292, 4295, 4296, 4297

OMHRS

Anxiety disorder

OHIP
CIHI-DAD
OMHRS

Congestive heart failure

OHIP
CIHI-DAD

Chronic kidney disease

OHIP
CIHI-DAD

Hypertension

OHIP
CIHI-DAD

Chronic liver disease

OHIP
CIHI-DAD

Hypothyroidism

OHIP
CIHI-DAD

Cancer

OHIP
CIHI-DAD

OHIP
Diabetes Mellitus

CIHI-DAD

Pneumonia

OHIP
CIHI-DAD

Coronary artery disease

CIHI-DAD
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OHIP
Angina

CIHI-DAD

Atrial fibrillation/flutter

OHIP
CIHI-DAD

Previous hyponatremia

CIHI-DAD

Myocardial Infarction
Haemorrhagic stroke

CIHI-DAD

Ischemic stroke

CIHI-DAD

Transient ischemic attack

CIHI-DAD

Chronic lung disease

CIHI-DAD

OHIP
Epilepsy/Seizure

CIHI-DAD

Acute kidney injury

CIHI-DAD

Hypotension

CIHI-DAD

Acute urinary retention

CIHI-DAD

Delirium

CIHI-DAD

Peripheral vascular
disease

CIHI-DAD

OHIP

Outcomes
Hyponatremia*
Delirium

CIHI-DAD
CIHI-DAD
OMHRS
CIHI-DAD

Bowel obstruction
Median Medication Doses
Citalopram
ODB
Escitalopram
Duloxetine
Fluvoxamine

ICD-10 I21, I22, I23, I24, I25, Z955, Z958, Z959, R931, T822
CCP 4801, 4802, 4803, 4804, 4805, 481, 482, 483
CCI 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76
410, 412, R741, R742, R743, G298, E646, E651, E652,
E654, E655, G262, Z434, Z448
ICD-9 413
ICD-10 I20
413
ICD-9 4273
ICD-10 I48
ICD-9 2761
ICD-10 E871
ICD-9 410
ICD-10 I21, I22
ICD-9 430, 431
ICD-10 I600, I601, I602, I603, I604, I605, I606, I607, I609, I61
ICD-9 436, 4340, 4341, 4349, 3623
ICD-10 I630, I631, I632, I633, I634, I635, I638, I639, I64,
H341
ICD-9 435
ICD-10 G450, G451, G452, G453, G458, G459, H340
ICD-9 491, 492, 493, 494, 495, 496, 500, 501, 502, 503, 504,
505, 5064, 5069, 5081, 515, 516, 517, 5185, 5188, 5198,
5199, 4168, 4169
ICD-10 I272, I278, I279, J40, J41, J42, J43, J44, J45, J47,
J60, J61, J62, J63, J64, J65, J66, J67, J68, J701, J703, J704,
J708, J709, J82, J84, J92, J941, J949, J953, J961, J969,
J984, J988, J989, J99
491, 492, 493, 494, 496, 501, 502, 515, 518, 519
J689, J889
ICD-9 345, 7803
ICD-10 G40, G41, R560, R568
ICD-9 584
ICD-10 N17
ICD-9 458
ICD-10 I95
ICD-9 7882
ICD-10 R33
ICD-9 293
ICD-10 F05
ICD-9 4402, 4408, 4409, 5571, 4439, 444
ICD-10 I700, I702, I708, I709, I731, I738, I739, K551
CCP 5125, 5129, 5014, 5016, 5018, 5028, 5038
CCI 1KA76, 1KA50, 1KE76, 1KG26, 1KG50, 1KG57,
1KG76MI, 1KG87
R787, R780, R797, R804, R809, R875, R815, R936, R783,
R784,R785, E626, R814, R786, R937, R860, R861, R855,
R856, R933, R934, R791, E672, R794, R813, R867, E649
ICD-10 E871
ICD-10 F05
DSM IV 29300, 78009
ICD-10 K56
Higher dose: >20 mg/day; Normal dose ≤20 mg/day
Higher dose: >10 mg/day; Normal dose ≤10 mg/day
Higher dose: >30 mg/day; Normal dose ≤30 mg/day
Higher dose: >50 mg/day; Normal dose ≤50 mg/day
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Fluoxetine
Mirtazapine
Paroxetine
Sertraline
Venlafaxine

Not included in the assessment of higher vs. normal dose.
Higher dose: >15 mg/day; Normal dose ≤15 mg/day
Higher dose: >20 mg/day; Normal dose ≤20 mg/day
Higher dose: >50 mg/day; Normal dose ≤50 mg/day
Higher dose: >56.25 mg/day; Normal dose ≤56.25 mg/day

CCI=Canadian Classification of Health Interventions. CCP=Canadian Classification of Diagnostic,
Therapeutic and Surgical Procedures. CIHI-DAD=Canadian Institute for Health Information Discharge
Abstract Database. ICD-9=International Classification of Diseases, Ninth Revision. ICD-10=International
Classification of Diseases, Tenth Revision. Ontario Drug Benefit database=ODB. OHIP=Ontario Health
Insurance Plan database. OMHRS=Ontario Mental Health Reporting System database. RPDB=Ontario’s
Registered Persons Database.
*Validation of the code for hyponatremia was performed on approximately 64 499 hospitalizations with
linked laboratory measurements for serum sodium. See Methods section for a description of the validation.
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Table B-3. Variables included in propensity score model
Variable Category
Demographics
Income
Index date
Comorbid conditions

Concurrent medication
use

Number of healthcare
contacts
Number of healthcare
uses

Variable
Age, sex, rural neighborhood

Charlson comorbidity index, Johns Hopkins ACG System Aggregated
Diagnosis Groups, mood disorder, anxiety disorder, congestive heart failure,
chronic kidney disease, hypertension, chronic liver disease, hypothyroidism,
cancer, diabetes mellitus, pneumonia, coronary artery disease, angina, atrial
fibrillation/flutter, myocardial infarction, hemorrhagic stroke, ischemic stroke,
transient ischemic attack, chronic lung disease, epilepsy/seizure, acute kidney
injury, hypotension, acute urinary retention, peripheral vascular disease
Number of unique drug products, anticonvulsant, antipsychotic, antidiabetics,
antineoplastic, thyroxin, potassium sparing diuretic, non-potassium sparing
diuretic, ACE inhibitor and/or ARB, NSAID (excluding aspirin), calcium
channel blocker, beta-adrenergic antagonist, statin, benzodiazepine, digoxin,
overactive bladder medication, antibiotic, warfarin, anticoagulant, antiplatelet,
acetylcholine inhaler, corticosteroid inhaler, beta-agonist inhaler,
cholinesterase inhibitor, lithium, glucose tests strips.
Hospitalization, emergency department visit, family physician visit,
psychiatrist visit, geriatrician visit, neurologist visit, nephrologist visit,
cardiologist visit, urologist visit, obstetrician/gynecologist visit
Previous sodium tests, carotid ultrasound, cardiac catheterization,
echocardiography, holter monitoring, cardiac stress test, coronary
endarterectomy, colorectal cancer screening, cervical cancer screening,
prostate-specific antigen test, mammography, flu shot, bone mineral density
test, hearing test, cystoscopy, cataract surgery, computed tomography of the
head, computed tomography of the neck, computed tomography of the
thorax, computed tomography of the abdomen, computed tomography of the
pelvis, computed tomography of the spine, computed tomography of the
extremities, chest x-ray, pulmonary function test, electroencephalography,
urine culture, heart valve replacement, at-home physician service, cholesterol
test

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin
II receptor blocker. NSAID=non-steroidal anti-inflammatory drug.
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Table B-4. Full baseline characteristics of second-generation antidepressant users and non-users*
Characteristic
Antidepressant
users
(n=172 552)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Year of cohort entry
2003-2004
2005-2006
2007-2008
2009-2010
2011-2012
Rural residence
Long-term care
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Mood disorder
Anxiety disorderd
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancere
Diabetes mellitus
Pneumonia
Coronary artery diseasef

Unmatched
Antidepressant
non-users
(n=297 501)

Standardized
Differencea

Antidepressant
users
(n=138 246)

Matched
Antidepressant
non-users
(n=138 246)

Standardized
Differencea

76 (7.5)
116 830 (67.7%)

75 (7.2)
177 662 (59.2%)

5.9%
16.7%

76 (7.3)
93 303 (67.5%)

76 (7.2)
93 303 (67.5%)

0.3%
0%

35 747 (20.7%)
35 935 (20.8%)
33 863 (19.6%)
33 049 (19.2%)
33 958 (19.7%)

59 184 (19.9%)
61 849 (20.8%)
58 284 (19.6%)
58 377 (19.6%)
59 807 (20.1%)

2.0%
0.1%
0.1%
1.2%
1.1%

28 057 (20.3%)
28 853 (20.9%)
27 166 (19.7%)
26 684 (19.3%)
27 486 (19.9%)

28 574 (20.7%)
28 954 (20.9%)
27 279 (19.7%)
26 504 (19.2%)
26 935 (19.5%)

0.9%
0.2%
0.2%
0.3%
1.0%

42 604 (24.7%)
38 283 (22.2%)
33 371 (19.3%)
37 114 (21.5%)
21 180 (12.3%)
21 796 (12.6%)
14 989 (8.7%)

49 712 (16.7%)
60 244 (20.3%)
68 544 (23.0%)
70 972 (23.9%)
48 029 (16.1%)
34 381 (11.6%)
10 812 (3.6%)

19.8%
4.7%
9.1%
5.6%
11.1%
3.3%
21.1%

31 266 (22.6%)
30 224 (21.9%)
27 577 (19.9%)
31 101 (22.5%)
18 078 (13.1%)
17 660 (12.8%)
6859 (5.0%)

31 020 (22.4%)
30 251 (21.9%)
27 931 (20.2%)
30 804 (22.3%)
18 240 (13.2%)
17 015 (12.3%)
6859 (5.0%)

0.4%
0%
0.6%
0.5%
0.3%
1.4%
0%

0.8 (1.5)
13.5 (3.8)

0.6 (1.3)
12.5 (3.7)

14.0%
25.0%

0.6 (1.3)
13.0 (3.8)

0.6 (1.4)
13.1 (3.7)

3.0%
0.8%

44 363 (25.7%)
159 901 (92.7%)
25 766 (14.9%)
10 798 (6.3%)
129 149 (74.8%)
6608 (3.8%)
20 098 (11.7%)
26 002 (15.1%)
14 371 (8.3%)
9350 (5.4%)
54 319 (31.5%)

34 484 (11.6%)
282 632 (95.0%)
35 778 (12.0%)
17 931 (6.0%)
226 854 (76.3%)
10 759 (3.6%)
32 199 (10.8%)
43 459 (14.6%)
26 405 (8.9%)
10 796 (3.6%)
89 377 (30.0%)

0.4%
10.0%
8.5%
1.0%
3.3%
1.1%
2.6%
1.3%
2.0%
8.6%
3.1%

24 207 (17.5%)
129 861 (93.9%)
16 735 (12.1%)
6094 (4.4%)
102 983 (74.5%)
5152 (3.7%)
15 723 (11.4%)
19 741 (14.3%)
11 298 (8.2%)
5681 (4.1%)
40 738 (29.5%)

24 207 (17.5%)
129 861 (93.9%)
16 735 (12.1%)
6094 (4.4%)
101 948 (73.7%)
4966 (3.6%)
15 472 (11.2%)
20 943 (15.1%)
11 234 (8.1%)
5775 (4.2%)
41 051 (29.7%)

0
0
0
0
1.7%
0.7%
0.6%
2.5%
0.2%
0.3%
0.5%
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Angina
Atrial fibrillation/flutter
Previous hyponatremia
Myocardial infarction
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Lung disease
Epilepsy/seizure
Acute kidney injury
Hypotension
Acute urinary retention
Previous delirium
Peripheral vascular disease
Concurrent medication useg
Number of unique drug products, mean
(SD)
Antiepileptics
Antipsychotics
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Digoxin
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatlets
Acetylcholine inhalers
Corticosteroid inhalers

40 486 (23.5%)
12 991 (7.5%)
3889 (2.3%)
7488 (4.3%)
857 (0.5%)
6685 (3.9%)
2445 (1.4%)
53 458 (31.0%)
1763 (1.0%)
3745 (2.2%)
3462 (2.0%)
3099 (1.8%)
4015 (2.3%)
2974 (1.7%)

62 974 (21.2%)
17 860 (6.0%)
3941 (1.3%)
11 084 (3.7%)
712 (0.2%)
5802 (2.0%)
2754 (0.9%)
78 087 (26.3%)
2056 (0.7%)
4689 (1.6%)
3837 (1.3%)
4100 (1.4%)
3640 (1.2%)
3973 (1.3%)

5.5%
6.1%
7.0%
3.1%
4.3%
11.5%
4.6%
10.5%
3.6%
4.4%
5.6%
3.3%
8.4%
3.2%

30 250 (21.9%)
8527 (6.2%)
2353 (1.7%)
5007 (3.6%)
479 (0.3%)
3653 (2.6%)
1582 (1.1%)
40 129 (29.0%)
1053 (0.8%)
1964 (1.4%)
2071 (1.5%)
1913 (1.4%)
2104 (1.5%)
1923 (1.4%)

30 287 (21.9%)
8781 (6.4%)
2257 (1.6%)
5107 (3.7%)
472 (0.3%)
3771 (2.7%)
1571 (1.1%)
40 321 (29.2%)
1092 (0.8%)
2009 (1.5%)
2024 (1.5%)
1981 (1.4%)
2103 (1.5%)
1999 (1.4%)

0.1%
0.8%
0.5%
0.4%
0.1%
0.5%
0.1%
0.3%
0.3%
0.3%
0.3%
0.4%
0
0.5%

11.5 (7.4)

9.4 (6.1)

31.0%

10.5 (6.6)

10.4 (6.5)

0.9%

16 212 (9.4%)
13 052 (7.6%)
27 160 (15.7%)
6848 (4.0%)
29 654 (17.2%)
6498 (3.8%)
51 687 (30.0%)
79 341 (46.0%)
34 309 (19.9%)
44 345 (25.7%)
48 093 (27.9%)
64 831 (37.6%)
67 701 (39.2%)
3 498 (2.0%)
3 833 (2.2%)
45 116 (26.1%)
2418 (1.4%)
760 (0.4%)
7591 (4.4%)
8329 (4.8%)
7889 (4.6%)

15 602 (5.2%)
11 759 (4.0%)
50 240 (16.9%)
11 287 (3.8%)
48 974 (16.5%)
10 213 (3.4%)
86 612 (29.1%)
149 937 (50.4%)
53 241 (17.9%)
80 594 (27.1%)
88 616 (29.8%)
128 405 (43.2%)
61 887 (20.8%)
4 641 (1.6%)
4 558 (1.5%)
75 710 (25.4%)
3380 (1.1%)
887 (0.3%)
11 651 (3.9%)
10 790 (3.6%)
11 531 (3.9%)

16.0%
15.5%
3.1%
0.9%
1.9%
1.8%
1.8%
8.9%
5.1%
3.2%
4.2%
11.4%
41.1%
3.5%
5.1%
1.6%
2.4%
2.3%
2.4%
6.0%
3.5%

10 901 (7.9%)
7609 (5.5%)
20 847 (15.1%)
5199 (3.8%)
23 403 (16.9%)
4827 (3.5%)
38 879 (28.1%)
63 863 (46.2%)
26 986 (19.5%)
35 214 (25.5%)
37 652 (27.2%)
53 052 (38.4%)
48 049 (34.8%)
2420 (1.8%)
2765 (2.0%)
37 379 (27.0%)
1731 (1.3%)
479 (0.3%)
5507 (4.0%)
5965 (4.3%)
5929 (4.3%)

10 499 (7.6%)
7659 (5.5%)
21 461 (15.5%)
5636 (4.1%)
23 457 (17.0%)
5020 (3.6%)
38 550 (27.9%)
63 390 (45.9%)
27 803 (20.1%)
35 342 (25.6%)
37 995 (27.5%)
52 777 (38.2%)
46 320 (33.5%)
2437 (1.8%)
2747 (2.0%)
37 911 (27.4%)
1725 (1.2%)
483 (0.3%)
5687 (4.1%)
5910 (4.3%)
6103 (4.4%)

1.1%
0.2%
1.2%
2.0%
0.1%
0.8%
0.5%
0.7%
1.5%
0.2%
0.6%
0.4%
2.6%
0.1%
0.1%
0.9%
0
0
0.7%
0.2%
0.6%
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Beta-agonist inhalers
Cholinesterase inhibitors
Lithium
Glucose test strips
Healthcare contacts, mean (SD)h
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits
Healthcare usei
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis

17 997 (10.4%)
8201 (4.8%)
413 (0.2%)
16 961 (9.8%)

24 697 (8.3%)
6621 (2.2%)
604 (0.2%)
31 425 (10.6%)

7.3%
13.8%
0.8%
2.4%

13 258 (9.6%)
4800 (3.5%)
258 (0.2%)
13 228 (9.6%)

13 343 (9.7%)
4853 (3.5%)
285 (0.2%)
13 545 (9.8%)

0.2%
0.2%
0.4%
0.8%

0.4 (0.8)
1.0 (1.8)
19.3 (19.9)
0.4 (2.9)
0.6 (3.9)
0 (0.2)
0 (0.1)
0.1 (0.2)
0 (0.2)
0 (0.1)

0.2 (0.5)
0.6 (1.3)
14.8 (14.0)
0.2 (1.5)
0.2 (2.0)
0 (0.1)
0 (0.1)
0.1 (0.2)
0 (0.2)
0 (0.1)

25.4%
27.1%
26.8%
13.3%
13.4%
6.3%
0
4.3%
0
0

0.3 (0.6)
0.8 (1.5)
16.9 (16.4)
0.3 (1.6)
0.3 (2.3)
0 (0.2)
0 (0.1)
0.1 (0.2)
0 (0.2)
0 (0.1)

0.3 (0.7)
0.7 (1.5)
16.5 (15.3)
0.2 (1.6)
0.2 (2.3)
0 (0.2)
0 (0.1)
0.1 (0.2)
0 (0.2)
0 (0.1)

1.7%
3.4%
2.1%
3.2%
4.0%
0
0
0
0
0

108 033 (62.6%)
10 937 (6.3%)
3293 (1.9%)
31 184 (18.1%)
13 196 (7.6%)
21 156 (12.3%)
154 (0.1%)
35 246 (20.4%)
12 870 (7.5%)
5637 (3.3%)
16 702 (9.7%)
96 940 (56.2%)
103 460 (60.0%)
23 220 (13.5%)
10 395 (6.0%)
8203 (4.8%)
8594 (5.0%)
28 544 (16.5%)
1854 (1.1%)
12 431 (7.2%)
17 791 (10.3%)
15 897 (9.2%)

172 302 (57.9%)
14 166 (4.8%)
4401 (1.5%)
47 863 (16.1%)
18 248 (6.1%)
32 566 (10.9%)
204 (0.1%)
63 516 (21.3%)
22 600 (7.6%)
12 656 (4.3%)
28 363 (9.5%)
172 764 (58.1%)
162 166 (54.5%)
40 668 (13.7%)
15 668 (5.3%)
12 430 (4.2%)
15 050 (5.1%)
22 761 (7.7%)
1999 (0.7%)
14 432 (4.9%)
20 987 (7.1%)
18 778 (6.3%)

9.6%
6.9%
3.3%
5.3%
6.0%
4.1%
0.7%
2.3%
0.5%
5.2%
0.5%
3.8%
11.0%
0.6%
3.3%
2.8%
0.4%
27.5%
4.3%
9.9%
11.6%
10.9%

83 879 (60.7%)
7816 (5.7%)
2327 (1.7%)
23 425 (16.9%)
9913 (7.2%)
16 265 (11.8%)
112 (0.1%)
28 856 (20.9%)
11 054 (8.0%)
5052 (3.7%)
14 038 (10.2%)
79 259 (57.3%)
81 060 (58.6%)
19 452 (14.1%)
8086 (5.8%)
6054 (4.4%)
6960 (5.0%)
17 175 (12.4%)
1220 (0.9%)
8335 (6.0%)
12 036 (8.7%)
10 743 (7.8%)

80 886 (58.5%)
7996 (5.8%)
2311 (1.7%)
23 657 (17.1%)
9844 (7.1%)
16 400 (11.9%)
121 (0.1%)
27 638 (20.0%)
11 111 (8.0%)
4860 (3.5%)
14 086 (10.2%)
78 450 (56.7%)
80 776 (58.4%)
19 433 (14.1%)
7967 (5.8%)
6130 (4.4%)
6867 (5.0%)
16 389 (11.9%)
1306 (0.9%)
8813 (6.4%)
12 509 (9.0%)
11 185 (8.1%)

4.4%
0.6%
0.1%
0.4%
0.2%
0.3%
0.2%
2.2%
0.2%
0.7%
0.1%
1.2%
0.4%
0
0.4%
0.3%
0.3%
1.7%
0.7%
1.4%
1.2%
1.2%
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Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray
Pulmonary function test
Electroencephalography
Urine culture
Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsj
Evidence of baseline serum sodium
measurement, N (%)
Most recent serum sodium, mean (SD)

4534 (2.6%)
1276 (0.7%)
74 792 (43.3%)
17 023 (9.9%)
1867 (1.1%)
49 199 (28.5%)
331 (0.2%)
10 642 (6.2%)
90 701 (52.6%)

4642 (1.6%)
1288 (0.4%)
97 878 (32.9%)
25 317 (8.5%)
1516 (0.5%)
67 274 (22.6%)
350 (0.1%)
9556 (3.2%)
172 646 (58.0%)

7.5%
4.0%
21.6%
4.7%
6.4%
13.6%
1.9%
14.0%
11.0%

2957 (2.1%)
798 (0.6%)
54 158 (39.2%)
12 975 (9.4%)
1132 (0.8%)
35 905 (26.0%)
201 (0.1%)
6417 (4.6%)
75 382 (54.5%)

3009 (2.2%)
734 (0.5%)
54 782 (39.6%)
13 134 (9.5%)
1039 (0.8%)
35 819 (25.9%)
182 (0.1%)
6163 (4.5%)
74 923 (54.2%)

0.3%
0.6%
0.9%
0.4%
0.8%
0.1%
0.4%
0.9%
0.7%

31 228 (18.1%)

51 076 (17.2%)

2.4%

22 280 (16.1%)

22 280 (16.1%)

0

140.2 (3.4)

140.6 (3.1)

12.3%

140.4 (3.3)

140.5 (3.2)

3.1%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 0.10 was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive depression” was included into the anxiety disorder category
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
g Concurrent medication use in the six months preceding the index date were considered.
h Healthcare contacts in the year preceding the index date were considered.
i Healthcare use in the year preceding the index date was considered.
j Serum sodium measurements were obtained at a mean (SD) of 140 (102) days in users and 149 (101) days in non-users (matched groups), prior to the index
date.
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Table B-5. Baseline characteristics of second-generation antidepressant users and non-users for a subpopulation residing in a hospital
catchment area with available serum sodium data*
Characteristic
Antidepressant
users
(n=7423)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residence
Long-term care
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Mood disorder
Anxiety disorderd
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancere
Diabetes mellitus
Pneumonia
Coronary artery diseasef
Angina
Atrial fibrillation/flutter
Previous hyponatremia

Unmatched
Antidepressant
non-users
(n=9754)

Standardized
Differencea

Antidepressant
users
(n=4186)

Matched
Antidepressant
non-users
(n=4186)

Standardized
Differencea

76 (7.5)
5072 (68.3%)

76 (7.3)
5917 (60.6%)

3.1%
16.1%

75 (6.9)
2889 (69.0%)

75 (6.8)
2889 (69.0%)

0
0

1725 (23.2%)
1317 (17.7%)
1502 (20.2%)
1231 (16.6%)
1648 (22.2%)
674 (9.1%)
570 (7.7%)

2195 (22.5%)
1890 (19.4%)
1969 (20.2%)
1637 (16.8%)
2063 (21.2%)
998 (10.2%)
396 (4.1%)

1.8%
4.2%
0.1%
0.5%
2.6%
3.9%
15.4%

915 (21.9%)
749 (17.9%)
878 (21.0%)
727 (17.4%)
917 (21.9%)
367 (8.8%)
57 (1.4%)

928 (22.2%)
872 (20.8%)
824 (19.7%)
711 (17.0%)
851 (20.3%)
421 (10.1%)
57 (1.4%)

0.7%
7.4%
3.2%
1.0%
3.9%
4.4%
0

0.7 (1.5)
13.3 (3.7)

0.6 (1.3)
12.2 (3.7)

13.9%
30.3%

0.5 (1.2)
12.5 (3.6)

0.5 (1.2%)
12.3 (3.6%)

0
3.3%

2038 (27.5%)
6679 (90.0%)
1051 (14.2%)
330 (4.4%)
5691 (76.7%)
246 (3.3%)
911 (12.3%)
1203 (16.2%)
577 (7.8%)
356 (4.8%)
2034 (27.4%)
1422 (19.2%)
524 (7.1%)
143 (1.9%)

1163 (11.9%)
9212 (94.4)
1233 (12.6)
417 (4.3)
7798 (79.9)
286 (2.9)
1140 (11.7)
1441 (14.8)
857 (8.8)
316 (3.2)
2848 (29.2)
1730 (17.7)
597 (6.1)
109 (1.1)

40.0%
17.0%
4.5%
0.8%
8.0%
2.2%
1.8%
4.0%
3.7%
7.9%
4.0%
3.7%
3.8%
6.6%

424 (10.1%)
4023 (96.1%)
251 (6.0%)
42 (1.0%)
3177 (75.9%)
123 (2.9%)
515 (12.3%)
619 (14.8%)
326 (7.8%)
104 (2.5%)
919 (22.0%)
633 (15.1%)
181 (4.3%)
45 (1.1%)

424 (10.1%)
4023 (96.1%)
251 (6.0%)
42 (1.0%)
3249 (77.6%)
117 (2.8%)
535 (12.8%)
622 (14.9%)
326 (7.8%)
112 (2.7%)
1047 (25.0%)
654 (15.6%)
198 (4.7%)
32 (0.8%)

0
0
0
0
4.0%
0.9%
1.4%
0.2%
0
1.2%
7.2%
1.4%
2.0%
3.3%
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Myocardial infarction
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Lung disease
Epilepsy/seizure
Acute kidney injury
Hypotension
Acute urinary retention
Previous delirium
Peripheral vascular disease
Concurrent medication useg
Number of unique drug products, mean
(SD)
Antiepileptics
Antipsychotics
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Digoxin
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatlets
Acetylcholine inhalers
Corticosteroid inhalers
Beta-agonist inhalers
Cholinesterase inhibitors
Lithium

337 (4.5%)
33 (0.4%)
241 (3.2%)
97 (1.3%)
2078 (28.0%)
87 (1.2%)
153 (2.1%)
131 (1.8%)
141 (1.9%)
141 (1.9%)
119 (1.6%)

416 (4.3)
22 (0.2)
180 (1.8%)
67 (0.7%)
2230 (22.9%)
61 (0.6%)
167 (1.7%)
108 (1.1%)
124 (1.3%)
103 (1.1%)
116 (1.2%)

1.3%
3.8%
8.9%
6.2%
11.8%
5.8%
2.6%
5.5%
5.0%
7.0%
3.5%

123 (2.9%)
8 (0.2%)
68 (1.6%)
28 (0.7%)
1020 (24.4%)
27 (0.6%)
32 (0.8%)
41 (1.0%)
53 (1.3%)
44 (1.1%)
43 (1.0%)

138 (3.3%)
7 (0.2%)
70 (1.7%)
33 (0.80%)
988 (23.6%)
19 (0.5%)
37 (0.9%)
33 (0.8%)
34 (0.8%)
26 (0.6%)
41 (1.0%)

2.1%
0.6%
0.4%
1.4%
1.8%
2.6%
1.3%
2.0%
4.5%
4.7%
0.5%

10.9 (6.8)

9.4 (5.6)

23.4%

9.2 (5.6)

9.3 (5.4)

1.6%

648 (8.7%)
490 (6.6%)
1181 (15.9%)
352 (4.7%)
1381 (18.6%)
360 (4.9%)
2361 (31.8%)
3291 (44.3%)
1807 (24.3%)
1933 (26.0%)
2138 (28.8%)
2663 (35.9%)
2931 (39.5%)
160 (2.2%)
183 (2.5%)
2187 (29.5%)
96 (1.3%)
31 (0.4%)
286 (3.9%)
354 (4.8%)
257 (3.5%)
725 (9.8%)
309 (4.2%)
15 (0.2%)

609 (6.2%)
458 (4.7%)
1776 (18.2%)
425 (4.4%)
1888 (19.4%)
426 (4.4%)
3364 (34.5%)
5285 (54.2%)
1393 (14.3%)
2772 (28.4%)
3282 (33.6%)
4508 (46.2%)
2422 (24.8%)
179 (1.8%)
177 (1.8%)
2669 (27.4%)
129 (1.3%)
28 (0.3%)
382 (3.9%)
417 (4.3%)
323 (3.3%)
840 (8.6%)
221 (2.3%)
29 (0.3%)

9.5%
8.3%
6.1%
1.8%
1.9%
2.3%
5.7%
19.8%
25.7%
5.3%
10.5%
21.1%
31.8%
2.3%
4.5%
4.7%
0.3%
2.2%
0.3%
2.4%
0.8%
4.0%
10.8%
1.9%

276 (6.6%)
147 (3.5%)
625 (14.9%)
189 (4.5%)
781 (18.7%)
186 (4.4%)
1109 (26.5%)
1867 (44.6%)
769 (18.4%)
1039 (24.8%)
1113 (26.6%)
1558 (37.2%)
1352 (32.3%)
59 (1.4%)
83 (2.0%)
1121 (26.8%)
47 (1.1%)
12 (0.3%)
136 (3.2%)
159 (3.8%)
131 (3.1%)
354 (8.5%)
92 (2.2%)
≤ 5 (≤0.1%)

292 (7.0%)
160 (3.8%)
629 (15.0%)
197 (4.7%)
838 (20.0%)
150 (3.6%)
1127 (26.9%)
2028 (48.4%)
881 (21.0%)
1086 (25.9%)
1234 (29.5%)
1711 (40.9%)
1407 (33.6%)
60 (1.4%)
79 (1.9%)
1189 (28.4%)
47 (1.1%)
11 (0.3%)
143 (3.4%)
181 (4.3%)
165 (3.9%)
386 (9.2%)
93 (2.2%)
8 (0.2%)

1.5%
1.7%
0.3%
0.9%
3.4%
4.4%
1.0%
7.7%
6.7%
2.6%
6.4%
7.5%
2.8%
0.2%
0.7%
3.6%
0
0.5%
0.9%
2.7%
4.4%
2.7%
0.2%
≤1.8%
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Glucose test strips
Healthcare contacts, mean (SD)h
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits
Healthcare usei
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis
Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray

706 (9.5%)

1122 (11.5%)

6.5%

396 (9.5%)

404 (9.7%)

0.7%

0.4 (0.8)
1.0 (1.7)
18.1 (17.0)
0.7 (4.7)
0.4 (3.0)
0 (0.2)
0 (0.1)
0 (0.2)
0 (0.2)
0 (0.1)

0.2 (0.6)
0.6 (1.3)
14.2 (11.7)
0.1 (1.6)
0.1 (1.8)
0 (0.1)
0 (0.1)
0 (0.2)
0 (0.2)
0 (0.1)

25.2%
24.2%
27.0%
18.5%
9.6%
6.7%
0%
6.1%
0
8.3%

0.2 (0.5)
0.7 (1.2)
14.6 (12.4)
0.3 (1.5)
0.1 (0.8)
0 (0.2)
0 (0.1)
0 (0.2)
0 (0.2)
0 (0.1)

0.2 (0.6)
0.7 (1.3)
14.3 (11.7)
0 (1.4)
0 (1.6)
0 (0.2)
0 (0.1)
0 (0.2)
0 (0.2)
0 (0.1)

1.9%
0.8%
2.9%
9.2%
0
0
0
0
6.1%
8.3%

4544 (61.2%)
494 (6.7%)
131 (1.8%)
956 (12.9%)
483 (6.5%)
884 (11.9%)
6 (0.1%)
1637 (22.1%)
472 (6.4%)
328 (4.4%)
583 (7.9%)
4377 (59.0%)
4258 (57.4%)
803 (10.8%)
526 (7.1%)
289 (3.9%)
390 (5.3%)
1188 (16.0%)
70 (0.9%)
476 (6.4%)
820 (11.0%)
710 (9.6%)
198 (2.7%)
69 (0.9%)
3164 (42.6%)

5780 (59.3%)
574 (5.9%)
133 (1.4%)
1117 (11.5%)
575 (5.9%)
1006 (10.3%)
≤ 5 (≤ 0.1%)
2123 (21.8%)
563 (5.8%)
558 (5.7%)
711 (7.3%)
5882 (60.3%)
5132 (52.6%)
967 (9.9%)
575 (5.9%)
316 (3.2%)
528 (5.4%)
713 (7.3%)
48 (0.5%)
377 (3.9%)
684 (7.0%)
593 (6.1%)
180 (1.8%)
50 (0.5%)
3022 (31.0%)

4.0%
3.2%
3.2%
4.4%
2.5%
5.1%
≤ 1.2%
0.7%
2.5%
5.9%
2.1%
2.7%
9.6%
3.0%
4.8%
3.5%
0.7%
27.3%
5.3%
11.6%
14.1%
13.0%
5.5%
4.9%
24.3%

2432 (58.1%)
228 (5.4%)
44 (1.1%)
437 (10.4%)
247 (5.9%)
440 (10.5%)
≤ 5 (≤ 0.1%)
954 (22.8%)
317 (7.6%)
224 (5.4%)
367 (8.8%)
2601 (62.1%)
2353 (56.2%)
497 (11.9%)
266 (6.4%)
148 (3.5%)
213 (5.1%)
410 (9.8%)
26 (0.6%)
186 (4.4%)
344 (8.2%)
293 (7.0%)
84 (2.0%)
26 (0.6%)
1433 (34.2%)

2404 (57.4%)
258 (6.2%)
59 (1.4%)
477 (11.4%)
263 (6.3%)
443 (10.6%)
≤ 5 (≤ 0.1%)
951 (22.7%)
298 (7.1%)
214 (5.1%)
359 (8.6%)
2525 (60.3%)
2385 (57.0%)
475 (11.3%)
261 (6.2%)
134 (3.2%)
222 (5.3%)
374 (8.9%)
27 (0.6%)
201 (4.8%)
347 (8.3%)
306 (7.3%)
110 (2.6%)
26 (0.6%)
1448 (34.6%)

1.4%
3.1%
3.3%
3.1%
1.6%
0.2%
0
0.2%
1.7%
1.1%
0.7%
3.7%
1.5%
1.6%
0.5%
1.9%
1.0%
3.0%
0.3%
1.7%
0.3%
1.2%
4.1%
0
0.8%
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Pulmonary function test
Electroencephalography
Urine culture
Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsj
Evidence of baseline serum sodium
measurement, N (%)
Most recent serum sodium, mean (SD)

690 (9.3%)
83 (1.1%)
1988 (26.8%)
9 (0.1%)
419 (5.6%)
3693 (49.8%)

748 (7.7%)
56 (0.6%)
1965 (20.1%)
17 (0.2%)
291 (3.0%)
5590 (57.3%)

5.8%
5.9%
15.7%
1.4%
13.1%
15.2%

319 (7.6%)
33 (0.8%)
921 (22.0%)
≤ 5 (≤ 0.1%)
115 (2.7%)
2263 (54.1%)

388 (9.3%)
32 (0.8%)
901 (21.5%)
6 (0.1%)
129 (3.1%)
2379 (56.8%)

5.9%
0.3%
1.2%
≤ 0.7%
2.0%
5.6%

4243 (57.2%)

4709 (48.3%)

17.8%

2153 (51.4%)

2153 (51.4%)

0

139.0 (3.6)

139.6 (3.5)

16.9

139.3 (3.6)

139.6 (3.5)

8.5%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive depression” was included into the anxiety disorder category
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
g Concurrent medication use in the six months preceding the index date were considered.
h Healthcare contacts in the year preceding the index date were considered.
i Healthcare use in the year preceding the index date was considered.
j Serum sodium measurements were obtained at a mean (SD) of 123 (100) days in users and 142 (100) days in non-users (matched groups), prior to the index
date.
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Table B-6. Baseline characteristics of matched second-generation antidepressant users
and non-users at 90 days prior to the index date*
Characteristic
Antidepressant
users
(n=90 195)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residence
Long-term care
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Mood disorder
Anxiety disorderd
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancere
Diabetes mellitus
Pneumonia
Coronary artery diseasef
Angina
Atrial fibrillation/flutter
Previous hyponatremia
Myocardial infarction
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Lung disease
Epilepsy/seizure
Acute kidney injury
Hypotension
Acute urinary retention
Previous delirium
Peripheral vascular disease
Concurrent medication useg
Number of unique drug products, mean
(SD)
Antiepileptics
Antipsychotics
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics

Matched
Antidepressant
non-users
(n=90 195)

Standardized
Differencea

76 (7.2)
61 315 (68.0%)

76 (7.2)
61 311 (68.0%)

0
0

18 475 (20.5%)
19 044 (21.1%)
17 788 (19.7%)
17 179 (19.0%)
17 709 (19.6%)
11 041 (12.2%)
3693 (4.1%)

18 573 (20.6%)
18 974 (21.0%)
17 769 (19.7%)
17 235 (19.1%)
17 644 (19.6%)
11 013 (12.2%)
5371 (6.0%)

0.3%
0.2%
0.1%
0.2%
0.2%
0.1%
8.5%

0.5 (1.2)
13.2 (3.7)

0.6 (1.2)
13.2 (3.7)

4.1%
0.5%

12 884 (14.3%)
86 097 (95.5%)
10 523 (11.7%)
3898 (4.3%)
67 790 (75.2%)
3243 (3.6%)
10 450 (11.6%)
12 695 (14.1%)
28 286 (31.4%)
3154 (3.5%)
26 872 (29.8%)
19 826 (22.0%)
5340 (5.9%)
1358 (1.5%)
2960 (3.3%)
248 (0.3%)
1913 (2.1%)
884 (1.0%)
25 727 (28.5%)
623 (0.7%)
1088 (1.2%)
1206 (1.3%)
1564 (1.7%)
1244 (1.4%)
1279 (1.4%)

13 997 (15.5%)
86 216 (95.6%)
10 733 (11.9%)
4006 (4.4%)
66 871 (74.1%)
3339 (3.7%)
10 291 (11.4%)
13 314 (14.8%)
28 378 (31.5%)
3374 (3.7%)
27 196 (30.2%)
19 850 (22.0%)
5823 (6.5%)
1429 (1.6%)
3151 (3.5%)
307 (0.3%)
2271 (2.5%)
873 (1.0%)
26 087 (28.9%)
660 (0.6%)
1156 (1.3%)
1257 (1.4%)
1701 (1.9%)
1300 (1.4%)
1374 (1.5%)

3.0%
1.0%
0.7%
0.6%
2.3%
0.6%
0.6%
2.0%
0.2%
1.3%
0.8%
0.1%
2.2%
0.6%
1.2%
1.2%
2.6%
0.1%
0.9%
0.5%
0.7%
0.5%
1.1%
0.5%
0.5%

7.18 (4.8)

7.38 (4.8)

4.1%

6724 (7.5%)
4496 (5.0%)
12 265 (13.6%)
3241 (3.6%)
15 411 (17.1%)
4860 (5.4%)

6628 (7.3%)
4925 (5.5%)
12 397 (13.7%)
3582 (4.0%)
15 349 (17.1%)
5465 (6.1%)

0.4%
2.1%
0.4%
2.0%
0.2%
2.9%
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Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatlets
Acetylcholine inhalers
Corticosteroid inhalers
Beta-agonist inhalers
Cholinesterase inhibitors
Lithium
Glucose test strips
Healthcare contacts, mean (SD)h
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits
Healthcare usei
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis
Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray
Pulmonary function test

25 190 (27.9%)
42 038 (46.6%)
18 197 (20.2%)
23 071 (25.6%)
24 582 (27.3%)
34 500 (38.3%)
30 317 (33.6%)
3311 (3.7%)
30 204 (33.5%)
6599 (7.3%)
397 (0.4%)
4273 (4.7%)
4680 (5.2%)
5086 (5.6%)
10 697 (11.9%)
5352 (5.9%)
252 (0.3%)
9702 (10.8%)

25 297 (28.0%)
41 329 (45.8%)
17 848 (19.8%)
23 068 (25.6%)
24 775 (27.5%)
34 050 (37.8%)
29 265 (32.4%)
3189 (3.5%)
32 123 (35.6%)
8338 (9.2%)
561 (0.6%)
4666 (5.2%)
4956 (5.5%)
5655 (6.3%)
11 521 (12.8%)
4659 (5.2%)
408 (0.5%)
9963 (11.0%)

0.3%
1.6%
1.0%
0
0.5%
1.0%
2.5%
0.7%
4.5%
7.0%
2.5%
2.0%
1.4%
2.7%
2.8%
3.4%
2.9%
0.9%

0.2 (0.6)
0.7 (1.3)
11.6 (10.7)
0.1 (1.11)
0.3 (1.9)
0.2 (1.1)
0.1 (0.7)
1.0 (2.5)
0.3 (1.3)
0.1 (0.8)

0.2 (0.6)
0.7 (1.4)
11.9 (10.8)
0.1 (1.3)
0.2 (2.2)
0.2 (1.0)
0.1 (0.8)
1.1 (2.6)
0.3 (1.3)
0.1 (0.8)

3.3%
2.2%
2.8%
0
1.4%
2.9%
1.4%
3.1%
0
1.2%

53 136 (58.9%)
4669 (5.2%)
1278 (1.4%)
14 180 (15.7%)
6003 (6.7%)
10 054 (11.1%)
53 (0.1%)
18 334 (20.3%)
7157 (7.9%)
3058 (3.4%)
9356 (10.4%)
52 749 (58.5%)
51 277 (56.9%)
12 965 (14.4%)
5406 (6.0%)
3822 (4.2%)
4495 (5.0%)
9239 (10.2%)
669 (0.7%)
4586 (5.1%)
6905 (7.7%)
6131 (6.8%)
1819 (2.0%)
434 (0.5%)
32 787 (36.4%)
8041 (8.9%)

51 989 (57.6%)
5137 (5.7%)
1407 (1.6%)
14 664 (16.3%)
6145 (6.8%)
10 131 (11.2%)
72 (0.1%)
17 613 (19.5%)
7084 (7.9%)
2971 (3.3%)
9260 (10.3%)
51 683 (57.3%)
51 532 (57.1%)
12 979 (14.4%)
5025 (5.6%)
3893 (4.3%)
4435 (4.9%)
9792 (10.9%)
770 (0.9%)
5214 (5.8%)
7451 (8.3%)
6598 (7.3%)
1800 (2.0%)
453 (0.5%)
34 123 (37.8%)
8059 (8.9%)

2.6%
2.3%
1.2%
1.5%
0.6%
0.3%
0.8%
2.0%
0.3%
0.5%
0.3%
2.4%
0.6%
0
1.8%
0.4%
0.3%
2.0%
1.3%
3.1%
2.2%
2.0%
0.2%
0.3%
3.1%
0.1%
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Electroencephalography
Urine culture
Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsj
Evidence of baseline serum sodium
measurement, N (%)
Most recent serum sodium, mean (SD)

646 (0.7%)
22 785 (25.3%)
99 (0.1%)
3771 (4.2%)
48 526 (53.8%)

652 (0.7%)
22 922 (25.4%)
111 (0.1%)
3756 (4.2%)
48 209 (53.4%)

0.1%
0.3%
0.4%
0.1%
0.7%

13 697 (15.2%)

13 911 (15.4%)

0.7%

140.6 (3.1)

140.60 (3.1)

0

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin
II receptor blocker. IQR=interquartile range. NSAID=Non-steroidal anti-inflammatory drug. SD=standard
deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a
measure of the difference between groups with respect to the pooled standard deviation; a standardized
difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Code 300 for “Anxiety neurosis, hysteria, neurasthenia, obsessive compulsive neurosis, reactive
depression” was included into the anxiety disorder category
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin
lymphoma, liver, ovarian, esophageal
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous
coronary intervention.
g Concurrent medication use in the six months preceding the index date were considered.
h Healthcare contacts in the year preceding the index date were considered.
i Healthcare use in the year preceding the index date was considered.
j Laboratory measurements in the seven days to one year preceding the index date were considered.
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Figure B-1. Sensitivity analysis of hidden bias
A sensitivity analysis for the maximum p-value for a significance level of α (0.05) when γ > 1 and Δ > 1.
The solid curve represents values of γ and Δ where the maximum p-value equals to α. The shaded area
represents values of γ and Δ where the maximum p-value is less than α. The white area represents values of
γ and Δ where the maximum p-value is greater than α.
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Appendix C
Table C-1. STROBE Checklist

Title and abstract

Introduction
Background/rationale

Item
No
1

2

Objectives

3

Methods
Study design

4

Setting

5

Participants

6

Variables

7

Data sources/measurement

8

Bias

9

Study size

10

Quantitative variables

11

Statistical methods

12

Recommendation

Reported

(a) Indicate the study’s design with a
commonly used term in the title or the
abstract
(b) Provide in the abstract an informative and
balanced summary of what was done and
what was found

Title, Abstract

Explain the scientific background and
rationale for the investigation being reported
State specific objectives, including any prespecified hypotheses

Introduction

Present key elements of study design early
in the paper
Describe the setting, locations, and relevant
dates, including periods of recruitment,
exposure, follow-up, and data collection
(a) Give the eligibility criteria, and the
sources and methods of selection of
participants. Describe methods of follow-up
(b) For matched studies, give matching
criteria and number of exposed and
unexposed
Clearly define all outcomes, exposures,
predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if
applicable
For each variable of interest, give sources of
data and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than
one group
Describe any efforts to address potential
sources of bias
Explain how the study size was arrived at

Methods

Explain how quantitative variables were
handled in the analyses. If applicable,
describe which groupings were chosen and
why
(a) Describe all statistical methods, including
those used to control for confounding
(b) Describe any methods used to examine
subgroups and interactions
(c) Explain how missing data were
addressed
(d) If applicable, explain how loss to followup was addressed
(e) Describe any sensitivity analyses

Abstract

Introduction

Methods

Methods, Figure
1
Methods, Table
1, Appendix
Table 3, 4, 5
Methods,
Appendix Table
2
Methods,
Appendix
Tables 2

Methods,
Discussion
Methods; based
on availability of
the data
Methods

Methods
Methods
Methods
Not applicable
Methods

210

Results
Participants

Descriptive data

13

14

Outcome data

15

Main results

16

Other analyses

17

Discussion
Key results

18

Limitations

19

Interpretation

20

Generalizability

21

Other information
Funding

22

(a) Report numbers of individuals at each
stage of study—e.g. numbers potentially
eligible, examined for eligibility, confirmed
eligible, included in the study, completing
follow-up, and analyzed
(b) Give reasons for non-participation at
each stage
(c) Consider use of a flow diagram
(a) Give characteristics of study participants
(e.g. demographic, clinical, social) and
information on exposures and potential
confounders
(b) Indicate number of participants with
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Table C-2. Coding definitions for comorbid conditions, outcomes and exposures
Variable
Comorbidities
Dementia

Database

Code/Definition

CIHI-DAD

ICD-9 2900, 2901, 2903, 2904, 2908, 2909, 2948, 2949,
3310, 3311, 3312, 2941, 797
ICD-10 F065, F066, F068, F069, F09, F00, F01, F02, F03,
F051, G30, G31, R54
DSM-IV 29040, 29041, 29042, 29043, 29120, 29282,
29410, 29411, 29480, 78090
290, 331, 797
ICD-9 2950, 2951, 2952, 2953, 2954, 2955, 2956, 2957,
2958, 2959, 2970, 2971, 2972, 2973, 2978, 2979, 2980,
2981, 2983, 2984, 2988, 2989
ICD-10 F060, F062, F105, F107, F115, F117, F125, F127,
F135, F137, F145, F147, F155, F157, F165, F167, F175,
F177, F185, F187, F195, F197, F200, F201, F202, F203,
F204, F205, F206, F208, F209, F220, F228, F229, F230,
F231, F232, F233, F238, F239, F24, F250, F251, F252,
F258, F259, F28, F29
DSM-IV 29130, 29150, 29211, 29212, 29381, 29382,
29510, 29520, 29530, 29540, 29560, 29570, 29590,
29710, 29730, 29880, 29890
291, 292, 295, 297, 298, Q021
ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968
ICD-10 F300, F301, F302, F308, F309, F310, F311, F312,
F313, F314, F315, F316, F317, F318, F319
DSM-IV 29600, 29601, 29602, 29603, 29604, 29605,
29606, 29640, 29641, 29642, 29643, 29644, 29645,
29646, 29650, 29651, 29652, 29653, 29654, 29655,
29656, 29660, 29661, 29662, 29663, 29664, 29665,
29666, 29670, 29680, 29689
296, Q020
ICD-9 2962, 2963, 3000, 3002, 3003, 3004, 3091, 311
ICD-10 F063, F064, F320, F321, F322, F323, F328, F329,
F330, F331, F332, F333, F334, F338, F339, F341, F400,
F401, F402, F408, F409, F410, F411, F412, F413, F418,
F419, F420, F421, F422, F428, F429, F430, F431
DSM-IV 29189, 29284, 29289, 29383, 29384, 29620,
29621, 29622, 29623, 29624, 29625, 29626, 29630,
29631, 29632, 29633, 29634, 29635, 29636, 30000,
30001, 30002, 30021, 30022, 30023, 30029, 30030,
30040, 30113
311
ICD-9 332
ICD-10 G20, F023
332
ICD-9 425, 5184, 514, 428
ICD-10 I500, I501, I509, I255, J81
CCP 4961, 4962, 4963, 4964
CCI 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR,
1HZ53SYFR
428, R701, R702, Z429
ICD-9 4030, 4031, 4039, 4040, 4041, 4049, 582, 583,
580, 581, 584, 585, 586, 587, 5880, 5888, 5889, 5937
ICD-10 E102, E112, E132, E142, I12, I13, N08, N18, N19
403, 585

OMHRS

Schizophrenia or other
psychotic disorder

OHIP
CIHI-DAD

OMHRS

Bipolar disorder

OHIP
CIHI-DAD

OMHRS

Major depression and/or
anxiety disorder

OHIP
CIHI-DAD

OMHRS

Parkinson’s disease

OHIP
CIHI-DAD

Congestive heart failure

OMHRS
CIHI-DAD

Chronic kidney disease

OHIP
CIHI-DAD

OHIP

212

Hypertension

CIHI-DAD

Chronic liver disease

OHIP
CIHI-DAD

Hypothyroidism

OHIP
CIHI-DAD

Cancer

OHIP
CIHI-DAD

OHIP
Diabetes Mellitus

CIHI-DAD

Pneumonia

OHIP
CIHI-DAD

Coronary artery disease

CIHI-DAD

OHIP
Angina

CIHI-DAD

Atrial fibrillation/flutter

OHIP
CIHI-DAD

Previous hyponatremia

CIHI-DAD

Myocardial Infarction
Haemorrhagic stroke

CIHI-DAD

Ischemic stroke

CIHI-DAD

Transient ischemic
attack
Chronic lung disease

CIHI-DAD
CIHI-DAD

ICD-9 401, 402, 403, 404, 405
ICD10 I10, I11, I12, I13, I15
401, 402, 403,
ICD-9 4561, 4562, 070, 5722, 5723, 5724, 5728, 573,
7824, V026, 2750, 2751, 7891, 7895, 571
ICD-10 B16, B17, B18, B19, I85, R17, R18, R160, R162,
B942, Z225, E831, E830, K70, K713, K714, K715, K717,
K721, K729, K73, K74, K753, K754, K758, K759, K76,
K77
571, 573, 070, Z551, Z554
ICD-9 243, 2440, 2441, 2442, 2443, 2448, 2449
ICD-10 E030, E031, E032, E033, E034, E035, E038,
E039, E890
243, 244
ICD-9 150, 154, 155, 157, 162, 174, 175, 185, 203, 204,
205, 206, 207, 208
ICD-10 971, 980, 982, 984, 985, 986, 987, 988, 989, 990,
991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56,
C61, C82, C83, C85, C91, C92, C93, C94, C95, C00, D05
203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162,
174, 175, 183, 185
ICD-9 250
ICD-10 E10, E11, E13, E14
250, K029, K030, Q040
ICD-9 480, 481, 482, 483, 484, 485, 486, 7700
ICD-10 J12, J13, J14, J15, J16, J17, J18, P23
ICD-9 410 412, 414, 4292, 4295, 4296, 4297
ICD-10 I21, I22, I23, I24, I25, Z955, Z958, Z959, R931,
T822
CCP 4801, 4802, 4803, 4804, 4805, 481, 482, 483
CCI 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76
410, 412, R741, R742, R743, G298, E646, E651, E652,
E654, E655, G262, Z434, Z448
ICD-9 413
ICD-10 I20
413
ICD-9 4273
ICD-10 I48
ICD-9 2761
ICD-10 E871
ICD-9 410
ICD-10 I21, I22
ICD-9 430, 431
ICD-10 I600, I601, I602, I603, I604, I605, I606, I607, I609,
I61
ICD-9 436, 4340, 4341, 4349, 3623
ICD-10 I630, I631, I632, I633, I634, I635, I638, I639, I64,
H341
ICD-9 435
ICD-10 G450, G451, G452, G453, G458, G459, H340
ICD-9 491, 492, 493, 494, 495, 496, 500, 501, 502, 503,
504, 505, 5064, 5069, 5081, 515, 516, 517, 5185, 5188,
5198, 5199, 4168, 4169
ICD-10 I272, I278, I279, J40, J41, J42, J43, J44, J45, J47,
J60, J61, J62, J63, J64, J65, J66, J67, J68, J701, J703,
J704, J708, J709, J82, J84, J92, J941, J949, J953, J961,
J969, J984, J988, J989, J99
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OHIP
Seizure

CIHI-DAD

Acute kidney injury

CIHI-DAD

Hypotension

CIHI-DAD

Acute urinary retention

CIHI-DAD

Delirium

CIHI-DAD

Peripheral vascular
disease

CIHI-DAD

OHIP

Outcomes
Hyponatremia*
Bowel obstruction
Exposures
Risperidone
Olanzapine
Quetiapine

491, 492, 493, 494, 496, 501, 502, 515, 518, 519
J689, J889
ICD-9 345, 7803
ICD-10 G40, G41, R560, R568
ICD-9 584
ICD-10 N17
ICD-9 458
ICD-10 I95
ICD-9 7882
ICD-10 R33
ICD-9 293
ICD-10 F05
ICD-9 4402, 4408, 4409, 5571, 4439, 444
ICD-10 I700, I702, I708, I709, I731, I738, I739, K551
CCP 5125, 5129, 5014, 5016, 5018, 5028, 5038
CCI 1KA76, 1KA50, 1KE76, 1KG26, 1KG50, 1KG57,
1KG76MI, 1KG87
R787, R780, R797, R804, R809, R875, R815, R936,
R783, R784,R785, E626, R814, R786, R937, R860, R861,
R855, R856, R933, R934, R791, E672, R794, R813,
R867, E649

CIHI-DAD
CIHI-DAD

ICD-10 E871
ICD-10 K56

ODB

Higher dose: >0.5 mg/day; Normal dose ≤0.5 mg/day
Higher dose: >2.5 mg/day; Normal dose ≤2.5 mg/day
Higher dose: >25 mg/day; Normal dose ≤25 mg/day

CCI=Canadian Classification of Health Interventions. CCP=Canadian Classification of Diagnostic,
Therapeutic and Surgical Procedures. CIHI-DAD=Canadian Institute for Health Information Discharge
Abstract Database. ICD-9=International Classification of Diseases, Ninth Revision. ICD-10=International
Classification of Diseases, Tenth Revision. Ontario Drug Benefit database=ODB. OHIP=Ontario Health
Insurance Plan database. OMHRS=Ontario Mental Health Reporting System database. RPDB=Ontario’s
Registered Persons Database.
*Validation of the code for hyponatremia was performed on approximately 64 499 hospitalizations with
linked laboratory measurements for serum sodium. See Methods section for a description of the validation.
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Table C-3. Variables included in propensity score model
Demographics
Income
Index date
Residential status
(community-dwelling or
long-term care)
Comorbid conditions

Concurrent medication
use

Number of healthcare
contacts
Number of healthcare
uses

Age, sex, rural neighborhood

Charlson comorbidity index, Johns Hopkins ACG System Aggregated
Diagnosis Groups, dementia, schizophrenia, bipolar disorder, unipolar
depression/anxiety, Parkinson’s disease, congestive heart failure, chronic
kidney disease, hypertension, chronic liver disease, hypothyroidism, cancer,
diabetes mellitus, pneumonia, coronary artery disease, angina, atrial
fibrillation/flutter, myocardial infarction, hemorrhagic stroke, ischemic stroke,
transient ischemic attack, chronic lung disease, seizure, acute kidney injury,
hypotension, acute urinary retention, peripheral vascular disease
Number of unique drug products, anticonvulsant, antidepressant,
antidiabetics, antineoplastic, thyroxin, potassium sparing diuretic, nonpotassium sparing diuretic, ACE inhibitor and/or ARB, NSAID (excluding
aspirin), calcium channel blocker, beta-adrenergic antagonist, statin,
benzodiazepine, digoxin, overactive bladder medication, antibiotic, warfarin,
anticoagulant, antiplatelet, acetylcholine inhaler, corticosteroid inhaler, betaagonist inhaler, cholinesterase inhibitor, lithium, glucose tests strips.
Hospitalization, emergency department visit, family physician visit,
psychiatrist visit, geriatrician visit, neurologist visit, nephrologist visit,
cardiologist visit, urologist visit, obstetrician/gynecologist visit
Previous sodium tests, carotid ultrasound, cardiac catheterization,
echocardiography, holter monitoring, cardiac stress test, coronary
endarterectomy, colorectal cancer screening, cervical cancer screening,
prostate-specific antigen test, mammography, flu shot, bone mineral density
test, hearing test, cystoscopy, cataract surgery, computed tomography of the
head, computed tomography of the neck, computed tomography of the
thorax, computed tomography of the abdomen, computed tomography of the
pelvis, computed tomography of the spine, computed tomography of the
extremities, chest x-ray, pulmonary function test, electroencephalography,
urine culture, heart valve replacement, at-home physician service,
cholesterol test

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin
II receptor blocker. NSAID=non-steroidal anti-inflammatory drug.
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Table C-4. Full baseline characteristics of atypical antipsychotic medication users and non-users*
Characteristic
Antipsychotic
users
(n=92 090)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Year of cohort entry
2003-2004
2005-2006
2007-2008
2009-2010
2011-2012
Rural residence
Long-term care
Prescribing Physician
Family Physician
Psychiatrist
Geriatrician
Neurologist
Other
Missing
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Dementia
Schizophrenia
Bipolar disorder
Unipolar depression/anxiety

Unmatched
Antipsychotic
non-users
(n=175 836)

Standardized
Differencea

Antipsychotic
users
(n=58 008)

Matched
Antipsychotic
non-users
(n=58 008)

Standardized
Differencea

81 (7.8)
58 647 (63.7%)

79 (7.9)
111 968 (63.7%)

29.2%
0

81 (7.7)
38 736 (66.8%)

81 (7.7)
38 736 (66.8%)

0.3%
0

20 160 (21.9%)
18 854 (20.5%)
17 999 (19.6%)
17 607 (19.1%)
17 058 (18.5%)

37 436 (21.3%)
36 395 (20.7%)
33 861 (19.3%)
33 206 (18.9%)
34 373 (19.6%)

1.5%
0.6%
0.7%
0.6%
2.6%

12 331 (21.3%)
11 888 (20.5%)
11 630 (20.1%)
11 213 (19.3%)
10 946 (18.9%)

13 081 (22.6%)
12 057 (20.8%)
11 408 (19.7%)
10 847 (18.7%)
10 615 (18.3%)

3.1%
0.7%
1.0%
1.6%
1.5%

19 653 (21.3%)
21 756 (23.6%)
18 970 (20.6%)
19 814 (21.5%)
11 897 (12.9%)
11 759 (12.8%)
32 644 (35.5%)

31 335 (17.8%)
38 010 (21.6%)
35 337 (20.1%)
42 371 (24.1%)
28 783 (16.4%)
23 484 (13.4%)
26 705 (15.2%)

8.9%
4.8%
1.3%
6.2%
9.8%
1.7%
47.9%

11 417 (19.7%)
13 395 (23.1%)
11 962 (20.6%)
13 317 (23.0%)
7917 (13.7%)
7671 (13.2%)
16 409 (28.3%)

11 312 (19.5%)
13 430 (23.2%)
11 762 (20.3%)
13 341 (23.0%)
8163 (14.1%)
7557 (13.0%)
16 409 (28.3%)

0.5%
0.1%
0.9%
0.1%
1.2%
0.6%
0

64 900 (70.5%)
7420 (8.1%)
4387 (4.8%)
1943 (2.1%)
3383 (3.7%)
10 057 (10.9%)

40 829 (70.4%)
3989 (6.9%)
3356 (5.8%)
1367 (2.4%)
2139 (3.7%)
6328 (10.9%)

1.68 (1.8)
13.90 (4.2)

1.56 (1.8)
13.69 (4.0)

6.7%
5.2%

0.87 (1.5)
13.37 (4.2)

0.94 (1.5)
13.69 (4.1)

4.7%
7.8%

71 933 (78.1%)
14 838 (16.1%)
10 174 (11.1%)
28 419 (30.9%)

92 049 (52.4%)
14 072 (8.0%)
11 377 (6.5%)
74 574 (42.4%)

56.2%
25.1%
16.3%
24.2%

44 715 (77.1%)
4756 (8.2%)
3295 (5.7%)
15 038 (25.9%)

44 715 (77.1%)
4756 (8.2%)
3295 (5.7%)
15 038 (25.9%)

0
0
0
0
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Parkinson’s disease
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancerd
Diabetes mellitus
Pneumonia
Coronary artery diseasee
Angina
Atrial fibrillation/flutter
Previous hyponatremia
Myocardial infarction
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Lung disease
Seizure
Acute kidney injury
Hypotension
Acute urinary retention
Delirium
Peripheral vascular disease
Concurrent medication usef
Number of unique drug products, mean
(SD)
Antiepileptics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists

8652 (9.4%)
19 029 (20.7%)
8127 (8.8%)
65 205 (70.8%)
2980 (3.2%)
10 213 (11.1%)
12 145 (13.2%)
14 245 (15.5%)
8006 (8.7%)
31 417 (34.1%)
20 496 (22.3%)
9841 (10.7%)
3403 (3.7%)
4741 (5.2%)
698 (0.8%)
5328 (5.8%)
1818 (2.0%)
26 237 (28.5%)
1782 (1.9%)
3453 (3.8%)
2704 (2.9%)
3337 (3.6%)
7112 (7.7%)
1939 (2.1%)

19 015 (10.8%)
33 627 (19.1%)
15 323 (8.7%)
131 562 (74.8%)
6388 (3.6%)
20 354 (11.6%)
25 758 (14.7%)
30 491 (17.3%)
12 843 (7.3%)
61 334 (34.9%)
42 264 (24.0%)
17 100 (9.7%)
5416 (3.1%)
9010 (5.1%)
935 (0.5%)
7628 (4.3%)
3074 (1.8%)
53 842 (30.6%)
2780 (1.6%)
5616 (3.2%)
4572 (2.6%)
5179 (3.0%)
6013 (3.4%)
4061 (2.3%)

4.7%
3.9%
0.4%
9.0%
2.2%
1.5%
4.2%
5.1%
5.1%
1.6%
4.2%
3.2%
3.4%
0.1%
2.8%
6.6%
1.7%
4.7%
2.7%
3.0%
2.1%
3.8%
18.8%
1.4%

3780 (6.5%)
10 038 (17.3%)
3140 (5.4%)
40 929 (70.6%)
1664 (2.9%)
6222 (10.7%)
7321 (12.6%)
17 590 (30.3%)
4237 (7.3%)
18 641 (32.1%)
12 166 (21.0%)
5428 (9.4%)
1766 (3.0%)
2585 (4.5%)
331 (0.6%)
2725 (4.7%)
1023 (1.8%)
15 489 (26.7%)
879 (1.5%)
1482 (2.6%)
1320 (2.3%)
1650 (2.8%)
3424 (5.9%)
1043 (1.8%)

3780 (6.5%)
10 038 (17.3%)
3140 (5.4%)
40 419 (69.7%)
1807 (3.1%)
6198 (10.7%)
7864 (13.6%)
18 457 (31.8%)
4755 (8.2%)
19 184 (33.1%)
12 462 (21.5%)
5613 (9.7%)
2111 (3.6%)
2696 (4.7%)
404 (0.7%)
3340 (5.8%)
1176 (2.0%)
16 891 (29.1%)
1087 (1.9%)
1501 (2.6%)
1398 (2.4%)
1774 (3.1%)
2546 (4.4%)
1238 (2.1%)

0
0
0
1.9%
1.5%
0.1%
2.8%
3.2%
3.3%
2.0%
1.3%
1.1%
3.3%
0.9%
1.6%
4.8%
1.9%
5.4%
2.8%
0.2%
0.9%
1.3%
6.9%
2.4%

9.71 (6.4)

8.94 (5.5)

13.0%

8.91 (5.9%)

9.41 (5.6)

8.7%

10 970 (11.9%)
46 600 (50.6%)
14 245 (15.5%)
3240 (3.5%)
16 580 (18.0%)
5390 (5.9%)
31 051 (33.7%)
39 596 (43.0%)
13 638 (14.8%)
22 902 (24.9%)
26 099 (28.3%)

16 409 (9.3%)
65 227 (37.1%)
21 969 (12.5%)
6863 (3.9%)
33 499 (19.1%)
11 025 (6.3%)
61 131 (34.8%)
88 563 (50.4%)
30 146 (17.1%)
49 786 (28.3%)
55 259 (31.4%)

8.4%
27.5%
8.6%
2.0%
2.7%
1.8%
2.2%
14.8%
6.4%
7.8%
6.7%

5552 (9.6%)
25 197 (43.4%)
8526 (14.7%)
1958 (3.4%)
10 406 (17.9%)
3267 (5.6%)
18 611 (32.1%)
24 853 (42.8%)
8667 (14.9%)
14 642 (25.2%)
16 169 (27.9%)

6688 (11.5%)
26 871 (46.3%)
9307 (16.0%)
2151 (3.7%)
10 846 (18.7%)
3236 (5.6%)
18 665 (32.2%)
25 660 (44.2%)
9047 (15.6%)
15 011 (25.9%)
16 254 (28.0%)

6.4%
5.8%
3.7%
1.8%
2.0%
0.2%
0.2%
2.8%
1.8%
1.5%
0.3%
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Statins
Benzodiazepines
Digoxin
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatlets
Acetylcholine inhalers
Corticosteroid inhalers
Beta-agonist inhalers
Cholinesterase inhibitors
Lithium
Glucose test strips
Healthcare contacts, mean (SD)g
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits
Healthcare useh
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot

29 558 (32.1%)
33 031 (35.9%)
5923 (6.4%)
5188 (5.6%)
35 094 (38.1%)
9610 (10.4%)
895 (1.0%)
6665 (7.2%)
6454 (7.0%)
5309 (34.2%)
11 801 (12.8%)
31 505 (34.2%)
1176 (1.3%)
10 411 (11.3%)

72 878 (41.5%)
45 988 (26.2%)
10 434 (5.9%)
8652 (4.9%)
63 965 (36.4%)
19 752 (11.2%)
1287 (0.7%)
13 455 (7.7%)
13 153 (7.5%)
11 301 (13.8%)
25 019 (14.2%)
24 342 (13.8%)
1042 (0.6%)
23 666 (13.5%)

19.48%
21.12%
2.07%
3.19%
3.58%
2.57%
2.61%
1.58%
1.82%
49.09%
4.14%
49.09%
7.12%
6.54%

19 171 (33.1%)
17 616 (30.4%)
3 523 (6.1%)
3 094 (5.3%)
20 856 (36.0%)
5 761 (9.9%)
476 (0.8%)
4009 (6.9%)
3731 (6.4%)
3183 (5.5%)
6974 (12.0%)
18 139 (31.3%)
367 (0.6%)
6162 (10.6%)

19 514 (33.6%)
18 692 (32.2%)
3848 (6.6%)
3311 (5.7%)
21 900 (37.8%)
6189 (10.7%)
463 (0.8%)
4511 (7.8%)
4319 (7.5%)
3647 (6.3%)
8061 (13.9%)
16 804 (29.0%)
412 (0.7%)
6784 (11.7%)

1.3%
4.0%
2.3%
1.6%
3.7%
2.4%
0.3%
3.3%
4.0%
3.4%
5.6%
5.0%
1.0%
3.4%

0.51 (0.9)
1.29 (2.1)
18.57 (18.0)
0.82 (3.6)
1.69 (7.5)
0.43 (2.2)
0.16 (1.1)
1.23 (3.2)
0.32 (1.5)
0.07 (0.6)

0.32 (0.8)
0.84 (1.6)
13.61 (13.1)
0.34 (2.1)
0.36 (2.5)
0.29 (1.2)
0.15 (1.0)
1.16 (2.9)
0.33 (1.3)
0.09 (0.6)

22.6%
24.7%
31.9%
16.9%
26.6%
8.2%
0.9%
2.3%
0.7%
3.3%

0.40 (0.8)
1.04 (1.6)
15.84 (15.5)
0.58 (2.5)
0.64 (2.4)
0.30 (1.2)
0.11 (0.9)
1.03 (2.7)
0.28 (1.3)
0.07 (0.5)

0.39 (0.8)
1.00 (1.7)
16.30 (15.3)
0.49 (2.4)
0.40 (2.2)
0.31 (1.3)
0.12 (0.9)
1.03 (2.7)
0.29 (1.3)
0.07 (0.5)

1.3%
2.5%
3.0%
3.7%
10.0%
0.8%
1.1%
0
0.8%
0

63 335 (68.8%)
4568 (5.0%)
742 (0.8%)
12 411 (13.5%)
4818 (5.2%)
5757 (6.3%)
45 (0.1%)
10 653 (11.6%)
2047 (2.2%)
1147 (1.3%)
3507 (3.8%)
42 439 (46.1%)

79 930 (45.5%)
9137 (5.2%)
2334 (1.3%)
27 264 (15.5%)
10 904 (6.2%)
15 993 (9.1%)
112 (0.1%)
29 013 (16.5%)
8290 (4.7%)
4580 (2.6%)
12 320 (7.0%)
95 645 (54.4%)

48.5%
1.1%
5.1%
5.8%
4.2%
10.7%
0.6%
14.2%
13.7%
9.9%
14.2%
16.7%

38 190 (64.8%)
2721 (4.7%)
414 (0.7%)
7247 (12.5%)
2962 (5.1%)
3542 (6.1%)
32 (0.1%)
6767 (11.7%)
1447 (2.5%)
770 (1.3%)
2425 (4.2%)
27 859 (48.0%)

38 145 (65.8%)
2883 (5.0%)
477 (0.8%)
7355 (12.7%)
3032 (5.2%)
3700 (6.4%)
31 (0.1%)
6823 (11.8%)
1427 (2.5%)
792 (1.4%)
2370 (4.1%)
27 553 (47.5%)

0.2%
1.3%
1.2%
0.6%
0.6%
1.1%
0.1%
0.3%
0.2%
0.3%
0.5%
1.1%
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Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis
Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray
Pulmonary function test
Electroencephalography
Urine culture
Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsi
Most recent serum sodium, N (%)
Most recent serum sodium, mean (SD)

57 414 (62.4%)
5792 (6.3%)
3705 (4.0%)
3959 (4.3%)
3233 (3.5%)
26 927 (29.2%)
741 (0.8%)
5054 (5.5%)
7773 (8.4%)
7177 (7.8%)
2003 (2.2%)
675 (0.7%)
43 501 (47.2%)
4882 (5.3%)
1664 (1.8%)
35 750 (38.8%)
72 (0.1%)
11 389 (12.4%)
33 009 (35.8%)

100 900 (57.4%)
18 558 (10.6%)
9327 (5.3%)
7739 (4.4%)
8372 (4.8%)
25 724 (14.6%)
1309 (0.7%)
9369 (5.3%)
13 668 (7.8%)
12 371 (7.0%)
3474 (2.0%)
1085 (0.6%)
69 077 (39.3%)
13 764 (7.8%)
1836 (1.0%)
49 370 (28.1%)
208 (0.1%)
11 474 (6.5%)
83 296 (47.4%)

10.1%
15.4%
6.1%
0.5%
6.3%
35.9%
0.7%
0.7%
2.5%
2.9%
1.4%
1.4%
16.1%
10.2%
6.4%
22.9%
1.3%
20.1%
23.6%

34 911 (60.2%)
4040 (7.0%)
2375 (4.1%)
2253 (3.9%)
2137 (3.7%)
13 261 (22.9%)
417 (0.7%)
2638 (4.6%)
4109 (7.1%)
3799 (6.6%)
1030 (1.8%)
368 (0.6%)
24 600 (42.4%)
2901 (5.0%)
791 (1.4%)
20 385 (35.1%)
43 (0.1%)
5832 (10.1%)
21 686 (37.4%)

34 766 (59.9%)
4110 (7.1%)
2537 (4.4%)
2325 (4.0%)
2122 (3.7%)
12 896 (22.2%)
469 (0.8%)
3175 (5.5%)
4574 (7.9%)
4165 (7.2%)
1106 (1.9%)
392 (0.7%)
25 086 (43.3%)
3404 (5.9%)
826 (1.4%)
19 477 (33.6%)
32 (0.1%)
5684 (9.8%)
20 975 (36.2%)

0.5%
0.5%
1.4%
0.6%
0.1%
1.5%
1.0%
4.2%
3.1%
2.5%
1.0%
0.5%
1.7%
3.8%
0.5%
3.3%
0.8%
0.9%
2.5%

14 346 (15.6%)
140.3 (3.5)

21 948 (23.8%)
140.4 (3.22)

20.9%
2.7%

7242 (12.5%)
140.43 (3.4)

7242 (12.5%)
140.28 (3.4)

0
4.4%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal
e Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
f Concurrent medication use in the six months preceding the index date were considered.
g Healthcare contacts in the year preceding the index date were considered.
h Healthcare use in the year preceding the index date was considered.
i Serum sodium measurements were obtained at a mean (SD) of 140 (102) days in users and 149 (101) days in non-users, prior to the index date.
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Table C-5. Baseline characteristics of matched atypical antipsychotic users and nonusers at 90 days prior to the index date*
Characteristic
Antipsychotic
users
(n=42 698)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residence
Long-term care
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancerd
Diabetes mellitus
Pneumonia
Coronary artery diseasee
Angina
Atrial fibrillation/flutter
Previous hyponatremia
Myocardial infarction
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Lung disease
Seizure
Acute kidney injury
Hypotension
Acute urinary retention
Delirium
Peripheral vascular disease
Concurrent medication usef
Number of unique drug products, mean
(SD)
Antiepileptics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs

Matched
Antipsychotic
non-users
(n=42 698)

Standardized
Differencea

81 (7.6)
28 842 (67.6%)

81 (7.6)
28 842 (67.6%)

0.3%
0%

9552 (22.4%)
8899 (20.8%)
8389 (19.7%)
8003 (18.7%)
7855 (18.4%)
5698 (13.3%)
9303 (21.8%)

8927 (20.9%)
8726 (20.4%)
8615 (20.2%)
8362 (19.6%)
8068 (18.9%)
5586 (13.1%)
12 168 (28.5%)

3.6%
1.0%
1.3%
2.1%
1.3%
0.8%
15.5%

1.39 (1.6)
13.28 (4.1)

1.49 (1.7)
13.61 (4.1)

6.2%
8.1%

6911 (16.2%)
2001 (4.7%)
30 047 (70.4%)
1159 (2.7%)
4666 (10.9%)
5154 (12.1%)
12 666 (29.7%)
2771 (6.5%)
13 535 (31.7%)
8930 (20.9%)
3600 (8.4%)
1129 (2.6%)
1703 (4.0%)
222 (0.5%)
1771 (4.2%)
745 (1.7%)
11 061 (25.9%)
616 (1.4%)
904 (2.1%)
889 (2.1%)
1055 (2.5%)
1815 (4.3%)
682 (1.6%)

7118 (16.7%)
2097 (4.9%)
29 571 (69.3%)
1234 (2.9%)
4616 (10.8%)
5612 (13.1%)
13 389 (31.4%)
3270 (7.7%)
13 873 (32.5%)
9049 (21.2%)
3925 (9.2%)
1493 (3.5%)
1835 (4.3%)
290 (0.7%)
2411 (5.7%)
827 (1.9%)
12 066 (28.3%)
757 (1.8%)
963 (2.3%)
979 (2.3%)
1268 (3.0%)
1993 (4.7%)
840 (2.0%)

1.3%
1.1%
2.4%
1.1%
0.4%
3.2%
3.7%
4.6%
1.7%
0.7%
2.7%
4.9%
1.6%
2.1%
7.0%
1.4%
5.3%
2.6%
0.9%
1.4%
3.1%
2.0%
2.8%

8.49 (5.6)

9.15 (5.5)

11.9%

3739 (8.8%)
17 715 (41.5%)
1389 (3.3%)
1364 (3.2%)
7811 (18.3%)
2298 (5.4%)
13 157 (30.8%)
18 563 (43.5%)

4745 (11.1%)
19 285 (45.2%)
1734 (4.1%)
1518 (3.6%)
7933 (18.6%)
2279 (5.3%)
13 513 (31.7%)
18 720 (43.8%)

7.9%
7.4%
4.3%
2.0%
0.7%
0.2%
1.8%
0.7%
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NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatlets
Acetylcholine inhalers
Corticosteroid inhalers
Beta-agonist inhalers
Cholinesterase inhibitors
Lithium
Glucose test strips
Healthcare contacts, mean (SD)g
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits
Healthcare useh
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis
Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray
Pulmonary function test
Electroencephalography
Urine culture

6379 (14.9%)
10 735 (25.1%)
11 686 (27.4%)
14 073 (33.0%)
11 309 (26.5%)
2308 (5.4%)
14 310 (33.5%)
4407 (10.3%)
241 (0.6%)
2874 (6.7%)
2515 (5.9%)
2257 (5.3%)
5694 (13.3%)
12 415 (29.1%)
262 (0.6%)
4239 (9.9%)

6737 (15.8%)
10 881 (25.5%)
11 732 (27.5%)
13 956 (32.7%)
13 273 (31.1%)
2406 (5.6%)
15 890 (37.2%)
4050 (9.5%)
327 (0.8%)
3132 (7.3%)
2944 (6.9%)
2687 (6.3%)
4801 (11.2%)
14 273 (33.4%)
273 (0.6%)
4866 (11.4%)

2.3%
0.8%
0.2%
0.6%
10.2%
1.0%
7.8%
2.8%
2.5%
2.4%
4.1%
4.3%
6.4%
9.4%
0.3%
4.8%

0.29 (0.7)
0.84 (1.4)
14.22 (14.1)
0.44 (2.0)
0.39 (1.8)
0.28 (1.0)
0.08 (0.7)
0.86 (2.3)
0.25 (1.1)
0.07 (0.5)

0.36 (0.8)
0.93 (1.6)
16.05 (15.2)
0.48 (2.5)
0.38 (2.2)
0.31 (1.3)
0.10 (0.8)
0.96 (2.6)
0.28 (1.2)
0.07 (0.5)

9.7%
5.9%
12.5%
1.8%
0.5%
2.6%
2.7%
4.1%
2.6%
0

27 877 (65.3%)
1798 (4.2%)
278 (0.7%)
4654 (10.9%)
2055 (4.8%)
2399 (5.6%)
17 (0)
4910 (11.5%)
1083 (2.5%)
550 (1.3%)
1839 (4.3%)
21 271 (49.8%)
24 803 (58.1%)
3055 (7.2%)
1769 (4.1%)
1550 (3.6%)
1669 (3.9%)
7717 (18.1%)
222 (0.5%)
2017 (4.7%)
2461 (5.8%)
2256 (5.3%)
632 (1.5%)
204 (0.5%)
15 965 (37.4%)
2014 (4.7%)
505 (1.2%)
13 942 (32.7%)

27 206 (63.7%)
2085 (4.9%)
304 (0.7%)
5124 (12.0%)
2189 (5.1%)
2668 (6.3%)
15 (0)
5094 (11.9%)
1055 (2.5%)
560 (1.3%)
1823 (4.3%)
20 476 (48.0%)
25 398 (59.5%)
3142 (7.4%)
1885 (4.4%)
1700 (4.0%)
1623 (3.8%)
8868 (20.8%)
296 (0.7%)
1528 (3.6%)
3082 (7.2%)
2802 (6.6%)
767 (1.8%)
246 (0.6%)
17 569 (41.2%)
2385 (5.6%)
575 (1.4%)
14 178 (33.2%)

3.3%
3.2%
0.7%
3.5%
1.4%
2.7%
0.2%
1.3%
0.4%
0.2%
0.2%
3.7%
2.8%
0.8%
1.3%
1.8%
0.6%
6.8%
2.2%
5.7%
5.9%
5.4%
2.5%
1.4%
7.7%
3.9%
1.5%
1.2%
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Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsi
Most recent serum sodium, N (%)
Most recent serum sodium, mean (SD)

14 (0)
3706 (8.7%)
15 636 (36.6%)

19 (0)
4035 (9.5%)
15 309 (35.9%)

0.6%
2.7%
1.6%

5452 (12.8%)
140.6 (3.3)

5452 (12.8%)
140.4 (3.4)

0
6.9%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin
II receptor blocker. IQR=interquartile range. NSAID=Non-steroidal anti-inflammatory drug. SD=standard
deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a
measure of the difference between groups with respect to the pooled standard deviation; a standardized
difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin
lymphoma, liver, ovarian, esophageal
e Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous
coronary intervention.
f Concurrent medication use in the six months preceding the index date were considered.
g Healthcare contacts in the year preceding the index date were considered.
h Healthcare use in the year preceding the index date was considered.
i Serum sodium measurements were obtained at a mean (SD) of 151 (104) days in users and 151 (105) days
in non-users, prior to the index date.
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Appendix D
Table D-1. STROBE Checklist
Recommendation

Reported

Title and abstract

Item
No
1

(a) Indicate the study’s design with a commonly
used term in the title or the abstract
(b) Provide in the abstract an informative and
balanced summary of what was done and what
was found

Title,
Abstract
Abstract

Introduction
Background/rationale

2

Explain the scientific background and rationale
for the investigation being reported
State specific objectives, including any prespecified hypotheses

Introduction

Present key elements of study design early in
the paper
Describe the setting, locations, and relevant
dates, including periods of recruitment,
exposure, follow-up, and data collection
(a) Give the eligibility criteria, and the sources
and methods of selection of participants.
Describe methods of follow-up
(b) For matched studies, give matching criteria
and number of exposed and unexposed

Methods

Objectives

3

Methods
Study design

4

Setting

5

Participants

6

Variables

7

Data sources/
measurement

8

Bias

9

Study size

10

Quantitative variables

11

Statistical methods

12

Results

Clearly define all outcomes, exposures,
predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if applicable
For each variable of interest, give sources of
data and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than one
group
Describe any efforts to address potential
sources of bias
Explain how the study size was arrived at

Explain how quantitative variables were handled
in the analyses. If applicable, describe which
groupings were chosen and why
(a) Describe all statistical methods, including
those used to control for confounding
(b) Describe any methods used to examine
subgroups and interactions
(c) Explain how missing data were addressed
(d) If applicable, explain how loss to follow-up
was addressed
(e) Describe any sensitivity analyses

Introduction

Methods

Methods,
Appendix
Figure 1
Methods,
Table 1, 2,
Appendix
Table 3, 4, 5
Methods,
Appendix
Table 2
Methods,
Appendix
Tables 2

Discussion
Methods;
based on
availability of
the data
Methods

Methods
Methods
Methods
Not
applicable
Methods
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Participants

13

(a) Report numbers of individuals at each stage
of study—e.g. numbers potentially eligible,
examined for eligibility, confirmed eligible,
included in the study, completing follow-up, and
analyzed
(b) Give reasons for non-participation at each
stage
(c) Consider use of a flow diagram

Descriptive data

14

(a) Give characteristics of study participants
(e.g. demographic, clinical, social) and
information on exposures and potential
confounders
(b) Indicate number of participants with missing
data for each variable of interest
(c) Summarize follow-up time (e.g. average and
total amount)

Outcome data

15

Report numbers of outcome events or summary
measures over time

Main results

16

(a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their
precision (e.g. 95% confidence interval). Make
clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when
continuous variables were categorized
(c) If relevant, consider translating estimates of
relative risk into absolute risk for a meaningful
time period

Other analyses

17

Report other analyses done—e.g. analyses of
subgroups and interactions, and sensitivity
analyses

Discussion
Key results

18

Limitations

19

Interpretation

20

Generalizability

21

Summarize key results with reference to study
objectives
Discuss limitations of the study, taking into
account sources of potential bias or imprecision.
Discuss both direction and magnitude of any
potential bias
Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other
relevant evidence
Discuss the generalizability (external validity) of
the study results

Other information

Methods,
Results,
Appendix
Figure 1
Methods,
Appendix
Figure 1
Appendix
Figure 1
Table 1, 2
Appendix
Tables 4, 5
Table 1, 2
Appendix
Tables 4, 5
Results,
Table 3,
Figure 1,
Appendix
Table 6, 7
Results,
Table 3,
Figure 1,
Appendix
Table 6, 7, 8,
9
Results,
Table 3,
Figure 1,
Appendix
Table 6, 7, 8,
9
Not
applicable
Results,
Table 3,
Appendix
Table 6, 7
Results,
Appendix
Table 6, 7, 8,
9
Discussion
Discussion

Discussion

Discussion
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Funding

22

Give the source of funding and the role of the
funders for the present study and, if applicable,
for the original study on which the present article
is based

Role of
funding
source
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Table D-2. Coding definitions for comorbid conditions, outcomes and exposures
Variable
Comorbidities
Benign brain tumour

Database

Code/Definition

CIHI-DAD

ICD-9 2250
ICD-10 D330, D331, D332, D339
225
ICD-9 4373
ICD-10 I671
ICD-9 850, 851, 852, 853, 854
ICD-10 S06
ICD-9 191
ICD-10 C71
191
ICD-9 320, 321, 322
ICD-10 G00, G01, G02, G03
320, 321
ICD-9 323
ICD-10 G04, G05
323
ICD-9 74781, 74789, 7479
ICD-10 Q28
ICD-9 34500, 34501, 34510, 34511, 3452, 3453, 34540,
34541, 34550, 34551, 34560, 34561, 34570, 34571,
34580, 34581, 34590, 34591, 7803
ICD-10 G40, G41, R5680, R5688
345, 780
ICD-9 3460, 3461, 3462, 3468, 3469
ICD-10 G430, G431, G432, G433, G438, G439
346
ICD-9 425, 5184, 514, 428
ICD-10 I500, I501, I509, I255, J81
428, R701, R702, Z429
ICD-9 4030, 4031, 4039, 4040, 4041, 4049, 584, 586,
5888, 5889, 5937, 2504
ICD-10 E102, E112, E132, E142, I12, I13, N08, N18, N19
403, 585
ICD-9 401, 402, 403, 404, 405
ICD10 I10, I11, I12, I13, I15
401, 402, 403
ICD-9 4561, 4562, 070, 5722, 5723, 5724, 5728, 573,
7824, V026, 2750, 2751, 7891, 7895, 571
ICD-10 B16, B17, B18, B19, I85, R17, R18, R160, R162,
B942, Z225, E831, E830, K70, K713, K714, K715, K717,
K721, K729, K73, K74, K753, K754, K758, K759, K76,
K77
571, 573, 070, Z551, Z554
ICD-9 243, 2440, 2441, 2442, 2443, 2448, 2449
ICD-10 E030, E031, E032, E033, E034, E035, E038,
E039, E890
243, 244
ICD-9 150, 154, 155, 157, 162, 174, 175, 185, 203, 204,
205, 206, 207, 208
ICD-10 971, 980, 982, 984, 985, 986, 987, 988, 989, 990,
991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56,
C61, C82, C83, C85, C91, C92, C93, C94, C95, C00, D05
203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162,

Brain aneurysm

OHIP
CIHI-DAD

Brain injury

CIHI-DAD

Brain cancer

CIHI-DAD

Meningitis

OHIP
CIHI-DAD

Encephalitis

OHIP
CIHI-DAD

Congenital
malformations
Epilepsy/seizure

OHIP
CIHI-DAD
CIHI-DAD

Migraine

OHIP
CIHI-DAD

Congestive heart failure

OHIP
CIHI-DAD

Chronic kidney disease

OHIP
CIHI-DAD

Hypertension

OHIP
CIHI-DAD

Chronic liver disease

OHIP
CIHI-DAD

Hypothyroidism

OHIP
CIHI-DAD

Cancer

OHIP
CIHI-DAD

OHIP
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Diabetes mellitus

CIHI-DAD

Diabetic neuropathy

OHIP
CIHI-DAD

Diabetic retinopathy

CIHI-DAD

Pneumonia

CIHI-DAD

Coronary artery disease

CIHI-DAD
OHIP

Angina

CIHI-DAD

Atrial fibrillation/flutter

OHIP
CIHI-DAD

Previous hyponatremia

CIHI-DAD

Myocardial Infarction
Haemorrhagic stroke

CIHI-DAD

Ischemic stroke

CIHI-DAD

Transient ischemic
attack
Chronic lung disease

CIHI-DAD
CIHI-DAD

OHIP
Acute kidney injury

CIHI-DAD

Adrenal Insufficiency

CIHI-DAD

Hypotension

CIHI-DAD

Acute urinary retention

CIHI-DAD

Delirium

CIHI-DAD

Bipolar Disorder

DSM-IV
CIHI-DAD

174, 175, 183, 185
ICD-9 250
ICD-10 E10, E11, E13, E14
250, K029, K030, Q040
ICD-9 3572, 25060
ICD-10 E1040, E1041, E1042, E1048, E1049, E1140,
E1141, E1142, E1148, E1149, E1340, E1341, E1342,
E1348, E1349, E1440, E1441, E1442, E1448, E1449,
G590, G632
ICD-9 36201, 36202, 36210, 36212, 36229
ICD-10 E1030, E1031, E1032, E1033, E1034, E1130,
E1131, E1131, E1132, E1133, E1134, H360
ICD-9 480, 481, 482, 483, 484, 485, 486, 7700
ICD-10 J12, J13, J14, J15, J16, J17, J18, P23
ICD-9 410, 412, 414, 4292, 4295, 4296, 4297
ICD-10 I21, I22, I24, I25, Z955, Z958, Z959, R931, T822
410, 412, R741, R742, R743, G298, E646, E651, E652,
E654, E655, G262, Z434, Z448
ICD-9 413
ICD-10 I20, I23
413
ICD-9 4273
ICD-10 I48
ICD-9 2761
ICD-10 E871
ICD-9 410
ICD-10 I21, I22
ICD-9 430, 431
ICD-10 I600, I601, I602, I603, I604, I605, I606, I607, I609,
I61
ICD-9 436, 4340, 4341, 4349, 3623
ICD-10 I630, I631, I632, I633, I634, I635, I638, I639, I64,
H341
ICD-9 435
ICD-10 G450, G451, G452, G453, G458, G459, H340
ICD-9 491, 492, 493, 494, 495, 496, 500, 501, 502, 503,
504, 505, 5064, 5069, 5081, 515, 516, 517, 5185, 5188,
5198, 5199, 4168, 4169
ICD-10 I272, I278, I279, J40, J41, J42, J43, J44, J45, J47,
J60, J61, J62, J63, J64, J65, J66, J67, J68, J701, J703,
J704, J708, J709, J82, J84, J92, J941, J949, J953, J961,
J969, J984, J988, J989, J99
491, 492, 493, 494, 496, 501, 502, 515, 518, 519, J689,
J889
ICD-9 584
ICD-10 N17
ICD-9 2554
ICD-10 E271, E272, E273, E274
ICD-9 458
ICD-10 I95
ICD-9 7882
ICD-10 R33
ICD-9 29011, 2903, 2910, 29281, 2930, 2931
ICD-10 F05
78009, 29300
ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968
ICD-10 F300, F301, F302, F308, F309, F310, F311, F312,
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OHIP
DSM-IV

Neuropathic Pain

CIHI-DAD

Mood Disorders

CIHI-DAD

DSM-IV

Anxiety Disorders

OHIP
CIHI-DAD
DSM-IV

Parkinson Disease

OHIP
CIHI-DAD

Trigeminal Neuralgia

OHIP
CIHI-DAD

Peripheral vascular
disease

OHIP
CIHI-DAD
OHIP

Outcomes
Hyponatremia*
Bowel obstruction
Exposures

CIHI-DAD
CIHI-DAD

F313, F314, F315, F316, F317, F318, F319
296, Q020
29600, 29601, 29602, 29603, 29604, 29605, 29606,
29640, 29641, 29642, 29643, 29644, 29645, 29646,
29650, 29651, 29652, 29653, 29654, 29655, 29656,
29660, 29661, 29662, 29663, 29664, 29665, 29666,
29670, 29680, 29689
ICD-9 7292, 3510, 3511, 3518, 3519, 3520, 3521, 3522,
3523, 3524, 3525, 3526, 3529, 3530, 3531, 3532, 3533,
3534, 3535, 3536, 3538, 3539, 3540, 3541, 3542, 3543,
3544, 3545, 3548, 3549, 3550, 3551, 3552, 3553, 3554,
3555, 3556, 3557, 3558, 3559
ICD-10 M7920, M7921, M7922, M7923, M7924, M7925,
M7926, M7927, M7928, M7929, G628, G629, G630,
G631, G530, G531, G532, G533, G538, G540, G541,
G542, G543, G544, G545, G546, G547, G548, G549,
G550, G551, G552, G553, G558, G560, G561, G562,
G563, G564, G568, G569, G570, G571, G572, G573,
G574, G575, G576, G577, G578, G579, G580, G587,
G588, G589, G590, G598, G600, G601, G602, G603,
G608, G609, G610, G611, G618, G619, G620, G621,
G622, G628, G629, G630, G631, G633, G634, G635,
G636, G638
ICD-9 2960, 2961, 2964, 2965, 2966, 2967, 2968, 3004,
311, 2962, 2963, 2969
ICD-10 F30, F31, F340, F32, F33, F341, F381, F348,
F349, F380, F388, F39
29600, 29601, 29602, 29603, 29604, 29605, 29606,
29640, 29641, 29642, 29643, 29644, 29645, "9646,
29650, 29651, 29652, 29653, 29654, 29655, 29656,
29660, 29661, 29662, 29663, 29664, 29665, 29666,
29670, 29680, 29689, 30113, 29383, 29690, 29620,
29621, 29622, 29623, 29624, 29625, 29626, 29630,
29631, 29632, 29633, 29634, 29635, 29636, 30040,
31100
296, 311, Q020
ICD-9 3000, 3002, 3003, 3098, 3083
ICD-10 F40, F41, F42, F430, F431, F438, F439
30001, 30021, 30022, 30029, 30023, 30030, 30981,
30830, 30002, 29384, 30000
300
ICD-9 332
ICD-10 G20, F023
332
ICD-9 3501, 3502, 3508, 3509
ICD-10 G500, G501, G508, G509
350
ICD-9 4402, 4408, 4409, 5571, 4439, 444
ICD-10 I700, I702, I708, I709, I731, I738, I739, K551
R787, R780, R797, R804, R809, R875, R815, R936,
R783, R784, R785, E626, R814, R786, R937, R860,
R861, R855, R856, R933, R934, R791, E672, R794,
R813, R867, E649
ICD-10 E871
ICD-10 K56
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Carbamazepine
Valproic acid
Phenytoin
Topiramate

ODB

Higher dose: >300 mg/day; Normal dose ≤300 mg/day
Higher dose: >500 mg/day; Normal dose ≤500 mg/day
Higher dose: >300 mg/day; Normal dose ≤300 mg/day
Higher dose: >50 mg/day; Normal dose ≤50 mg/day

CCI=Canadian Classification of Health Interventions. CCP=Canadian Classification of Diagnostic,
Therapeutic and Surgical Procedures. CIHI-DAD=Canadian Institute for Health Information Discharge
Abstract Database. ICD-9=International Classification of Diseases, Ninth Revision. ICD-10=International
Classification of Diseases, Tenth Revision. Ontario Drug Benefit database=ODB. OHIP=Ontario Health
Insurance Plan database. RPDB=Ontario’s Registered Persons Database.
*Validation of the code for hyponatremia was performed on approximately 64 499 hospitalizations with
linked laboratory measurements for serum sodium. See Methods section for a description of the validation.
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Table D-3. Variables included in propensity score model
Demographics
Income
Index date
Residential status
(community-dwelling or longterm care)
Comorbid conditions

Concurrent medication use

Number of healthcare
contacts
Number of healthcare uses

Age, sex, rural neighborhood

Charlson comorbidity index, Johns Hopkins ACG System Aggregated
Diagnosis Groups, benign brain tumour, brain aneurysm, brain cancer,
brain injury, encephalitis, meningitis, epilepsy/seizure, migraine,
congenital malformations, congestive heart failure, chronic kidney
disease, hypertension, chronic liver disease, hypothyroidism, cancer,
diabetes mellitus, pneumonia, coronary artery disease, angina, atrial
fibrillation/flutter, myocardial infarction, adrenal insufficiency,
hemorrhagic stroke, ischemic stroke, transient ischemic attack, lung
disease, acute kidney injury, hypotension, acute urinary retention,
peripheral vascular disease, bipolar disorder, neuropathic pain, mood
disorders, anxiety disorders, Parkinson’s disease, trigeminal neuralgia,
diabetic neuropathy, diabetic retinopathy
Number of unique drug products, antipsychotic, antidepressant,
antidiabetics, antineoplastic, thyroxin, potassium sparing diuretic, nonpotassium sparing diuretic, ACE inhibitor and/or ARB, NSAID (excluding
aspirin), calcium channel blocker, beta-adrenergic antagonist, statins,
benzodiazepine, digoxin, overactive bladder, antibiotics, warfarin,
anticoagulant, antiplatelet, acetylcholine inhaler, corticosteroid inhaler,
beta-agonist inhaler, cholinesterase inhibitor, lithium, glucose tests
strips, baclofen.
Hospitalization, emergency department visit, family physician visit,
psychiatrist visit, geriatrician visit, neurologist visit, nephrologist visit,
cardiologist visit, urologist visit, obstetrician/gynecologist visit
Previous sodium tests, carotid ultrasound, cardiac catheterization,
echocardiography, holter monitoring, cardiac stress test, coronary
endarterectomy, colorectal cancer screening, cervical cancer screening,
prostate-specific antigen test, mammography, flu shot, bone mineral
density test, hearing test, cystoscopy, cataract surgery, magnetic
resonance imaging of the head, computed tomography of the head,
computed tomography of the neck, computed tomography of the thorax,
computed tomography of the abdomen, computed tomography of the
pelvis, computed tomography of the spine, computed tomography of the
extremities, chest x-ray, pulmonary function test,
electroencephalography, urine culture, heart valve replacement, athome physician service, cholesterol test

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin
II receptor blocker. NSAID=non-steroidal anti-inflammatory drug.
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Table D-4. Full baseline characteristics of carbamazepine users and non-users (1:3 matching ratio)*
Characteristic
Carbamazepine
users
(n= 24 905)
Demographic
Age, mean (SD), years
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Year of cohort entry
2003-2004
2005-2006
2007-2008
2009-2010
2011-2012
2013-2015
Rural residencec
Long-term care
Prescribing physician
Family Physician
Psychiatrist
Geriatrician
Neurologist
Other
Missing
Comorbid conditionsd
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Epilepsy/seizuree
Migraine
Trigeminal neuralgia

Unmatched
Antiepileptic
non-users
(n= 1 289 530)

Standardized
Differencea

Carbamazepine
users
(n=21 191)

Matched
Antiepileptic
non-users
(n=63 573)

Standardized
Differencea

76 (7.1)
15 436 (62.0%)

76 (7.2)
742 126 (57.6%)

0.8%
9.0%

76 (6.9)
13 284 (62.7%)

76 (6.8)
39 852 (62.7%)

0.3%
0

5388 (21.6%)
5171 (20.8%)
4960 (19.9%)
4798 (19.3%)
4495 (18.1%)

251 859 (19.5%)
269 597 (20.9%)
252 663 (19.6%)
253 301 (19.6%)
258 046 (20.0%)

5.2%
0.4%
0.8%
1.0%
5.0%

4508 (21.3%)
4415 (20.8%)
4314 (20.3%)
4099 (19.3%)
3855 (18.2%)

13 924 (21.9%)
13 123 (20.6%)
12 960 (20.4%)
12 261 (19.3%)
11 305 (17.8%)

1.5%
0.5%
0.1%
0.1%
1.1%

5825 (23.4%)
5757 (23.1%)
4433 (17.8%)
3740 (15.0%)
2840 (11.4%)
2310 (9.3%)
4108 (16.5%)
1691 (6.8%)

232 137 (18.0%)
254 656 (19.8%)
213 249 (16.5%)
204 621 (15.9%)
196 140 (15.2%)
188 727 (14.6%)
182 927 (14.2%)
57 445 (4.5%)

13.3%
8.2%
3.4%
2.4%
11.2%
16.6%
6.4%
10.2%

4894 (23.1%)
4974 (23.5%)
3822 (18.0%)
3161 (14.9%)
2376 (11.2%)
1964 (9.3%)
3461 (16.3%)
984 (4.6%)

14 761 (23.2%)
14 854 (23.4%)
11 474 (18.1%)
9509 (15.0%)
7096 (11.2%)
5879 (9.3%)
10 623 (16.7%)
2 952 (4.6%)

0.3%
0.3%
0
0.1%
0.2%
0.1%
1.0%
0

117 850 (71.7%)
239 (1.0%)
148 (0.6%)
2075 (8.3%)
1533 (6.2%)
3060 (12.3%)

15 323 (72.3%)
211 (1.0%)
128 (0.6%)
1629 (7.7%)
1308 (6.2%)
2592 (12.2%)

0.8 (1.5)
13.2 (4.3)

0.6 (1.3)
11.5 (4.2)

15.9%
41.0%

0.7 (1.4)
12.9 (4.2)

0.7 (1.4)
13.0 (4.1)

0
2.2%

12 046 (48.4%)
1780 (7.2%)
3235 (13.0%)

396 047 (30.7%)
39 661 (3.1%)
11 567 (0.9%)

36.7%
18.6%
49.0%

9802 (46.3%)
1358 (6.4%)
1377 (6.5%)

29 406 (46.3%)
4095 (6.4%)
3817 (6.0%)

0
0.1%
2.0%
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Neuropathic pain
Bipolar disorder
Mood disorder
Anxiety disorder
Benign brain tumour
Brain aneurysm
Brain cancer
Brain injury
Encephalitis
Meningitis
Parkinson’s disease
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancerf
Diabetes mellitus
Diabetic neuropathy
Diabetic retinopathy
Pneumonia
Coronary artery diseaseg
Angina
Atrial fibrillation/flutter
Previous hyponatremia
Previous delirium
Myocardial infarction
Adrenal insufficiency
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Acute kidney injury
Hypotension
Acute urinary retention
Peripheral vascular disease
Lung disease
Concurrent medication useh
Number of unique drug products, mean

734 (3.0%)
143 (0.6%)
683 (2.7%)
11 293 (45.3%)
446 (1.8%)
30 (0.1%)
234 (0.9%)
127 (0.5%)
40 (0.2%)
42 (0.2%)
671 (2.7%)
3516 (14.1%)
1640 (6.6%)
18 180 (73.0%)
842 (3.4%)
2571 (10.3%)
3553 (14.3%)
7116 (28.6%)
172 (0.7%)
155 (0.6%)
1187 (4.8%)
7785 (31.3%)
5885 (23.6%)
1621 (6.5%)
536 (2.2%)
444 (1.8%)
988 (4.0%)
9 (0%)
123 (0.5%)
807 (3.2%)
336 (1.4%)
460 (1.9%)
428 (1.7%)
558 (2.2%)
585 (2.4%)
7392 (29.7%)

18 587 (1.4%)
2154 (0.2%)
15 713 (1.2%)
463 445 (35.9%)
7600 (0.6%)
423 (0%)
3001 (0.2%)
3896 (0.3%)
676 (0.1%)
840 (0.1%)
24 413 (1.9%)
144 842 (11.2%)
77 172 (6.0%)
953 061 (73.9%)
39 103 (3.0%)
121 865 (9.5%)
168 419 (13.1%)
358 136 (27.8%)
3216 (0.3%)
5031 (0.4%)
43 322 (3.4%)
356 915 (27.7%)
245 038 (19.0%)
73 573 (5.7%)
16 299 (1.3%)
14 306 (1.1%)
43 693 (3.4%)
471 (0%)
2561 (0.2%)
22 836 (1.8%)
9789 (0.8%)
20 448 (1.6%)
16 113 (1.3%)
21 821 (1.7%)
18 175 (1.4%)
310 878 (24.1%)

10.3%
6.7%
11.0%
19.2%
11.1%
3.2%
9.3%
3.3%
3.3%
3.0%
5.4%
8.7%
2.5%
2.1%
2.0%
2.9%
3.5%
1.8%
6.5%
3.3%
7.1%
7.9%
11.3%
3.4%
6.9%
5.6%
3.1%
0%
5.0%
9.4%
5.8%
2.0%
3.9%
4.0%
6.9%
12.6%

535 (2.5%)
561 (2.7%)
2442 (11.5%)
9335 (44.1%)
312 (1.5%)
25 (0.1%)
141 (0.7%)
97 (0.5%)
25 (0.1%)
30 (0.1%)
508 (2.4%)
2417 (11.4%)
920 (4.3%)
15 300 (72.2%)
686 (3.2%)
2186 (10.3%)
2969 (14.0%)
5943 (28.0%)
112 (0.5%)
109 (0.5%)
868 (4.1%)
6276 (29.6%)
4763 (22.5%)
1235 (5.8%)
378 (1.8%)
276 (1.3%)
745 (3.5%)
7 (0%)
77 (0.4%)
568 (2.7%)
231 (1.1%)
272 (1.3%)
289 (1.4%)
422 (2.0%)
417 (2.0%)
6067 (28.6%)

1530 (2.4%)
1667 (2.6%)
7286 (11.5%)
28 233 (44.4%)
952 (1.5%)
64 (0.1%)
437 (0.7%)
266 (0.4%)
69 (0.1%)
88 (0.1%)
1537 (2.4%)
7251 (11.4%)
2760 (4.3%)
45 888 (72.2%)
2026 (3.2%)
6474 (10.2%)
8803 (13.9%)
17 346 (27.3%)
275 (0.4%)
334 (0.5%)
2442 (3.8%)
18 916 (29.8%)
14 575 (22.9%)
3587 (5.6%)
1158 (1.8%)
919 (1.5%)
2225 (3.5%)
16 (0%)
246 (0.4%)
1655 (2.6%)
694 (1.1%)
787 (1.2%)
853 (1.3%)
1205 (1.9%)
1290 (2.0%)
18 487 (29.1%)

0.8%
0.2%
0.2%
0.7%
0.2%
0.5%
0.3%
0.6%
0.3%
0.1%
0.1%
0
0
0
0.3%
0.4%
0.5%
1.7%
1.4%
0.2%
1.3%
0.3%
1.1%
0.8%
0.3%
1.2%
0.1%
0.5%
0.4%
0.5%
0
0.4%
0.2%
0.7%
0.4%
1.0%

8.9 (6.0)

7.1 (4.7)

33.5%

8.4 (5.6)

8.4 (5.4)

0.2%
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(SD)
Antipsychotics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic antagonists
Statins
Benzodiazepines
Digoxin
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatelets
Acetylcholine inhalers
Corticosteroid inhalers
Beta-agonist inhalers
Cholinesterase inhibitors
Lithium
Glucose test strips
Baclofen
Healthcare contacts, mean (SD)i
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits

1473 (5.9%)
7781 (31.2%)
4496 (18.1%)
960 (3.9%)
4136 (16.6%)
1578 (6.3%)
7563 (30.4%)
11 605 (46.6%)
6267 (25.2%)
6940 (27.9%)
7165 (28.8%)
9439 (37.9%)
6597 (26.5%)
1044 (4.2%)
986 (4.0%)
9553 (38.4%)
1947 (7.8%)
213 (0.9%)
1555 (6.2%)
1528 (6.1%)
1623 (3.9%)
3278 (13.2%)
970 (3.9%)
101 (0.4%)
3562 (14.3%)
449 (1.8%)

48 323 (3.7%)
215 229 (16.7%)
225 528 (17.5%)
44 902 (3.5%)
204 370 (15.8%)
69 702 (5.4%)
383 139 (29.7%)
627 455 (48.7%)
224 624 (17.4%)
361 121 (28.0%)
385 357 (29.9%)
542 836 (42.1%)
216 925 (16.8%)
46 646 (3.6%)
35 023 (2.7%)
388 511 (30.1%)
100 225 (7.8%)
13 884 (1.1%)
63 795 (4.9%)
69 110 (5.4%)
74 369 (3.6%)
150 199 (11.6%)
45 953 (3.6%)
2397 (0.2%)
165 484 (12.8%)
6414 (0.5%)

10.1%
34.6%
1.5%
2.0%
2.1%
4.0%
1.4%
4.1%
19.0%
0.3%
2.4%
8.6%
23.6%
3.0%
6.9%
17.4%
0.2%
2.3%
5.6%
3.3%
1.7%
4.6%
1.7%
4.0%
4.3%
12.3%

1070 (5.1%)
6056 (28.6%)
3766 (17.8%)
799 (3.8%)
3513 (16.6%)
1278 (6.0%)
6053 (28.6%)
9815 (46.3%)
5286 (24.9%)
5789 (27.3%)
6011 (28.4%)
8082 (38.1%)
5289 (25.0%)
812 (3.8%)
811 (3.8%)
7870 (37.1%)
1549 (7.3%)
170 (0.8%)
1224 (5.8%)
1204 (5.7%)
1375 (3.6%)
2681 (12.7%)
752 (3.6%)
76 (0.4%)
2958 (13.0%)
294 (1.4%)

3276 (5.2%)
18 644 (29.3%)
10 934 (17.2%)
2416 (3.8%)
10 393 (16.4%)
3600 (5.7%)
18 324 (28.8%)
29 171 (45.9%)
16 556 (26.0%)
17 310 (27.2%)
17 643 (27.8%)
23 835 (37.5%)
16 528 (26.0%)
2459 (3.9%)
2433 (3.8%)
23 707 (37.3%)
4635 (7.3%)
469 (0.7%)
3550 (5.6%)
3769 (5.9%)
4085 (3.6%)
8069 (12.7%)
2315 (3.6%)
249 (0.4%)
8543 (13.4%)
924 (1.5%)

0.5%
1.7%
1.5%
0.2%
0.6%
1.6%
0.6%
0.9%
2.5%
0.2%
1.4%
1.3%
2.4%
0.2%
0
0.3%
0.1%
0.7%
0.8%
1.1%
0.5%
0.1%
0.5%
0.5%
1.5%
0.6%

0.6 (1.1)
1.0 (1.8)
12.8 (13.0)
0.2 (1.9)
0.4 (3.7)
0.4 (2.0)
0.1 (0.9)
1.1 (2.6)
0.3 (1.4)
0.1 (0.6)

0.4 (0.9)
0.5 (1.2)
9.0 (9.2)
0.1 (1.1)
0.1 (1.8)
0.1 (0.7)
0.1 (0.7)
0.9 (2.3)
0.3 (1.2)
0.1 (0.7)

19.4%
29.5%
34.4%
6.7%
9.1%
23.9%
2.4%
7.7%
3.1%
1.6%

0.6 (1.1)
0.8 (1.6)
11.5 (10.9)
0.1 (1.5)
0.3 (3.2)
0.31 (1.0)
0.1 (0.8)
1.0 (2.4)
0.3 (1.4)
0.1 (0.6)

0.6 (1.1)
0.8 (1.7)
11.5 (11.2)
0.1 (1.3)
0.3 (3.2)
0.2 (1.1)
0.1 (0.7)
1.0 (2.3)
0.3 (1.3)
0.1 (0.7)

0.9%
1.3%
0.4%
0
0.3%
6.6%
1.3%
0.9%
0
1.6%
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Healthcare usej
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Magnetic resonance imaging of the head
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis
Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray
Pulmonary function test
Electroencephalography
Urine culture
Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsk
Most recent serum sodium, N (%)
Most recent serum sodium, mean (SD)

14 835 (59.6%)
1750 (7.0%)
380 (1.5%)
4106 (16.5%)
1761 (7.1%)
3095 (12.4%)
22 (0.1%)
4510 (18.1%)
1364 (5.5%)
783 (3.1%)
2250 (9.0%)
13 809 (55.4%)
13 181 (52.9%)
2871 (11.5%)
1403 (5.6%)
1160 (4.7%)
1221 (4.9%)
1581 (6.3%)
4443 (17.8%)

745 101 (57.8%)
53 990 (4.2%)
18 080 (1.4%)
190 435 (14.8%)
70 045 (5.4%)
127 001 (9.8%)
788 (0.1%)
243 069 (18.8%)
77 134 (6.0%)
48 576 (3.8%)
120 405 (9.3%)
703 334 (54.5%)
665 897 (51.6%)
151 488 (11.7%)
58 607 (4.5%)
48 227 (3.7%)
61 776 (4.8%)
20 572 (1.6%)
90 235 (7.0%)

3.6%
12.4%
1.0%
4.7%
6.8%
8.2%
1.0%
1.9%
2.2%
3.4%
1.0%
1.8%
2.6%
0.7%
5.0%
4.6%
0.5%
24.5%
33.3%

12 217 (57.7%)
1382 (6.5%)
2572 (12.1%)
1308 (6.2%)
315 (1.5%)
3309 (15.6%)
20 (0.1%)
3846 (18.2%)
1234 (5.8%)
683 (3.2%)
1994 (9.4%)
11 829 (55.8%)
11 073 (52.3%)
2542 (12.0%)
1164 (5.5%)
951 (4.5%)
1046 (4.9%)
997 (4.7%)
3130 (14.8%)

36 567 (57.5%)
4024 (6.3%)
7795 (12.3%)
3971 (6.3%)
890 (1.4%)
9737 (15.3%)
50 (0.1%)
11 413 (18.0%)
3687 (5.8%)
2127 (3.4%)
6117 (9.6%)
35 703 (56.2%)
32 855 (51.7%)
7582 (11.9%)
3478 (5.5%)
2909 (4.6%)
3193 (5.0%)
2942 (4.6%)
9373 (14.7%)

0.3%
0.8%
0.4%
0.3%
0.7%
0.8%
0.5%
0.5%
0.1%
0.7%
0.7%
0.7%
1.2%
0.2%
0.1%
0.4%
0.4%
0.4%
0.1%

348 (1.4%)
1563 (6.3%)
2237 (9.0%)
1999 (8.0%)
939 (3.8%)
197 (0.8%)
9594 (38.5%)
2127 (8.5%)
860 (3.5%)
6081 (24.4%)
31 (0.1%)
1163 (4.7%)
12 830 (51.5%)

7581 (0.6%)
56 709 (4.4%)
81 533 (6.3%)
72 632 (5.6%)
18 193 (1.4%)
5709 (0.4%)
388 460 (30.1%)
95 359 (7.4%)
4318 (0.3%)
260 583 (20.2%)
1444 (0.1%)
36 321 (2.8%)
732 331 (56.8%)

8.2%
8.4%
10.0%
9.5%
14.9%
4.4%
17.8%
4.2%
23.0%
10.1%
0.4%
9.8%
10.6%

250 (1.2%)
1256 (5.9%)
1759 (8.3%)
1560 (7.4%)
706 (3.3%)
152 (0.7%)
7697 (36.3%)
1766 (8.3%)
454 (2.1%)
4865 (23.0%)
26 (0.1%)
864 (4.1%)
11 054 (52.2%)

762 (1.2%)
3680 (5.8%)
5361 (8.4%)
4750 (7.5%)
2021 (3.2%)
445 (0.7%)
23 389 (36.8%)
5248 (8.3%)
1125 (1.8%)
14 487 (22.8%)
61 (0.1%)
2539 (4.0%)
32 633 (51.3%)

0.2%
0.6%
0.5%
0.4%
0.9%
0.2%
1.0%
0.3%
2.7%
0.4%
0.8%
0.4%
1.7%

3631 (14.6%)
140.3 (3.4)

183 468 (14.2%)
140.6 (3.0)

1.0%
9.8%

2592 (12.2%)
140.4 (3.3)

7776 (12.2%)
140.5 (3.0)

0
4.1%
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ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.32% missing values in matched users and non-users.
These patients were included in income quintile 3 (“average” income).
c There were less than 0.04% missing values in both matched users and non-users. These patients were included in the urban category.
d Comorbid conditions in the five years preceding the index date were considered.
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the
condition.
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal.
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
h Concurrent medication use in the six months preceding the index date were considered.
i Healthcare contacts in the year preceding the index date were considered.
j Healthcare use in the year preceding the index date was considered.
k Serum sodium measurements were obtained at a median (IQR) of 132 (58 to 229) days prior to the index date in users, and 134 (64 to 230) days in non-users.
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Table D-5. Full baseline characteristics of valproic acid (V), phenytoin (P), and topiramate (T) users and non-users (1:2 matching
ratio)*
Characteristic

Demographic
Age, years, mean (SD)
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Year of cohort entry
2003-2004
2005-2006
2007-2008
2009-2010
2011-2012
2013-2015
Rural residencec
Long-term care
Prescribing physician
Family Physician
Psychiatrist
Geriatrician
Neurologist
Other
Missing
Comorbid conditionsd
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)

V-P-T
users
(n= 26 365)

Unmatched
Antiepileptic
non-users
(n= 1 289 530)

76 (7.7)
14 780 (56.1%)

76 (7.2)
742 126 (57.6%)

5.6%
3.0%

76 (7.7)
11 708 (58.1%)

76 (7.6)
23 416 (58.1%)

0%
0%

5693 (21.6%)
5424 (20.6%)
5020 (19.0%)
5078 (19.3%)
5044 (19.1%)

251 859 (19.5%)
269 597 (20.9%)
252 663 (19.6%)
253 301 (19.6%)
258 046 (20.0%)

5.1%
0.8%
1.4%
1.0%
2.2%

4321 (21.4%)
4182 (20.8%)
3897 (19.3%)
3908 (19.4%)
3847 (19.1%)

8818 (21.9%)
8280 (20.5%)
7799 (19.4%)
7687 (19.1%)
7726 (19.2%)

1.1%
0.5%
0%
0.8%
0.2%

4513 (17.1%)
5072 (19.2%)
4216 (16.0%)
4033 (15.3%)
4273 (16.2%)
4258 (16.2%)
3601 (13.7%)
7071 (26.8%)

232 137 (18.0%)
254 656 (19.7%)
213 249 (16.5%)
204 621 (15.9%)
196 140 (15.2%)
188 727 (14.6%)
182 927 (14.2%)
57 445 (4.5%)

2.3%
1.3%
1.5%
1.6%
2.7%
4.2%
1.5%
64.7%

3738 (18.6%)
4056 (20.1%)
3172 (15.7%)
2908 (14.4%)
3132 (15.5%)
3149 (15.6%)
2835 (14.1%)
4482 (22.2%)

7461 (18.5%)
8154 (20.2%)
6308 (15.7%)
5844 (14.5%)
6275 (15.6%)
6268 (15.6%)
5887 (14.6%)
8964 (22.2%)

0.1%
0.3%
0.3%
0.2%
0.1%
0.2%
1.5%
0%

0.9 (1.6)
13.0 (4.3)

0.7%
1.4%

Standardized
Differencea

16 630 (63.1%)
2202 (8.4%)
255 (1.0%)
2678 (10.2%)
1603 (6.1%)
2997 (11.4%)
1.2 (1.7)
13.5 (4.5)

V-P-T
users
(n= 20 155)

Matched
Antiepileptic
non-users
(n= 40 310)

Standardized
Differencea

12 924 (64.1%)
1495 (7.4%)
181 (0.9%)
2060 (10.2%)
1242 (6.2%)
2253 (11.2%)
0.6 (1.3)
11.5 (4.2)

37.5%
45.4%

0.9 (1.5)
13.0 (4.5)
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Epilepsy/seizuree
Migraine
Trigeminal neuralgia
Neuropathic pain
Bipolar disorder
Mood disorder
Anxiety disorder
Benign brain tumour
Brain aneurysm
Brain cancer
Brain injury
Encephalitis
Meningitis
Parkinson’s disease
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancerf
Diabetes
Diabetic neuropathy
Diabetic retinopathy
Pneumonia
Coronary artery diseaseg
Angina
Atrial fibrillation/flutter
Previous hyponatremia
Previous delirium
Myocardial infarction
Adrenal Insufficiency
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Acute kidney injury
Hypotension
Acute urinary retention

16 029 (60.8%)
2461 (9.3%)
470 (1.8%)
476 (1.8%)
1176 (4.5%)
2461 (9.3%)
15 118 (57.3%)
898 (3.4%)
56 (0.2%)
864 (3.3%)
716 (2.7%)
123 (0.5%)
89 (0.3%)
1522 (5.8%)
3933 (14.9%)
1990 (7.5%)
17 695 (67.1%)
978 (3.7%)
2733 (10.4%)
3910 (14.8%)
7416 (28.1%)
147 (0.6%)
128 (0.5%)
1910 (7.2%)
7848 (29.8%)
5275 (20.0%)
2404 (9.1%)
874 (3.3%)
1454 (5.5%)
1078 (4.1%)
27 (0.1%)
506 (1.9%)
2101 (8.0%)
611 (2.3%)
899 (3.4%)
698 (2.6%)
821 (3.1%)

396 047 (30.7%)
39 661 (3.1%)
11 567 (0.9%)
18 587 (1.4%
2154 (0.2%)
15 713 (1.2%)
463 445 (35.9%)
7600 (0.6%)
423 (0%)
3001 (0.2%)
3896 (0.3%)
676 (0.1%)
840 (0.1%)
24 413 (1.9%)
144 842 (11.2%)
77 172 (6.0%)
953 061 (73.9%)
39 103 (3.0%)
121 865 (9.5%)
168 419 (13.1%)
358 136 (27.8%)
3216 (0.2%)
5031 (0.4%)
43 322 (3.4%)
356 915 (27.7%)
245 038 (19.0%)
73 573 (5.7%)
16 299 (1.3%)
14 306 (1.1%)
43 693 (3.4%)
471 (0%)
2561 (0.2%)
22 836 (1.8%)
9789 (0.8%)
20 448 (1.6%)
16 113 (1.2%)
21 821 (1.7%)

63.3%
26.2%
7.7%
2.9%
28.9%
36.9%
43.9%
20.2%
5.1%
23.3%
19.9%
8.1%
6.1%
20.3%
10.9%
6.2%
14.9%
3.8%
3.1%
5.1%
0.8%
4.9%
1.4%
17.4%
4.6%
2.5%
13.1%
13.7%
24.8%
3.7%
2.5%
16.9%
29.1%
12.7%
11.7%
10.1%
9.3%

11 602 (57.6%)
1831 (9.1%)
364 (1.8%)
350 (1.7%)
1962 (9.7%)
4556 (22.6%)
10 918 (54.2%)
466 (2.3%)
29 (0.1%)
353 (1.8%)
360 (1.8%)
55 (0.3%)
43 (0.2%)
1024 (5.1%)
2294 (11.4%)
787 (3.9%)
13 253 (65.8%)
697 (3.5%)
2014 (10.0%)
2856 (14.2%)
5337 (26.5%)
87 (0.4%)
65 (0.3%)
1174 (5.8%)
5593 (27.7%)
3802 (18.9%)
1507 (7.5%)
529 (2.6%)
766 (3.8%)
707 (3.5%)
15 (0.1%)
248 (1.2%)
1199 (5.9%)
391 (1.9%)
420 (2.1%)
414 (2.1%)
503 (2.5%)

23 204 (57.6%)
3878 (9.6%)
784 (1.9%)
730 (1.8%)
3773 (9.4%)
9210 (22.8%)
22 697 (56.3%)
928 (2.3%)
55 (0.1%)
702 (1.7%)
595 (1.5%)
75 (0.2%)
76 (0.2%)
2001 (5.0%)
4588 (11.4%)
1574 (3.9%)
25 604 (63.5%)
1390 (3.4%)
3924 (9.7%)
5929 (14.7%)
9930 (24.6%)
159 (0.4%)
144 (0.4%)
2281 (5.7%)
11 096 (27.5%)
7598 (18.8%)
2930 (7.3%)
1037 (2.6%)
1436 (3.6%)
1420 (3.5%)
40 (0.1%)
399 (1.0%)
2350 (5.8%)
771 (1.9%)
716 (1.8%)
806 (2.0%)
980 (2.4%)

0.0%
1.8%
1.0%
0.6%
1.3%
0.6%
4.3%
0.1%
0.2%
0.1%
2.4%
1.8%
0.6%
0.5%
0.0%
0.0%
4.7%
0.1%
0.9%
1.5%
4.2%
0.6%
0.6%
0.7%
0.5%
0.0%
0.8%
0.3%
1.3%
0.1%
0.8%
2.3%
0.5%
0.2%
2.2%
0.4%
0.4%
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Peripheral vascular disease
Lung disease
Concurrent medication useh
Number of unique drug products, mean
(SD)
Antipsychotics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Digoxin
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatlets
Acetylcholine inhalers
Corticosteroid inhalers
Beta-agonist inhalers
Cholinesterase inhibitors
Lithium
Glucose test strips
Baclofen
Healthcare contacts, mean (SD)i
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits

573 (2.2%)
7547 (28.6%)

18 175 (1.4%)
310 878 (24.1%)

5.8%
10.3%

397 (2.0%)
5515 (27.4%)

795 (2.0%)
11 110 (27.6%)

0.0%
0.4%

9.1 (6.7)

7.1 (4.7)

35.3%

8.5 (6.3)

8.4 (5.6)

1.9%

6978 (26.5%)
10 751 (40.8%)
4096 (15.5%)
919 (3.5%)
4417 (16.8%)
1193 (4.5%)
6980 (26.5%)
10 045 (38.1%)
4027 (15.3%)
5673 (21.5%)
6746 (25.6%)
8540 (32.4%)
7956 (30.2%)
1026 (3.9%)
959 (3.6%)
9449 (35.8%)
2234 (8.5%)
440 (1.7%)
2191 (8.3%)
1676 (6.4%)
1532 (13.2%)
3318 (12.6%)
3473 (13.2%)
839 (3.2%)
3085 (11.7%)
335 (1.3%)

48 323 (3.7%)
215 229 (16.7%)
225 528 (17.5%)
44 902 (3.5%)
204 370 (15.8%)
69 702 (5.4%)
383 139 (29.7%)
627 455 (48.7%)
224 624 (17.4%)
361 121 (28.0%)
385 357 (29.9%)
542 836 (42.1%)
216 925 (16.8%)
46 646 (3.6%)
35 023 (2.7%)
388 511 (30.1%)
100 225 (7.8%)
13 884 (1.1%)
63 795 (4.9%)
69 110 (5.4%)
74 369 (3.6%)
150 199 (11.6%)
45 953 (3.6%)
2397 (0.2%)
165 484 (12.8%)
6414 (0.5%)

66.9%
55.2%
5.3%
0%
2.4%
4.1%
7.2%
21.4%
5.8%
15.1%
9.6%
20.2%
31.9%
1.4%
5.3%
12.2%
2.6%
5.1%
13.5%
4.2%
35.2%
2.9%
35.2%
23.4%
3.5%
8.3%

4369 (21.7%)
7617 (37.8%)
2991 (14.8%)
671 (3.3%)
3321 (16.5%)
863 (4.3%)
4951 (24.6%)
7706 (38.2%)
3266 (16.2%)
4343 (21.5%)
5085 (25.2%)
6516 (32.3%)
5633 (27.9%)
739 (3.7%)
709 (3.5%)
7114 (35.3%)
1603 (8.0%)
303 (1.5%)
1502 (7.5%)
1225 (6.1%)
1209 (11.8%)
2527 (12.5%)
2381 (11.8%)
332 (1.6%)
2251 (11.2%)
230 (1.1%)

8520 (21.1%)
15 852 (39.3%)
5735 (14.2%)
1394 (3.5%)
6754 (16.8%)
1701 (4.2%)
9791 (24.3%)
14 777 (36.7%)
6583 (16.3%)
8205 (20.4%)
9607 (23.8%)
12 125 (30.1%)
11 896 (29.5%)
1494 (3.7%)
1446 (3.6%)
14 184 (35.2%)
3167 (7.9%)
536 (1.3%)
3044 (7.6%)
2427 (6.0%)
2373 (11.8%)
4958 (12.3%)
4738 (11.8%)
660 (1.6%)
4244 (10.5%)
485 (1.2%)

1.3%
3.2%
1.7%
0.7%
0.7%
0.3%
0.6%
3.3%
0.3%
2.9%
3.2%
4.9%
3.5%
0.2%
0.4%
0.2%
0.4%
1.5%
0.4%
0.2%
0.2%
0.7%
0.2%
0.1%
2.1%
0.6%

0.8 (1.3)
1.3 (1.9)
17.2 (19.1)
0.6 (3.6)
2.7 (11.5)
0.8 (2.9)

0.4 (0.9)
0.5 (1.2)
9.0 (9.2)
0.1 (1.1)
0.1 (1.8)
0.1 (0.7)

33.0%
46.3%
58.4%
19.7%
38.2%
39.5%

0.7 (1.2)
1.0 (1.6)
14.5 (15.5)
0.4 (2.5)
1.2 (4.8)
0.5 (1.6)

0.6 (1.1)
1.0 (1.8)
14.2 (14.7)
0.3 (2.1)
0.8 (4.1)
0.4 (1.5)

3.5%
2.9%
2.1%
3.1%
10.1%
8.5%
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Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits
Healthcare usej
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot
Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Magnetic resonance imaging of the head
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis
Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray
Pulmonary function test
Electroencephalography
Urine culture
Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsk

0.2 (1.2)
1.4 (3.4)
0.3 (1.5)
0.1 (0.6)

0.1 (0.7)
0.9 (2.3)
0.3 (1.2)
0.1 (0.7)

7.1%
17.0%
2.9%
3.3%

0.1 (0.9)
1.1 (2.7)
0.3 (1.3)
0.1 (0.6)

0.1 (0.8)
1.1 (2.6)
0.3 (1.3)
0.1 (0.6)

1.2%
1.5%
0.8%
1.7%

17 093 (64.8%)
2639 (10.0%)
389 (1.5%)
4921 (18.7%)
2397 (9.1%)
2485 (9.4%)
45 0.2%)
3823 (14.5%)
1014 (3.8%)
704 (2.7%)
1771 (6.7%)
11 305 (42.9%)
15 359 (58.3%)
2148 (8.1%)
1124 (4.3%)
1215 (4.6%)
958 (3.6%)
3094 (11.7%)
9758 (37.0%)
540 (2.0%)
2268 (8.6%)
2789 (10.6%)
2495 (9.5%)
762 (2.9%)
262 (1.0%)
12 588 (47.7%)
1996 (7.6%)
2672 (10.1%)
8332 (31.6%)
72 (0.3%)
1978 (7.5%)
11 674 (44.3%)

745 101 (57.8%)
53 990 (4.2%)
18 080 (1.4%)
190 435 (14.8%)
70 045 (5.4%)
127 001 (9.8%)
788 (0.1%)
243 069 (18.8%)
77 134 (6.0%)
48 576 (3.8%)
120 405 (9.3%)
703 334 (54.5%)
665 897 (51.6%)
151 488 (11.7%)
58 607 (4.5%)
48 227 (3.7%)
61 776 (4.8%)
20 572 (1.6%)
90 235 (7.0%)
7581 (0.6%)
56 709 (4.4%)
81 533 (6.3%)
72 632 (5.6%)
18 193 (1.4%)
5709 (0.4%)
388 460 (30.1%)
95 359 (7.4%)
4318 (0.3%)
260 583 (20.2%)
1444 (0.1%)
36 321 (2.8%)
732 331 (56.8%)

14.5%
22.8%
0.6%
10.5%
14.1%
1.4%
3.2%
11.7%
9.9%
6.2%
9.7%
23.5%
13.3%
12.1%
1.4%
4.3%
5.8%
41.5%
77.7%
12.8%
17.1%
15.3%
14.5%
10.2%
6.5%
36.7%
0.7%
45.1%
26.2%
3.7%
21.3%
25.2%

12 566 (62.3%)
1554 (7.7%)
257 (1.3%)
3187 (15.8%)
1528 (7.6%)
1833 (9.1%)
22 (0.1%)
3010 (14.9%)
878 (4.4%)
567 (2.8%)
1437 (7.1%)
8988 (44.6%)
11 412 (56.6%)
1766 (8.8%)
890 (4.4%)
841 (4.2%)
767 (3.8%)
1492 (7.4%)
5500 (27.3%)
293 (1.5%)
1451 (7.2%)
1860 (9.2%)
1631 (8.1%)
485 (2.4%)
163 (0.8%)
8411 (41.7%)
1497 (7.4%)
826 (4.1%)
5965 (29.6%)
33 (0.2%)
1256 (6.2%)
9136 (45.3%)

24 958 (61.9%)
3378 (8.4%)
555 (1.4%)
6374 (15.8%)
3023 (7.5%)
3643 (9.0%)
53 (0.1%)
5838 (14.5%)
1648 (4.1%)
1182 (2.9%)
2889 (7.2%)
17 657 (43.8%)
22 543 (55.9%)
3325 (8.2%)
1762 (4.4%)
1690 (4.2%)
1493 (3.7%)
2982 (7.4%)
11 201 (27.8%)
642 (1.6%)
3045 (7.6%)
3725 (9.2%)
3249 (8.1%)
912 (2.3%)
333 (0.8%)
17 024 (42.2%)
3066 (7.6%)
1240 (3.1%)
11 710 (29.0%)
81 (0.2%)
2402 (6.0%)
17 461 (43.3%)

0.9%
2.5%
0.9%
0.0%
0.3%
0.2%
0.6%
1.3%
1.3%
0.7%
0.1%
1.6%
1.4%
1.8%
0.2%
0.1%
0.5%
0.0%
1.1%
1.1%
1.4%
0.0%
0.1%
1.0%
0.2%
1.0%
0.7%
5.5%
1.2%
0.9%
1.1%
4.1%
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Most recent serum sodium, N (%)
Most recent serum sodium, mean (SD)

3681 (14.0%)
140.3 (3.4)

183 468 (14.2%)
140.6 (3.0)

0.8%
7.9%

2253 (11.2%)
140.4 (3.3)

4506 (11.2%)
140.5 (3.1)

0%
3.1%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin II receptor blocker. IQR=interquartile range.
NSAID=Non-steroidal anti-inflammatory drug. SD=standard deviation.
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups with
respect to the pooled standard deviation; a standardized difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date. There were 0.35% and 0.32% missing values in matched users and nonusers, respectively. These patients were included in income quintile 3 (“average” income).
c There were less than 0.07% missing values in matched users and non-users. These patients were included in the urban category.
d Comorbid conditions in the five years preceding the index date were considered.
e Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present to hospital, which underestimates the prevalence of the
condition.
f Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, esophageal.
g Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous coronary intervention.
h Concurrent medication use in the six months preceding the index date were considered.
i Healthcare contacts in the year preceding the index date were considered.
j Healthcare use in the year preceding the index date was considered.
k Serum sodium measurements were obtained at a median (IQR) of 128 (56 to 234) days prior to the index date in users, and 139 (63 to 237) days in non-users.
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Table D-6. Baseline characteristics of carbamazepine users and non-users for a
subpopulation residing in a hospital catchment area with available serum sodium data*
Characteristic
Carbamazepine
users
(n=678)
Demographic
Age, years, mean (SD)
Women
Income quintileb
1 (low)
2
3 (medium)
4
5 (high)
Rural residence
Long-term care
Comorbid conditionsc
Charlson comorbidity index, mean (SD)
Johns Hopkins ACG System Aggregated
Diagnosis Groups, mean (SD)
Epilepsy/seizured
Migraine
Trigeminal neuralgia
Neuropathic pain
Bipolar disorder
Mood disorder
Anxiety disorder
Benign brain tumour
Brain aneurysm
Brain cancer
Brain injury
Encephalitis
Meningitis
Parkinson’s disease
Congestive heart failure
Chronic kidney disease
Hypertension
Chronic liver disease
Hypothyroidism
Cancere
Diabetes
Diabetic neuropathy
Diabetic retinopathy
Pneumonia
Coronary artery diseasef
Angina
Atrial fibrillation/flutter
Previous hyponatremia
Previous delirium
Myocardial infarction
Adrenal Insufficiency
Hemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Acute kidney injury

Matched
Antiepileptic
non-users
(n=2034)

Standardized
Differencea

75 (6.6)
435 (64.2%)

75 (6.5)
1305 (64.2%)

0.2%
0%

162 (23.9%)
123 (18.1%)
148 (21.8%)
128 (18.9%)
117 (17.3%)
98 (14.5%)
12 (1.8%)

441 (21.7%)
390 (19.2%)
434 (21.3%)
406 (20.0%)
363 (17.8%)
362 (17.8%)
36 (1.8%)

5.3%
2.7%
1.2%
2.7%
1.6%
9.1%
0.0%

0.5 (1.1)
11.7 (3.7)

0.5 (1.1)
11.9 (3.9)

3.7%
4.7%

239 (35.3%)
33 (4.9%)
0 (0%)
10 (1.5%)
7 (1.0%)
57 (8.4%)
264 (38.9%)
≤5 (≤0.7%)
≤5 (≤0.7%)
0 (0%)
≤5 (≤0.7%)
0 (0%)
0 (0%)
13 (1.9%)
41 (6.1%)
≤5 (≤0.7%)
494 (72.9%)
18 (2.7%)
63 (9.3%)
92 (13.6%)
162 (23.9%)
≤5 (≤0.7%)
≤5 (≤0.7%)
19 (2.8%)
160 (23.6%)
107 (15.8%)
30 (4.4%)
10 (1.5%)
≤5 (≤0.7%)
25 (3.7%)
≤5 (≤0.7%)
0 (0%)
18 (2.7%)
≤5 (≤0.7%)
≤5 (≤0.7%)

717 (35.3%)
80 (3.9%)
0 (0%)
34 (1.7%)
17 (0.8%)
174 (8.6%)
776 (38.2%)
9 (0.4%)
≤5 (≤0.3%)
≤5 (≤0.3%)
6 (0.3%)
0 (0%)
≤5 (≤0.3%)
35 (1.7%)
123 (6.1%)
6 (0.3%)
1495 (73.5%)
42 (2.2%)
206 (10.1%)
265 (13.0%)
474 (23.3%)
≤5 (≤0.3%)
11 (0.5%)
50 (2.5%)
487 (23.9%)
326 (16.0%)
95 (4.7%)
26 (1.3%)
15 (0.7%)
58 (2.9%)
≤5 (≤0.3%)
≤5 (≤0.3%)
30 (1.5%)
10 (0.5%)
11 (0.5%)

0%
4.6%
0%
1.6%
2.0%
0.5%
1.6%
≤2.4%
≤3.1%
≤7.0%
0%
0%
≤7.0%
1.5%
0%
0%
1.4%
3.9%
2.8%
1.6%
1.4%
3.1%
3.8%
2.2%
0.8%
0.7%
1.2%
1.7%
≤0%
4.7%
≤3.1%
6.3%
8.3%
≤1.3%
≤1.4%
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Hypotension
Acute urinary retention
Peripheral vascular disease
Lung disease
Concurrent medication useg
Number of unique drug products, mean
(SD)
Antipsychotics
Antidepressants
Antidiabetics
Antineoplastics
Thyroxine
Potassium sparing diuretics
Non-potassium sparing diuretics
ACE inhibitors and/or ARBs
NSAIDs (excl. ASA)
Calcium channel blockers
Beta-adrenergic agonists
Statins
Benzodiazepines
Digoxin
Overactive bladder
Antibiotics
Warfarin
Anticoagulents
Antiplatlets
Acetylcholine inhalers
Corticosteroid inhalers
Beta-agonist inhalers
Cholinesterase inhibitors
Lithium
Glucose test strips
Baclofen
Healthcare contacts, mean (SD)h
Hospitalizations
Emergency department visits
Family physician visits
Geriatrician visits
Psychiatrist visits
Neurologist visits
Nephrologist visits
Cardiologist visits
Urologist visits
Obstetrician/Gynecologist visits
Healthcare usei
Previous sodium tests
Carotid ultrasound
Cardiac catheterization
Echocardiography
Holter monitoring
Cardiac stress test
Coronary endarterectomy
Colorectal cancer screening
Cervical cancer screening
Prostate specific antigen test
Mammography
Flu shot

≤5 (≤0.7%)
13 (1.9%)
15 (2.2%)
164 (24.2%)

21 (1.0%)
33 (1.6%)
37 (1.8%)
472 (23.2%)

≤4.9%
2.2%
2.8%
2.3%

7.3 (4.4)

6.7 (4.1)

12.6%

20 (3.0%)
162 (23.9%)
116 (17.1%)
29 (4.3%)
90 (13.3%)
47 (6.9%)
196 (28.9%)
302 (44.5%)
184 (27.1%)
182 (26.8%)
197 (29.1%)
254 (37.5%)
159 (23.5%)
31 (4.6%)
29 (4.3%)
258 (38.1%)
0 (0%)
≤5 (≤0.7%)
25 (3.7%)
32 (4.7%)
35 (1.6%)
67 (9.9%)
11 (1.6%)
≤5 (≤0.7%)
77 (11.4%)
≤5 (≤0.7%)

64 (3.2%)
520 (25.6%)
290 (14.3%)
76 (3.7%)
324 (15.9%)
136 (6.7%)
585 (28.8%)
887 (43.6%)
515 (25.3%)
493 (24.2%)
552 (27.1%)
661 (32.5%)
534 (26.3%)
74 (3.6%)
71 (3.5%)
660 (32.5%)
0 (0%)
≤5 (≤0.3%)
78 (3.8%)
113 (5.6%)
86 (2.5%)
216 (10.6%)
51 (2.5%)
9 (0.4%)
243 (12.0%)
10 (0.5%)

1.1%
3.9%
7.9%
2.8%
7.5%
1.0%
0.3%
1.9%
4.1%
6.0%
4.3%
10.4%
6.5%
4.7%
4.1%
11.8%
0%
≤6.3%
0.8%
3.8%
6.2%
2.4%
6.2%
≤5.4%
1.8%
0.7%

0.5 (0.9)
0.6 (1.1)
10.1 (7.5)
0.2 (2.1)
0.1 (0.8)
0.2 (0.6)
0 (0.3)
0.5 (1.4)
0.2 (1.1)
0.1 (0.4)

0.4 (0.8)
0.6 (1.2)
9.4 (7.8)
0.1 (1.0)
0.1 (1.2)
0.1 (0.6)
0 (0.2)
0.6 (1.5)
0.3 (1.1)
0.1 (0.6)

3.5%
0.9%
8.5%
4.6%
4.1%
8.3%
0%
2.7%
2.8%
4.1%

362 (53.4%)
38 (5.6%)
≤5 (≤0.7%)
73 (10.8%)
31 (4.6%)
67 (9.9%)
0 (0%)
135 (19.9%)
37 (5.5%)
31 (4.6%)
56 (8.3%)
431 (63.6%)

1099 (54.0%)
103 (5.1%)
22 (1.1%)
176 (8.7%)
89 (4.4%)
210 (10.3%)
0 (0%)
399 (19.6%)
117 (5.8%)
70 (3.4%)
159 (7.8%)
1232 (60.6%)

1.3%
2.4%
≤5.4%
7.1%
2.0%
1.5%
0%
0.7%
1.3%
5.8%
1.6%
6.2%
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Thyroid stimulating hormone
Bone mineral density test
Hearing test
Cytoscopy
Cataract surgery
Magnetic resonance imaging of the head
Computed tomography of the head
Computed tomography of the neck
Computed tomography of the thorax
Computed tomography of the abdomen
Computed tomography of the pelvis
Computed tomography of the spine
Computed tomography of the extremities
Chest x-ray
Pulmonary function test
Electroencephalography
Urine culture
Heart valve replacement
At-home physician services
Cholesterol tests
Laboratory measurementsj
Most recent serum sodium, N (%)
Most recent serum sodium, mean (SD)

286 (42.2%)
73 (10.8%)
38 (5.6%)
12 (1.8%)
40 (5.9%)
9 (1.3%)
63 (9.3%)
9 (1.3%)
29 (4.3%)
57 (8.4%)
49 (7.2%)
17 (2.5%)
9 (1.3%)
206 (30.4%)
32 (4.7%)
≤5 (≤0.7%)
119 (17.6%)
0 (0%)
24 (3.5%)
335 (49.4%)

900 (44.3%)
224 (11.0%)
110 (5.4%)
72 (3.5%)
114 (5.6%)
28 (1.4%)
152 (7.5%)
16 (0.8%)
69 (3.4%)
134 (6.6%)
120 (5.9%)
55 (2.7%)
12 (0.6%)
589 (29.0%)
150 (7.4%)
0 (0%)
374 (18.39%)
≤5 (≤0.3%)
47 (2.3%)
972 (47.8%)

4.2%
0.8%
0.9%
11.0%
1.3%
0.4%
6.6%
5.3%
4.6%
6.9%
5.4%
1.2%
7.6%
3.1%
11.2%
≤5.4%
2.2%
3.1%
7.3%
3.3%

231 (34.1%)
139.8 (3.3)

693 (34.1%)
140.0 (3.0)

0%
8.6%

ACE inhibitor=angiotensin-converting enzyme inhibitor. ACG=adjusted clinical groups. ARB=angiotensin
II receptor blocker. IQR=interquartile range. NSAID=Non-steroidal anti-inflammatory drug. SD=standard
deviation.
Characteristics in which there were ≤5 events were not presented for reasons of privacy
* Data are presented as the number (percentage) of patients, unless otherwise reported.
a Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a
measure of the difference between groups with respect to the pooled standard deviation; a standardized
difference greater than 10% was considered as a meaningful difference between the groups.
b Income was categorized into fifths of average neighborhood income on the index date.
c Comorbid conditions in the five years preceding the index date were considered.
d Epilepsy/seizure codes are hospital diagnosis codes and do not capture those patients who do not present
to hospital, which underestimates the prevalence of the condition.
e Cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin
lymphoma, liver, ovarian, esophageal.
f Coronary artery disease includes receipt of coronary artery bypass graft surgery, and percutaneous
coronary intervention.
g Concurrent medication use in the six months preceding the index date were considered.
h Healthcare contacts in the year preceding the index date were considered.
i Healthcare use in the year preceding the index date was considered.
j Serum sodium measurements were obtained at a median (IQR) of 150 (69 to 236) days in users and 130
(58 to 226) days in non-users, prior to the index date.
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Appendix E

Validity of the International Classification of Diseases Tenth
Revision Code for Hospitalization with Hyponatremia in
Elderly Patients*

*A version of this chapter has been published elsewhere as: Gandhi S, Shariff SZ, Fleet
JL, Weir MA, Jain AK, Garg AX. Validity of the International Classification of Diseases
10th revision code for hospitalisation with hyponatraemia in elderly patients. BMJ Open.
2012;2:e001727.
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Abstract
Objective: To evaluate the validity of the International Classification of Diseases, Tenth
Revision (ICD-10) diagnosis code for hyponatremia (E87.1) in two settings: at
presentation to the emergency department and at hospital admission.
Design: Population-based retrospective validation study.
Setting: Twelve hospitals in Southwestern Ontario, Canada, from 2003 to 2010.
Participants: Patients aged 66 years and older with serum sodium laboratory
measurements at presentation to the emergency department (n=64,581) and at hospital
admission (n=64,499).
Main outcome measures: Sensitivity, specificity, positive predictive value and negative
predictive value comparing various ICD-10 diagnostic coding algorithms for
hyponatremia to serum sodium laboratory measurements (reference standard). Median
serum sodium values comparing patients who were code positive and code negative for
hyponatremia.
Results: The sensitivity of hyponatremia (defined by a serum sodium ≤132 mmol/L) for
the best performing ICD-10 coding algorithm was 7.5% at presentation to the emergency
department (95% confidence interval (CI): 7.0% to 8.2%) and 10.6% at hospital
admission (95% CI: 9.9% to 11.2%). Both specificities were greater than 99%. In the two
settings, the positive predictive values were 96.4% (95% CI: 94.6% to 97.6 %) and 82.3%
(95% CI: 80.03% to 84.4%), while the negative predictive values were 89.2% (95% CI:
89.0% to 89.5%) and 87.1% (95% CI: 86.8% to 87.4%). In patients who were code
positive for hyponatremia, the median (interquartile range) serum sodium measurements
were 123 (119 to 126) mmol/L and 125 (120 to 130) mmol/L in the two settings. In code
negative patients, the measurements were 138 (136 to 140) mmol/L and 137 (135 to 139)
mmol/L.
Conclusions: The ICD-10 diagnostic code for hyponatremia differentiates between two
groups of patients with distinct serum sodium measurements at both presentation to the
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emergency department and at hospital admission. However, these codes underestimate
the true incidence of hyponatremia due to low sensitivity.

Keywords: hyponatremia, hyponatraemia, serum sodium, validation, validity, diagnostic
accuracy, sensitivity, specificity, International Classification of Diseases
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Introduction
Large health administrative databases are widely used in pharmacoepidemiologic and
health services research.1 They offer several advantages including increased efficiency
and large sample sizes. Despite their usefulness, an important limitation of these
databases is that researchers frequently rely on hospital-based diagnostic codes contained
within the databases to define conditions of interest, rather than reference standard
diagnoses.2 The inaccuracy of codes may introduce measurement error, which has a
number of implications including underestimation of the true incidence of a condition.
Accordingly, understanding the validity of various diagnostic codes remains of
paramount importance.
Hyponatremia is an electrolyte disorder and is generally defined by a low serum
sodium concentration.3,4 It is one of the most common types of abnormalities of its kind
affecting 15% to 30% of hospitalized patients.5,6 Depending on its severity and rapidity of
onset, hyponatremia has been associated with morbidities such as confusion, seizures,
falls, fractures as well as mortality.7–9 There are a number of causes of hyponatremia such
as dehydration from prolonged vomiting, congestive heart failure, some forms of kidney
disease, and medication use (e.g. diuretics).
To date, the validity of the International Classification of Diseases, Ninth Revision
(ICD-9) code for hyponatremia has been described in two studies. Movig et al. compared
discharge records for hospitalized patients with laboratory data and found sensitivities of
1.7% and 13.4% for serum sodium measurements ≤135 mmol and ≤125 mmol/L,
respectively.10 Specificities were greater than 99%. Shea et al. evaluated outpatient
records against laboratory measurements and reported sensitivities of 3.5% and 29.6%
using the same thresholds to define hyponatremia.11 Specificities remained high at over
99%.
ICD-10 was introduced in Canada in 2002 and is currently used by 117 countries
worldwide.12 To date there has been no validation of the ICD-10 code for hyponatremia.
Therefore, the goal of our study was to evaluate the validity of the ICD-10 diagnosis code
for hyponatremia (E87.1) in two settings: at presentation to the emergency department
and at hospital admission.
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Methods
Study Design and Setting
We conducted a population-based retrospective validation study using the health
administrative databases and laboratory data in Southwestern Ontario, Canada. These
data come from 12 hospitals that serviced a catchment area of approximately 80,000
adults aged 65 and older in 2006 (most recent available census information).13 All
residents received universal access to hospital and physician services. Coverage for
medical services and medications from a single provincial payer provided a
comprehensive set of health administrative data.
Using a diagnostic test assessment framework, we obtained metrics of sensitivity,
specificity, positive predictive value and negative predictive value comparing various
ICD-10 diagnostic coding algorithms for hyponatremia to serum sodium laboratory
measurements (the latter serving as the reference standard; see online supplementary
Appendix A for sample two-by-two table). Since serum sodium concentration is a
continuous measure, we also compared these values in patients who were code positive
with those who were code negative. We conducted our study according to a pre-specified
protocol that was approved by the institutional review board at Sunnybrook Health
Sciences Centre (Toronto, Ontario). The relevant datasets and the analyses were held and
conducted at the Institute for Clinical Evaluative Sciences. The reporting of this study
follows guidelines set out for studies of diagnostic accuracy (see online supplementary
Appendix B).14

Data Sources
Records from seven databases were linked using encrypted unique identifiers. We
identified laboratory measurements, including serum sodium using Cerner® (Kansas City,
Missouri, USA), a system that keeps patient electronic medical records.13,15 This system
contains inpatient, outpatient and emergency room laboratory measurements. We
identified emergency department visits using the National Ambulatory Care Reporting
System database, and inpatient hospital admissions using the Canadian Institutes of
Health Information Discharge Abstract Database (CIHI-DAD). These databases contain
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detailed diagnostic and procedural information coded using ICD-9 (pre-2002) and ICD10 (post-2002). We obtained patient demographic data from the Registered Persons
Database, which contains demographic information on all Ontarians ever issued a health
card. We collected additional covariate information from the CIHI-DAD, the Ontario
Health Insurance Plan database, which contains health claims information for both
inpatient and outpatient services and the Ontario Drug Benefits database, which contains
highly accurate records of all outpatient prescriptions dispensed to patients ≥65 years of
age (error rate <1%).16 For a subpopulation, we also obtained baseline laboratory
measurements prior to hospital encounters from Gamma-Dynacare, a provider of
outpatient laboratory services to residents in Southwestern Ontario. These databases have
been used extensively to research health outcomes and health services.17–20

Participants
In order to assess the validity of the hyponatremia code, we created two separate cohorts
restricting cohort entry to patients with at least one serum sodium measurement at
presentation to an emergency department or at hospital admission, respectively. These
measurements were available beginning 1 June 2003, which is when we began accrual for
the study and continued to 30 September 2010. To ensure all participants had at least one
full year of medication use data, we restricted entry to those aged 66 years and older at
the time of the serum sodium measurement. The selection criteria are described below
and outlined in online supplementary Appendix C.
We excluded measurements when the date of an emergency department or inpatient
serum sodium test did not align with an emergency department visit or inpatient hospital
admission included in the administrative databases (see online supplementary Appendix
C for alignment definitions). To ensure we had data for the full hospital admission to the
time of discharge (particularly for patients accrued in the second half of 2010) we
excluded admissions where the duration of the visit exceeded 90 days. As such, study
follow-up occurred until 31 December 2010. To assess hyponatremia upon presentation
to the emergency department, patients had to have at least one emergency department
serum sodium measurement on the day of or one day after the emergency department
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registration date. To assess hyponatremia at hospital admission, we restricted to patients
who had at least one emergency department serum sodium measurement two days prior
to the hospital admission date or one inpatient serum sodium measurement the day of or
one day after the hospital admission date. For both settings, when multiple serum sodium
tests were performed, we selected the lowest value to define the presence of
hyponatremia. In cases where multiple emergency department visits or hospital
encounters were identified per patient over the study period, we randomly selected one
visit/encounter. We denoted the emergency department registration date or inpatient
hospital admission date as the index date.

Diagnostic Test (Hyponatremia ICD-10 coding algorithms)
In Canada, trained coders record appropriate diagnostic codes and their associated
attributes based on information from a patient’s chart. Coders follow the Canadian
Coding Standards developed by CIHI.21 Based on these guidelines, coders are not
permitted to interpret laboratory test results but can record a laboratory-based condition if
the physician has documented the diagnosis in the medical chart. Within the NACRS
database, coders are allowed to include up to 10 diagnoses per visit. The first diagnosis
listed is the main problem for the client’s visit that required evaluation and/or treatment
or management as determined by the physician at the end of the visit. CIHI-DAD
provides the ability to record up to 25 diagnoses, each with a corresponding diagnosis
type. For example, a diagnosis type of ‘M’ is used to refer to the diagnosis that was most
responsible for the greatest portion of the length of stay or greatest use of resources,
while a diagnosis type of ‘1’ refers to a condition that existed prior to admission.
In this study, we developed two unique algorithms to assess hyponatremia at
presentation to the emergency department and four unique algorithms at hospital
admission based on possible diagnosis types. We used the ICD-10 code E87.1, which is
defined as “hypo-osmolality and hyponatraemia”. The two emergency department
algorithms identified records with code E87.1 recorded: i) as the main problem (referred
to as “main diagnosis”), or ii) in any of the 10 potential diagnostic fields (referred to as
“all diagnosis”). The four hospital admission algorithms identified records with code
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E87.1 recorded: i) with the diagnosis type of ‘M’ (most responsible) (referred to as “most
responsible diagnosis”), ii) with the diagnosis type of ‘1’ (pre-admit comorbidity) or ‘W’,
‘X’ or ‘Y’ (service transfer diagnosis) (referred to as “admission diagnosis”), iii) with a
diagnosis type of ‘M’ and a diagnosis type of ‘1’ (referred to as “admission diagnosis and
most responsible diagnosis”), or iv) in any one of 25 potential diagnosis fields and any
diagnosis type (referred to as “all diagnosis”).

Reference Standard (serum sodium values)
Serum sodium was analyzed in the laboratory using a Roche Modular Ion Selective
Electrode® system (Basel, Switzerland). We considered four thresholds when defining our
reference standard of hyponatremia: serum sodium <135 mmol/L, ≤132 mmol/L, ≤130
mmol/L, and ≤125 mmol/L. Our primary definition of hyponatremia was a serum sodium
≤132 mmol/L while the other definitions were explored to investigate the impact of
disease severity.7,8

Statistical Analysis
We used descriptive statistics to summarize demographic characteristics, comorbidities,
prescription drug claim information and prior laboratory testing for patients in both
settings. We calculated sensitivity, specificity, positive predictive value and negative
predictive value for each diagnostic coding algorithm (formulas presented in Appendix
A). We calculated 95% confidence intervals (CI) for single proportions using the Wilson
Score method.22 We repeated these calculations for each hyponatremia threshold. We
expressed continuous variables as medians with interquartile ranges (IQR). We compared
means using independent samples t-tests. We conducted all analysis using SAS
(Statistical Analysis Software) version 9.2 (SAS Institute Incorporated, Cary, North
Carolina, USA, 2008).

251

Results
Over the seven-year study period, there were a total 64 581 patients with serum sodium
measurements at presentation to the emergency department and 64 499 at hospital
admission. Of these patients, 7446 (11.5%) and 9135 (14.2%) had serum sodium
measurements ≤132 mmol/L, respectively. Baseline characteristics of the two cohorts are
presented in Table F-1. The median age of the patients on the index date was 77 years
and just over half the patients were women. Over 50% of each cohort had serum sodium
measurements available prior to the index date and mean values were normal (Table F-1).
Table E-1. Baseline characteristics for patients with serum sodium measurements
obtained in the emergency department and upon hospital admission
Characteristic
Demographics
Median age (IQR), years
Women
Income Quintile
1 (low)
2
3 (middle)
4
5 (high)
Year of Cohort Entrya
2003-2004
2005-2006
2007-2008
2009-2010
Rural Location
From a Long-term Care Facility
Comorbiditiesb
Chronic kidney disease
Diabetes mellitusc
Peripheral vascular disease
Coronary artery diseased
Congestive heart failure
Systemic malignancye
Stroke/Transient ischemic attack
Chronic liver disease
Medication use in preceding 6 months
Angiotensin-converting enzyme inhibitor
Angiotensin-receptor blocker
Potassium sparing diuretic
Non-potassium sparing diuretic
Calcium channel blocker
β-Adrenergic antagonist
Statins
NSAIDs (excluding aspirin)

Emergency Department
(n = 64 581)

Hospital Admission
(n = 64 499)

77 (71 to 83)
35 361 (55.2%)

77 (71 to 83)
32 965 (51.1%)

14 224 (22.0%)
12 862 (19.9%)
12 564 (19.5%)
11 511 (17.8%)
12 431 (19.3%)

13 879 (21.5%)
12 974 (20.1%)
12 795 (19.8%)
11 601 (18.0%)
12 435 (19.3%)

6535 (10.1%)
15 208 (23.6%)
20 586 (31.2%)
22 252 (34.5%)
11 417 (17.7%)
4147 (6.42%)

11 599 (18.0%)
15 639 (24.3%)
18 437 (28.6%)
18 824 (29.2%)
13 286 (20.6%)
3674 (5.7%)

5339 (8.3%)
13 148 (20.4%)
1685 (2.6%)
26 963 (41.8%)
13 674 (21.2%)
27 003 (41.8%)
2508 (3.9%)
1217 (1.9%)

6399 (9.9%)
13 640 (21.2%)
2940 (4.6%)
30 608 (47.5%)
15 249 (23.6%)
29 835 (46.3%)
2671 (4.1%)
1684 (2.6%)

22 706 (35.2%)
10 474 (16.2%)
5699 (8.8%)
25 930 (40.2%)
19 092 (29.6%)
21 957 (34.0%)
24 873 (38.5%)
11 637 (18.0%)

23 759 (36.8%)
10 005 (15.5%)
6166 (9.6%)
27 144 (42.1%)
19 895 (30.9%)
23 417 (36.3%)
25 303 (39.2%)
12 530 (19.4%)
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Antiepileptics
Antidepressants
Antipsychotics
Benzodiazepines
Antineoplastic agents
Hypothyroidism agents
Baseline Laboratory Measurementsf
Serum sodium levels, mmol/L
Median (IQR)
Range
Hyponatremia category
<135 mmol/L
≤132 mmol/L
≤130 mmol/L
≤125 mmol/L
Serum potassium levels, mmol/L, median
(IQR)
Serum creatinine levels, µmol/L, median (IQR)
eGFR mL/min/1.73 m2, median (IQR)g
eGFR category, n (%)
≥60 mL/min/1.73m2
45-59 mL/min/1.73m2
30-44 mL/min/1.73m2
15-29 mL/min/1.73m2
<15 mL/min/1.73m2

3828 (5.9%)
15 710 (24.3%)
3944 (6.1%)
15 274 (23.7%)
3280 (5.1%)
10 444 (16.2%)

3733 (5.8%)
15 102 (23.4%)
3611 (5.6%)
15 532 (24.1%)
3631 (5.6%)
9954 (15.4%)

139 (137 to 141)
95 to 180

139 (137 to 141)
95 to 173

5587 (17.0%)
2064 (6.3%)
1030 (3.1%)
130 (0.4%)
4.2 (3.8 to 4.5)

6561 (16.7%)
2397 (6.1%)
1169 (3.0%)
171 (0.4%)
4.1 (3.8 to 4.5)

90 (74 to 114)
62.8 (46.6 to 78.6)

90 (74 to 114)
63.1 (46.9 to 78.9)

20 809 (54.7%)
8521 (22.4%)
5520 (14.5%)
2368 (6.2%)
842 (2.2%)

23 726 (55.1%)
9600 (22.3%)
6036 (14.0%)
2687 (6.2%)
1035 (2.4%)

Abbreviations: IQR, interquartile range; eGFR, estimated glomerular filtration rate
a The year of cohort entry is also referred to as the index date
b Assessed by administrative database ICD-9 and ICD-10 codes in the 5 years prior to the hospital
encounter (unless stated otherwise)
c Assessed by diabetic medication use (oral hypoglycemic or insulin use) in previous 6 months
d Coronary artery disease includes receipt of coronary artery bypass graft surgery, percutaneous coronary
intervention and diagnoses of angina
e Includes the following types of malignancies: skin, mouth (lip, tonsil, etc), throat, stomach, small/large
intestine, liver, gall bladder, pancreas, breast, male/female reproductive organs, heart, lung, bone, urinary
system (kidney, bladder, etc), endocrine glands, as well as leukemias and lymphomas
f Available for a subpopulation. Emergency Department cohort: A total of 32,916 (51.0%), 33,190 (51.4%)
and 38,060 (58.9%) of the 64,581 patients had a most recent baseline serum sodium, potassium and
creatinine measurement available in the 7 to 365 days prior to the index date, respectively. Among these
patients, the baseline measurements were taken at a median (IQR) of 75 (26-175), 75 (26-175), and 76 (27173) days prior to the index date, respectively. Hospital Admission cohort: A total of 39,373 (61.0%),
39,502 (61.2%) and 43,084 (66.8%) of the 64,499 patients had a most recent baseline serum sodium,
potassium and creatinine measurement available in the 7 to 365 days prior to the index date, respectively.
Among these patients, the baseline measurements were taken at a median (IQR) of 29 (14-97), 29 (14-97),
and 31 (14-101) days prior to the index date, respectively
g eGFR was calculated using the CKD-Epi equation.
CKD-Epi equation: 141 x min([serum creatinine in umol/L /88·4 ]/κ, 1)α x max([serum creatinine in
umol/L / 88·4]/κ, 1)-1·209 x 0·993Age x 1·018 [if female] x 1·159 [if African American] κ=0·7 for
females and 0·9 for males, α= -0·329 for females and -0·411 for males, min=the minimum of Scr/κ or 1,
max=the maximum of Scr/κ or 1.Racial information was not available in our data sources and all patients
were assumed not to be of non African-Canadian race. This was a reasonable assumption; as of 2006,
African-Canadians represented less than 7% of the Ontario population. Source:
http://www12.statcan.ca/census-recensement/2006/dp-pd/hlt/97-562/index.cfm?Lang=E
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The sensitivity of hyponatremia when defined by a serum sodium ≤132 mmol/L
was highest when considering evidence of code E87.1 among all potential diagnoses for
both settings: at presentation to emergency department, 7.5% (95% CI: 7.0% to 8.2%)
and at hospital admission, 10.6% (95% CI: 9.9% to 11.2%). In both settings the
specificities were greater than 99%. The positive predictive values were 96.4% (95% CI:
94.6% to 97.6%) and 82.3% (95% CI: 80.0% to 84.4%) and the negative predictive
values were 89.2% (95% CI: 89.0% to 89.5%) and 87.1% (95% CI: 86.8% to 87.4%),
respectively (Table F-2).
In patients with and without baseline hyponatremia (7 to 365 days prior to hospital
encounter), the sensitivity of the all diagnosis ICD-10 coding algorithm in the emergency
department setting was 11.6% in those with baseline hyponatremia and 5.4% in those
without. For similar patients in the hospital admission setting, the sensitivities were
16.9% and 7.6%, respectively (online supplementary Appendix D).
In both settings, the sensitivity of each ICD-10 coding algorithm for hyponatremia
increased as the thresholds for serum sodium decreased (Table F-3). The positive
predictive value of each ICD-10 coding algorithm for hyponatremia decreased with
decreasing thresholds for serum sodium, as lower thresholds are less common (i.e. 25.0%
of hospital admissions had a serum sodium ≤135 mmol/L vs. 2.3% with a value ≤ 125
mmol/L).
When considering all potential diagnoses, 582 (0.9%) patients were code positive
for hyponatremia at presentation to the emergency department and 1171 (1.8%) at
hospital admission. The median (IQR) serum sodium values among code positive patients
were 123 (119 to 126) mmol/L and 125 (120 to 130) mmol/L in each setting,
respectively. For those patients who were code negative, the median values were 138
(136 to 140) mmol/L and 137 (135 to 139) mmol/L, respectively (Table F-4).
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Table E-2. Performance of the ICD-10 coding algorithms for hyponatremia using a serum sodium measurement as the reference
standard
ICD-10 E87.1
Coding Algorithms

Reference Standard Hyponatremia (≤132 mmol/L)
Emergency Department
+

-

+

561

21

-

6885

57 114

+

309

11

-

7137

57 124

Performance
Measures

Hospital Admission
+

-

964

207

8171

55 157

+

773

90

-

8362

55 274

+

251

4

-

8884

55 360

+

248

4

-

8887

55 360

All Diagnosis

Main Diagnosis

95% CI

Sn= 7.53%
Sp= 99.96%
PPV= 96.39%
NPV= 89.24%

6.96% to 8.16%
99.94% to 99.98%
94.55% to 97.63%
89.00% to 9.48%

Sn= 4.15%
Sp= 99.98%
PPV= 96.56%
NPV= 88.89%

3.72% to 4.63%
99.97% to 99.99%
93.95% to 98.07%
88.65% to 89.13%

Admission Diagnosis

Most Responsible
Diagnosis

Admission Diagnosis +
Most Responsible
Diagnosis

Performance
Measures

95% CI

Sn= 10.55%
Sp= 99.63%
PPV= 82.32%
NPV= 87.10%

9.94% to 11.20%
99.57% to 99.67%
80.03% to 84.40%
86.83% to 87.36%

Sn= 8.46%
Sp= 99.84%
PPV= 89.57%
NPV= 86.86%

7.91% to 9.05%
99.80% to 99.87%
87.35% to 91.44%
86.59% to 87.12%

Sn= 2.75%
Sp= 99.99%
PPV= 98.43%
NPV= 86.17%

2.43% to 3.10%
99.98% to 100.00%
96.04% to 99.39%
85.90% to 86.44%

Sn= 2.71%
Sp= 99.99%
PPV= 98.41%
NPV= 86.17%

1.36% to 1.74%
99.98% to 100.00%
95.99% to 99.38%
74.99% to 75.66%

Abbreviations: ICD-10=International Classification of Diseases, tenth revision; CI=confidence interval; Sn=sensitivity; Sp=specificity; PPV=positive predictive
value; NPV=negative predictive value; +=hyponatremia yes; -=hyponatremia no
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Table E-3. Performance of the ICD-10 coding algorithms for hyponatremia for different
levels of serum sodium measurements
Serum sodium measurements (mmol/L)a
Emergency Department
Hospital Admission
≤ 135
≤ 130
≤ 125
≤ 135
≤ 130
≤ 125

ICD-10 E87.1
Coding Algorithms
All Diagnosis

Performance
Measures
Sensitivity
Specificity
PPV
NPV

4.49%
99.97%
97.42%
81.17%

12.58%
99.95%
94.33%
94.04%

34.43%
99.71%
68.21%
98.82%

Main Diagnosis

Sensitivity
Specificity
PPV
NPV

2.48%
99.99%
97.81%
80.86%

6.94%
99.97%
94.69%
93.68%

20.64%
99.87%
74.38%
98.58%

Admission
Diagnosis

6.42%
99.72%
88.30%
76.21%

17.06%
99.55%
77.20%
93.06%

41.68%
99.12%
52.43%
98.64%

Sensitivity
Specificity
PPV
NPV

4.97%
99.87%
92.70%
75.96%

14.02%
99.80%
86.10%
92.84%

36.66%
99.49%
62.57%
98.53%

Most Responsible
Diagnosis

Sensitivity
Specificity
PPV
NPV

1.56%
99.99%
98.43%
75.33%

4.70%
99.99%
97.65%
92.14%

15.48%
99.96%
89.41%
98.06%

Admission
Diagnosis + Most
Responsible
Diagnosis

Sensitivity
Specificity
PPV
NPV

1.54%
99.99%
98.41%
75.33%

4.64%
99.99%
97.62%
92.14%

15.41%
99.96%
90.08%
98.06%

Abbreviations: ICD-10=International Classification of Diseases, tenth revision; PPV=positive predictive
value; NPV=negative predictive value.
a 95% confidence intervals were calculated using the Wilson score method but were not reported. All
intervals were within ±4% of the point estimate.
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Table E-4. Serum sodium concentration (mmol/L) describing those patients where the
ICD-10 coding algorithms did and did not indicate hyponatremia (code positive and code
negative)
ICD-10 E87.1
Coding Algorithms
All Diagnosis

Emergency Department
N
Median
IQR
+
-

582
63 999

123
138

119-126
136-140

Main Diagnosis

+
-

320
64 261

122
138

117-126
136-140

Admission Diagnosis

Hospital Admission
N
Median
IQR
1171
63 328

125
137

120-130
135-139

+
-

863
63 636

124
137

119-128
135-139

Most Responsible Diagnosis

+
-

255
64 244

120
137

116-123
135-139

Admission Diagnosis + Most
Responsible Diagnosis

+
-

252
64 247

120
137

116-123
135-139

Abbreviations: ICD-10=International Classification of Diseases, tenth revision; N=number;
IQR=interquartile range; +=code positive; -=code negative. Code positive and code negative patients were
significantly different (p < 0.0001) (means presented in box plot; Figure F-1)

In both settings there were significant differences in mean serum sodium values
between patients who were code positive and code negative for hyponatremia for all ICD10 coding algorithms (p < 0.0001 in each setting). The mean difference in serum sodium
values between patients who were code positive and code negative in the two settings
was 15.2 (95% CI: 14.6 to 15.7) mmol/L and 11.4 (95% CI: 10.9 to 11.9) mmol/L,
respectively (Figure F-1).
In the subgroup of patients with baseline pre-hospital encounter serum sodium
measurements, the median (IQR) decrement in serum sodium values among patients who
were code positive was 10.0 (6.0 to 15.0) mmol/L at presentation to the emergency
department and 8.0 (4.0 to 13.0) mmol/L at hospital admission. Similar results in patients
who were code negative were 1.0 (1.0 to 4.0) mmol/L and 2.0 (0.0 to 4.0) mmol/L,
respectively. The mean difference in the decrement in serum sodium values between
patients who were code positive and code negative in the two settings was 9.4 (95% CI
8.6 to 10.2) mmol/L and 6.8 (95% CI 6.2 to 7.4) mmol/L, respectively (p < 0.0001 in
each setting) (online supplementary Appendix E).
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Figure E-1. Serum sodium measurements among patients who are code positive and
code negative for hyponatremia when considering any evidence of hyponatremia (all
diagnosis).
For both presentations to emergency department and at hospital admission, patients who were code positive
for hyponatremia had significantly lower serum sodium measurement than patients who were code
negative. The boxes represent the interquartile range (50% of the values). The line across the box indicates
the median. The star indicates the mean. The whiskers extend to the 95 th and 5th percentile.
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Discussion
In this population-based validation study, we found that the best performing ICD-10
coding algorithm for hyponatremia for presentation to the emergency department and at
hospital admission settings was when the code was included in any diagnosis field,
regardless of the associated diagnosis type. Overall, while the ICD-10 code for
hyponatremia was highly specific, the sensitivity of the code was low. In both settings,
there was a high false negative rate - a large number of patients with a serum sodium
measurement below 133 mmol/L were not coded as having hyponatremia (≥90%). Even
for severe hyponatremia (serum sodium ≤125 mmol/L), the sensitivity was maximally
about 42%. The most responsible diagnosis is one that is responsible for the longest
length of stay/greatest use of resources and may also be one that was present at
admission. This was the poorest performing algorithm in our study possibly because the
hospital admission is attributed to the underlying condition that caused the hyponatremia
(e.g. congestive heart failure) rather than the hyponatremia per se.
The sensitivities we observed are similar to those reported by Movig et al. and Shea
et al. for ICD-9 coding although the sensitivities and positive predictive values found in
our study are slightly higher for all thresholds of hyponatremia (depending on the specific
ICD-10 coding algorithm). Also consistent with the previous validation studies, the
sensitivity increased as the severity of hyponatremia increased. This may be because
more mild forms of hyponatremia tend to be asymptomatic and do not usually require
treatment, making the physician less inclined to record a diagnosis of hyponatremia in the
medical chart.23–25
Of the patients who had hyponatremia at presentation to the emergency department
and at hospital admission (defined by a value ≤132 mmol/L), only 7.5% and 10.6% were
correctly coded as demonstrating this. In other words, the diagnosis was not being written
by a physician in the medical chart and may suggest the condition receives less attention
than it deserves. Despite this, the code was successful in differentiating between two
groups of patients with distinctly different serum sodium measurements at the hospital
encounter. Patients who were code negative for hyponatremia had measurements in the
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normal range (135-145 mmol/L) and code positive patients had much lower
measurements (≤125 mmol/L). Patients who were code positive at hospital admission
also demonstrated an average decrement of 8.7 mmol/L in serum sodium from a baseline
value, the latter taken at a median of 29 days prior to hospital admission. This further
exemplifies the point that new and more severe forms of hyponatremia tend to be
recorded.
Our study has several strengths. It is the first study to validate the ICD-10 code for
hyponatremia. We validated the ICD-10 code in both the emergency department and at
hospital admission examining different types of diagnoses. Previous studies have not
looked at these settings nor did they examine all the possible diagnosis types as we did.
The study was made possible by the province of Ontario’s universal healthcare and
provincial drug plan benefits with collection of all healthcare encounters of all citizens.
We had a large sample size to base our validation on using laboratory data from a number
of hospitals across the province. This helped improve study generalizability and differs
from the ICD-9 validation study of Movig et al. who used only a single hospital. Our
large sample also provided good precision around the point estimates.
The validity measures that we used in this study have also been used in several
other studies comparing ICD codes with clinical outcomes.8,9,26–29 Many validation
studies compare diagnostic codes to information written in medical charts, whereas we
compared the diagnostic code for hyponatremia to a reference standard of laboratory
values. Where appropriate, this is the most accurate way to determine the presence of
hyponatremia.
Our study does have some limitations. We evaluated the validity of the
hyponatremia code in an elderly population and the results best generalize to adults over
the age of 65. This patient population is very vulnerable to developing hyponatremia.3,30
Additionally, since most pharmacoepidemiologic research using the Ontario databases
are conducted on the elderly where receipt of prescription medications is a universal
benefit, these findings would be especially applicable. Additional studies are required to
validate these codes in younger patients, where hospitalization with hyponatremia is
expected to be less frequent.
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Laboratory data were available for about 5% of Ontario elderly residents. This
should be considered when generalizing the results to the entire province, Canada, or
other countries. Given that the results obtained from this study are similar to those found
with the ICD-9 code for hyponatremia in the United States and the Netherlands, we
anticipate the results are broadly applicable.
We did not know the degree to which patients with hyponatremia were
symptomatic from their low sodium values or the indication that prompted presentation to
the emergency department or hospital admission. However, we do know the codes did
identify acute decrements in serum creatinine as previously described. Patients with acute
changes in serum sodium are those most likely to be symptomatic from the condition.
We could not examine the validity of outpatient claims for hyponatremia in this
study as there is no code available for this in our jurisdiction. Nevertheless, emergency
department and hospital records do detect more severe forms of hyponatremia making
this of particular interest to clinicians and policy decision makers.
Finally, we recognize we did not capture those patients who may have had severe
hyponatremia but did not present to the emergency department or hospital, or those who
presented but failed to have serum sodium measured. However, the latter is less of a
concern given serum sodium measurements are a ubiquitous and standard test for most
patients who present for acute medical care.

Conclusion
Although administrative databases have inherent advantages, they have limitations in
identifying certain conditions such as hyponatremia. As observed in this study, the ICD10 code for hyponatremia was able to differentiate between two groups of elderly patients
with distinct serum sodium measurements during presentation to the emergency
department and at hospital admission. However, the sensitivity of hyponatremia was very
low, particularly at less severe forms of the condition, which will underestimate the true
incidence of the condition. The results from this study will guide judicious use of the
hyponatremia code in future research, which uses healthcare administrative databases.
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